# data[].attributes.title
Lab Study Uncovers New Findings On How Cancer Cells Hijack The Immune System to Promote Tumor Growth 

# data[].attributes.metatag_normalized[].attributes.content
Lab Study Uncovers New Findings On How Cancer Cells Hijack The Immune System to Promote Tumor Growth  | BCRF

# data[].attributes.metatag_normalized[].attributes.content
As tumors develop and grow, individual tumor cells acquire the ability to adapt to changes in the environment that would normally kill the tumor cells. One way they do this is to trick the immune system.
Myeloid-derived suppressor cells (MDSCs) are a class of immune cells that are known to suppress the immune system. It is well known that tumor cells can recruit MDSCs to promote tumor growth by avoiding destruction by the immune system. But, how cancer cells attract MDSCs and interact to cause tumor growth is poorly understood.
A new study led by Dr. Shawn Zhang from the Baylor College of Medicine, and supported in part by BCRF, sheds new light on a well-known pathway and helps to explain one way in which tumor cells hijack MDSCs to promote growth.
In a report published in Nature Cell Biology , Xiang and colleagues identified a novel function of the mTOR pathway in regulating MDSC recruitment and immune suppression by increasing amounts of an immune factor called G-CSF.
The mTOR pathway is a master regulator of cell growth and division. It responds to many different stimuli including the presence or absence of nutrients, the energy the cell needs, and other signaling molecules. Deregulation of the mTOR pathway has been associated with many types of cancer, including breast cancer. However, the complexity of the mTOR pathway, along with the fact that it also functions in normal cells, presents many challenges to targeted therapy.  The present study suggests that combining mTOR therapy with immunotherapy could overcome some of these barriers.
Using laboratory models, Dr. Zhang and his team showed that certain cancer cells that depend on mTOR signaling for growth produce high amounts of a factor called G-CFS, which acts to attract MDSC to the tumor.  The MDSCs in turn stimulate the production of tumor initiating cells, which produce more G-CSF, creating a vicious tumor-promoting cycle. The connection between mTOR and the immune system through G-CSF is a novel finding and sheds new light on how MDSCs work to promote tumor growth.
“Determining that a patient's tumor is using the mTOR pathway would indicate that the cancer cells are more likely to depend on MDSCs for progression. This information suggests for example, that combining mTOR therapies with therapies for MDSCs represent potential therapeutic strategies," Dr. Zhang explained to ScienceNews.
Commenting on this study, Dr. Zhang credited BCRF for providing “the freedom to explore areas where I…[am] deeply interested. We hope this work will provide [the] foundation for novel immunology-related therapies.”
Immunotherapy is an active area of research among BCRF investigators. The newly launched Drug Research Collaborative has generated nearly two-dozen proposals to study various aspects of immunotherapy from basic science to clinical trials. In addition, BCRF is currently funding 24 projects–totaling more than $6.5 million related to cancer immunology and immunotherapies.
 

# data[].attributes.metatag_normalized[].attributes.content
Lab Study Uncovers New Findings On How Cancer Cells Hijack The Immune System to Promote Tumor Growth

# data[].attributes.metatag_normalized[].attributes.content
As tumors develop and grow, individual tumor cells acquire the ability to adapt to changes in the environment that would normally kill the tumor cells. One way they do this is to trick the immune system.
Myeloid-derived suppressor cells (MDSCs) are a class of immune cells that are known to suppress the immune system. It is well known that tumor cells can recruit MDSCs to promote tumor growth by avoiding destruction by the immune system. But, how cancer cells attract MDSCs and interact to cause tumor growth is poorly understood.

# data[].attributes.metatag_normalized[].attributes.content
Lab Study Uncovers New Findings On How Cancer Cells Hijack The Immune System to Promote Tumor Growth

# data[].attributes.metatag_normalized[].attributes.content
As tumors develop and grow, individual tumor cells acquire the ability to adapt to changes in the environment that would normally kill the tumor cells. One way they do this is to trick the immune system.
Myeloid-derived suppressor cells (MDSCs) are a class of immune cells that are known to suppress the immune system. It is well known that tumor cells can recruit MDSCs to promote tumor growth by avoiding destruction by the immune system. But, how cancer cells attract MDSCs and interact to cause tumor growth is poorly understood.

# data[].attributes.metatag_normalized[].attributes.content
Lab Study Uncovers New Findings On How Cancer Cells Hijack The Immune System to Promote Tumor Growth

# data[].attributes.body.value
As tumors develop and grow, individual tumor cells acquire the ability to adapt to changes in the environment that would normally kill the tumor cells. One way they do this is to trick the immune system.

Myeloid-derived suppressor cells (MDSCs) are a class of immune cells that are known to suppress the immune system. It is well known that tumor cells can recruit MDSCs to promote tumor growth by avoiding destruction by the immune system. But, how cancer cells attract MDSCs and interact to cause tumor growth is poorly understood.

A new study led by Dr. Shawn Zhang from the Baylor College of Medicine, and supported in part by BCRF, sheds new light on a well-known pathway and helps to explain one way in which tumor cells hijack MDSCs to promote growth.

In a report published in Nature Cell Biology , Xiang and colleagues identified a novel function of the mTOR pathway in regulating MDSC recruitment and immune suppression by increasing amounts of an immune factor called G-CSF.

The mTOR pathway is a master regulator of cell growth and division. It responds to many different stimuli including the presence or absence of nutrients, the energy the cell needs, and other signaling molecules. Deregulation of the mTOR pathway has been associated with many types of cancer, including breast cancer. However, the complexity of the mTOR pathway, along with the fact that it also functions in normal cells, presents many challenges to targeted therapy.  The present study suggests that combining mTOR therapy with immunotherapy could overcome some of these barriers.

Using laboratory models, Dr. Zhang and his team showed that certain cancer cells that depend on mTOR signaling for growth produce high amounts of a factor called G-CFS, which acts to attract MDSC to the tumor.  The MDSCs in turn stimulate the production of tumor initiating cells, which produce more G-CSF, creating a vicious tumor-promoting cycle. The connection between mTOR and the immune system through G-CSF is a novel finding and sheds new light on how MDSCs work to promote tumor growth.

“Determining that a patient's tumor is using the mTOR pathway would indicate that the cancer cells are more likely to depend on MDSCs for progression. This information suggests for example, that combining mTOR therapies with therapies for MDSCs represent potential therapeutic strategies," Dr. Zhang explained to ScienceNews.

Commenting on this study, Dr. Zhang credited BCRF for providing “the freedom to explore areas where I…[am] deeply interested. We hope this work will provide [the] foundation for novel immunology-related therapies.”

Immunotherapy is an active area of research among BCRF investigators. The newly launched Drug Research Collaborative has generated nearly two-dozen proposals to study various aspects of immunotherapy from basic science to clinical trials. In addition, BCRF is currently funding 24 projects–totaling more than $6.5 million related to cancer immunology and immunotherapies.

# data[].attributes.body.processed
As tumors develop and grow, individual tumor cells acquire the ability to adapt to changes in the environment that would normally kill the tumor cells. One way they do this is to trick the immune system.

Myeloid-derived suppressor cells (MDSCs) are a class of immune cells that are known to suppress the immune system. It is well known that tumor cells can recruit MDSCs to promote tumor growth by avoiding destruction by the immune system. But, how cancer cells attract MDSCs and interact to cause tumor growth is poorly understood.

A new study led by Dr. Shawn Zhang from the Baylor College of Medicine, and supported in part by BCRF, sheds new light on a well-known pathway and helps to explain one way in which tumor cells hijack MDSCs to promote growth.

In a report published in Nature Cell Biology , Xiang and colleagues identified a novel function of the mTOR pathway in regulating MDSC recruitment and immune suppression by increasing amounts of an immune factor called G-CSF.

The mTOR pathway is a master regulator of cell growth and division. It responds to many different stimuli including the presence or absence of nutrients, the energy the cell needs, and other signaling molecules. Deregulation of the mTOR pathway has been associated with many types of cancer, including breast cancer. However, the complexity of the mTOR pathway, along with the fact that it also functions in normal cells, presents many challenges to targeted therapy.  The present study suggests that combining mTOR therapy with immunotherapy could overcome some of these barriers.

Using laboratory models, Dr. Zhang and his team showed that certain cancer cells that depend on mTOR signaling for growth produce high amounts of a factor called G-CFS, which acts to attract MDSC to the tumor.  The MDSCs in turn stimulate the production of tumor initiating cells, which produce more G-CSF, creating a vicious tumor-promoting cycle. The connection between mTOR and the immune system through G-CSF is a novel finding and sheds new light on how MDSCs work to promote tumor growth.

“Determining that a patient's tumor is using the mTOR pathway would indicate that the cancer cells are more likely to depend on MDSCs for progression. This information suggests for example, that combining mTOR therapies with therapies for MDSCs represent potential therapeutic strategies," Dr. Zhang explained to ScienceNews.

Commenting on this study, Dr. Zhang credited BCRF for providing “the freedom to explore areas where I…[am] deeply interested. We hope this work will provide [the] foundation for novel immunology-related therapies.”

Immunotherapy is an active area of research among BCRF investigators. The newly launched Drug Research Collaborative has generated nearly two-dozen proposals to study various aspects of immunotherapy from basic science to clinical trials. In addition, BCRF is currently funding 24 projects–totaling more than $6.5 million related to cancer immunology and immunotherapies.

# data[].attributes.field_caption
BCRF researcher Dr. Shawn Zhang from the Baylor College of Medicine.

# data[].attributes.title
BCRF Investigators Honored by the American Society for Clinical Oncology

# data[].attributes.metatag_normalized[].attributes.content
BCRF Investigators Honored by the American Society for Clinical Oncology | BCRF

# data[].attributes.metatag_normalized[].attributes.content
At the 52nd Annual American Society for Clinical Oncology Conference in Chicago (June 3-7, 2016), two longtime BCRF investigators were honored for their achievements in the field.
Dr. C. Kent Osborne of Baylor College of Medicine is the 2016 recipient of the Gianni Bonadonna Breast Cancer Award. This award recognizes an active clinical and/or translational researcher for their significant contributions to advancing the field of breast cancer and their mentorship of early career scientists in pursuits of a career in breast cancer research. Dr. Osborne’s award honored his 40-year research career dedicated to improving the lives of breast cancer patients through his groundbreaking work that led to advancing HER2-targeted therapies. In his award lecture, Dr. Osborne took a look back at his career from the early days of breast cancer research highlighting discoveries from his lab that would advance our understanding of the complicated interplay between hormones and growth factor pathways that led to drug resistance and tumor progression. Throughout his talk, he gave credit for the work to the many early career scientists and clinicians who he mentored throughout his career, many who have gone on to become leaders in the field themselves. Dr. Osborne joins a list of BCRF investigators who have been honored with the Gianni Bonadonna award in past years: Matthew Ellis (2015), BCRF Scientific Director, Larry Norton (2013), Nancy Davidson (2010), Carlos Arteaga (2009) and Daniel Hayes (recipient of the inaugural award in 2007). BCRF is proud to have supported the work and accomplishments of these distinguished scientists and congratulate Dr. Osborne on his 2016 award. 
Dr. William G. Kaelin, Jr. of the Dana Farber Cancer Institute, BCRF investigator since 2006, is the 2016 recipient of the Science of Oncology Award and Lecture in recognition of his outstanding contributions in cancer research that have provided valuable insights into the biochemical functions of tumor suppressor proteins and their role in cancer development. Dr. Kaelin’s career has focused on understanding the role of mutations in this group of proteins on tumor formation and growth. His research in this area laid the groundwork for the development of novel anti-cancer therapies. One of his most notable accomplishments was the development of targeted therapy in kidney cancer by identifying a growth factor protein that was defective in the majority of these cancers. Dr. Kaelin’s BCRF research focuses on a novel target in breast cancer called EglN2 that regulates tumor cell growth, drug resistance and metastasis. BCRF congratulates Dr. Kaelin on this prestigious award and is proud to support is research in breast cancer. 
 
 

# data[].attributes.metatag_normalized[].attributes.content
BCRF Investigators Honored by the American Society for Clinical Oncology

# data[].attributes.metatag_normalized[].attributes.content
At the 52nd Annual American Society for Clinical Oncology Conference in Chicago (June 3-7, 2016), two longtime BCRF investigators were honored for their achievements in the field.

# data[].attributes.metatag_normalized[].attributes.content
BCRF Investigators Honored by the American Society for Clinical Oncology

# data[].attributes.metatag_normalized[].attributes.content
Drs. Kent Osborne and William Kaelin Are Recognized for Their Contributions to Clinical Oncology at ASCO’s 2016 Annual Meeting

# data[].attributes.metatag_normalized[].attributes.content
At the 52nd Annual American Society for Clinical Oncology Conference in Chicago (June 3-7, 2016), two longtime BCRF investigators were honored for their achievements in the field.

# data[].attributes.metatag_normalized[].attributes.content
BCRF Investigators Honored by the American Society for Clinical Oncology

# data[].attributes.body.value
At the 52nd Annual American Society for Clinical Oncology Conference in Chicago (June 3-7, 2016), two longtime BCRF investigators were honored for their achievements in the field.

Dr. C. Kent Osborne of Baylor College of Medicine is the 2016 recipient of the Gianni Bonadonna Breast Cancer Award. This award recognizes an active clinical and/or translational researcher for their significant contributions to advancing the field of breast cancer and their mentorship of early career scientists in pursuits of a career in breast cancer research. Dr. Osborne’s award honored his 40-year research career dedicated to improving the lives of breast cancer patients through his groundbreaking work that led to advancing HER2-targeted therapies. In his award lecture, Dr. Osborne took a look back at his career from the early days of breast cancer research highlighting discoveries from his lab that would advance our understanding of the complicated interplay between hormones and growth factor pathways that led to drug resistance and tumor progression. Throughout his talk, he gave credit for the work to the many early career scientists and clinicians who he mentored throughout his career, many who have gone on to become leaders in the field themselves. Dr. Osborne joins a list of BCRF investigators who have been honored with the Gianni Bonadonna award in past years: Matthew Ellis (2015), BCRF Scientific Director, Larry Norton (2013), Nancy Davidson (2010), Carlos Arteaga (2009) and Daniel Hayes (recipient of the inaugural award in 2007). BCRF is proud to have supported the work and accomplishments of these distinguished scientists and congratulate Dr. Osborne on his 2016 award.

Dr. William G. Kaelin, Jr. of the Dana Farber Cancer Institute, BCRF investigator since 2006, is the 2016 recipient of the Science of Oncology Award and Lecture in recognition of his outstanding contributions in cancer research that have provided valuable insights into the biochemical functions of tumor suppressor proteins and their role in cancer development. Dr. Kaelin’s career has focused on understanding the role of mutations in this group of proteins on tumor formation and growth. His research in this area laid the groundwork for the development of novel anti-cancer therapies. One of his most notable accomplishments was the development of targeted therapy in kidney cancer by identifying a growth factor protein that was defective in the majority of these cancers. Dr. Kaelin’s BCRF research focuses on a novel target in breast cancer called EglN2 that regulates tumor cell growth, drug resistance and metastasis. BCRF congratulates Dr. Kaelin on this prestigious award and is proud to support is research in breast cancer.

# data[].attributes.body.processed
At the 52nd Annual American Society for Clinical Oncology Conference in Chicago (June 3-7, 2016), two longtime BCRF investigators were honored for their achievements in the field.

Dr. C. Kent Osborne of Baylor College of Medicine is the 2016 recipient of the Gianni Bonadonna Breast Cancer Award. This award recognizes an active clinical and/or translational researcher for their significant contributions to advancing the field of breast cancer and their mentorship of early career scientists in pursuits of a career in breast cancer research. Dr. Osborne’s award honored his 40-year research career dedicated to improving the lives of breast cancer patients through his groundbreaking work that led to advancing HER2-targeted therapies. In his award lecture, Dr. Osborne took a look back at his career from the early days of breast cancer research highlighting discoveries from his lab that would advance our understanding of the complicated interplay between hormones and growth factor pathways that led to drug resistance and tumor progression. Throughout his talk, he gave credit for the work to the many early career scientists and clinicians who he mentored throughout his career, many who have gone on to become leaders in the field themselves. Dr. Osborne joins a list of BCRF investigators who have been honored with the Gianni Bonadonna award in past years: Matthew Ellis (2015), BCRF Scientific Director, Larry Norton (2013), Nancy Davidson (2010), Carlos Arteaga (2009) and Daniel Hayes (recipient of the inaugural award in 2007). BCRF is proud to have supported the work and accomplishments of these distinguished scientists and congratulate Dr. Osborne on his 2016 award.

Dr. William G. Kaelin, Jr. of the Dana Farber Cancer Institute, BCRF investigator since 2006, is the 2016 recipient of the Science of Oncology Award and Lecture in recognition of his outstanding contributions in cancer research that have provided valuable insights into the biochemical functions of tumor suppressor proteins and their role in cancer development. Dr. Kaelin’s career has focused on understanding the role of mutations in this group of proteins on tumor formation and growth. His research in this area laid the groundwork for the development of novel anti-cancer therapies. One of his most notable accomplishments was the development of targeted therapy in kidney cancer by identifying a growth factor protein that was defective in the majority of these cancers. Dr. Kaelin’s BCRF research focuses on a novel target in breast cancer called EglN2 that regulates tumor cell growth, drug resistance and metastasis. BCRF congratulates Dr. Kaelin on this prestigious award and is proud to support is research in breast cancer.

# data[].attributes.field_caption
Dr. Kent Osborne accepts the Gianni Bonadonna Award

# data[].attributes.field_subtitle
Drs. Kent Osborne and William Kaelin Are Recognized for Their Contributions to Clinical Oncology at ASCO’s 2016 Annual Meeting

# data[].attributes.title
New Combination Treatment Holds Promise for Treatment of Breast Cancer Brain Metastasis

# data[].attributes.metatag_normalized[].attributes.content
New Combination Treatment Holds Promise for Treatment of Breast Cancer Brain Metastasis | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Metastasis, when cancer cells leave the breast and spread to other sites in the body, is the major cause of mortality from breast cancer. Common sites of breast cancer metastasis are bone, lung, liver and brain. Cancers that spread to the brain are particularly challenging as the blood brain barrier can block transport of cancer drugs and create a safe haven for tumors to grow.
When HER2-positive breast cancers spread, they often spread to the brain and these tumors represent one of the greatest clinical challenges in treating HER2-positive breast cancer. In a new article published in Nature Medicine, a team of BCRF investigators report that a promising drug combination was highly effective at stopping human HER2-positive breast cancer brain metastases (BCBMs) in experimental models.
Drs. Jean Zhao, Charles Wang, Dirk Iglehart, Ian Kropp, Eric Winer and Nancy Lin from the Dana Farber Cancer Institute have been working together to devise a laboratory model of human brain metastasis to test potential new therapies for this devastating disease. The models, called PDX are developed from human tumors that are grown outside the body. The PDX resemble the human tumors from which they were derived in their expression of hormone receptors and HER2, as well as gene mutation profiles, and had the same drug sensitivity or resistance that the patient’s tumor exhibited in the clinic.
In the process of testing a number of different drug combinations, the research team discovered a very unexpected combination of drugs that was very effective against the PDX tumors.  The drugs, called BKM120 and RAD001 were originally included as negative control in the experimental design.  As expected, when either drug was used alone, it had no effect on  growth of the PDX tumors, but when the research team combined the drugs, they saw a dramatic inhibition of tumor growth and an increase in tumor cell death. 
Importantly, the treatment did not work the same for all PDX tumors. The tumors with a high mutation profile – meaning there were sections of the DNA with a high density of gene mutations – were less likely to respond to the therapy than tumors with fewer mutations. The researchers believe that this finding may help to identify patients most likely to respond to the therapy.
While this study only included five patient PDXs, the findings were supported by other research, strongly suggesting that the combination of BKM120 and RAD001 could be a viable option for some HER2+ BCBM. Since both drugs are currently in clinical trials for advanced breast cancer, the therapy could advance quickly to patients. Read more about the study here.

# data[].attributes.metatag_normalized[].attributes.content
New Combination Treatment Holds Promise for Treatment of Breast Cancer Brain Metastasis

# data[].attributes.metatag_normalized[].attributes.content
Metastasis, when cancer cells leave the breast and spread to other sites in the body, is the major cause of mortality from breast cancer. Common sites of breast cancer metastasis are bone, lung, liver and brain. Cancers that spread to the brain are particularly challenging as the blood brain barrier can block transport of cancer drugs and create a safe haven for tumors to grow.

# data[].attributes.metatag_normalized[].attributes.content
New Combination Treatment Holds Promise for Treatment of Breast Cancer Brain Metastasis

# data[].attributes.metatag_normalized[].attributes.content
BCRF researchers uncover potential new therapy for brain metastasis

# data[].attributes.metatag_normalized[].attributes.content
Metastasis, when cancer cells leave the breast and spread to other sites in the body, is the major cause of mortality from breast cancer. Common sites of breast cancer metastasis are bone, lung, liver and brain. Cancers that spread to the brain are particularly challenging as the blood brain barrier can block transport of cancer drugs and create a safe haven for tumors to grow.

# data[].attributes.metatag_normalized[].attributes.content
New Combination Treatment Holds Promise for Treatment of Breast Cancer Brain Metastasis

# data[].attributes.body.value
Metastasis, when cancer cells leave the breast and spread to other sites in the body, is the major cause of mortality from breast cancer. Common sites of breast cancer metastasis are bone, lung, liver and brain. Cancers that spread to the brain are particularly challenging as the blood brain barrier can block transport of cancer drugs and create a safe haven for tumors to grow.

When HER2-positive breast cancers spread, they often spread to the brain and these tumors represent one of the greatest clinical challenges in treating HER2-positive breast cancer. In a new article published in Nature Medicine, a team of BCRF investigators report that a promising drug combination was highly effective at stopping human HER2-positive breast cancer brain metastases (BCBMs) in experimental models.

Drs. Jean Zhao, Charles Wang, Dirk Iglehart, Ian Kropp, Eric Winer and Nancy Lin from the Dana Farber Cancer Institute have been working together to devise a laboratory model of human brain metastasis to test potential new therapies for this devastating disease. The models, called PDX are developed from human tumors that are grown outside the body. The PDX resemble the human tumors from which they were derived in their expression of hormone receptors and HER2, as well as gene mutation profiles, and had the same drug sensitivity or resistance that the patient’s tumor exhibited in the clinic.

In the process of testing a number of different drug combinations, the research team discovered a very unexpected combination of drugs that was very effective against the PDX tumors.  The drugs, called BKM120 and RAD001 were originally included as negative control in the experimental design.  As expected, when either drug was used alone, it had no effect on  growth of the PDX tumors, but when the research team combined the drugs, they saw a dramatic inhibition of tumor growth and an increase in tumor cell death.

Importantly, the treatment did not work the same for all PDX tumors. The tumors with a high mutation profile – meaning there were sections of the DNA with a high density of gene mutations – were less likely to respond to the therapy than tumors with fewer mutations. The researchers believe that this finding may help to identify patients most likely to respond to the therapy.

While this study only included five patient PDXs, the findings were supported by other research, strongly suggesting that the combination of BKM120 and RAD001 could be a viable option for some HER2+ BCBM. Since both drugs are currently in clinical trials for advanced breast cancer, the therapy could advance quickly to patients. Read more about the study here.

# data[].attributes.body.processed
Metastasis, when cancer cells leave the breast and spread to other sites in the body, is the major cause of mortality from breast cancer. Common sites of breast cancer metastasis are bone, lung, liver and brain. Cancers that spread to the brain are particularly challenging as the blood brain barrier can block transport of cancer drugs and create a safe haven for tumors to grow.

When HER2-positive breast cancers spread, they often spread to the brain and these tumors represent one of the greatest clinical challenges in treating HER2-positive breast cancer. In a new article published in Nature Medicine, a team of BCRF investigators report that a promising drug combination was highly effective at stopping human HER2-positive breast cancer brain metastases (BCBMs) in experimental models.

Drs. Jean Zhao, Charles Wang, Dirk Iglehart, Ian Kropp, Eric Winer and Nancy Lin from the Dana Farber Cancer Institute have been working together to devise a laboratory model of human brain metastasis to test potential new therapies for this devastating disease. The models, called PDX are developed from human tumors that are grown outside the body. The PDX resemble the human tumors from which they were derived in their expression of hormone receptors and HER2, as well as gene mutation profiles, and had the same drug sensitivity or resistance that the patient’s tumor exhibited in the clinic.

In the process of testing a number of different drug combinations, the research team discovered a very unexpected combination of drugs that was very effective against the PDX tumors.  The drugs, called BKM120 and RAD001 were originally included as negative control in the experimental design.  As expected, when either drug was used alone, it had no effect on  growth of the PDX tumors, but when the research team combined the drugs, they saw a dramatic inhibition of tumor growth and an increase in tumor cell death.

Importantly, the treatment did not work the same for all PDX tumors. The tumors with a high mutation profile – meaning there were sections of the DNA with a high density of gene mutations – were less likely to respond to the therapy than tumors with fewer mutations. The researchers believe that this finding may help to identify patients most likely to respond to the therapy.

While this study only included five patient PDXs, the findings were supported by other research, strongly suggesting that the combination of BKM120 and RAD001 could be a viable option for some HER2+ BCBM. Since both drugs are currently in clinical trials for advanced breast cancer, the therapy could advance quickly to patients. Read more about the study here.

# data[].attributes.field_subtitle
BCRF researchers uncover potential new therapy for brain metastasis

# data[].attributes.title
GSN’s “Skin Wars” Feature Young Breast Cancer Survivors on June 8

# data[].attributes.metatag_normalized[].attributes.content
GSN’s “Skin Wars” Feature Young Breast Cancer Survivors on June 8 | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Felicity was diagnosed with invasive estrogen-positive breast cancer on February 26, 2013, one week before her 29th birthday. She found a lump a few months prior and was referred to a doctor who was confident it was a benign cyst – that it could not be cancerous – because of her young age. After multiple tests, the result was positive.
“He didn’t look at me when he said I had cancer,” said Felicity. “I had so many questions; ‘Am I going to lose my hair? Am I going to die?’ and all he could say was ‘I don’t know.’”
She went on to find a surgeon at Memorial Sloan Kettering Cancer Center who was able to work on a treatment plan with her. After opting for a lumpectomy, Felicity took the OncotypeDx test, a test that analyzes a group of genes to determine how a cancer is likely to behave and respond to treatment. The test came unclear whether the benefits of chemotherapy outweigh the risks of side effects. She was left to choose to forego or undergo treatment on her own.
While determining to enter the long road of chemotherapy, Felicity was also experiencing emotional hurdles that affect young women with breast cancer. She was planning on undergoing costly fertility preservation treatment, all while managing being in a young relationship.  Eventually she opted out of chemotherapy and instead underwent radiation and ovarian suppression. The latter forces the body into temporary menopause in order to decrease the amount of estrogen in the body, and as a result, lessens the chances of feeding the estrogen receptor-positive tumor. She is now on Tamoxifen for the next 10 years.
“Cancer’s not over when it’s over,” said Felicity. She has dealt with depression, sexual health problems, joint pain, hot flashes and many more side effects from treatment. She utilizes therapy and yoga to cope.
“I felt so alone throughout my process, until I made friends who had been through it. Regardless of how we went about it, or if our ideals are different, there is so much value in speaking to someone who ‘gets it.’”

Sharing her story nationwide
Shortly after her diagnosis and the beginning of treatment, Felicity joined the Young Survival Coalition, an organization dedicated to the critical issues unique to young women who are diagnosed with breast cancer. They put a call out on Facebook for survivors to participate in “Skin Wars,” a body-painting competition TV show on GSN that welcomes 12 new contestants to compete in weekly challenges for a shot at winning a prize package. Each week there is a different competition theme, and Felicity was chosen to participate in a special episode where the artists are asked to paint a representation of a survivor’s breast cancer journey using their body as a canvas.
As a women’s health advocate, particularly for metastatic research, Felicity used this as an opportunity to promote breast cancer awareness on a nationwide level.
“The best part about participating in 'Skin Wars' was meeting other girls [in the competition] who had been through it, too. It was lovely to spend the day with these young survivors, we felt connected,” Felicity said. “Even after just two days of filming there was a wonderful bond that brought us all together.”
Today, Felicity resides in New York City and focuses on sharing the stories and advocating on behalf of young women living with the disease and championing women’s rights through her documentary filmmaking and photography. 
 “The few things that I care about most post-breast cancer is showing the world that young women can and do get breast cancer,” said Felicity. “I want young women to see that there are people out there that can support you, and we can feel connected even when we feel isolated or depressed.”
The “Survive and Thrive” episode airs tonight on GSN 9:00pm.
 

# data[].attributes.metatag_normalized[].attributes.content
GSN’s “Skin Wars” Feature Young Breast Cancer Survivors on June 8

# data[].attributes.metatag_normalized[].attributes.content
Felicity was diagnosed with invasive estrogen-positive breast cancer on February 26, 2013, one week before her 29th birthday. She found a lump a few months prior and was referred to a doctor who was confident it was a benign cyst – that it could not be cancerous – because of her young age. After multiple tests, the result was positive.
“He didn’t look at me when he said I had cancer,” said Felicity. “I had so many questions; ‘Am I going to lose my hair? Am I going to die?’ and all he could say was ‘I don’t know.’”

# data[].attributes.metatag_normalized[].attributes.content
GSN’s “Skin Wars” Feature Young Breast Cancer Survivors on June 8

# data[].attributes.metatag_normalized[].attributes.content
BCRF sits down with participant Felicity to discuss how her experience inspired her to advocate for the young survivor community

# data[].attributes.metatag_normalized[].attributes.content
Felicity was diagnosed with invasive estrogen-positive breast cancer on February 26, 2013, one week before her 29th birthday. She found a lump a few months prior and was referred to a doctor who was confident it was a benign cyst – that it could not be cancerous – because of her young age. After multiple tests, the result was positive.
“He didn’t look at me when he said I had cancer,” said Felicity. “I had so many questions; ‘Am I going to lose my hair? Am I going to die?’ and all he could say was ‘I don’t know.’”

# data[].attributes.metatag_normalized[].attributes.content
GSN’s “Skin Wars” Feature Young Breast Cancer Survivors on June 8

# data[].attributes.body.value
Felicity was diagnosed with invasive estrogen-positive breast cancer on February 26, 2013, one week before her 29th birthday. She found a lump a few months prior and was referred to a doctor who was confident it was a benign cyst – that it could not be cancerous – because of her young age. After multiple tests, the result was positive.

“He didn’t look at me when he said I had cancer,” said Felicity. “I had so many questions; ‘Am I going to lose my hair? Am I going to die?’ and all he could say was ‘I don’t know.’”

She went on to find a surgeon at Memorial Sloan Kettering Cancer Center who was able to work on a treatment plan with her. After opting for a lumpectomy, Felicity took the OncotypeDx test, a test that analyzes a group of genes to determine how a cancer is likely to behave and respond to treatment. The test came unclear whether the benefits of chemotherapy outweigh the risks of side effects. She was left to choose to forego or undergo treatment on her own.

While determining to enter the long road of chemotherapy, Felicity was also experiencing emotional hurdles that affect young women with breast cancer. She was planning on undergoing costly fertility preservation treatment, all while managing being in a young relationship.  Eventually she opted out of chemotherapy and instead underwent radiation and ovarian suppression. The latter forces the body into temporary menopause in order to decrease the amount of estrogen in the body, and as a result, lessens the chances of feeding the estrogen receptor-positive tumor. She is now on Tamoxifen for the next 10 years.

“Cancer’s not over when it’s over,” said Felicity. She has dealt with depression, sexual health problems, joint pain, hot flashes and many more side effects from treatment. She utilizes therapy and yoga to cope.

“I felt so alone throughout my process, until I made friends who had been through it. Regardless of how we went about it, or if our ideals are different, there is so much value in speaking to someone who ‘gets it.’”

Sharing her story nationwide

Shortly after her diagnosis and the beginning of treatment, Felicity joined the Young Survival Coalition, an organization dedicated to the critical issues unique to young women who are diagnosed with breast cancer. They put a call out on Facebook for survivors to participate in “Skin Wars,” a body-painting competition TV show on GSN that welcomes 12 new contestants to compete in weekly challenges for a shot at winning a prize package. Each week there is a different competition theme, and Felicity was chosen to participate in a special episode where the artists are asked to paint a representation of a survivor’s breast cancer journey using their body as a canvas.

As a women’s health advocate, particularly for metastatic research, Felicity used this as an opportunity to promote breast cancer awareness on a nationwide level.

“The best part about participating in 'Skin Wars' was meeting other girls [in the competition] who had been through it, too. It was lovely to spend the day with these young survivors, we felt connected,” Felicity said. “Even after just two days of filming there was a wonderful bond that brought us all together.”

Today, Felicity resides in New York City and focuses on sharing the stories and advocating on behalf of young women living with the disease and championing women’s rights through her documentary filmmaking and photography.

“The few things that I care about most post-breast cancer is showing the world that young women can and do get breast cancer,” said Felicity. “I want young women to see that there are people out there that can support you, and we can feel connected even when we feel isolated or depressed.”

The “Survive and Thrive” episode airs tonight on GSN 9:00pm.

# data[].attributes.body.processed
Felicity was diagnosed with invasive estrogen-positive breast cancer on February 26, 2013, one week before her 29th birthday. She found a lump a few months prior and was referred to a doctor who was confident it was a benign cyst – that it could not be cancerous – because of her young age. After multiple tests, the result was positive.

“He didn’t look at me when he said I had cancer,” said Felicity. “I had so many questions; ‘Am I going to lose my hair? Am I going to die?’ and all he could say was ‘I don’t know.’”

She went on to find a surgeon at Memorial Sloan Kettering Cancer Center who was able to work on a treatment plan with her. After opting for a lumpectomy, Felicity took the OncotypeDx test, a test that analyzes a group of genes to determine how a cancer is likely to behave and respond to treatment. The test came unclear whether the benefits of chemotherapy outweigh the risks of side effects. She was left to choose to forego or undergo treatment on her own.

While determining to enter the long road of chemotherapy, Felicity was also experiencing emotional hurdles that affect young women with breast cancer. She was planning on undergoing costly fertility preservation treatment, all while managing being in a young relationship.  Eventually she opted out of chemotherapy and instead underwent radiation and ovarian suppression. The latter forces the body into temporary menopause in order to decrease the amount of estrogen in the body, and as a result, lessens the chances of feeding the estrogen receptor-positive tumor. She is now on Tamoxifen for the next 10 years.

“Cancer’s not over when it’s over,” said Felicity. She has dealt with depression, sexual health problems, joint pain, hot flashes and many more side effects from treatment. She utilizes therapy and yoga to cope.

“I felt so alone throughout my process, until I made friends who had been through it. Regardless of how we went about it, or if our ideals are different, there is so much value in speaking to someone who ‘gets it.’”

Sharing her story nationwide

Shortly after her diagnosis and the beginning of treatment, Felicity joined the Young Survival Coalition, an organization dedicated to the critical issues unique to young women who are diagnosed with breast cancer. They put a call out on Facebook for survivors to participate in “Skin Wars,” a body-painting competition TV show on GSN that welcomes 12 new contestants to compete in weekly challenges for a shot at winning a prize package. Each week there is a different competition theme, and Felicity was chosen to participate in a special episode where the artists are asked to paint a representation of a survivor’s breast cancer journey using their body as a canvas.

As a women’s health advocate, particularly for metastatic research, Felicity used this as an opportunity to promote breast cancer awareness on a nationwide level.

“The best part about participating in 'Skin Wars' was meeting other girls [in the competition] who had been through it, too. It was lovely to spend the day with these young survivors, we felt connected,” Felicity said. “Even after just two days of filming there was a wonderful bond that brought us all together.”

Today, Felicity resides in New York City and focuses on sharing the stories and advocating on behalf of young women living with the disease and championing women’s rights through her documentary filmmaking and photography.

“The few things that I care about most post-breast cancer is showing the world that young women can and do get breast cancer,” said Felicity. “I want young women to see that there are people out there that can support you, and we can feel connected even when we feel isolated or depressed.”

The “Survive and Thrive” episode airs tonight on GSN 9:00pm.

# data[].attributes.field_subtitle
BCRF sits down with participant Felicity to discuss how her experience inspired her to advocate for the young survivor community

# data[].attributes.title
All Heart On and Off the Ice: Pittsburgh Penguins Knock Breast Cancer Out of Play 

# data[].attributes.metatag_normalized[].attributes.content
All Heart On and Off the Ice: Pittsburgh Penguins Knock Breast Cancer Out of Play  | BCRF

# data[].attributes.metatag_normalized[].attributes.content
With the Stanley Cup in sight, the Breast Cancer Research Foundation (BCRF) is proudly cheering on the Pittsburgh Penguins as they head to game five in the final round of the playoffs. The NHL team, along with the Pittsburgh Penguins Foundation, are strong supporters of BCRF’s mission to advance lifesaving breast cancer research. Throughout the most recent season, the team and the Foundation have truly given back in a meaningful way.
On March 31, the inaugural “We Love Moms Night” raised a combined total of $250,000. The unique event paid tribute to all moms – especially hockey moms and women facing breast cancer.
“This is a great opportunity for all of us to salute moms and show them how much they mean to us,” said Dave Soltesz, President of the Pittsburgh Penguins Foundation.“ ‘We Love Moms Night’ provided an important platform to raise money for BCRF’s mission of funding the world’s most innovative breast cancer research.”
The evening gave fans at the CONSOL Energy Center exciting ways to get involved, including a silent auction for chances to win “Glam” items, specially produced Michael Kors canvas totes for the first 3,200 female fans and the ability to text donations with special messages to BCRF. Messages of love, support and well wishes flooded the jumbotron throughout the night.
The Pittsburgh Penguins Foundation has also stepped up with a grant to support BCRF’s millennial focused partner, The Pink Agenda, whose mission is to make breast cancer history as the Penguins make history on the ice.
The Pittsburgh community is rich in scientific excellence. Four BCRF investigators call Steel City home, including BCRF Scientific Advisory Board Member Dr. Nancy Davidson, Director of the University of Pittsburgh Cancer Institute (UPCI). Drs. Adrian Lee, Steffi Oesterreich and Thomas Kensler, also from UPCI, have been BCRF investigators for many years.
“I see how BCRF has touched our field. I see how it's touched individuals, and I know how grateful everybody is for the support that BCRF provides - both financial support and networking support,” said Pittsburgh-based BCRF researcher Dr. Nancy Davidson.
Cheer on the Pittsburgh Penguins quest for the Stanley Cup by making a donation in honor of a special woman in your life. Text your name and donation amount to 646-681-5166.

# data[].attributes.metatag_normalized[].attributes.content
All Heart On and Off the Ice: Pittsburgh Penguins Knock Breast Cancer Out of Play

# data[].attributes.metatag_normalized[].attributes.content
With the Stanley Cup in sight, the Breast Cancer Research Foundation (BCRF) is proudly cheering on the Pittsburgh Penguins as they head to game five in the final round of the playoffs. The NHL team, along with the Pittsburgh Penguins Foundation, are strong supporters of BCRF’s mission to advance lifesaving breast cancer research. Throughout the most recent season, the team and the Foundation have truly given back in a meaningful way.

# data[].attributes.metatag_normalized[].attributes.content
All Heart On and Off the Ice: Pittsburgh Penguins Knock Breast Cancer Out of Play

# data[].attributes.metatag_normalized[].attributes.content
Inaugural ‘We Love Moms Night’ raised $250,000 for breast cancer research

# data[].attributes.metatag_normalized[].attributes.content
With the Stanley Cup in sight, the Breast Cancer Research Foundation (BCRF) is proudly cheering on the Pittsburgh Penguins as they head to game five in the final round of the playoffs. The NHL team, along with the Pittsburgh Penguins Foundation, are strong supporters of BCRF’s mission to advance lifesaving breast cancer research. Throughout the most recent season, the team and the Foundation have truly given back in a meaningful way.

# data[].attributes.metatag_normalized[].attributes.content
All Heart On and Off the Ice: Pittsburgh Penguins Knock Breast Cancer Out of Play

# data[].attributes.body.value
With the Stanley Cup in sight, the Breast Cancer Research Foundation (BCRF) is proudly cheering on the Pittsburgh Penguins as they head to game five in the final round of the playoffs. The NHL team, along with the Pittsburgh Penguins Foundation, are strong supporters of BCRF’s mission to advance lifesaving breast cancer research. Throughout the most recent season, the team and the Foundation have truly given back in a meaningful way.

On March 31, the inaugural “We Love Moms Night” raised a combined total of $250,000. The unique event paid tribute to all moms – especially hockey moms and women facing breast cancer.

“This is a great opportunity for all of us to salute moms and show them how much they mean to us,” said Dave Soltesz, President of the Pittsburgh Penguins Foundation.“ ‘We Love Moms Night’ provided an important platform to raise money for BCRF’s mission of funding the world’s most innovative breast cancer research.”

The evening gave fans at the CONSOL Energy Center exciting ways to get involved, including a silent auction for chances to win “Glam” items, specially produced Michael Kors canvas totes for the first 3,200 female fans and the ability to text donations with special messages to BCRF. Messages of love, support and well wishes flooded the jumbotron throughout the night.

The Pittsburgh Penguins Foundation has also stepped up with a grant to support BCRF’s millennial focused partner, The Pink Agenda, whose mission is to make breast cancer history as the Penguins make history on the ice.

The Pittsburgh community is rich in scientific excellence. Four BCRF investigators call Steel City home, including BCRF Scientific Advisory Board Member Dr. Nancy Davidson, Director of the University of Pittsburgh Cancer Institute (UPCI). Drs. Adrian Lee, Steffi Oesterreich and Thomas Kensler, also from UPCI, have been BCRF investigators for many years.

“I see how BCRF has touched our field. I see how it's touched individuals, and I know how grateful everybody is for the support that BCRF provides - both financial support and networking support,” said Pittsburgh-based BCRF researcher Dr. Nancy Davidson.

Cheer on the Pittsburgh Penguins quest for the Stanley Cup by making a donation in honor of a special woman in your life. Text your name and donation amount to 646-681-5166.

# data[].attributes.body.processed
With the Stanley Cup in sight, the Breast Cancer Research Foundation (BCRF) is proudly cheering on the Pittsburgh Penguins as they head to game five in the final round of the playoffs. The NHL team, along with the Pittsburgh Penguins Foundation, are strong supporters of BCRF’s mission to advance lifesaving breast cancer research. Throughout the most recent season, the team and the Foundation have truly given back in a meaningful way.

On March 31, the inaugural “We Love Moms Night” raised a combined total of $250,000. The unique event paid tribute to all moms – especially hockey moms and women facing breast cancer.

“This is a great opportunity for all of us to salute moms and show them how much they mean to us,” said Dave Soltesz, President of the Pittsburgh Penguins Foundation.“ ‘We Love Moms Night’ provided an important platform to raise money for BCRF’s mission of funding the world’s most innovative breast cancer research.”

The evening gave fans at the CONSOL Energy Center exciting ways to get involved, including a silent auction for chances to win “Glam” items, specially produced Michael Kors canvas totes for the first 3,200 female fans and the ability to text donations with special messages to BCRF. Messages of love, support and well wishes flooded the jumbotron throughout the night.

The Pittsburgh Penguins Foundation has also stepped up with a grant to support BCRF’s millennial focused partner, The Pink Agenda, whose mission is to make breast cancer history as the Penguins make history on the ice.

The Pittsburgh community is rich in scientific excellence. Four BCRF investigators call Steel City home, including BCRF Scientific Advisory Board Member Dr. Nancy Davidson, Director of the University of Pittsburgh Cancer Institute (UPCI). Drs. Adrian Lee, Steffi Oesterreich and Thomas Kensler, also from UPCI, have been BCRF investigators for many years.

“I see how BCRF has touched our field. I see how it's touched individuals, and I know how grateful everybody is for the support that BCRF provides - both financial support and networking support,” said Pittsburgh-based BCRF researcher Dr. Nancy Davidson.

Cheer on the Pittsburgh Penguins quest for the Stanley Cup by making a donation in honor of a special woman in your life. Text your name and donation amount to 646-681-5166.

# data[].attributes.field_subtitle
Inaugural ‘We Love Moms Night’ raised $250,000 for breast cancer research 

# data[].attributes.title
VP Joe Biden Announces the Launch of National Genomic Data Commons as Part of Cancer Moonshot During Annual Meeting of the American Society for Clinical Oncology

# data[].attributes.metatag_normalized[].attributes.content
VP Joe Biden Announces the Launch of National Genomic Data Commons as Part of Cancer Moonshot During Annual Meeting of the American Society for Clinical Oncology | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Vice President Joe Biden addressed the ASCO membership during a special session of the ASCO Annual meeting in Chicago (June 3-7). Mr. Biden’s talk focused on the White House’s Cancer Moonshot Initiative. As in his earlier address at the AACR annual meeting in April, the Vice President emphasized the need for collaboration, data sharing and to rethink how we reward research and design clinical trials.
At the ASCO meeting, Mr. Biden announced a new initiative of the Moonshot- a National Genomic Data Commons (GDC) that will centralize, standardize and make accessible data from large-scale National Cancer Institute programs such as The Cancer Genome Atlas (TCGA) and its pediatric equivalent, Therapeutically Applicable Research to Generate Effective Treatments (TARGET), two of the largest and most comprehensive cancer genomics datasets in the world.
The genomic data housed within the GDC, representing thousands of patients and their tumors, will be managed by the University of Chicago Center for Data Intensive Science and will be accessible to researchers for studies to enhance understanding of which patients are most likely to respond to targeted therapies, accelerate new drug discovery and guide the clinical management of cancer on a more individualized basis.
Commenting on the hope of the CDA, NCI Acting-Director Douglas Lowy, MD. Said, “The explanatory power of data in the GDC will grow over time as data from more patients are included, and ultimately the GDC will accelerate our efforts in precision medicine.”

# data[].attributes.metatag_normalized[].attributes.content
VP Joe Biden Announces the Launch of National Genomic Data Commons as Part of Cancer Moonshot During Annual Meeting of the American Society for Clinical Oncology

# data[].attributes.metatag_normalized[].attributes.content
Vice President Joe Biden addressed the ASCO membership during a special session of the ASCO Annual meeting in Chicago (June 3-7). Mr. Biden’s talk focused on the White House’s Cancer Moonshot Initiative. As in his earlier address at the AACR annual meeting in April, the Vice President emphasized the need for collaboration, data sharing and to rethink how we reward research and design clinical trials.

# data[].attributes.metatag_normalized[].attributes.content
VP Joe Biden Announces the Launch of National Genomic Data Commons as Part of Cancer Moonshot During Annual Meeting of the American Society for Clinical Oncology

# data[].attributes.metatag_normalized[].attributes.content
National public database will facilitate cancer research and treatment and advance precision medicine.

# data[].attributes.metatag_normalized[].attributes.content
Vice President Joe Biden addressed the ASCO membership during a special session of the ASCO Annual meeting in Chicago (June 3-7). Mr. Biden’s talk focused on the White House’s Cancer Moonshot Initiative. As in his earlier address at the AACR annual meeting in April, the Vice President emphasized the need for collaboration, data sharing and to rethink how we reward research and design clinical trials.

# data[].attributes.metatag_normalized[].attributes.content
VP Joe Biden Announces the Launch of National Genomic Data Commons as Part of Cancer Moonshot During Annual Meeting of the American Society for Clinical Oncology

# data[].attributes.body.value
Vice President Joe Biden addressed the ASCO membership during a special session of the ASCO Annual meeting in Chicago (June 3-7). Mr. Biden’s talk focused on the White House’s Cancer Moonshot Initiative. As in his earlier address at the AACR annual meeting in April, the Vice President emphasized the need for collaboration, data sharing and to rethink how we reward research and design clinical trials.

At the ASCO meeting, Mr. Biden announced a new initiative of the Moonshot- a National Genomic Data Commons (GDC) that will centralize, standardize and make accessible data from large-scale National Cancer Institute programs such as The Cancer Genome Atlas (TCGA) and its pediatric equivalent, Therapeutically Applicable Research to Generate Effective Treatments (TARGET), two of the largest and most comprehensive cancer genomics datasets in the world.

The genomic data housed within the GDC, representing thousands of patients and their tumors, will be managed by the University of Chicago Center for Data Intensive Science and will be accessible to researchers for studies to enhance understanding of which patients are most likely to respond to targeted therapies, accelerate new drug discovery and guide the clinical management of cancer on a more individualized basis.

Commenting on the hope of the CDA, NCI Acting-Director Douglas Lowy, MD. Said, “The explanatory power of data in the GDC will grow over time as data from more patients are included, and ultimately the GDC will accelerate our efforts in precision medicine.”

# data[].attributes.body.processed
Vice President Joe Biden addressed the ASCO membership during a special session of the ASCO Annual meeting in Chicago (June 3-7). Mr. Biden’s talk focused on the White House’s Cancer Moonshot Initiative. As in his earlier address at the AACR annual meeting in April, the Vice President emphasized the need for collaboration, data sharing and to rethink how we reward research and design clinical trials.

At the ASCO meeting, Mr. Biden announced a new initiative of the Moonshot- a National Genomic Data Commons (GDC) that will centralize, standardize and make accessible data from large-scale National Cancer Institute programs such as The Cancer Genome Atlas (TCGA) and its pediatric equivalent, Therapeutically Applicable Research to Generate Effective Treatments (TARGET), two of the largest and most comprehensive cancer genomics datasets in the world.

The genomic data housed within the GDC, representing thousands of patients and their tumors, will be managed by the University of Chicago Center for Data Intensive Science and will be accessible to researchers for studies to enhance understanding of which patients are most likely to respond to targeted therapies, accelerate new drug discovery and guide the clinical management of cancer on a more individualized basis.

Commenting on the hope of the CDA, NCI Acting-Director Douglas Lowy, MD. Said, “The explanatory power of data in the GDC will grow over time as data from more patients are included, and ultimately the GDC will accelerate our efforts in precision medicine.”

# data[].attributes.field_subtitle
National public database will facilitate cancer research and treatment and advance precision medicine.

# data[].attributes.title
American Society of Clinical Oncology hosts 54th Annual Meeting in Chicago

# data[].attributes.metatag_normalized[].attributes.content
American Society of Clinical Oncology hosts 54th Annual Meeting in Chicago | BCRF

# data[].attributes.metatag_normalized[].attributes.content
The American Society of Clinical Oncology hosted its 54th annual meeting in Chicago, June 3- 6. The ASCO annual meeting is the largest oncology meeting in the world and this year hosted more than 36,000 cancer care physicians, medical professionals, patient advocates and industry representatives. The theme of this year’s meeting was "Collective Wisdom: The Future of Patient-centered Care and Research." In her opening address, ASCO president, Julie Vose, MD, MBA, FASCO emphasized the need to bring together the collective wisdom of multidisciplinary teams to help patients and their families and for research to be centered on improving patient care. 
More than 80 BCRF investigators attended the meeting to serve as session chairs, give podium talks on critical topics in breast cancer, or present data in one or more of the five posters sessions throughout the four and a half day meeting. BCRF was also recognized for it's longtime support of young scientists through its partnership with the Conquer Cancer Foundation. 
Here are key highlights of new breast cancer research studies reported at ASCO:

Treatment for Early Stage Breast Cancer
Treatment for Advanced Breast Cancer  
Prevention
Survivorship and Quality of Life

# data[].attributes.metatag_normalized[].attributes.content
American Society of Clinical Oncology hosts 54th Annual Meeting in Chicago

# data[].attributes.metatag_normalized[].attributes.content
The American Society of Clinical Oncology hosted its 54th annual meeting in Chicago, June 3- 6. The ASCO annual meeting is the largest oncology meeting in the world and this year hosted more than 36,000 cancer care physicians, medical professionals, patient advocates and industry representatives.

# data[].attributes.metatag_normalized[].attributes.content
American Society of Clinical Oncology hosts 54th Annual Meeting in Chicago

# data[].attributes.metatag_normalized[].attributes.content
BCRF presents breast cancer research highlights from ASCO’s Annual Meeting focusing on Collective Wisdom and the Future of Patient- Centered Care and Research

# data[].attributes.metatag_normalized[].attributes.content
The American Society of Clinical Oncology hosted its 54th annual meeting in Chicago, June 3- 6. The ASCO annual meeting is the largest oncology meeting in the world and this year hosted more than 36,000 cancer care physicians, medical professionals, patient advocates and industry representatives.

# data[].attributes.metatag_normalized[].attributes.content
American Society of Clinical Oncology hosts 54th Annual Meeting in Chicago

# data[].attributes.body.value
The American Society of Clinical Oncology hosted its 54th annual meeting in Chicago, June 3- 6. The ASCO annual meeting is the largest oncology meeting in the world and this year hosted more than 36,000 cancer care physicians, medical professionals, patient advocates and industry representatives. The theme of this year’s meeting was "Collective Wisdom: The Future of Patient-centered Care and Research." In her opening address, ASCO president, Julie Vose, MD, MBA, FASCO emphasized the need to bring together the collective wisdom of multidisciplinary teams to help patients and their families and for research to be centered on improving patient care.

More than 80 BCRF investigators attended the meeting to serve as session chairs, give podium talks on critical topics in breast cancer, or present data in one or more of the five posters sessions throughout the four and a half day meeting. BCRF was also recognized for it's longtime support of young scientists through its partnership with the Conquer Cancer Foundation.

Here are key highlights of new breast cancer research studies reported at ASCO:

Treatment for Early Stage Breast Cancer

Treatment for Advanced Breast Cancer

Prevention

Survivorship and Quality of Life

# data[].attributes.body.processed
The American Society of Clinical Oncology hosted its 54th annual meeting in Chicago, June 3- 6. The ASCO annual meeting is the largest oncology meeting in the world and this year hosted more than 36,000 cancer care physicians, medical professionals, patient advocates and industry representatives. The theme of this year’s meeting was "Collective Wisdom: The Future of Patient-centered Care and Research." In her opening address, ASCO president, Julie Vose, MD, MBA, FASCO emphasized the need to bring together the collective wisdom of multidisciplinary teams to help patients and their families and for research to be centered on improving patient care.

More than 80 BCRF investigators attended the meeting to serve as session chairs, give podium talks on critical topics in breast cancer, or present data in one or more of the five posters sessions throughout the four and a half day meeting. BCRF was also recognized for it's longtime support of young scientists through its partnership with the Conquer Cancer Foundation.

Here are key highlights of new breast cancer research studies reported at ASCO:

Treatment for Early Stage Breast Cancer

Treatment for Advanced Breast Cancer

Prevention

Survivorship and Quality of Life

# data[].attributes.field_caption
This year's meeting was themed Collective Wisdom: The Future of Patient-centered Care and Research

# data[].attributes.field_subtitle
BCRF presents breast cancer research highlights from ASCO’s Annual Meeting focusing on Collective Wisdom and the Future of Patient- Centered Care and Research

# data[].attributes.title
ASCO Highlights: Breast Cancer Prevention

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Prevention | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Ten Years of Hormone Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life  
Estrogen receptor (ER+) positive breast cancer is the most common form of breast cancer and when treated early has a 95% survival rate at five years. However, this disease can recur 10-20 years after diagnosis and successful treatment. Endocrine therapies – tamoxifen and aromatase inhibitors (AIs) have been shown to reduce the risk of recurrence of ER-positive breast cancer when therapy is continued for five years. Long-term studies are now showing that 10 years of endocrine therapy can further reduce risk. 
The MA.17R study was a double-blind, placebo-controlled trial to test the effectiveness of extending aromatase inhibitor (AI) treatment for an additional five years using letrozole. The trial included three cohorts of post-menopausal women with early stage ER-positive breast cancer, two of which had received prior tamoxifen and one that had no prior tamoxifen therapy. All patients had received four to six years of AI therapy. A total of 1,918 women were randomly assigned to receive either extended letrozole or placebo for an additional five years, for a total of ten years AI therapy. Median follow-up was 75 months (6.3 years). Presenting at the plenary session, Dr. Paul E. Goss (Massachusetts General Hospital) reported a significant decrease incidence of contralateral breast cancer in the extended letrozole group compared to placebo. There was no difference in overall survival, however, as an equal number of women, 100 in each group, died from their disease during the follow up period. In a separate quality of life analysis, there were no differences in quality of life between the two groups. 
In a press conference announcing the study results, Dr. Harold Burstein (Dana Farber Cancer Institute) noted “there will be tremendous interest in longer duration of AI therapy, but it will most likely be tailored to specific patient risk factors.” Discussant for the study Dr. Ian Smith (Royal Marsden Hospital, UK) commented that the difference in disease free survival (DFS) between the groups was 1.1%, but was nonetheless optimistic that the extended AI therapy could provide added benefit for women who were able to manage the side effects. 
The study results stimulated significant discussion on recommendations of extending AI therapy, with some in the audience feeling that the benefit did not outweigh the associated costs of AI- associated side effects, including increased risk of osteoporosis and bone fracture. Commenting in The New York Times, BCRF investigators Drs. Eric Winer and Lisa Carey present a cautious view of the study results emphasizing the need to consider patient risks, preferences and side effect tolerance. The study was conducted by the Canadian Cancer Trials Group in collaboration with US National Clinical Trials network. BCRF investigators Drs. Lois Shepherd, James Ingle, Hyman Muss, Julie Gralow, Antonio Wolff, Clifford Hudis and Eric Winer were co-authors on the study. 
Minority BRCA-Positive Breast Cancer Survivors Appear Less Likely to Receive Preventive Surgery
According to the National Cancer Institute, a woman with a BRCA mutation has an increased risk of breast and ovarian cancer by 45-65 percent and 20-40 percent, respectively. Prophylactic mastectomy and/or oophorectomy is recommended for BRCA mutation carriers and can dramatically reduce that risk of breast or ovarian cancer. An interim analysis of a study in a racially diverse group of more than 1,600 women found that African American women were significantly less likely to receive preventive surgery than White or Hispanic women. While acknowledging some limitations of the study, lead author, Dr. Tuya Pal (Lee Moffitt Cancer Center) commented in the ASCO Post, “It is imperative to understand why these disparities exist, so we can develop interventions to ensure that women with inherited disease make informed decisions about their cancer risk management. Listen to an interview of Dr. Pal with BCRF investigator, Lisa Carey here.

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Prevention

# data[].attributes.metatag_normalized[].attributes.content
Ten Years of Hormone Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life  

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Prevention

# data[].attributes.metatag_normalized[].attributes.content
Two new studies highlight the prevention of recurrence

# data[].attributes.metatag_normalized[].attributes.content
Ten Years of Hormone Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life  

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Prevention

# data[].attributes.body.value
Ten Years of Hormone Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life

Estrogen receptor (ER+) positive breast cancer is the most common form of breast cancer and when treated early has a 95% survival rate at five years. However, this disease can recur 10-20 years after diagnosis and successful treatment. Endocrine therapies – tamoxifen and aromatase inhibitors (AIs) have been shown to reduce the risk of recurrence of ER-positive breast cancer when therapy is continued for five years. Long-term studies are now showing that 10 years of endocrine therapy can further reduce risk.

The MA.17R study was a double-blind, placebo-controlled trial to test the effectiveness of extending aromatase inhibitor (AI) treatment for an additional five years using letrozole. The trial included three cohorts of post-menopausal women with early stage ER-positive breast cancer, two of which had received prior tamoxifen and one that had no prior tamoxifen therapy. All patients had received four to six years of AI therapy. A total of 1,918 women were randomly assigned to receive either extended letrozole or placebo for an additional five years, for a total of ten years AI therapy. Median follow-up was 75 months (6.3 years). Presenting at the plenary session, Dr. Paul E. Goss (Massachusetts General Hospital) reported a significant decrease incidence of contralateral breast cancer in the extended letrozole group compared to placebo. There was no difference in overall survival, however, as an equal number of women, 100 in each group, died from their disease during the follow up period. In a separate quality of life analysis, there were no differences in quality of life between the two groups.

In a press conference announcing the study results, Dr. Harold Burstein (Dana Farber Cancer Institute) noted “there will be tremendous interest in longer duration of AI therapy, but it will most likely be tailored to specific patient risk factors.” Discussant for the study Dr. Ian Smith (Royal Marsden Hospital, UK) commented that the difference in disease free survival (DFS) between the groups was 1.1%, but was nonetheless optimistic that the extended AI therapy could provide added benefit for women who were able to manage the side effects.

The study results stimulated significant discussion on recommendations of extending AI therapy, with some in the audience feeling that the benefit did not outweigh the associated costs of AI- associated side effects, including increased risk of osteoporosis and bone fracture. Commenting in The New York Times, BCRF investigators Drs. Eric Winer and Lisa Carey present a cautious view of the study results emphasizing the need to consider patient risks, preferences and side effect tolerance. The study was conducted by the Canadian Cancer Trials Group in collaboration with US National Clinical Trials network. BCRF investigators Drs. Lois Shepherd, James Ingle, Hyman Muss, Julie Gralow, Antonio Wolff, Clifford Hudis and Eric Winer were co-authors on the study.

Minority BRCA-Positive Breast Cancer Survivors Appear Less Likely to Receive Preventive Surgery

According to the National Cancer Institute, a woman with a BRCA mutation has an increased risk of breast and ovarian cancer by 45-65 percent and 20-40 percent, respectively. Prophylactic mastectomy and/or oophorectomy is recommended for BRCA mutation carriers and can dramatically reduce that risk of breast or ovarian cancer. An interim analysis of a study in a racially diverse group of more than 1,600 women found that African American women were significantly less likely to receive preventive surgery than White or Hispanic women. While acknowledging some limitations of the study, lead author, Dr. Tuya Pal (Lee Moffitt Cancer Center) commented in the ASCO Post, “It is imperative to understand why these disparities exist, so we can develop interventions to ensure that women with inherited disease make informed decisions about their cancer risk management. Listen to an interview of Dr. Pal with BCRF investigator, Lisa Carey here.

# data[].attributes.body.processed
Ten Years of Hormone Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life

Estrogen receptor (ER+) positive breast cancer is the most common form of breast cancer and when treated early has a 95% survival rate at five years. However, this disease can recur 10-20 years after diagnosis and successful treatment. Endocrine therapies – tamoxifen and aromatase inhibitors (AIs) have been shown to reduce the risk of recurrence of ER-positive breast cancer when therapy is continued for five years. Long-term studies are now showing that 10 years of endocrine therapy can further reduce risk.

The MA.17R study was a double-blind, placebo-controlled trial to test the effectiveness of extending aromatase inhibitor (AI) treatment for an additional five years using letrozole. The trial included three cohorts of post-menopausal women with early stage ER-positive breast cancer, two of which had received prior tamoxifen and one that had no prior tamoxifen therapy. All patients had received four to six years of AI therapy. A total of 1,918 women were randomly assigned to receive either extended letrozole or placebo for an additional five years, for a total of ten years AI therapy. Median follow-up was 75 months (6.3 years). Presenting at the plenary session, Dr. Paul E. Goss (Massachusetts General Hospital) reported a significant decrease incidence of contralateral breast cancer in the extended letrozole group compared to placebo. There was no difference in overall survival, however, as an equal number of women, 100 in each group, died from their disease during the follow up period. In a separate quality of life analysis, there were no differences in quality of life between the two groups.

In a press conference announcing the study results, Dr. Harold Burstein (Dana Farber Cancer Institute) noted “there will be tremendous interest in longer duration of AI therapy, but it will most likely be tailored to specific patient risk factors.” Discussant for the study Dr. Ian Smith (Royal Marsden Hospital, UK) commented that the difference in disease free survival (DFS) between the groups was 1.1%, but was nonetheless optimistic that the extended AI therapy could provide added benefit for women who were able to manage the side effects.

The study results stimulated significant discussion on recommendations of extending AI therapy, with some in the audience feeling that the benefit did not outweigh the associated costs of AI- associated side effects, including increased risk of osteoporosis and bone fracture. Commenting in The New York Times, BCRF investigators Drs. Eric Winer and Lisa Carey present a cautious view of the study results emphasizing the need to consider patient risks, preferences and side effect tolerance. The study was conducted by the Canadian Cancer Trials Group in collaboration with US National Clinical Trials network. BCRF investigators Drs. Lois Shepherd, James Ingle, Hyman Muss, Julie Gralow, Antonio Wolff, Clifford Hudis and Eric Winer were co-authors on the study.

Minority BRCA-Positive Breast Cancer Survivors Appear Less Likely to Receive Preventive Surgery

According to the National Cancer Institute, a woman with a BRCA mutation has an increased risk of breast and ovarian cancer by 45-65 percent and 20-40 percent, respectively. Prophylactic mastectomy and/or oophorectomy is recommended for BRCA mutation carriers and can dramatically reduce that risk of breast or ovarian cancer. An interim analysis of a study in a racially diverse group of more than 1,600 women found that African American women were significantly less likely to receive preventive surgery than White or Hispanic women. While acknowledging some limitations of the study, lead author, Dr. Tuya Pal (Lee Moffitt Cancer Center) commented in the ASCO Post, “It is imperative to understand why these disparities exist, so we can develop interventions to ensure that women with inherited disease make informed decisions about their cancer risk management. Listen to an interview of Dr. Pal with BCRF investigator, Lisa Carey here.

# data[].attributes.field_subtitle
Two new studies highlight the prevention of recurrence

# data[].attributes.title
Husband Takes On Nationwide 3,000-Mile Bicycle Race For BCRF 

# data[].attributes.metatag_normalized[].attributes.content
Husband Takes On Nationwide 3,000-Mile Bicycle Race For BCRF  | BCRF

# data[].attributes.metatag_normalized[].attributes.content
When Ray Brown’s wife Tammy was diagnosed with breast cancer last October he immediately wanted to do something to advance breast cancer research. An avid endurance cyclist, he decided to participate in the epic Race Across America (RAAM) – a 3,065-mile, 12-day race spanning from California to Maryland to support BCRF.
“Tammy is pretty independent, stubborn and strong willed, so I said to myself, what can I do to help? And it hit me: raise some money so we can kick this nasty big C,” he said describing why he decided to participate.
“BCRF was the only choice since darn near every dollar goes to research.”

This isn’t the first time the 58-year-old retired business executive took on a challenge for BCRF. In January he prepared for his upcoming RAAM race by biking 1,000 miles on Zwift, a virtual software training tool, and raised nearly $3,000 for BCRF.
Beginning June 14, he will be accompanied by a crew of seven, including his wife, as he tackles this nationwide journey solo. It’s a challenge few have achieved. The route is usually done by relay teams who take turns cycling each leg of the race.
“The failure rate is an astronomical – 72 percent – but I have ridden 50,000 miles in preparation,” he said.
Still, Brown is determined to finish the incredible feat. He has even sponsored 52 time stations that will “go pink” throughout the race, distributing BCRF brochures, bracelets and ribbons. He hopes his efforts will encourage others to get their annual mammograms, speak with their doctors if they experience any changes in their breasts and understand the power of research.
“My wife has since had a successful surgery and radiation treatments and we are optimistic she is cancer-free,” he said. “Others aren’t so fortunate.”
Support Ray and his efforts to #BeTheEnd of breast cancer. Donate to his ride today! Every dollar counts. 

# data[].attributes.metatag_normalized[].attributes.content
Husband Takes On Nationwide 3,000-Mile Bicycle Race For BCRF

# data[].attributes.metatag_normalized[].attributes.content
When Ray Brown’s wife Tammy was diagnosed with breast cancer last October he immediately wanted to do something to advance breast cancer research. An avid endurance cyclist, he decided to participate in the epic Race Across America (RAAM) – a 3,065-mile, 12-day race spanning from California to Maryland to support BCRF.

# data[].attributes.metatag_normalized[].attributes.content
Husband Takes On Nationwide 3,000-Mile Bicycle Race For BCRF

# data[].attributes.metatag_normalized[].attributes.content
Ray Brown will attempt to cycle across the nation in 12 days to honor his wife, a breast cancer survivor

# data[].attributes.metatag_normalized[].attributes.content
When Ray Brown’s wife Tammy was diagnosed with breast cancer last October he immediately wanted to do something to advance breast cancer research. An avid endurance cyclist, he decided to participate in the epic Race Across America (RAAM) – a 3,065-mile, 12-day race spanning from California to Maryland to support BCRF.

# data[].attributes.metatag_normalized[].attributes.content
Husband Takes On Nationwide 3,000-Mile Bicycle Race For BCRF

# data[].attributes.body.value
When Ray Brown’s wife Tammy was diagnosed with breast cancer last October he immediately wanted to do something to advance breast cancer research. An avid endurance cyclist, he decided to participate in the epic Race Across America (RAAM) – a 3,065-mile, 12-day race spanning from California to Maryland to support BCRF.

“Tammy is pretty independent, stubborn and strong willed, so I said to myself, what can I do to help? And it hit me: raise some money so we can kick this nasty big C,” he said describing why he decided to participate.

“BCRF was the only choice since darn near every dollar goes to research.”

This isn’t the first time the 58-year-old retired business executive took on a challenge for BCRF. In January he prepared for his upcoming RAAM race by biking 1,000 miles on Zwift, a virtual software training tool, and raised nearly $3,000 for BCRF.

Beginning June 14, he will be accompanied by a crew of seven, including his wife, as he tackles this nationwide journey solo. It’s a challenge few have achieved. The route is usually done by relay teams who take turns cycling each leg of the race.

“The failure rate is an astronomical – 72 percent – but I have ridden 50,000 miles in preparation,” he said.

Still, Brown is determined to finish the incredible feat. He has even sponsored 52 time stations that will “go pink” throughout the race, distributing BCRF brochures, bracelets and ribbons. He hopes his efforts will encourage others to get their annual mammograms, speak with their doctors if they experience any changes in their breasts and understand the power of research.

“My wife has since had a successful surgery and radiation treatments and we are optimistic she is cancer-free,” he said. “Others aren’t so fortunate.”

Support Ray and his efforts to #BeTheEnd of breast cancer. Donate to his ride today! Every dollar counts.

# data[].attributes.body.processed
When Ray Brown’s wife Tammy was diagnosed with breast cancer last October he immediately wanted to do something to advance breast cancer research. An avid endurance cyclist, he decided to participate in the epic Race Across America (RAAM) – a 3,065-mile, 12-day race spanning from California to Maryland to support BCRF.

“Tammy is pretty independent, stubborn and strong willed, so I said to myself, what can I do to help? And it hit me: raise some money so we can kick this nasty big C,” he said describing why he decided to participate.

“BCRF was the only choice since darn near every dollar goes to research.”

This isn’t the first time the 58-year-old retired business executive took on a challenge for BCRF. In January he prepared for his upcoming RAAM race by biking 1,000 miles on Zwift, a virtual software training tool, and raised nearly $3,000 for BCRF.

Beginning June 14, he will be accompanied by a crew of seven, including his wife, as he tackles this nationwide journey solo. It’s a challenge few have achieved. The route is usually done by relay teams who take turns cycling each leg of the race.

“The failure rate is an astronomical – 72 percent – but I have ridden 50,000 miles in preparation,” he said.

Still, Brown is determined to finish the incredible feat. He has even sponsored 52 time stations that will “go pink” throughout the race, distributing BCRF brochures, bracelets and ribbons. He hopes his efforts will encourage others to get their annual mammograms, speak with their doctors if they experience any changes in their breasts and understand the power of research.

“My wife has since had a successful surgery and radiation treatments and we are optimistic she is cancer-free,” he said. “Others aren’t so fortunate.”

Support Ray and his efforts to #BeTheEnd of breast cancer. Donate to his ride today! Every dollar counts.

# data[].attributes.field_subtitle
Ray Brown will attempt to cycle across the nation in 12 days to honor his wife, a breast cancer survivor

# data[].attributes.title
ASCO Highlights: Survivorship and Quality of Life After Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Survivorship and Quality of Life After Breast Cancer | BCRF

# data[].attributes.metatag_normalized[].attributes.content
There are over 3.1 million breast cancer survivors in the United States, and this number is projected to increase to more than four million by 2024. Caring for this population is fraught with both clinical and economic challenges including managing side effects of long-term treatment and preventive therapies and their associated costs. According to data presented by Dr. Beverly Moy (Massachusetts General Hospital Cancer Center) in an educational session on strategies to improve survivorship care, the cost of breast cancer survivorship care was $8 billion in 2014, more than all other cancers combined.  While breast cancer survivors are living longer, they are living with the long-term effects of curative therapies and a chronic risk of recurrence.
In December 2015, ASCO and the American Cancer Society jointly published the Breast Cancer Survivorship Care Guidelines to help physicians care for patients after therapy. The guidelines were developed by a multidisciplinary team that included BCRF investigators Drs. Arti Hurria and Patricia Ganz and included recommendations for assessment and management of physical and psychosocial long-term and late effects of breast cancer and treatment. 
Dr. Moy pointed out that in spite of ongoing survivorship initiatives by many cancer organizations and recommendations for survivorship care plans, little progress has been made on implementing these recommendations consistently across cancer care centers. Several care models have been developed that differ by amount of time, infrastructure and resources required. Implementation is hampered by insufficient staff, funding and resources at many cancer care centers, as well as lack of evidence of their effectiveness on patient outcomes and quality of life.
Endocrine therapies are very effective in both treating cancer, as well as reducing the risk of it returning. Because of the strong data from prevention studies, endocrine therapies (tamoxifen and aromatase inhibitors (AIs)) may be prescribed for five years or more, but their anti-estrogenic effects as well as effects on bone make long-term use intolerable for many women. BCRF investigator Dr. Debra Barton recommended the following steps that oncologists can take to improve patient adherence to endocrine therapies:

Educate patients from the start about what kind of symptoms to expect so they can make an informed decision based on the side effects they feel they can tolerate.
Be proactive about symptom management and switch therapies, if needed.
Encourage patients to exercise and provide tools to help them increase daily exercise levels.

Side effects of treatment are a major reason women discontinue their prescribed endocrine therapy. Because they block the effects or production of estrogen, endocrine therapies may cause menopause-like symptoms, which differ somewhat between tamoxifen and aromatase inhibitors (AIs), but include hot flashes, vaginal dryness, joint pain and fatigue.
Studies suggest that for some women, short-term, a low dose anti-depressant in combination with sustained cognitive behavioral therapy may reduce the discomfort of hot flashes, while limited evidence exists to support the use of dietary supplements including soy, vitamin E, black cohosh, magnesium or flaxseed. To treat vaginal dryness, Dr. Barton suggested vaginal moisturizers over lubricants as they have a more lasting effect. Lubricants that contain glycerin, she noted, can cause vaginal yeast infections.
Additionally, she cautioned against the used of low-dose vaginal estrogens. In spite of evidence that the estrogen exposure did not increase cancer risk, long-term prospective studies on safety are lacking, particularly in women taking aromatase inhibitors. Vaginal testosterone has been shown to improve symptoms, albeit with androgen-associated side effects such as hair growth and acne. Dr. Barton’s group has studied the use of DHEA – a natural precursor to estrogen and androgen. Her studies, which will be published soon, showed that nightly use of a DHEA-containing cream over 12 weeks significantly improved vaginal dryness compared to moisturizers.
Studies of interventions for joint pain do not support the use of non-steroidal anti-inflammatories (NSAIDS) or omega 3 fatty acids; however, one small study found that glucosamine with chondroitin improved symptoms in 39/56 patients studied. While there is evidence that low Vitamin D levels are associated with joint pain, randomized controlled clinical trials of vitamin D supplementation have had mixed results. Acupuncture and exercise have been shownin small studies to improve AI-induced joint pain.
Dr. William Gradishar finished the session with a discussion on the role of bone modulating agents for symptom management in breast cancer. Chemotherapy can have direct effects on bone as well as estrogen metabolism and production, which further impacts bone mineral density, increasing the risk of fracture. Radiation therapy and hormonal therapy, particularly aromatase inhibitors, also weaken bones directly and indirectly. In pre-menopausal breast cancer patients, an ovarian suppressing agent may be used in combination with endocrine therapy to reduce estrogen production – also affecting bone health. Bisphosphonates and a targeted therapy called denosumab have been shown to reduce fractures in these patients and have also been used in patients with advanced breast cancer who are at a high risk of fracture and bone metastasis.
The effects of cancer treatment can linger long after treatment ends.  Patients should discuss lingering side effects with their oncologists to ensure they recieve appropriate care for symptom management. 

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Survivorship and Quality of Life After Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
There are over 3.1 million breast cancer survivors in the United States, and this number is projected to increase to more than four million by 2024. Caring for this population is fraught with both clinical and economic challenges including managing side effects of long-term treatment and preventive therapies and their associated costs. According to data presented by Dr.

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Survivorship and Quality of Life After Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
There are over 3.1 million breast cancer survivors in the United States, and this number is projected to increase to more than four million by 2024. Caring for this population is fraught with both clinical and economic challenges including managing side effects of long-term treatment and preventive therapies and their associated costs. According to data presented by Dr.

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Survivorship and Quality of Life After Breast Cancer

# data[].attributes.body.value
There are over 3.1 million breast cancer survivors in the United States, and this number is projected to increase to more than four million by 2024. Caring for this population is fraught with both clinical and economic challenges including managing side effects of long-term treatment and preventive therapies and their associated costs. According to data presented by Dr. Beverly Moy (Massachusetts General Hospital Cancer Center) in an educational session on strategies to improve survivorship care, the cost of breast cancer survivorship care was $8 billion in 2014, more than all other cancers combined.  While breast cancer survivors are living longer, they are living with the long-term effects of curative therapies and a chronic risk of recurrence.

In December 2015, ASCO and the American Cancer Society jointly published the Breast Cancer Survivorship Care Guidelines to help physicians care for patients after therapy. The guidelines were developed by a multidisciplinary team that included BCRF investigators Drs. Arti Hurria and Patricia Ganz and included recommendations for assessment and management of physical and psychosocial long-term and late effects of breast cancer and treatment.

Dr. Moy pointed out that in spite of ongoing survivorship initiatives by many cancer organizations and recommendations for survivorship care plans, little progress has been made on implementing these recommendations consistently across cancer care centers. Several care models have been developed that differ by amount of time, infrastructure and resources required. Implementation is hampered by insufficient staff, funding and resources at many cancer care centers, as well as lack of evidence of their effectiveness on patient outcomes and quality of life.

Endocrine therapies are very effective in both treating cancer, as well as reducing the risk of it returning. Because of the strong data from prevention studies, endocrine therapies (tamoxifen and aromatase inhibitors (AIs)) may be prescribed for five years or more, but their anti-estrogenic effects as well as effects on bone make long-term use intolerable for many women. BCRF investigator Dr. Debra Barton recommended the following steps that oncologists can take to improve patient adherence to endocrine therapies:

Educate patients from the start about what kind of symptoms to expect so they can make an informed decision based on the side effects they feel they can tolerate.

Be proactive about symptom management and switch therapies, if needed.

Encourage patients to exercise and provide tools to help them increase daily exercise levels.

Side effects of treatment are a major reason women discontinue their prescribed endocrine therapy. Because they block the effects or production of estrogen, endocrine therapies may cause menopause-like symptoms, which differ somewhat between tamoxifen and aromatase inhibitors (AIs), but include hot flashes, vaginal dryness, joint pain and fatigue.

Studies suggest that for some women, short-term, a low dose anti-depressant in combination with sustained cognitive behavioral therapy may reduce the discomfort of hot flashes, while limited evidence exists to support the use of dietary supplements including soy, vitamin E, black cohosh, magnesium or flaxseed. To treat vaginal dryness, Dr. Barton suggested vaginal moisturizers over lubricants as they have a more lasting effect. Lubricants that contain glycerin, she noted, can cause vaginal yeast infections.

Additionally, she cautioned against the used of low-dose vaginal estrogens. In spite of evidence that the estrogen exposure did not increase cancer risk, long-term prospective studies on safety are lacking, particularly in women taking aromatase inhibitors. Vaginal testosterone has been shown to improve symptoms, albeit with androgen-associated side effects such as hair growth and acne. Dr. Barton’s group has studied the use of DHEA – a natural precursor to estrogen and androgen. Her studies, which will be published soon, showed that nightly use of a DHEA-containing cream over 12 weeks significantly improved vaginal dryness compared to moisturizers.

Studies of interventions for joint pain do not support the use of non-steroidal anti-inflammatories (NSAIDS) or omega 3 fatty acids; however, one small study found that glucosamine with chondroitin improved symptoms in 39/56 patients studied. While there is evidence that low Vitamin D levels are associated with joint pain, randomized controlled clinical trials of vitamin D supplementation have had mixed results. Acupuncture and exercise have been shownin small studies to improve AI-induced joint pain.

Dr. William Gradishar finished the session with a discussion on the role of bone modulating agents for symptom management in breast cancer. Chemotherapy can have direct effects on bone as well as estrogen metabolism and production, which further impacts bone mineral density, increasing the risk of fracture. Radiation therapy and hormonal therapy, particularly aromatase inhibitors, also weaken bones directly and indirectly. In pre-menopausal breast cancer patients, an ovarian suppressing agent may be used in combination with endocrine therapy to reduce estrogen production – also affecting bone health. Bisphosphonates and a targeted therapy called denosumab have been shown to reduce fractures in these patients and have also been used in patients with advanced breast cancer who are at a high risk of fracture and bone metastasis.

The effects of cancer treatment can linger long after treatment ends.  Patients should discuss lingering side effects with their oncologists to ensure they recieve appropriate care for symptom management.

# data[].attributes.body.processed
There are over 3.1 million breast cancer survivors in the United States, and this number is projected to increase to more than four million by 2024. Caring for this population is fraught with both clinical and economic challenges including managing side effects of long-term treatment and preventive therapies and their associated costs. According to data presented by Dr. Beverly Moy (Massachusetts General Hospital Cancer Center) in an educational session on strategies to improve survivorship care, the cost of breast cancer survivorship care was $8 billion in 2014, more than all other cancers combined.  While breast cancer survivors are living longer, they are living with the long-term effects of curative therapies and a chronic risk of recurrence.

In December 2015, ASCO and the American Cancer Society jointly published the Breast Cancer Survivorship Care Guidelines to help physicians care for patients after therapy. The guidelines were developed by a multidisciplinary team that included BCRF investigators Drs. Arti Hurria and Patricia Ganz and included recommendations for assessment and management of physical and psychosocial long-term and late effects of breast cancer and treatment.

Dr. Moy pointed out that in spite of ongoing survivorship initiatives by many cancer organizations and recommendations for survivorship care plans, little progress has been made on implementing these recommendations consistently across cancer care centers. Several care models have been developed that differ by amount of time, infrastructure and resources required. Implementation is hampered by insufficient staff, funding and resources at many cancer care centers, as well as lack of evidence of their effectiveness on patient outcomes and quality of life.

Endocrine therapies are very effective in both treating cancer, as well as reducing the risk of it returning. Because of the strong data from prevention studies, endocrine therapies (tamoxifen and aromatase inhibitors (AIs)) may be prescribed for five years or more, but their anti-estrogenic effects as well as effects on bone make long-term use intolerable for many women. BCRF investigator Dr. Debra Barton recommended the following steps that oncologists can take to improve patient adherence to endocrine therapies:

Educate patients from the start about what kind of symptoms to expect so they can make an informed decision based on the side effects they feel they can tolerate.

Be proactive about symptom management and switch therapies, if needed.

Encourage patients to exercise and provide tools to help them increase daily exercise levels.

Side effects of treatment are a major reason women discontinue their prescribed endocrine therapy. Because they block the effects or production of estrogen, endocrine therapies may cause menopause-like symptoms, which differ somewhat between tamoxifen and aromatase inhibitors (AIs), but include hot flashes, vaginal dryness, joint pain and fatigue.

Studies suggest that for some women, short-term, a low dose anti-depressant in combination with sustained cognitive behavioral therapy may reduce the discomfort of hot flashes, while limited evidence exists to support the use of dietary supplements including soy, vitamin E, black cohosh, magnesium or flaxseed. To treat vaginal dryness, Dr. Barton suggested vaginal moisturizers over lubricants as they have a more lasting effect. Lubricants that contain glycerin, she noted, can cause vaginal yeast infections.

Additionally, she cautioned against the used of low-dose vaginal estrogens. In spite of evidence that the estrogen exposure did not increase cancer risk, long-term prospective studies on safety are lacking, particularly in women taking aromatase inhibitors. Vaginal testosterone has been shown to improve symptoms, albeit with androgen-associated side effects such as hair growth and acne. Dr. Barton’s group has studied the use of DHEA – a natural precursor to estrogen and androgen. Her studies, which will be published soon, showed that nightly use of a DHEA-containing cream over 12 weeks significantly improved vaginal dryness compared to moisturizers.

Studies of interventions for joint pain do not support the use of non-steroidal anti-inflammatories (NSAIDS) or omega 3 fatty acids; however, one small study found that glucosamine with chondroitin improved symptoms in 39/56 patients studied. While there is evidence that low Vitamin D levels are associated with joint pain, randomized controlled clinical trials of vitamin D supplementation have had mixed results. Acupuncture and exercise have been shownin small studies to improve AI-induced joint pain.

Dr. William Gradishar finished the session with a discussion on the role of bone modulating agents for symptom management in breast cancer. Chemotherapy can have direct effects on bone as well as estrogen metabolism and production, which further impacts bone mineral density, increasing the risk of fracture. Radiation therapy and hormonal therapy, particularly aromatase inhibitors, also weaken bones directly and indirectly. In pre-menopausal breast cancer patients, an ovarian suppressing agent may be used in combination with endocrine therapy to reduce estrogen production – also affecting bone health. Bisphosphonates and a targeted therapy called denosumab have been shown to reduce fractures in these patients and have also been used in patients with advanced breast cancer who are at a high risk of fracture and bone metastasis.

The effects of cancer treatment can linger long after treatment ends.  Patients should discuss lingering side effects with their oncologists to ensure they recieve appropriate care for symptom management.

# data[].attributes.title
ASCO Highlights: Breast Cancer Treatments for Early Stage Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Treatments for Early Stage Breast Cancer | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Recent studies have suggested that standard treatments such as chemotherapy, radiation and surgery, particularly mastectomy, that are recommended for early stage breast cancer may not always be needed for precancerous lesions, such as ductal carcinoma in situ (DCIS). These treatments may expose women with DCIS to unnecessary adverse effects without added benefit. There is disagreement in the oncology community whether DCIS should be treated like early stage breast cancer or if a “watch and wait” strategy may be more appropriate for, or even desired, by some patients. 
BCRF investigator Dr. Fatima Cardoso chaired an education session to discuss the latest evidence on overtreatment and the appropriate use of available therapies. In her presentation, Dr. Cardoso discussed the use of gene signatures for a more individualized approach. For some patients, she said, chemotherapy is still the best approach and is “indispensable for achieving cure.” The challenge is in identifying which women need chemotherapy and which do not. New gene-based diagnostic tests such as Oncotype DX® and the MammaPrint® have been shown to help in this regard.  Dr. Cardoso discussed the recent results from the MINDACT trial that demonstrated that the MammaPrint 70 gene recurrence score was better than clinical assessment of tumors in predicting which women were at low-risk of recurrence and thus could forego chemotherapy after surgery (known as adjuvant therapy). Similar results from the TAILORx study reported that the Oncotype DX® recurrence score could help identify women with early stage, estrogen receptor-positive breast cancer who could forgo chemotherapy.
In the same session, BCRF investigator, Dr. Laura Esserman presented a case that indolent or “ultra-low” risk cancers now comprise up to 30 percent of screening-detected breast cancers. She presented data based on studies with more than 20 years of follow up supporting a “less is more” approach to some DCIS. The major challenge remains in being able to identify which DCIS are “ultra-low” risk from those that are high-risk and should be treated. She referred to soon-to-be published work from her group validating a MammaPrint®- derived ultra-low risk predictive score in a large cohort of Swedish women. She also recommended adapting a personalized approach to screening based on risk as opposed to age and pointed to the WISDOM trial (Women Informed to Screen Depending on Risk) as an effort to learn from risk-based screening in order to improve screening strategies. 
Dr. Shelley Hwang (Duke University) ended the session with a discussion on how to balance the risks of treatment options (systemic therapy, surgery and radiation) with benefits for patients with low grade DCIS. She emphasized the need for precision medicine for low-risk DCIS that balances the risk of morbidities associated with treatment and accepts some degree of uncertainty of outcomes.  Dr. Hwang described the COMET trial (Comparison of Operative vs. Medical Endocrine Therapy for low-riskDCIS) which plans to recruit about 1,200 women who will be randomized to receive usual care or receive active surveillance. The trial seeks to reduce the uncertainty of outcomes for either method and will compare clinical outcomes as well as patient reported outcomes, such as psychosocial stress. The study has the potential to guide care choices for early stage breast cancers and potentially help women avoid the adverse effects of treatments that would provide no benefit. 

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Treatments for Early Stage Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
Recent studies have suggested that standard treatments such as chemotherapy, radiation and surgery, particularly mastectomy, that are recommended for early stage breast cancer may not always be needed for precancerous lesions, such as ductal carcinoma in situ (DCIS). These treatments may expose women with DCIS to unnecessary adverse effects without added benefit. There is disagreement in the oncology community whether DCIS should be treated like early stage breast cancer or if a “watch and wait” strategy may be more appropriate for, or even desired, by some patients. 

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Treatments for Early Stage Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
When less is more in breast cancer treatment

# data[].attributes.metatag_normalized[].attributes.content
Recent studies have suggested that standard treatments such as chemotherapy, radiation and surgery, particularly mastectomy, that are recommended for early stage breast cancer may not always be needed for precancerous lesions, such as ductal carcinoma in situ (DCIS). These treatments may expose women with DCIS to unnecessary adverse effects without added benefit. There is disagreement in the oncology community whether DCIS should be treated like early stage breast cancer or if a “watch and wait” strategy may be more appropriate for, or even desired, by some patients. 

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Treatments for Early Stage Breast Cancer

# data[].attributes.body.value
Recent studies have suggested that standard treatments such as chemotherapy, radiation and surgery, particularly mastectomy, that are recommended for early stage breast cancer may not always be needed for precancerous lesions, such as ductal carcinoma in situ (DCIS). These treatments may expose women with DCIS to unnecessary adverse effects without added benefit. There is disagreement in the oncology community whether DCIS should be treated like early stage breast cancer or if a “watch and wait” strategy may be more appropriate for, or even desired, by some patients.

BCRF investigator Dr. Fatima Cardoso chaired an education session to discuss the latest evidence on overtreatment and the appropriate use of available therapies. In her presentation, Dr. Cardoso discussed the use of gene signatures for a more individualized approach. For some patients, she said, chemotherapy is still the best approach and is “indispensable for achieving cure.” The challenge is in identifying which women need chemotherapy and which do not. New gene-based diagnostic tests such as Oncotype DX® and the MammaPrint® have been shown to help in this regard.  Dr. Cardoso discussed the recent results from the MINDACT trial that demonstrated that the MammaPrint 70 gene recurrence score was better than clinical assessment of tumors in predicting which women were at low-risk of recurrence and thus could forego chemotherapy after surgery (known as adjuvant therapy). Similar results from the TAILORx study reported that the Oncotype DX® recurrence score could help identify women with early stage, estrogen receptor-positive breast cancer who could forgo chemotherapy.

In the same session, BCRF investigator, Dr. Laura Esserman presented a case that indolent or “ultra-low” risk cancers now comprise up to 30 percent of screening-detected breast cancers. She presented data based on studies with more than 20 years of follow up supporting a “less is more” approach to some DCIS. The major challenge remains in being able to identify which DCIS are “ultra-low” risk from those that are high-risk and should be treated. She referred to soon-to-be published work from her group validating a MammaPrint®- derived ultra-low risk predictive score in a large cohort of Swedish women. She also recommended adapting a personalized approach to screening based on risk as opposed to age and pointed to the WISDOM trial (Women Informed to Screen Depending on Risk) as an effort to learn from risk-based screening in order to improve screening strategies.

Dr. Shelley Hwang (Duke University) ended the session with a discussion on how to balance the risks of treatment options (systemic therapy, surgery and radiation) with benefits for patients with low grade DCIS. She emphasized the need for precision medicine for low-risk DCIS that balances the risk of morbidities associated with treatment and accepts some degree of uncertainty of outcomes.  Dr. Hwang described the COMET trial (Comparison of Operative vs. Medical Endocrine Therapy for low-riskDCIS) which plans to recruit about 1,200 women who will be randomized to receive usual care or receive active surveillance. The trial seeks to reduce the uncertainty of outcomes for either method and will compare clinical outcomes as well as patient reported outcomes, such as psychosocial stress. The study has the potential to guide care choices for early stage breast cancers and potentially help women avoid the adverse effects of treatments that would provide no benefit.

# data[].attributes.body.processed
Recent studies have suggested that standard treatments such as chemotherapy, radiation and surgery, particularly mastectomy, that are recommended for early stage breast cancer may not always be needed for precancerous lesions, such as ductal carcinoma in situ (DCIS). These treatments may expose women with DCIS to unnecessary adverse effects without added benefit. There is disagreement in the oncology community whether DCIS should be treated like early stage breast cancer or if a “watch and wait” strategy may be more appropriate for, or even desired, by some patients.

BCRF investigator Dr. Fatima Cardoso chaired an education session to discuss the latest evidence on overtreatment and the appropriate use of available therapies. In her presentation, Dr. Cardoso discussed the use of gene signatures for a more individualized approach. For some patients, she said, chemotherapy is still the best approach and is “indispensable for achieving cure.” The challenge is in identifying which women need chemotherapy and which do not. New gene-based diagnostic tests such as Oncotype DX® and the MammaPrint® have been shown to help in this regard.  Dr. Cardoso discussed the recent results from the MINDACT trial that demonstrated that the MammaPrint 70 gene recurrence score was better than clinical assessment of tumors in predicting which women were at low-risk of recurrence and thus could forego chemotherapy after surgery (known as adjuvant therapy). Similar results from the TAILORx study reported that the Oncotype DX® recurrence score could help identify women with early stage, estrogen receptor-positive breast cancer who could forgo chemotherapy.

In the same session, BCRF investigator, Dr. Laura Esserman presented a case that indolent or “ultra-low” risk cancers now comprise up to 30 percent of screening-detected breast cancers. She presented data based on studies with more than 20 years of follow up supporting a “less is more” approach to some DCIS. The major challenge remains in being able to identify which DCIS are “ultra-low” risk from those that are high-risk and should be treated. She referred to soon-to-be published work from her group validating a MammaPrint®- derived ultra-low risk predictive score in a large cohort of Swedish women. She also recommended adapting a personalized approach to screening based on risk as opposed to age and pointed to the WISDOM trial (Women Informed to Screen Depending on Risk) as an effort to learn from risk-based screening in order to improve screening strategies.

Dr. Shelley Hwang (Duke University) ended the session with a discussion on how to balance the risks of treatment options (systemic therapy, surgery and radiation) with benefits for patients with low grade DCIS. She emphasized the need for precision medicine for low-risk DCIS that balances the risk of morbidities associated with treatment and accepts some degree of uncertainty of outcomes.  Dr. Hwang described the COMET trial (Comparison of Operative vs. Medical Endocrine Therapy for low-riskDCIS) which plans to recruit about 1,200 women who will be randomized to receive usual care or receive active surveillance. The trial seeks to reduce the uncertainty of outcomes for either method and will compare clinical outcomes as well as patient reported outcomes, such as psychosocial stress. The study has the potential to guide care choices for early stage breast cancers and potentially help women avoid the adverse effects of treatments that would provide no benefit.

# data[].attributes.field_subtitle
When less is more in breast cancer treatment 

# data[].attributes.title
ASCO Highlights: Breast Cancer Treatments for Advanced / Metastatic Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Treatments for Advanced / Metastatic Breast Cancer | BCRF

# data[].attributes.metatag_normalized[].attributes.content
CDK4/6 inhibitors may offer new treatments in metastatic breast cancer. Updates from two clinical trials of CDK4/6 targeted therapies reported promising results in metastatic breast cancer. Dr. Maura Dickler (Memorial Sloan Kettering Cancer Center) reported on the MONARCH trial, a phase II single-arm study designed to evaluate safety and efficacy of the CDK4/6 inhibitor abemaciclib as monotherapy in women with hormone receptor (HR)+/HER2 negative metastatic breast cancer. Patients qualified if their disease progressed during or after endocrine therapy and chemotherapy. Dr. Dickler reported that nearly 23 percent of patients had stable disease of six months. Seven percent of patients discontinued therapy due to adverse events including diarrhea, fatigue, nausea and loss of appetite.  Commenting on the study, Dr. Dickler noted that it “confirmed single-agent activity of abemaciclib in a heavily pre-treated population with HR+/HER- metastatic breast cancer.” BCRF investigator Drs. Hope Rugo is a co-author on the study.
Nicholas Turner (Royal Marsden Hospital) reported on the PALOMA 3 study, a randomized, double-blind, phase III study comparing the CDK4/6 inhibitor palbociclib plus fulvestrant with fulvestrant alone in pre- and postmenopausal women with HR+/HER2– metastatic breast cancer whose disease had progressed on prior endocrine therapy. In addition, the study included analysis of mutations in the ESR gene. Mutations in ESR1 have been implicated in resistance to endocrine therapy in metastatic breast cancer and the researchers aimed to determine whether ESR1 mutations affect sensitivity to palbociclib. According to Dr. Turner, analysis of blood in pre- and post-menopausal PALOMA 3 patients indicates that the CDK4/6 inhibitor may be beneficial in patients whose tumors harbor ESR1 mutations. Patients receiving the combination of palbociclib plus fulvestrant had significantly better overall survival than those receiving fulvestrant alone, regardless of ESR1 status. “Because of the frequency of ESR1 mutation in this patient population,” Dr. Turner commented, “the combination of fulvestrant and palbociclib presents an attractive treatment option for ESR1 mutant cancer.”  BCFR investigators Drs. Fabrice André and Sherene Loi are co-authors on the study.
Surgery plus systemic therapy, versus systemic therapy alone, may be beneficial for women who present with breast cancer that has already metastasized at the time of initial diagnosis (called de novo MBC). Results from a multicenter phase III randomized trial reported that loco-regional surgery (LRS) followed by systemic therapy (ST) improved survival in the treatment of naïve stage IV breast cancer patients compared to systemic therapy alone. The study was conducted across 25 institutions and included 274 women newly diagnosed with advanced breast cancer. Following 40 months of follow up, the women who received local therapy to remove the primary tumor lived an average of nine months longer than women who did not receive surgery and more than 42 percent of the surgery plus systemic therapy group lived five years after diagnosis compared to 25 percent in the group receiving systemic therapy alone. Read more about the study here.
Expanding Access to Targeted Breast Cancer Treatment: Biosimilar Shows Comparable Efficacy and Safety to Trastuzumab in HER2-Positive Metastatic Breast Cancer. Biosimilars are drugs that closely mimic a biological drug, a drug that is produced from a natural source such as human, animal or micro bacteria. Examples of biologic drugs include the HER2-targeted therapy trastuzmab, a human-derived antibody. BCRF investigator, Hope Rugo reported that MYL-1401O, trastuzumab biosimilar, was equally effective as trastuzumab in a randomized phase III trial conducted at 95 sites across Asia, Latin America, Africa, and Europe.  MYL-14010 had a similar safety profile as traztuzumab and an objective response rates at 24 weeks of 70 percent compared to 64 percent with trastuzumab. Commenting on the significance of the study to the ASCO Post, Dr. Rugo noted: “Trastuzumab has markedly improved survival of women with HER2-positive breast cancer, but many women around the world can’t benefit from trastuzumab due to its high cost. We hope that the introduction of biosimilars will expand patient access to this effective drug, which has already benefited the lives of thousands of people across the globe.” Read more about the study in the ASCO Post. 

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Treatments for Advanced / Metastatic Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
CDK4/6 inhibitors may offer new treatments in metastatic breast cancer. Updates from two clinical trials of CDK4/6 targeted therapies reported promising results in metastatic breast cancer. Dr. Maura Dickler (Memorial Sloan Kettering Cancer Center) reported on the MONARCH trial, a phase II single-arm study designed to evaluate safety and efficacy of the CDK4/6 inhibitor abemaciclib as monotherapy in women with hormone receptor (HR)+/HER2 negative metastatic breast cancer. Patients qualified if their disease progressed during or after endocrine therapy and chemotherapy. Dr.

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Treatments for Advanced / Metastatic Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
Three new reports look at improving treatment for metastatic breast cancer

# data[].attributes.metatag_normalized[].attributes.content
CDK4/6 inhibitors may offer new treatments in metastatic breast cancer. Updates from two clinical trials of CDK4/6 targeted therapies reported promising results in metastatic breast cancer. Dr. Maura Dickler (Memorial Sloan Kettering Cancer Center) reported on the MONARCH trial, a phase II single-arm study designed to evaluate safety and efficacy of the CDK4/6 inhibitor abemaciclib as monotherapy in women with hormone receptor (HR)+/HER2 negative metastatic breast cancer. Patients qualified if their disease progressed during or after endocrine therapy and chemotherapy. Dr.

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: Breast Cancer Treatments for Advanced / Metastatic Breast Cancer

# data[].attributes.body.value
CDK4/6 inhibitors may offer new treatments in metastatic breast cancer. Updates from two clinical trials of CDK4/6 targeted therapies reported promising results in metastatic breast cancer. Dr. Maura Dickler (Memorial Sloan Kettering Cancer Center) reported on the MONARCH trial, a phase II single-arm study designed to evaluate safety and efficacy of the CDK4/6 inhibitor abemaciclib as monotherapy in women with hormone receptor (HR)+/HER2 negative metastatic breast cancer. Patients qualified if their disease progressed during or after endocrine therapy and chemotherapy. Dr. Dickler reported that nearly 23 percent of patients had stable disease of six months. Seven percent of patients discontinued therapy due to adverse events including diarrhea, fatigue, nausea and loss of appetite.  Commenting on the study, Dr. Dickler noted that it “confirmed single-agent activity of abemaciclib in a heavily pre-treated population with HR+/HER- metastatic breast cancer.” BCRF investigator Drs. Hope Rugo is a co-author on the study.

Nicholas Turner (Royal Marsden Hospital) reported on the PALOMA 3 study, a randomized, double-blind, phase III study comparing the CDK4/6 inhibitor palbociclib plus fulvestrant with fulvestrant alone in pre- and postmenopausal women with HR+/HER2– metastatic breast cancer whose disease had progressed on prior endocrine therapy. In addition, the study included analysis of mutations in the ESR gene. Mutations in ESR1 have been implicated in resistance to endocrine therapy in metastatic breast cancer and the researchers aimed to determine whether ESR1 mutations affect sensitivity to palbociclib. According to Dr. Turner, analysis of blood in pre- and post-menopausal PALOMA 3 patients indicates that the CDK4/6 inhibitor may be beneficial in patients whose tumors harbor ESR1 mutations. Patients receiving the combination of palbociclib plus fulvestrant had significantly better overall survival than those receiving fulvestrant alone, regardless of ESR1 status. “Because of the frequency of ESR1 mutation in this patient population,” Dr. Turner commented, “the combination of fulvestrant and palbociclib presents an attractive treatment option for ESR1 mutant cancer.”  BCFR investigators Drs. Fabrice André and Sherene Loi are co-authors on the study.

Surgery plus systemic therapy, versus systemic therapy alone, may be beneficial for women who present with breast cancer that has already metastasized at the time of initial diagnosis (called de novo MBC). Results from a multicenter phase III randomized trial reported that loco-regional surgery (LRS) followed by systemic therapy (ST) improved survival in the treatment of naïve stage IV breast cancer patients compared to systemic therapy alone. The study was conducted across 25 institutions and included 274 women newly diagnosed with advanced breast cancer. Following 40 months of follow up, the women who received local therapy to remove the primary tumor lived an average of nine months longer than women who did not receive surgery and more than 42 percent of the surgery plus systemic therapy group lived five years after diagnosis compared to 25 percent in the group receiving systemic therapy alone. Read more about the study here.

Expanding Access to Targeted Breast Cancer Treatment: Biosimilar Shows Comparable Efficacy and Safety to Trastuzumab in HER2-Positive Metastatic Breast Cancer. Biosimilars are drugs that closely mimic a biological drug, a drug that is produced from a natural source such as human, animal or micro bacteria. Examples of biologic drugs include the HER2-targeted therapy trastuzmab, a human-derived antibody. BCRF investigator, Hope Rugo reported that MYL-1401O, trastuzumab biosimilar, was equally effective as trastuzumab in a randomized phase III trial conducted at 95 sites across Asia, Latin America, Africa, and Europe.  MYL-14010 had a similar safety profile as traztuzumab and an objective response rates at 24 weeks of 70 percent compared to 64 percent with trastuzumab. Commenting on the significance of the study to the ASCO Post, Dr. Rugo noted: “Trastuzumab has markedly improved survival of women with HER2-positive breast cancer, but many women around the world can’t benefit from trastuzumab due to its high cost. We hope that the introduction of biosimilars will expand patient access to this effective drug, which has already benefited the lives of thousands of people across the globe.” Read more about the study in the ASCO Post.

# data[].attributes.body.processed
CDK4/6 inhibitors may offer new treatments in metastatic breast cancer. Updates from two clinical trials of CDK4/6 targeted therapies reported promising results in metastatic breast cancer. Dr. Maura Dickler (Memorial Sloan Kettering Cancer Center) reported on the MONARCH trial, a phase II single-arm study designed to evaluate safety and efficacy of the CDK4/6 inhibitor abemaciclib as monotherapy in women with hormone receptor (HR)+/HER2 negative metastatic breast cancer. Patients qualified if their disease progressed during or after endocrine therapy and chemotherapy. Dr. Dickler reported that nearly 23 percent of patients had stable disease of six months. Seven percent of patients discontinued therapy due to adverse events including diarrhea, fatigue, nausea and loss of appetite.  Commenting on the study, Dr. Dickler noted that it “confirmed single-agent activity of abemaciclib in a heavily pre-treated population with HR+/HER- metastatic breast cancer.” BCRF investigator Drs. Hope Rugo is a co-author on the study.

Nicholas Turner (Royal Marsden Hospital) reported on the PALOMA 3 study, a randomized, double-blind, phase III study comparing the CDK4/6 inhibitor palbociclib plus fulvestrant with fulvestrant alone in pre- and postmenopausal women with HR+/HER2– metastatic breast cancer whose disease had progressed on prior endocrine therapy. In addition, the study included analysis of mutations in the ESR gene. Mutations in ESR1 have been implicated in resistance to endocrine therapy in metastatic breast cancer and the researchers aimed to determine whether ESR1 mutations affect sensitivity to palbociclib. According to Dr. Turner, analysis of blood in pre- and post-menopausal PALOMA 3 patients indicates that the CDK4/6 inhibitor may be beneficial in patients whose tumors harbor ESR1 mutations. Patients receiving the combination of palbociclib plus fulvestrant had significantly better overall survival than those receiving fulvestrant alone, regardless of ESR1 status. “Because of the frequency of ESR1 mutation in this patient population,” Dr. Turner commented, “the combination of fulvestrant and palbociclib presents an attractive treatment option for ESR1 mutant cancer.”  BCFR investigators Drs. Fabrice André and Sherene Loi are co-authors on the study.

Surgery plus systemic therapy, versus systemic therapy alone, may be beneficial for women who present with breast cancer that has already metastasized at the time of initial diagnosis (called de novo MBC). Results from a multicenter phase III randomized trial reported that loco-regional surgery (LRS) followed by systemic therapy (ST) improved survival in the treatment of naïve stage IV breast cancer patients compared to systemic therapy alone. The study was conducted across 25 institutions and included 274 women newly diagnosed with advanced breast cancer. Following 40 months of follow up, the women who received local therapy to remove the primary tumor lived an average of nine months longer than women who did not receive surgery and more than 42 percent of the surgery plus systemic therapy group lived five years after diagnosis compared to 25 percent in the group receiving systemic therapy alone. Read more about the study here.

Expanding Access to Targeted Breast Cancer Treatment: Biosimilar Shows Comparable Efficacy and Safety to Trastuzumab in HER2-Positive Metastatic Breast Cancer. Biosimilars are drugs that closely mimic a biological drug, a drug that is produced from a natural source such as human, animal or micro bacteria. Examples of biologic drugs include the HER2-targeted therapy trastuzmab, a human-derived antibody. BCRF investigator, Hope Rugo reported that MYL-1401O, trastuzumab biosimilar, was equally effective as trastuzumab in a randomized phase III trial conducted at 95 sites across Asia, Latin America, Africa, and Europe.  MYL-14010 had a similar safety profile as traztuzumab and an objective response rates at 24 weeks of 70 percent compared to 64 percent with trastuzumab. Commenting on the significance of the study to the ASCO Post, Dr. Rugo noted: “Trastuzumab has markedly improved survival of women with HER2-positive breast cancer, but many women around the world can’t benefit from trastuzumab due to its high cost. We hope that the introduction of biosimilars will expand patient access to this effective drug, which has already benefited the lives of thousands of people across the globe.” Read more about the study in the ASCO Post.

# data[].attributes.field_subtitle
Three new reports look at improving treatment for metastatic breast cancer

# data[].attributes.title
Teen Throws ‘Thumbs Up’ BCRF Fundraiser, Challenging Classmates to Give Up Social Media 

# data[].attributes.metatag_normalized[].attributes.content
Teen Throws ‘Thumbs Up’ BCRF Fundraiser, Challenging Classmates to Give Up Social Media  | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Arianna Bertolotti was only nine years old when her aunt was diagnosed with breast cancer. While her memories during that time are faint, today she sees how her aunt’s life has been forever altered by her diagnosis. To that end, the eighth grader decided to start a fundraiser for BCRF in her aunt’s honor – in a way that is true to her age.
“I thought it would be a good idea to ‘thumbs up’ or refrain from using social media for a week or more as an exercise to raise funds for breast cancer research while at the same time promoting interaction with family and friends,” Bertolotti said. The event, which took place in November, raised more than $800 for BCRF. 
She asked her classmates to give up social media for five days – and by doing so would receive donations to BCRF for their actions. Bertolotti nicknamed the event “Thumbs Up” since her peers literally had to keep their thumbs off away from all social networks including Facebook, Twitter, Instagram and Snapchat.
While the fundraiser was challenging, it held a deeper meaning for Bertolotti besides testing one’s strength of will.
“Taking away something as important as social media was an attempt to simulate how people with breast cancer feel when their lives are instantly and drastically changed when they are diagnosed,” she said.

Bertolotti admits the fundraiser was challenging at times, however her friends learned an impactful lesson from their experience.
“After we ‘survived’ without social media, we reflected on how hard it would be if something more drastic were taken away from us for instance, our hair,” she said. “Many women suffering from breast cancer lose their hair which, I can only imagine, would be much harder than losing social media.”  
A strong supporter for research, Bertolotti hopes new advances will not only help cure breast cancer but improve the quality of life for patients as well.
“Breast cancer research is important to me because the more people know about a cause, the better we can help prevent it from even happening in the first place,” she said. “It is wonderful and satisfying to participate in an effort to find the cure for breast cancer and prevent the loss of any future lives.”

# data[].attributes.metatag_normalized[].attributes.content
Teen Throws ‘Thumbs Up’ BCRF Fundraiser, Challenging Classmates to Give Up Social Media

# data[].attributes.metatag_normalized[].attributes.content
Arianna Bertolotti was only nine years old when her aunt was diagnosed with breast cancer. While her memories during that time are faint, today she sees how her aunt’s life has been forever altered by her diagnosis. To that end, the eighth grader decided to start a fundraiser for BCRF in her aunt’s honor – in a way that is true to her age.

# data[].attributes.metatag_normalized[].attributes.content
Teen Throws ‘Thumbs Up’ BCRF Fundraiser, Challenging Classmates to Give Up Social Media

# data[].attributes.metatag_normalized[].attributes.content
14-year-old Arianna Bertolotti created a challenging fundraiser in honor of her aunt, who is a breast cancer survivor

# data[].attributes.metatag_normalized[].attributes.content
Arianna Bertolotti was only nine years old when her aunt was diagnosed with breast cancer. While her memories during that time are faint, today she sees how her aunt’s life has been forever altered by her diagnosis. To that end, the eighth grader decided to start a fundraiser for BCRF in her aunt’s honor – in a way that is true to her age.

# data[].attributes.metatag_normalized[].attributes.content
Teen Throws ‘Thumbs Up’ BCRF Fundraiser, Challenging Classmates to Give Up Social Media

# data[].attributes.body.value
Arianna Bertolotti was only nine years old when her aunt was diagnosed with breast cancer. While her memories during that time are faint, today she sees how her aunt’s life has been forever altered by her diagnosis. To that end, the eighth grader decided to start a fundraiser for BCRF in her aunt’s honor – in a way that is true to her age.

“I thought it would be a good idea to ‘thumbs up’ or refrain from using social media for a week or more as an exercise to raise funds for breast cancer research while at the same time promoting interaction with family and friends,” Bertolotti said. The event, which took place in November, raised more than $800 for BCRF.

She asked her classmates to give up social media for five days – and by doing so would receive donations to BCRF for their actions. Bertolotti nicknamed the event “Thumbs Up” since her peers literally had to keep their thumbs off away from all social networks including Facebook, Twitter, Instagram and Snapchat.

While the fundraiser was challenging, it held a deeper meaning for Bertolotti besides testing one’s strength of will.

“Taking away something as important as social media was an attempt to simulate how people with breast cancer feel when their lives are instantly and drastically changed when they are diagnosed,” she said.

Bertolotti admits the fundraiser was challenging at times, however her friends learned an impactful lesson from their experience.

“After we ‘survived’ without social media, we reflected on how hard it would be if something more drastic were taken away from us for instance, our hair,” she said. “Many women suffering from breast cancer lose their hair which, I can only imagine, would be much harder than losing social media.”

A strong supporter for research, Bertolotti hopes new advances will not only help cure breast cancer but improve the quality of life for patients as well.

“Breast cancer research is important to me because the more people know about a cause, the better we can help prevent it from even happening in the first place,” she said. “It is wonderful and satisfying to participate in an effort to find the cure for breast cancer and prevent the loss of any future lives.”

# data[].attributes.body.processed
Arianna Bertolotti was only nine years old when her aunt was diagnosed with breast cancer. While her memories during that time are faint, today she sees how her aunt’s life has been forever altered by her diagnosis. To that end, the eighth grader decided to start a fundraiser for BCRF in her aunt’s honor – in a way that is true to her age.

“I thought it would be a good idea to ‘thumbs up’ or refrain from using social media for a week or more as an exercise to raise funds for breast cancer research while at the same time promoting interaction with family and friends,” Bertolotti said. The event, which took place in November, raised more than $800 for BCRF.

She asked her classmates to give up social media for five days – and by doing so would receive donations to BCRF for their actions. Bertolotti nicknamed the event “Thumbs Up” since her peers literally had to keep their thumbs off away from all social networks including Facebook, Twitter, Instagram and Snapchat.

While the fundraiser was challenging, it held a deeper meaning for Bertolotti besides testing one’s strength of will.

“Taking away something as important as social media was an attempt to simulate how people with breast cancer feel when their lives are instantly and drastically changed when they are diagnosed,” she said.

Bertolotti admits the fundraiser was challenging at times, however her friends learned an impactful lesson from their experience.

“After we ‘survived’ without social media, we reflected on how hard it would be if something more drastic were taken away from us for instance, our hair,” she said. “Many women suffering from breast cancer lose their hair which, I can only imagine, would be much harder than losing social media.”

A strong supporter for research, Bertolotti hopes new advances will not only help cure breast cancer but improve the quality of life for patients as well.

“Breast cancer research is important to me because the more people know about a cause, the better we can help prevent it from even happening in the first place,” she said. “It is wonderful and satisfying to participate in an effort to find the cure for breast cancer and prevent the loss of any future lives.”

# data[].attributes.field_subtitle
14-year-old Arianna Bertolotti created a challenging fundraiser in honor of her aunt, who is a breast cancer survivor

# data[].attributes.title
ASCO Highlights: BCRF Supports the Future of Breast Cancer Research, Nurturing Young Scientists through CCF

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: BCRF Supports the Future of Breast Cancer Research, Nurturing Young Scientists through CCF | BCRF

# data[].attributes.metatag_normalized[].attributes.content
BCRF’s annual grants program has supported the best minds in clinical, translational and basic breast cancer research for more than 20 years. Our investigators are selected by the Scientific Advisory Board based on their achievements and potential to move the field forward. Through the hard work and innovation of each BCRF investigator, BCRF has played a role in every major advancement in breast cancer research over the last 20 years.
All of our investigators started as trainees in clinics or labs around the world. Their passion and drive were fostered by dedicated mentors, who provided the critical training, support and inspiration to guide their fellows and postdocs in achieving success in their careers, and ultimately to improving the lives of breast cancer patients. Many of our current BCRF investigators started their careers under the mentorship of established BCRF investigators.
BCRF recognizes the importance of securing a path forward for early career clinician-scientists. They represent the next generation of innovators who will bring an end to suffering from breast cancer.  In 2001, BCRF partnered with the Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO) to support the career advancement of early career physician-scientists with a commitment to breast cancer research. CCF was created by ASCO to advance the science in prevention, treatment and cures for all types of cancer. Like BCRF, CCF provides critical funding for breakthrough cancer research that has improved quality of and access to cancer care around the world. CCF research grants support clinical and translational cancer research by gifted physician-scientists at every stage of their careers, from the best and brightest among young investigators to senior researchers. 
Over the last 15 years, BCRF has invested $10 million to support the career development of over 40 young scientists through CCF, many of whom have become leaders in the field including Drs. Vered Stearns and Lajos Pusztai, both of whom now serve on the BCRF Scientific Advisory Board.
At this year’s annual meeting of ASCO, BCRF was recognized for its 2016-2017 investment of $1 million in CCF. This commitment underscores our values in finding and nurturing young investigators who bring creative new ideas to bear. BCRF is proud to support the following young scientists.
The Young Investigator Award (YIA) is a one-year award for promising young physicians to help transition to faculty appointments and encourage quality research in clinical oncology. This year’s recipients of BCRF-CCF YIA are:

Sangeetha Reddy, MD, MSC, University of Texas MD Anderson Cancer Center, Awarded in memory of Evelyn H. Lauder.
Xiuning Le, MD, PhD, Beth Israel Deaconess Medical Center, Awarded in honor of Susan Hirschhorn and in memory of her mother.

 
The Career Development Award is a 3-year award for new faculty members in their first to third year to help them establish independent clinical cancer research programs. This year’s recipients of BCRF-CCF CDA are:

Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center
Aki Morikawa, MD, PhD, University of Michigan

The Advanced Clinical Research Award (ACRA) is a 4-year award to a physician-scientist within ten years of his/her faculty appointment to perform original research. This year’s ACRA awardee is:

Carey Anders, MD, University of North Carolina at Chapel Hill

BCRF congratulates these scientists on achieving the distinction of a BCRF-CCF awardee. They join a distinguished list of current BCRF-CCF awardees including Dr. Vandana Abramson (ACRA 2014), Dr. Priyanka Sharma (ACRA 2015), and Dr. Katherine Reeder Hayes (CDA 2015) and four 2015 YIA recipients Valerie Jansen, Kara Maxwell, David Page and Prabhjot Mundi.
This year’s new awardees will be formally announced during the BCRF October Luncheon and Symposium, held in New York on October 27.
Pictured above, from left to right: Dr. Maneesh Kumar (BCRF); Dr. Neil Iyengar (Memorial Sloan Kettering Cancer Center), Dr. Marc Hurlbert (BCRF Chief Missions Officer); Dr. Carey Anders (University of North Carolina, Chapel Hill); Dr. Sangeetha Reddy (UT MD Anderson Cancer Center); Dr. Xiuning Le (Beth Israel Deaconess Medical Center); Dr. Larry Norton (BCRF Scientific Director); Dr. Margaret Flowers (BCRF); Dr. Clifford Hudis (ASCO CEO and former Chair BCRF Scientific Advisory Board); Dr. Aki Morikawa (University of Michigan)

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: BCRF Supports the Future of Breast Cancer Research, Nurturing Young Scientists through CCF

# data[].attributes.metatag_normalized[].attributes.content
BCRF’s annual grants program has supported the best minds in clinical, translational and basic breast cancer research for more than 20 years. Our investigators are selected by the Scientific Advisory Board based on their achievements and potential to move the field forward. Through the hard work and innovation of each BCRF investigator, BCRF has played a role in every major advancement in breast cancer research over the last 20 years.

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: BCRF Supports the Future of Breast Cancer Research, Nurturing Young Scientists through CCF

# data[].attributes.metatag_normalized[].attributes.content
BCRF recognized for its longtime support of young scientists through its partnership with Conquer Cancer Foundation

# data[].attributes.metatag_normalized[].attributes.content
BCRF’s annual grants program has supported the best minds in clinical, translational and basic breast cancer research for more than 20 years. Our investigators are selected by the Scientific Advisory Board based on their achievements and potential to move the field forward. Through the hard work and innovation of each BCRF investigator, BCRF has played a role in every major advancement in breast cancer research over the last 20 years.

# data[].attributes.metatag_normalized[].attributes.content
ASCO Highlights: BCRF Supports the Future of Breast Cancer Research, Nurturing Young Scientists through CCF

# data[].attributes.body.value
BCRF’s annual grants program has supported the best minds in clinical, translational and basic breast cancer research for more than 20 years. Our investigators are selected by the Scientific Advisory Board based on their achievements and potential to move the field forward. Through the hard work and innovation of each BCRF investigator, BCRF has played a role in every major advancement in breast cancer research over the last 20 years.

All of our investigators started as trainees in clinics or labs around the world. Their passion and drive were fostered by dedicated mentors, who provided the critical training, support and inspiration to guide their fellows and postdocs in achieving success in their careers, and ultimately to improving the lives of breast cancer patients. Many of our current BCRF investigators started their careers under the mentorship of established BCRF investigators.

BCRF recognizes the importance of securing a path forward for early career clinician-scientists. They represent the next generation of innovators who will bring an end to suffering from breast cancer.  In 2001, BCRF partnered with the Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO) to support the career advancement of early career physician-scientists with a commitment to breast cancer research. CCF was created by ASCO to advance the science in prevention, treatment and cures for all types of cancer. Like BCRF, CCF provides critical funding for breakthrough cancer research that has improved quality of and access to cancer care around the world. CCF research grants support clinical and translational cancer research by gifted physician-scientists at every stage of their careers, from the best and brightest among young investigators to senior researchers.

Over the last 15 years, BCRF has invested $10 million to support the career development of over 40 young scientists through CCF, many of whom have become leaders in the field including Drs. Vered Stearns and Lajos Pusztai, both of whom now serve on the BCRF Scientific Advisory Board.

At this year’s annual meeting of ASCO, BCRF was recognized for its 2016-2017 investment of $1 million in CCF. This commitment underscores our values in finding and nurturing young investigators who bring creative new ideas to bear. BCRF is proud to support the following young scientists.

The Young Investigator Award (YIA) is a one-year award for promising young physicians to help transition to faculty appointments and encourage quality research in clinical oncology. This year’s recipients of BCRF-CCF YIA are:

Sangeetha Reddy, MD, MSC, University of Texas MD Anderson Cancer Center, Awarded in memory of Evelyn H. Lauder.

Xiuning Le, MD, PhD, Beth Israel Deaconess Medical Center, Awarded in honor of Susan Hirschhorn and in memory of her mother.

The Career Development Award is a 3-year award for new faculty members in their first to third year to help them establish independent clinical cancer research programs. This year’s recipients of BCRF-CCF CDA are:

Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center

Aki Morikawa, MD, PhD, University of Michigan

The Advanced Clinical Research Award (ACRA) is a 4-year award to a physician-scientist within ten years of his/her faculty appointment to perform original research. This year’s ACRA awardee is:

Carey Anders, MD, University of North Carolina at Chapel Hill

BCRF congratulates these scientists on achieving the distinction of a BCRF-CCF awardee. They join a distinguished list of current BCRF-CCF awardees including Dr. Vandana Abramson (ACRA 2014), Dr. Priyanka Sharma (ACRA 2015), and Dr. Katherine Reeder Hayes (CDA 2015) and four 2015 YIA recipients Valerie Jansen, Kara Maxwell, David Page and Prabhjot Mundi.

This year’s new awardees will be formally announced during the BCRF October Luncheon and Symposium, held in New York on October 27.

Pictured above, from left to right: Dr. Maneesh Kumar (BCRF); Dr. Neil Iyengar (Memorial Sloan Kettering Cancer Center), Dr. Marc Hurlbert (BCRF Chief Missions Officer); Dr. Carey Anders (University of North Carolina, Chapel Hill); Dr. Sangeetha Reddy (UT MD Anderson Cancer Center); Dr. Xiuning Le (Beth Israel Deaconess Medical Center); Dr. Larry Norton (BCRF Scientific Director); Dr. Margaret Flowers (BCRF); Dr. Clifford Hudis (ASCO CEO and former Chair BCRF Scientific Advisory Board); Dr. Aki Morikawa (University of Michigan)

# data[].attributes.body.processed
BCRF’s annual grants program has supported the best minds in clinical, translational and basic breast cancer research for more than 20 years. Our investigators are selected by the Scientific Advisory Board based on their achievements and potential to move the field forward. Through the hard work and innovation of each BCRF investigator, BCRF has played a role in every major advancement in breast cancer research over the last 20 years.

All of our investigators started as trainees in clinics or labs around the world. Their passion and drive were fostered by dedicated mentors, who provided the critical training, support and inspiration to guide their fellows and postdocs in achieving success in their careers, and ultimately to improving the lives of breast cancer patients. Many of our current BCRF investigators started their careers under the mentorship of established BCRF investigators.

BCRF recognizes the importance of securing a path forward for early career clinician-scientists. They represent the next generation of innovators who will bring an end to suffering from breast cancer.  In 2001, BCRF partnered with the Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO) to support the career advancement of early career physician-scientists with a commitment to breast cancer research. CCF was created by ASCO to advance the science in prevention, treatment and cures for all types of cancer. Like BCRF, CCF provides critical funding for breakthrough cancer research that has improved quality of and access to cancer care around the world. CCF research grants support clinical and translational cancer research by gifted physician-scientists at every stage of their careers, from the best and brightest among young investigators to senior researchers.

Over the last 15 years, BCRF has invested $10 million to support the career development of over 40 young scientists through CCF, many of whom have become leaders in the field including Drs. Vered Stearns and Lajos Pusztai, both of whom now serve on the BCRF Scientific Advisory Board.

At this year’s annual meeting of ASCO, BCRF was recognized for its 2016-2017 investment of $1 million in CCF. This commitment underscores our values in finding and nurturing young investigators who bring creative new ideas to bear. BCRF is proud to support the following young scientists.

The Young Investigator Award (YIA) is a one-year award for promising young physicians to help transition to faculty appointments and encourage quality research in clinical oncology. This year’s recipients of BCRF-CCF YIA are:

Sangeetha Reddy, MD, MSC, University of Texas MD Anderson Cancer Center, Awarded in memory of Evelyn H. Lauder.

Xiuning Le, MD, PhD, Beth Israel Deaconess Medical Center, Awarded in honor of Susan Hirschhorn and in memory of her mother.

The Career Development Award is a 3-year award for new faculty members in their first to third year to help them establish independent clinical cancer research programs. This year’s recipients of BCRF-CCF CDA are:

Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center

Aki Morikawa, MD, PhD, University of Michigan

The Advanced Clinical Research Award (ACRA) is a 4-year award to a physician-scientist within ten years of his/her faculty appointment to perform original research. This year’s ACRA awardee is:

Carey Anders, MD, University of North Carolina at Chapel Hill

BCRF congratulates these scientists on achieving the distinction of a BCRF-CCF awardee. They join a distinguished list of current BCRF-CCF awardees including Dr. Vandana Abramson (ACRA 2014), Dr. Priyanka Sharma (ACRA 2015), and Dr. Katherine Reeder Hayes (CDA 2015) and four 2015 YIA recipients Valerie Jansen, Kara Maxwell, David Page and Prabhjot Mundi.

This year’s new awardees will be formally announced during the BCRF October Luncheon and Symposium, held in New York on October 27.

Pictured above, from left to right: Dr. Maneesh Kumar (BCRF); Dr. Neil Iyengar (Memorial Sloan Kettering Cancer Center), Dr. Marc Hurlbert (BCRF Chief Missions Officer); Dr. Carey Anders (University of North Carolina, Chapel Hill); Dr. Sangeetha Reddy (UT MD Anderson Cancer Center); Dr. Xiuning Le (Beth Israel Deaconess Medical Center); Dr. Larry Norton (BCRF Scientific Director); Dr. Margaret Flowers (BCRF); Dr. Clifford Hudis (ASCO CEO and former Chair BCRF Scientific Advisory Board); Dr. Aki Morikawa (University of Michigan)

# data[].attributes.field_caption
2016 BCRF-CCF Awardees with BCRF's Scientific Leadership

# data[].attributes.field_subtitle
BCRF recognized for its longtime support of young scientists through its partnership with Conquer Cancer Foundation

# data[].attributes.title
Why Vice President Biden’s Cancer Moonshot Is A Game Changer

# data[].attributes.metatag_normalized[].attributes.content
Why Vice President Biden’s Cancer Moonshot Is A Game Changer | BCRF

# data[].attributes.metatag_normalized[].attributes.content
By Marc Hurlbert, PhD
In his final State of the Union address, President Obama tasked the Vice President with heading up a new national effort, the Cancer Moonshot. The ultimate goal is to double the rate of progress—to make a decade’s worth of advances in cancer research in five years—to ultimately end cancer as we know it. 
Since 1993, the Breast Cancer Research Foundation (BCRF) has been committed to ending breast cancer by advancing the world’s most promising research. The impact of our dedication is clear: BCRF has been involved in every major breakthrough in breast cancer research over the last twenty years. 
In response to Vice President Biden’s call for commitment, cooperation and collaboration, today, we announce an unprecedented goal of doubling our annual cancer research investment from $50 million to $100 million, aiming for a cumulative investment of $1 billion, by 2021. 
As the country’s largest non-governmental, nonprofit funder of breast cancer research, BCRF’s approach is multi-pronged: looking at the full spectrum of breast cancer research from prevention, diagnosis, treatment, survivorship and metastasis. 
With a bold vision to double our commitment, BCRF aims to accelerate the path from discovery to clinical implementation—improving treatment options for patients faster. We will launch a multi-million-dollar impact-investment program aimed at fostering productive teams to bring lifesaving, paradigm-changing discoveries to patients. 
Furthermore, BCRF intends to speed the understanding of what causes cancer in the first place—opening an avenue of discovery to stop it in its tracks or prevent it from occurring—by “connecting the dots” between amassing molecular information on tumors and how that sums together to cause the dozens of diseases we call cancer. 
To accomplish this, we will build on our twenty-three-year history of fostering collaborative science to convene and support an academy of biologists, physicians, physicists, mathematicians, computer scientists, lay advocates and other dedicated, creative individuals. 
The Cancer Moonshot aims to expand the very fabric on which BCRF was founded: to unite with others around research—the only way we’ll achieve a future beyond cancer. This Wednesday, we’ll join a collective group of organizations that are expanding their goals, working collaboratively and undoubtedly speeding our way to ending the devastating disease.
Editor's Note: This article originally appeared on The Huffington Post, June 28, 2016

# data[].attributes.metatag_normalized[].attributes.content
Why Vice President Biden’s Cancer Moonshot Is A Game Changer

# data[].attributes.metatag_normalized[].attributes.content
By Marc Hurlbert, PhD
In his final State of the Union address, President Obama tasked the Vice President with heading up a new national effort, the Cancer Moonshot. The ultimate goal is to double the rate of progress—to make a decade’s worth of advances in cancer research in five years—to ultimately end cancer as we know it. 

# data[].attributes.metatag_normalized[].attributes.content
Why Vice President Biden’s Cancer Moonshot Is A Game Changer

# data[].attributes.metatag_normalized[].attributes.content
BCRF Joins an Unprecedented Collective Commitment to End Cancer

# data[].attributes.metatag_normalized[].attributes.content
By Marc Hurlbert, PhD
In his final State of the Union address, President Obama tasked the Vice President with heading up a new national effort, the Cancer Moonshot. The ultimate goal is to double the rate of progress—to make a decade’s worth of advances in cancer research in five years—to ultimately end cancer as we know it. 

# data[].attributes.metatag_normalized[].attributes.content
Why Vice President Biden’s Cancer Moonshot Is A Game Changer

# data[].attributes.body.value
By Marc Hurlbert, PhD

In his final State of the Union address, President Obama tasked the Vice President with heading up a new national effort, the Cancer Moonshot. The ultimate goal is to double the rate of progress—to make a decade’s worth of advances in cancer research in five years—to ultimately end cancer as we know it.

Since 1993, the Breast Cancer Research Foundation (BCRF) has been committed to ending breast cancer by advancing the world’s most promising research. The impact of our dedication is clear: BCRF has been involved in every major breakthrough in breast cancer research over the last twenty years.

In response to Vice President Biden’s call for commitment, cooperation and collaboration, today, we announce an unprecedented goal of doubling our annual cancer research investment from $50 million to $100 million, aiming for a cumulative investment of $1 billion, by 2021.

As the country’s largest non-governmental, nonprofit funder of breast cancer research, BCRF’s approach is multi-pronged: looking at the full spectrum of breast cancer research from prevention, diagnosis, treatment, survivorship and metastasis.

With a bold vision to double our commitment, BCRF aims to accelerate the path from discovery to clinical implementation—improving treatment options for patients faster. We will launch a multi-million-dollar impact-investment program aimed at fostering productive teams to bring lifesaving, paradigm-changing discoveries to patients.

Furthermore, BCRF intends to speed the understanding of what causes cancer in the first place—opening an avenue of discovery to stop it in its tracks or prevent it from occurring—by “connecting the dots” between amassing molecular information on tumors and how that sums together to cause the dozens of diseases we call cancer.

To accomplish this, we will build on our twenty-three-year history of fostering collaborative science to convene and support an academy of biologists, physicians, physicists, mathematicians, computer scientists, lay advocates and other dedicated, creative individuals.

The Cancer Moonshot aims to expand the very fabric on which BCRF was founded: to unite with others around research—the only way we’ll achieve a future beyond cancer. This Wednesday, we’ll join a collective group of organizations that are expanding their goals, working collaboratively and undoubtedly speeding our way to ending the devastating disease.

Editor's Note: This article originally appeared on The Huffington Post, June 28, 2016

# data[].attributes.body.processed
By Marc Hurlbert, PhD

In his final State of the Union address, President Obama tasked the Vice President with heading up a new national effort, the Cancer Moonshot. The ultimate goal is to double the rate of progress—to make a decade’s worth of advances in cancer research in five years—to ultimately end cancer as we know it.

Since 1993, the Breast Cancer Research Foundation (BCRF) has been committed to ending breast cancer by advancing the world’s most promising research. The impact of our dedication is clear: BCRF has been involved in every major breakthrough in breast cancer research over the last twenty years.

In response to Vice President Biden’s call for commitment, cooperation and collaboration, today, we announce an unprecedented goal of doubling our annual cancer research investment from $50 million to $100 million, aiming for a cumulative investment of $1 billion, by 2021.

As the country’s largest non-governmental, nonprofit funder of breast cancer research, BCRF’s approach is multi-pronged: looking at the full spectrum of breast cancer research from prevention, diagnosis, treatment, survivorship and metastasis.

With a bold vision to double our commitment, BCRF aims to accelerate the path from discovery to clinical implementation—improving treatment options for patients faster. We will launch a multi-million-dollar impact-investment program aimed at fostering productive teams to bring lifesaving, paradigm-changing discoveries to patients.

Furthermore, BCRF intends to speed the understanding of what causes cancer in the first place—opening an avenue of discovery to stop it in its tracks or prevent it from occurring—by “connecting the dots” between amassing molecular information on tumors and how that sums together to cause the dozens of diseases we call cancer.

To accomplish this, we will build on our twenty-three-year history of fostering collaborative science to convene and support an academy of biologists, physicians, physicists, mathematicians, computer scientists, lay advocates and other dedicated, creative individuals.

The Cancer Moonshot aims to expand the very fabric on which BCRF was founded: to unite with others around research—the only way we’ll achieve a future beyond cancer. This Wednesday, we’ll join a collective group of organizations that are expanding their goals, working collaboratively and undoubtedly speeding our way to ending the devastating disease.

Editor's Note: This article originally appeared on The Huffington Post, June 28, 2016

# data[].attributes.field_caption
The Pink Agenda President Nicole Seagriff, alongside BCRF's Advisory Board Member Roz Goldstein, President Myra Biblowit, Chief Development Officer Lucretia Gilbert and Chief Mission Officer Marc Hurlbert

# data[].attributes.field_subtitle
BCRF Joins an Unprecedented Collective Commitment to End Cancer  

# data[].attributes.title
Cancer Immunotherapy, Yesterday and Today

# data[].attributes.metatag_normalized[].attributes.content
Cancer Immunotherapy, Yesterday and Today | BCRF

# data[].attributes.metatag_normalized[].attributes.content
As Cancer Immunotherapy Month passes, BCRF reviews the history of cancer immunotherapy, its recent advancements and its role in breast cancer treatment.
The immune system is the body’s natural defense against foreign pathogens. Under normal conditions, the immune system works through a coordination of on and off switches that identify and destroy diseased and abnormal cells. Defects in the on/off switches can result in immune-related diseases where the immune system fails to recognize pathogens as foreign (e.g. HIV-AIDS) or where the immune system fails to recognize normal cells as “self” and launches an inappropriate attack on healthy systems (e.g. rheumatoid arthritis). Likewise, when normal cells mutate to become cancerous they may appear different from normal cells and activate an immune response. Conversely, cancer cells may disguise themselves and go undetected or deactivate the immune system to block an immune response.
What is Cancer Immunotherapy?
At its simplest, cancer immunotherapy involves harnessing a patient’s immune system to attack cancer cells. Scientists have known for more than a century that the immune system can detect and kill cancer cells, but successful cancer immunotherapy has been elusive for patients. An explosion of research more recently has increased our understanding of immune- and tumor-cell biology and unveiled potential ways to unmask tumor cells and make them visible to the immune system. Major discoveries in immune-targeted therapies are leading the way in a new era of cancer immunotherapy and clinical trials are ongoing in different cancer types including breast cancer.
Where is Cancer Immunotherapy Today?
There are several immune-based strategies being pursued as potential anti-cancer therapies. These include cancer vaccines, adoptive cell transfer, and drugs that modulate the immune system.

Cancer vaccines are designed to prevent cancer from developing, or to strengthen the immune system to increase its efficacy in recognizing and killing cancer cells.

In 2010 the FDA approved the first cancer vaccine, Sipuleucel-T (Provenge) for treatment of advanced prostate cancer. The vaccine stimulates the immune system to target a protein expressed on prostate cancer cells.


Adoptive cell therapy involves removing immune cells from a patient, genetically or chemically re-engineering them to enhance their anti-tumor activity, and re-introducing them back into the patient.

A new trial is using advanced gene-editing technologies to modify T-cells to boost their anti-cancer killing efficiency of cancer in patients with myeloma, sarcoma, or melanoma who have stopped responding to existing treatments.


Immune checkpoint therapy restores the normal immune response by preventing tumor cells from shutting it down. Two targets of this therapy are:

PDL-1/ PD-1. Tumor cells increase these proteins to dampen immune response. Monoclonal antibodies to block PDL-1/PD-1 interaction have shown success in lung cancer and other cancer types.
CTLA-4. This protein also acts to put the brakes on the immune system. Targeted anti-CTLA-4 therapies have shown promise in patients advanced melanoma. 



Immunotherapy for Breast Cancer
The success of immunotherapy in melanoma, lung and other cancers has spurred interest in pursuing these strategies in breast cancer. In fact, some recent studies have demonstrated that in addition to blocking the HER2 receptor to prevent growth of cancer cells, trastuzumab (FDA approved in 1998 for the treatment of HER2+ breast cancer) also recruits immune cells to attack the cancer cells. BCRF investigator Sherene Loi has shown that a better immune response is associated with better outcomes. A new clinical trial co-chaired by Dr. Loi is currently underway. Other trials include:

A phase Ib/II trial (NCT02129556) evaluating the efficacy of targeting PD-1 with a new drug, MK-3475) in combination with trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancer. This study is currently recruiting patients and primary outcome results are expected by December 2017.
BCRF investigator, Leisha Emens is the principal investigator of a phase II study (NCT00399529) to assess the safety, clinical benefit, and bioactivity of the cancer vaccine GM-CSF in combination with other drugs in HER2-positive metastatic breast cancer. Study results published in 2014 showed a clinical benefit rate at six months and one year was 55 percent and 40 percent respectively. Median progression-free survival (PFS) and overall survival (OS) were 7 and 42 months respectively.

BCRF has been at the vanguard in breast cancer research since its founding 23 years ago and its commitment to fund innovative research. As a result, BCRF has played a role in every major clinical advancement in breast cancer. With the re-emergence of immunotherapy as a viable treatment for cancer, BCRF investigators are pursuing innovative research and clinical trials to explore its potential for breast cancer patients.
Last year, BCRF invested $6.5 million in immunology-related projects including studies to identify immune biomarkers that can ultimately be used to predict treatment response and new targeted and combination therapies that will hopefully lead to better outcomes in breast cancer. In addition to those mentioned above, BCRF investigators leading the way in this work include Karen Anderson, Susan Domchek,  Elizabeth Jaffee,  Annette Khaled, Silvia Formenti, Sandra Demaria, and Robert Vonderheide. 

# data[].attributes.metatag_normalized[].attributes.content
Cancer Immunotherapy, Yesterday and Today

# data[].attributes.metatag_normalized[].attributes.content
As Cancer Immunotherapy Month passes, BCRF reviews the history of cancer immunotherapy, its recent advancements and its role in breast cancer treatment.

# data[].attributes.metatag_normalized[].attributes.content
Cancer Immunotherapy, Yesterday and Today

# data[].attributes.metatag_normalized[].attributes.content
Immunotherapy is making a comeback in the treatment of cancer. What will that mean for breast cancer patients?

# data[].attributes.metatag_normalized[].attributes.content
As Cancer Immunotherapy Month passes, BCRF reviews the history of cancer immunotherapy, its recent advancements and its role in breast cancer treatment.

# data[].attributes.metatag_normalized[].attributes.content
Cancer Immunotherapy, Yesterday and Today

# data[].attributes.body.value
As Cancer Immunotherapy Month passes, BCRF reviews the history of cancer immunotherapy, its recent advancements and its role in breast cancer treatment.

The immune system is the body’s natural defense against foreign pathogens. Under normal conditions, the immune system works through a coordination of on and off switches that identify and destroy diseased and abnormal cells. Defects in the on/off switches can result in immune-related diseases where the immune system fails to recognize pathogens as foreign (e.g. HIV-AIDS) or where the immune system fails to recognize normal cells as “self” and launches an inappropriate attack on healthy systems (e.g. rheumatoid arthritis). Likewise, when normal cells mutate to become cancerous they may appear different from normal cells and activate an immune response. Conversely, cancer cells may disguise themselves and go undetected or deactivate the immune system to block an immune response.

What is Cancer Immunotherapy?

At its simplest, cancer immunotherapy involves harnessing a patient’s immune system to attack cancer cells. Scientists have known for more than a century that the immune system can detect and kill cancer cells, but successful cancer immunotherapy has been elusive for patients. An explosion of research more recently has increased our understanding of immune- and tumor-cell biology and unveiled potential ways to unmask tumor cells and make them visible to the immune system. Major discoveries in immune-targeted therapies are leading the way in a new era of cancer immunotherapy and clinical trials are ongoing in different cancer types including breast cancer.

Where is Cancer Immunotherapy Today?

There are several immune-based strategies being pursued as potential anti-cancer therapies. These include cancer vaccines, adoptive cell transfer, and drugs that modulate the immune system.

Cancer vaccines are designed to prevent cancer from developing, or to strengthen the immune system to increase its efficacy in recognizing and killing cancer cells.

In 2010 the FDA approved the first cancer vaccine, Sipuleucel-T (Provenge) for treatment of advanced prostate cancer. The vaccine stimulates the immune system to target a protein expressed on prostate cancer cells.

Adoptive cell therapy involves removing immune cells from a patient, genetically or chemically re-engineering them to enhance their anti-tumor activity, and re-introducing them back into the patient.

A new trial is using advanced gene-editing technologies to modify T-cells to boost their anti-cancer killing efficiency of cancer in patients with myeloma, sarcoma, or melanoma who have stopped responding to existing treatments.

Immune checkpoint therapy restores the normal immune response by preventing tumor cells from shutting it down. Two targets of this therapy are:

PDL-1/ PD-1. Tumor cells increase these proteins to dampen immune response. Monoclonal antibodies to block PDL-1/PD-1 interaction have shown success in lung cancer and other cancer types.

CTLA-4. This protein also acts to put the brakes on the immune system. Targeted anti-CTLA-4 therapies have shown promise in patients advanced melanoma.

Immunotherapy for Breast Cancer

The success of immunotherapy in melanoma, lung and other cancers has spurred interest in pursuing these strategies in breast cancer. In fact, some recent studies have demonstrated that in addition to blocking the HER2 receptor to prevent growth of cancer cells, trastuzumab (FDA approved in 1998 for the treatment of HER2+ breast cancer) also recruits immune cells to attack the cancer cells. BCRF investigator Sherene Loi has shown that a better immune response is associated with better outcomes. A new clinical trial co-chaired by Dr. Loi is currently underway. Other trials include:

A phase Ib/II trial (NCT02129556) evaluating the efficacy of targeting PD-1 with a new drug, MK-3475) in combination with trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancer. This study is currently recruiting patients and primary outcome results are expected by December 2017.

BCRF investigator, Leisha Emens is the principal investigator of a phase II study (NCT00399529) to assess the safety, clinical benefit, and bioactivity of the cancer vaccine GM-CSF in combination with other drugs in HER2-positive metastatic breast cancer. Study results published in 2014 showed a clinical benefit rate at six months and one year was 55 percent and 40 percent respectively. Median progression-free survival (PFS) and overall survival (OS) were 7 and 42 months respectively.

BCRF has been at the vanguard in breast cancer research since its founding 23 years ago and its commitment to fund innovative research. As a result, BCRF has played a role in every major clinical advancement in breast cancer. With the re-emergence of immunotherapy as a viable treatment for cancer, BCRF investigators are pursuing innovative research and clinical trials to explore its potential for breast cancer patients.

Last year, BCRF invested $6.5 million in immunology-related projects including studies to identify immune biomarkers that can ultimately be used to predict treatment response and new targeted and combination therapies that will hopefully lead to better outcomes in breast cancer. In addition to those mentioned above, BCRF investigators leading the way in this work include Karen Anderson, Susan Domchek,  Elizabeth Jaffee,  Annette Khaled, Silvia Formenti, Sandra Demaria, and Robert Vonderheide.

# data[].attributes.body.processed
As Cancer Immunotherapy Month passes, BCRF reviews the history of cancer immunotherapy, its recent advancements and its role in breast cancer treatment.

The immune system is the body’s natural defense against foreign pathogens. Under normal conditions, the immune system works through a coordination of on and off switches that identify and destroy diseased and abnormal cells. Defects in the on/off switches can result in immune-related diseases where the immune system fails to recognize pathogens as foreign (e.g. HIV-AIDS) or where the immune system fails to recognize normal cells as “self” and launches an inappropriate attack on healthy systems (e.g. rheumatoid arthritis). Likewise, when normal cells mutate to become cancerous they may appear different from normal cells and activate an immune response. Conversely, cancer cells may disguise themselves and go undetected or deactivate the immune system to block an immune response.

What is Cancer Immunotherapy?

At its simplest, cancer immunotherapy involves harnessing a patient’s immune system to attack cancer cells. Scientists have known for more than a century that the immune system can detect and kill cancer cells, but successful cancer immunotherapy has been elusive for patients. An explosion of research more recently has increased our understanding of immune- and tumor-cell biology and unveiled potential ways to unmask tumor cells and make them visible to the immune system. Major discoveries in immune-targeted therapies are leading the way in a new era of cancer immunotherapy and clinical trials are ongoing in different cancer types including breast cancer.

Where is Cancer Immunotherapy Today?

There are several immune-based strategies being pursued as potential anti-cancer therapies. These include cancer vaccines, adoptive cell transfer, and drugs that modulate the immune system.

Cancer vaccines are designed to prevent cancer from developing, or to strengthen the immune system to increase its efficacy in recognizing and killing cancer cells.

In 2010 the FDA approved the first cancer vaccine, Sipuleucel-T (Provenge) for treatment of advanced prostate cancer. The vaccine stimulates the immune system to target a protein expressed on prostate cancer cells.

Adoptive cell therapy involves removing immune cells from a patient, genetically or chemically re-engineering them to enhance their anti-tumor activity, and re-introducing them back into the patient.

A new trial is using advanced gene-editing technologies to modify T-cells to boost their anti-cancer killing efficiency of cancer in patients with myeloma, sarcoma, or melanoma who have stopped responding to existing treatments.

Immune checkpoint therapy restores the normal immune response by preventing tumor cells from shutting it down. Two targets of this therapy are:

PDL-1/ PD-1. Tumor cells increase these proteins to dampen immune response. Monoclonal antibodies to block PDL-1/PD-1 interaction have shown success in lung cancer and other cancer types.

CTLA-4. This protein also acts to put the brakes on the immune system. Targeted anti-CTLA-4 therapies have shown promise in patients advanced melanoma.

Immunotherapy for Breast Cancer

The success of immunotherapy in melanoma, lung and other cancers has spurred interest in pursuing these strategies in breast cancer. In fact, some recent studies have demonstrated that in addition to blocking the HER2 receptor to prevent growth of cancer cells, trastuzumab (FDA approved in 1998 for the treatment of HER2+ breast cancer) also recruits immune cells to attack the cancer cells. BCRF investigator Sherene Loi has shown that a better immune response is associated with better outcomes. A new clinical trial co-chaired by Dr. Loi is currently underway. Other trials include:

A phase Ib/II trial (NCT02129556) evaluating the efficacy of targeting PD-1 with a new drug, MK-3475) in combination with trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancer. This study is currently recruiting patients and primary outcome results are expected by December 2017.

BCRF investigator, Leisha Emens is the principal investigator of a phase II study (NCT00399529) to assess the safety, clinical benefit, and bioactivity of the cancer vaccine GM-CSF in combination with other drugs in HER2-positive metastatic breast cancer. Study results published in 2014 showed a clinical benefit rate at six months and one year was 55 percent and 40 percent respectively. Median progression-free survival (PFS) and overall survival (OS) were 7 and 42 months respectively.

BCRF has been at the vanguard in breast cancer research since its founding 23 years ago and its commitment to fund innovative research. As a result, BCRF has played a role in every major clinical advancement in breast cancer. With the re-emergence of immunotherapy as a viable treatment for cancer, BCRF investigators are pursuing innovative research and clinical trials to explore its potential for breast cancer patients.

Last year, BCRF invested $6.5 million in immunology-related projects including studies to identify immune biomarkers that can ultimately be used to predict treatment response and new targeted and combination therapies that will hopefully lead to better outcomes in breast cancer. In addition to those mentioned above, BCRF investigators leading the way in this work include Karen Anderson, Susan Domchek,  Elizabeth Jaffee,  Annette Khaled, Silvia Formenti, Sandra Demaria, and Robert Vonderheide.

# data[].attributes.field_subtitle
Immunotherapy is making a comeback in the treatment of cancer. What will that mean for breast cancer patients?

# data[].attributes.title
After Losing Her Mother to Breast Cancer, Marisa Renee Lee “Had to Do Something”

# data[].attributes.metatag_normalized[].attributes.content
After Losing Her Mother to Breast Cancer, Marisa Renee Lee “Had to Do Something” | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Unable to heal her mother’s breast cancer, Marisa Renee Lee sought a way to make an impact on the disease that ultimately took her mother’s life. Her desire to eradicate breast cancer and find some meaning in her mother’s battle became her driving force as well as a coping mechanism. Born was The Pink Agenda (TPA), a not-for-profit committed to raising money for breast cancer research and care, as well as awareness of the disease among young professionals.
Marisa was preparing to graduate from Harvard when she learned her mother had stage IV breast cancer. Her mother had experienced many health challenges over her lifetime, including multiple sclerosis, so wellness was always top of mind for the family. “She was someone who, given her health challenges, took really good care of herself. She had mammograms twice a year. More than anything [her diagnosis] was a shock,” said Marisa.
Forming an organization was never Marisa’s goal, instead, it happened organically as a way to cope with her mother’s disease. She vividly recalls her moment of inspiration: “It was after watching a really dramatic episode of ‘Grey’s Anatomy’ when the character George’s father was cut open after a heart attack and it turned out he had cancer. I realized what the disease looked like on organs, and realized this is what was happening inside my mom’s body. I needed to do something.”
TPA was founded in the spring of 2007 and started as a party at The Princeton Club which Marisa hosted alongside co-founders Liana M. Douillet Guzmán and Jaquelyn M. Scharnick to raise funds for breast cancer research. Marisa’s mother passed away less than a year later on February 28, 2008. “I was so broken by my loss, I needed something else to help me put the pieces back together. My mom was my best friend and I needed an outlet for my grief or else I thought I might lose my mind.”
Reflecting on the need to advance research, Marisa explains, “We’re in a place where we could see certain forms of cancer actually be eradicated in our lifetime.” Today, TPA has contributed over one million dollars to fund breast cancer research and care, and has galvanized young people across the nation to find a cure. This October, TPA will host its 9th Annual Gala in New York City, and continues to expand through its chapters in Washington D.C., Atlanta and Boston.
“This organization is a major part of what remains of my mom--my memories, my family and The Pink Agenda,” said Marisa.

Outside of the hard work that goes into leading a non-profit, Marisa currently serves as managing director of My Brother’s Keeper Alliance, a non-profit based on the White House's effort to improve the lives of boys and young men of color, an issue Marisa worked on previously during her tenure at the White House.
“Before my mom died, when she was no longer undergoing treatment, I promised her that while there would be sad days after we lost her, there would be no bad days. We would find a way to only produce good things from this loss we were forced to experience, and I think we are doing okay.”
Learn more about The Pink Agenda and follow on Facebook, Instagram and Twitter.
Read more about Marisa’s story on Huffington Post.
 
 

# data[].attributes.metatag_normalized[].attributes.content
After Losing Her Mother to Breast Cancer, Marisa Renee Lee “Had to Do Something”

# data[].attributes.metatag_normalized[].attributes.content
Unable to heal her mother’s breast cancer, Marisa Renee Lee sought a way to make an impact on the disease that ultimately took her mother’s life. Her desire to eradicate breast cancer and find some meaning in her mother’s battle became her driving force as well as a coping mechanism. Born was The Pink Agenda (TPA), a not-for-profit committed to raising money for breast cancer research and care, as well as awareness of the disease among young professionals.

# data[].attributes.metatag_normalized[].attributes.content
After Losing Her Mother to Breast Cancer, Marisa Renee Lee “Had to Do Something”

# data[].attributes.metatag_normalized[].attributes.content
By founding The Pink Agenda, “something” turned into over $1 million raised for research.

# data[].attributes.metatag_normalized[].attributes.content
Unable to heal her mother’s breast cancer, Marisa Renee Lee sought a way to make an impact on the disease that ultimately took her mother’s life. Her desire to eradicate breast cancer and find some meaning in her mother’s battle became her driving force as well as a coping mechanism. Born was The Pink Agenda (TPA), a not-for-profit committed to raising money for breast cancer research and care, as well as awareness of the disease among young professionals.

# data[].attributes.metatag_normalized[].attributes.content
After Losing Her Mother to Breast Cancer, Marisa Renee Lee “Had to Do Something”

# data[].attributes.body.value
Unable to heal her mother’s breast cancer, Marisa Renee Lee sought a way to make an impact on the disease that ultimately took her mother’s life. Her desire to eradicate breast cancer and find some meaning in her mother’s battle became her driving force as well as a coping mechanism. Born was The Pink Agenda (TPA), a not-for-profit committed to raising money for breast cancer research and care, as well as awareness of the disease among young professionals.

Marisa was preparing to graduate from Harvard when she learned her mother had stage IV breast cancer. Her mother had experienced many health challenges over her lifetime, including multiple sclerosis, so wellness was always top of mind for the family. “She was someone who, given her health challenges, took really good care of herself. She had mammograms twice a year. More than anything [her diagnosis] was a shock,” said Marisa.

Forming an organization was never Marisa’s goal, instead, it happened organically as a way to cope with her mother’s disease. She vividly recalls her moment of inspiration: “It was after watching a really dramatic episode of ‘Grey’s Anatomy’ when the character George’s father was cut open after a heart attack and it turned out he had cancer. I realized what the disease looked like on organs, and realized this is what was happening inside my mom’s body. I needed to do something.”

TPA was founded in the spring of 2007 and started as a party at The Princeton Club which Marisa hosted alongside co-founders Liana M. Douillet Guzmán and Jaquelyn M. Scharnick to raise funds for breast cancer research. Marisa’s mother passed away less than a year later on February 28, 2008. “I was so broken by my loss, I needed something else to help me put the pieces back together. My mom was my best friend and I needed an outlet for my grief or else I thought I might lose my mind.”

Reflecting on the need to advance research, Marisa explains, “We’re in a place where we could see certain forms of cancer actually be eradicated in our lifetime.” Today, TPA has contributed over one million dollars to fund breast cancer research and care, and has galvanized young people across the nation to find a cure. This October, TPA will host its 9th Annual Gala in New York City, and continues to expand through its chapters in Washington D.C., Atlanta and Boston.

“This organization is a major part of what remains of my mom--my memories, my family and The Pink Agenda,” said Marisa.

Outside of the hard work that goes into leading a non-profit, Marisa currently serves as managing director of My Brother’s Keeper Alliance, a non-profit based on the White House's effort to improve the lives of boys and young men of color, an issue Marisa worked on previously during her tenure at the White House.

“Before my mom died, when she was no longer undergoing treatment, I promised her that while there would be sad days after we lost her, there would be no bad days. We would find a way to only produce good things from this loss we were forced to experience, and I think we are doing okay.”

Learn more about The Pink Agenda and follow on Facebook, Instagram and Twitter.

Read more about Marisa’s story on Huffington Post.

# data[].attributes.body.processed
Unable to heal her mother’s breast cancer, Marisa Renee Lee sought a way to make an impact on the disease that ultimately took her mother’s life. Her desire to eradicate breast cancer and find some meaning in her mother’s battle became her driving force as well as a coping mechanism. Born was The Pink Agenda (TPA), a not-for-profit committed to raising money for breast cancer research and care, as well as awareness of the disease among young professionals.

Marisa was preparing to graduate from Harvard when she learned her mother had stage IV breast cancer. Her mother had experienced many health challenges over her lifetime, including multiple sclerosis, so wellness was always top of mind for the family. “She was someone who, given her health challenges, took really good care of herself. She had mammograms twice a year. More than anything [her diagnosis] was a shock,” said Marisa.

Forming an organization was never Marisa’s goal, instead, it happened organically as a way to cope with her mother’s disease. She vividly recalls her moment of inspiration: “It was after watching a really dramatic episode of ‘Grey’s Anatomy’ when the character George’s father was cut open after a heart attack and it turned out he had cancer. I realized what the disease looked like on organs, and realized this is what was happening inside my mom’s body. I needed to do something.”

TPA was founded in the spring of 2007 and started as a party at The Princeton Club which Marisa hosted alongside co-founders Liana M. Douillet Guzmán and Jaquelyn M. Scharnick to raise funds for breast cancer research. Marisa’s mother passed away less than a year later on February 28, 2008. “I was so broken by my loss, I needed something else to help me put the pieces back together. My mom was my best friend and I needed an outlet for my grief or else I thought I might lose my mind.”

Reflecting on the need to advance research, Marisa explains, “We’re in a place where we could see certain forms of cancer actually be eradicated in our lifetime.” Today, TPA has contributed over one million dollars to fund breast cancer research and care, and has galvanized young people across the nation to find a cure. This October, TPA will host its 9th Annual Gala in New York City, and continues to expand through its chapters in Washington D.C., Atlanta and Boston.

“This organization is a major part of what remains of my mom--my memories, my family and The Pink Agenda,” said Marisa.

Outside of the hard work that goes into leading a non-profit, Marisa currently serves as managing director of My Brother’s Keeper Alliance, a non-profit based on the White House's effort to improve the lives of boys and young men of color, an issue Marisa worked on previously during her tenure at the White House.

“Before my mom died, when she was no longer undergoing treatment, I promised her that while there would be sad days after we lost her, there would be no bad days. We would find a way to only produce good things from this loss we were forced to experience, and I think we are doing okay.”

Learn more about The Pink Agenda and follow on Facebook, Instagram and Twitter.

Read more about Marisa’s story on Huffington Post.

# data[].attributes.field_subtitle
By founding The Pink Agenda, “something” turned into over $1 million raised for research.

# data[].attributes.metatag_normalized[].attributes.content
Meet the Researcher: Annette Khaled | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Dr. Annette Khaled is the Head of the Division of Cancer Research in the Burnett School of Biomedical Sciences of the College of Medicine at University of Central Florida, Orlando, FL.  Building on a strong foundation of research “firsts” beginning with her training at the National Cancer Institute, Dr. Khaled's lab recently discovered a novel peptide (CT20p) that causes cancer-specific cell death.  BCRF recently spoke with Dr. Khaled about her research and her perspectives on the future of breast cancer.
Coming full circle and back to discovery research
I am an immunologist by training. My interest in breast cancer really grew from meeting our local donors, most of whom had some connection to breast cancer either as patients or as loved ones of patients. They really helped me to understand the patient perspective and the urgency breast cancer patients feel. I am also a lab scientist and it’s easy to for us to see our research solely in terms of the next publication. That is how our success and impact is measured in academia – and drives academic promotion. As a teacher and mentor of students and postdocs, though, I realize it’s very important to convey to them that medical research has to be clinically relevant.
As a postdoc at NCI, I was encouraged to try anything. A lot of it didn't work, but it was a great learning experience. When I became faculty, I had to apply for grants and I had to stick to things that were going to work to be funded. I didn't have the same freedom to explore new ideas. My BCRF award has helped to change that.
It all started with an unexpected discovery in the lab. We uncovered a very unusual protein that caused cells to die, but not through the usual processes. There was nothing in the scientific literature to explain what we found so I decided I was going to figure it out.  Our results were so unusual, that nobody really believed them and I couldn’t get the research money I needed to do the work. Then, about five years ago, our lab identified the protein and I was able to get an NIH grant to start our current project. We named the protein CT20p and set out to understand how it works to kill cancer cells. Our BCRF project is a continuation of this NIH grant.
The experience made me realize how difficult it is to do exploratory research within the traditional funding structure.  My BCRF award has given me the ability to return to my roots and pursue exploratory science again.
CT20p–Putting the brakes on tumor cell growth
The next breakthrough in the lab came when we discovered that CT20p regulates another protein called CCT. CCT is one of a family of proteins called chaperones. Chaperones play a very important part in protein regulation and can easily be overlooked as drug targets with all the focus on genes (DNA and RNA).  When a protein is made (from the instructions from DNA), it is a single strand, or chain, of amino acids. Chaperones fold the protein so that in can interact with other cellular components to work properly. If a protein has errors in the way it folds, it may not function at all or may function in a very different way.
CCT is involved in the folding of several key proteins that become dysregulated in tumor cells, making it a very interesting target for cancer therapy.
We are currently working to understand how CCT works, why it works differently in cancer cells and what pathways are involved in upregulating it.  Then, we want to understand how it functions in patients with cancer.
We began by looking at tumor gene expression in the TCGA database- a national repository of tumor gene mutations. We found that in 51 percent of breast cancer patients, the CCT gene was upregulated, regardless of hormone receptor status or other tumor biomarkers. We have seen similar things in advanced prostate, lung and liver cancers, as well as melanoma. These findings suggest that CCT overexpression is a unique feature of cancer cells, and I believe our research will ultimately show that CCT is a driver of cellular transformation. Because it functions at a very low level in normal cells, targeted therapy against CCT should have little effect on normal healthy cells, and we're hopeful that this will be particularly beneficial in metastatic breast cancers.
Understanding CCT to design better drugs
One of the first things we noticed when we treated cancer cells with CT20p in the lab was that they could not migrate, became unattached from the plate and caused tumors to liquefy, indicating that the tumor cells are losing their connectedness to each other. We believe this is through its action on CCT.  Once the tumor cells become unattached they lose the signals they need to survive and subsequently die.  It makes sense that these dying cells would then activate the part of the immune system that cleans up dead cells and lead to an immune response, much like a vaccine might. This is an area of study supported by our BCRF award.
We are also studying CCT amplification in different breast cancer subtypes, such as luminal or basal, to see if it is more frequent in certain types of breast cancer. Overall our BCRF funds are supporting two lines of research: The first question goes back to understanding what is unique about CCT in cancer cells, what types of cancer cells are most affected and how is CT20p interfering with its function? We'd like to use this information to identify which patients would benefit most from CCT-targeted therapy.  The second component of our BCRF work is in immunotherapy. We want to confirm that by targeting CCT we can create an immunogenic response.  Ultimately, we'd like to test the combination of immunotherapy drugs, such as the checkpoint inhibitors, with anti-CCT therapy.
At the AACR Annual meeting we presented work from our BCRF project that confirms that CCT is the target of CT20p, but we are also reporting that CT20p targets a very specific subunit of CCT. From this discovery, we further identified that this particular subunit called CCT2 is the portion of CCT that is up-regulated in breast cancer patients. We're in the process of performing high-throughput screening of potential inhibitors of CCT2, specifically.
Harnessing technology and building collaboration to move the science forward
Our lab is among the first to look at CCT in the context of cancer and we're creating the resources as we go. They don't exist because no one’s done work quite this way before. I have been very fortunate to have great people in my lab as well as great collaborators. One of our lab members is a biochemist, who developed the innovative protein folding assays that helped us to make the discoveries about CCT in breast cancer. A former student of mine is now one of my collaborators working out the protein structural assays that are allowing us to do in silico drug screening.
We’re also utilizing new technologies. We will use CRISPR gene-editing to delete the CCT gene to see how it affects response to CT20 and other anti-CCT agents. We are beginning to delve into studying circulating tumor cells (CTCs) from patient blood samples, so the liquid biopsy technology will be very important to our future work.  My next step will be in finding collaborators in the stem cell field to help us to establish the molecular toolbox we need to study stem cells in patient samples.
All of these new toolkits come from collaborations with experts from different fields and that is what will help move our work and cancer research in general forward.

A future without fear of breast cancer
I see a bright future for breast cancer patients. Doctors and scientists are thinking about cancer treatments in the context of individual patients, as opposed to a one-size fits all approach. We don't have all the tools yet, but that kind of thinking is what is going to get us there. I am very optimistic that we are going to be able to substantially improve people's lives such that they live to die of something else and that we'll get there in a reasonable period of time. I get excited thinking about what we can achieve if we can make the big data accessible to all scientists and harnessing the information it holds. The challenges are to make the data accessible and interpretable and in training the research community how to use it.  
If not for BCRF…
I love the way BCRF approaches science. We need the flexibility to adjust research aims based on new discoveries, as well as new technologies, and BCRF is the only funder that allows us to do that. Without BCRF, I would have eventually done what I wanted to do and perhaps made the same discoveries, but it would have taken so much longer. 

# data[].attributes.metatag_normalized[].attributes.content
Dr. Annette Khaled is the Head of the Division of Cancer Research in the Burnett School of Biomedical Sciences of the College of Medicine at University of Central Florida, Orlando, FL.  Building on a strong foundation of research “firsts” beginning with her training at the National Cancer Institute, Dr. Khaled's lab recently discovered a novel peptide (CT20p) that causes cancer-specific cell death.  BCRF recently spoke with Dr. Khaled about her research and her perspectives on the future of breast cancer.

# data[].attributes.metatag_normalized[].attributes.content
Dr. Annette Khaled is the Head of the Division of Cancer Research in the Burnett School of Biomedical Sciences of the College of Medicine at University of Central Florida, Orlando, FL.  Building on a strong foundation of research “firsts” beginning with her training at the National Cancer Institute, Dr. Khaled's lab recently discovered a novel peptide (CT20p) that causes cancer-specific cell death.  BCRF recently spoke with Dr. Khaled about her research and her perspectives on the future of breast cancer.

# data[].attributes.body.value
Dr. Annette Khaled is the Head of the Division of Cancer Research in the Burnett School of Biomedical Sciences of the College of Medicine at University of Central Florida, Orlando, FL.  Building on a strong foundation of research “firsts” beginning with her training at the National Cancer Institute, Dr. Khaled's lab recently discovered a novel peptide (CT20p) that causes cancer-specific cell death.  BCRF recently spoke with Dr. Khaled about her research and her perspectives on the future of breast cancer.

Coming full circle and back to discovery research

I am an immunologist by training. My interest in breast cancer really grew from meeting our local donors, most of whom had some connection to breast cancer either as patients or as loved ones of patients. They really helped me to understand the patient perspective and the urgency breast cancer patients feel. I am also a lab scientist and it’s easy to for us to see our research solely in terms of the next publication. That is how our success and impact is measured in academia – and drives academic promotion. As a teacher and mentor of students and postdocs, though, I realize it’s very important to convey to them that medical research has to be clinically relevant.

As a postdoc at NCI, I was encouraged to try anything. A lot of it didn't work, but it was a great learning experience. When I became faculty, I had to apply for grants and I had to stick to things that were going to work to be funded. I didn't have the same freedom to explore new ideas. My BCRF award has helped to change that.

It all started with an unexpected discovery in the lab. We uncovered a very unusual protein that caused cells to die, but not through the usual processes. There was nothing in the scientific literature to explain what we found so I decided I was going to figure it out.  Our results were so unusual, that nobody really believed them and I couldn’t get the research money I needed to do the work. Then, about five years ago, our lab identified the protein and I was able to get an NIH grant to start our current project. We named the protein CT20p and set out to understand how it works to kill cancer cells. Our BCRF project is a continuation of this NIH grant.

The experience made me realize how difficult it is to do exploratory research within the traditional funding structure.  My BCRF award has given me the ability to return to my roots and pursue exploratory science again.

CT20p–Putting the brakes on tumor cell growth

The next breakthrough in the lab came when we discovered that CT20p regulates another protein called CCT. CCT is one of a family of proteins called chaperones. Chaperones play a very important part in protein regulation and can easily be overlooked as drug targets with all the focus on genes (DNA and RNA).  When a protein is made (from the instructions from DNA), it is a single strand, or chain, of amino acids. Chaperones fold the protein so that in can interact with other cellular components to work properly. If a protein has errors in the way it folds, it may not function at all or may function in a very different way.

CCT is involved in the folding of several key proteins that become dysregulated in tumor cells, making it a very interesting target for cancer therapy.

We are currently working to understand how CCT works, why it works differently in cancer cells and what pathways are involved in upregulating it.  Then, we want to understand how it functions in patients with cancer.

We began by looking at tumor gene expression in the TCGA database- a national repository of tumor gene mutations. We found that in 51 percent of breast cancer patients, the CCT gene was upregulated, regardless of hormone receptor status or other tumor biomarkers. We have seen similar things in advanced prostate, lung and liver cancers, as well as melanoma. These findings suggest that CCT overexpression is a unique feature of cancer cells, and I believe our research will ultimately show that CCT is a driver of cellular transformation. Because it functions at a very low level in normal cells, targeted therapy against CCT should have little effect on normal healthy cells, and we're hopeful that this will be particularly beneficial in metastatic breast cancers.

Understanding CCT to design better drugs

One of the first things we noticed when we treated cancer cells with CT20p in the lab was that they could not migrate, became unattached from the plate and caused tumors to liquefy, indicating that the tumor cells are losing their connectedness to each other. We believe this is through its action on CCT.  Once the tumor cells become unattached they lose the signals they need to survive and subsequently die.  It makes sense that these dying cells would then activate the part of the immune system that cleans up dead cells and lead to an immune response, much like a vaccine might. This is an area of study supported by our BCRF award.

We are also studying CCT amplification in different breast cancer subtypes, such as luminal or basal, to see if it is more frequent in certain types of breast cancer. Overall our BCRF funds are supporting two lines of research: The first question goes back to understanding what is unique about CCT in cancer cells, what types of cancer cells are most affected and how is CT20p interfering with its function? We'd like to use this information to identify which patients would benefit most from CCT-targeted therapy.  The second component of our BCRF work is in immunotherapy. We want to confirm that by targeting CCT we can create an immunogenic response.  Ultimately, we'd like to test the combination of immunotherapy drugs, such as the checkpoint inhibitors, with anti-CCT therapy.

At the AACR Annual meeting we presented work from our BCRF project that confirms that CCT is the target of CT20p, but we are also reporting that CT20p targets a very specific subunit of CCT. From this discovery, we further identified that this particular subunit called CCT2 is the portion of CCT that is up-regulated in breast cancer patients. We're in the process of performing high-throughput screening of potential inhibitors of CCT2, specifically.

Harnessing technology and building collaboration to move the science forward

Our lab is among the first to look at CCT in the context of cancer and we're creating the resources as we go. They don't exist because no one’s done work quite this way before. I have been very fortunate to have great people in my lab as well as great collaborators. One of our lab members is a biochemist, who developed the innovative protein folding assays that helped us to make the discoveries about CCT in breast cancer. A former student of mine is now one of my collaborators working out the protein structural assays that are allowing us to do in silico drug screening.

We’re also utilizing new technologies. We will use CRISPR gene-editing to delete the CCT gene to see how it affects response to CT20 and other anti-CCT agents. We are beginning to delve into studying circulating tumor cells (CTCs) from patient blood samples, so the liquid biopsy technology will be very important to our future work.  My next step will be in finding collaborators in the stem cell field to help us to establish the molecular toolbox we need to study stem cells in patient samples.

All of these new toolkits come from collaborations with experts from different fields and that is what will help move our work and cancer research in general forward.

A future without fear of breast cancer

I see a bright future for breast cancer patients. Doctors and scientists are thinking about cancer treatments in the context of individual patients, as opposed to a one-size fits all approach. We don't have all the tools yet, but that kind of thinking is what is going to get us there. I am very optimistic that we are going to be able to substantially improve people's lives such that they live to die of something else and that we'll get there in a reasonable period of time. I get excited thinking about what we can achieve if we can make the big data accessible to all scientists and harnessing the information it holds. The challenges are to make the data accessible and interpretable and in training the research community how to use it.

If not for BCRF…

I love the way BCRF approaches science. We need the flexibility to adjust research aims based on new discoveries, as well as new technologies, and BCRF is the only funder that allows us to do that. Without BCRF, I would have eventually done what I wanted to do and perhaps made the same discoveries, but it would have taken so much longer.

# data[].attributes.body.processed
Dr. Annette Khaled is the Head of the Division of Cancer Research in the Burnett School of Biomedical Sciences of the College of Medicine at University of Central Florida, Orlando, FL.  Building on a strong foundation of research “firsts” beginning with her training at the National Cancer Institute, Dr. Khaled's lab recently discovered a novel peptide (CT20p) that causes cancer-specific cell death.  BCRF recently spoke with Dr. Khaled about her research and her perspectives on the future of breast cancer.

Coming full circle and back to discovery research

I am an immunologist by training. My interest in breast cancer really grew from meeting our local donors, most of whom had some connection to breast cancer either as patients or as loved ones of patients. They really helped me to understand the patient perspective and the urgency breast cancer patients feel. I am also a lab scientist and it’s easy to for us to see our research solely in terms of the next publication. That is how our success and impact is measured in academia – and drives academic promotion. As a teacher and mentor of students and postdocs, though, I realize it’s very important to convey to them that medical research has to be clinically relevant.

As a postdoc at NCI, I was encouraged to try anything. A lot of it didn't work, but it was a great learning experience. When I became faculty, I had to apply for grants and I had to stick to things that were going to work to be funded. I didn't have the same freedom to explore new ideas. My BCRF award has helped to change that.

It all started with an unexpected discovery in the lab. We uncovered a very unusual protein that caused cells to die, but not through the usual processes. There was nothing in the scientific literature to explain what we found so I decided I was going to figure it out.  Our results were so unusual, that nobody really believed them and I couldn’t get the research money I needed to do the work. Then, about five years ago, our lab identified the protein and I was able to get an NIH grant to start our current project. We named the protein CT20p and set out to understand how it works to kill cancer cells. Our BCRF project is a continuation of this NIH grant.

The experience made me realize how difficult it is to do exploratory research within the traditional funding structure.  My BCRF award has given me the ability to return to my roots and pursue exploratory science again.

CT20p–Putting the brakes on tumor cell growth

The next breakthrough in the lab came when we discovered that CT20p regulates another protein called CCT. CCT is one of a family of proteins called chaperones. Chaperones play a very important part in protein regulation and can easily be overlooked as drug targets with all the focus on genes (DNA and RNA).  When a protein is made (from the instructions from DNA), it is a single strand, or chain, of amino acids. Chaperones fold the protein so that in can interact with other cellular components to work properly. If a protein has errors in the way it folds, it may not function at all or may function in a very different way.

CCT is involved in the folding of several key proteins that become dysregulated in tumor cells, making it a very interesting target for cancer therapy.

We are currently working to understand how CCT works, why it works differently in cancer cells and what pathways are involved in upregulating it.  Then, we want to understand how it functions in patients with cancer.

We began by looking at tumor gene expression in the TCGA database- a national repository of tumor gene mutations. We found that in 51 percent of breast cancer patients, the CCT gene was upregulated, regardless of hormone receptor status or other tumor biomarkers. We have seen similar things in advanced prostate, lung and liver cancers, as well as melanoma. These findings suggest that CCT overexpression is a unique feature of cancer cells, and I believe our research will ultimately show that CCT is a driver of cellular transformation. Because it functions at a very low level in normal cells, targeted therapy against CCT should have little effect on normal healthy cells, and we're hopeful that this will be particularly beneficial in metastatic breast cancers.

Understanding CCT to design better drugs

One of the first things we noticed when we treated cancer cells with CT20p in the lab was that they could not migrate, became unattached from the plate and caused tumors to liquefy, indicating that the tumor cells are losing their connectedness to each other. We believe this is through its action on CCT.  Once the tumor cells become unattached they lose the signals they need to survive and subsequently die.  It makes sense that these dying cells would then activate the part of the immune system that cleans up dead cells and lead to an immune response, much like a vaccine might. This is an area of study supported by our BCRF award.

We are also studying CCT amplification in different breast cancer subtypes, such as luminal or basal, to see if it is more frequent in certain types of breast cancer. Overall our BCRF funds are supporting two lines of research: The first question goes back to understanding what is unique about CCT in cancer cells, what types of cancer cells are most affected and how is CT20p interfering with its function? We'd like to use this information to identify which patients would benefit most from CCT-targeted therapy.  The second component of our BCRF work is in immunotherapy. We want to confirm that by targeting CCT we can create an immunogenic response.  Ultimately, we'd like to test the combination of immunotherapy drugs, such as the checkpoint inhibitors, with anti-CCT therapy.

At the AACR Annual meeting we presented work from our BCRF project that confirms that CCT is the target of CT20p, but we are also reporting that CT20p targets a very specific subunit of CCT. From this discovery, we further identified that this particular subunit called CCT2 is the portion of CCT that is up-regulated in breast cancer patients. We're in the process of performing high-throughput screening of potential inhibitors of CCT2, specifically.

Harnessing technology and building collaboration to move the science forward

Our lab is among the first to look at CCT in the context of cancer and we're creating the resources as we go. They don't exist because no one’s done work quite this way before. I have been very fortunate to have great people in my lab as well as great collaborators. One of our lab members is a biochemist, who developed the innovative protein folding assays that helped us to make the discoveries about CCT in breast cancer. A former student of mine is now one of my collaborators working out the protein structural assays that are allowing us to do in silico drug screening.

We’re also utilizing new technologies. We will use CRISPR gene-editing to delete the CCT gene to see how it affects response to CT20 and other anti-CCT agents. We are beginning to delve into studying circulating tumor cells (CTCs) from patient blood samples, so the liquid biopsy technology will be very important to our future work.  My next step will be in finding collaborators in the stem cell field to help us to establish the molecular toolbox we need to study stem cells in patient samples.

All of these new toolkits come from collaborations with experts from different fields and that is what will help move our work and cancer research in general forward.

A future without fear of breast cancer

I see a bright future for breast cancer patients. Doctors and scientists are thinking about cancer treatments in the context of individual patients, as opposed to a one-size fits all approach. We don't have all the tools yet, but that kind of thinking is what is going to get us there. I am very optimistic that we are going to be able to substantially improve people's lives such that they live to die of something else and that we'll get there in a reasonable period of time. I get excited thinking about what we can achieve if we can make the big data accessible to all scientists and harnessing the information it holds. The challenges are to make the data accessible and interpretable and in training the research community how to use it.

If not for BCRF…

I love the way BCRF approaches science. We need the flexibility to adjust research aims based on new discoveries, as well as new technologies, and BCRF is the only funder that allows us to do that. Without BCRF, I would have eventually done what I wanted to do and perhaps made the same discoveries, but it would have taken so much longer.

# data[].attributes.field_caption
Anne Showalter Orielyz Fernandez-Flores Dr. Khaled Daniel Nierenberg Ana Carr Rania Bassiouni  

# data[].attributes.title
A New Normal. A Strident Supporter Of Research.

# data[].attributes.metatag_normalized[].attributes.content
A New Normal. A Strident Supporter Of Research. | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Rebecca Scheinkman was six days shy of her 33rd birthday when learned she had metastatic breast cancer. While the diagnosis came as a shock, she turned to her past for support. At 14 years old, she was diagnosed and successfully treated for acute lymphoblastic leukemia.
“My initial reaction was, well if I did this before, I can do this again,” she said. “At least I know what to expect from chemo but I was very angry that at the ripe old age of 33, I was already diagnosed with cancer twice.”
Today, two years after her breast cancer diagnosis, Scheinkman remains in treatment and a strident supporter of breast cancer research – raising $20,000 for BCRF.
“Breast cancer research is important to me for a very selfish reason,” she said. “I want to live as long a life as possible.”
Metastatic or stage IV breast cancer has a poor survival rate, with 22 percent living five years post-diagnosis.
“I need that statistic to change so I can live to at least see my 40th birthday!” she said. “Without continued research and the development of new treatment options that won’t happen.”
New Normal
As a young woman living with breast cancer, Scheinkman has learned to adjust to a new normal.  
“Normal for me means frequent blood tests, seeing at least four different doctors on a regular basis, brain MRIs and PET-scans every few months and having to plan ahead for everything,” she said.
Unfortunately this reality harks back to her experience with childhood cancer where her afterschool activities consisted of chemotherapy treatments and doctor’s appointments.
“I went through my freshman and sophomore years completely bald, bloated from steroids, exhausted and constantly nauseous from the heavy duty chemotherapies – and pale as a ghost. It was a very isolating experience,” she said.
Tremendous Support
The 19-year gap between her two cancer diagnoses has given Scheinkman a new perspective on the disease.  Not only has she seen how research advancements have lead to better treatments, but she also draws her strength from her extensive support circle.
“Now living with breast cancer, I get above and beyond the support that I craved as a teenage cancer patient. My friends and family have also all amazed me and surpassed any expectations I had,” she said describing their ongoing support whether it’s accompanying her to a doctor’s appointments or simply being a good listener.
Their support also extends to Scheinkman’s dedication to advancing breast cancer research. She has chronicled her journey through her BCRF personal fundraising page and encouraged family and friends to donate in her honor.
“I was particularly drawn to BCRF due to their commitment specifically to research,” she said. “I like knowing that the money I raise is mostly going to research and to support grants, and not administrative fees.”
She hopes support like hers will allow researchers to make the next big breakthrough and change the way cancer is viewed altogether.
“Cancer is not a sorority or a sisterhood that is joined by choice. BCRF has a much more realistic approach to a very serious disease,” she said.

“I hope someday all cancers will become a disease of the past – like small pox and polio – and that future generations will not ever have to be diagnosed with it.”
 
To visit Rebecca's fundraising page, click here.

# data[].attributes.metatag_normalized[].attributes.content
A New Normal. A Strident Supporter Of Research.

# data[].attributes.metatag_normalized[].attributes.content
Rebecca Scheinkman was six days shy of her 33rd birthday when learned she had metastatic breast cancer. While the diagnosis came as a shock, she turned to her past for support. At 14 years old, she was diagnosed and successfully treated for acute lymphoblastic leukemia.
“My initial reaction was, well if I did this before, I can do this again,” she said. “At least I know what to expect from chemo but I was very angry that at the ripe old age of 33, I was already diagnosed with cancer twice.”

# data[].attributes.metatag_normalized[].attributes.content
A New Normal. A Strident Supporter Of Research.

# data[].attributes.metatag_normalized[].attributes.content
Diagnosed at 33 with metastatic breast cancer, Rebecca Scheinkman has inspired others to donate to BCRF, raising $20,000 in two years

# data[].attributes.metatag_normalized[].attributes.content
Rebecca Scheinkman was six days shy of her 33rd birthday when learned she had metastatic breast cancer. While the diagnosis came as a shock, she turned to her past for support. At 14 years old, she was diagnosed and successfully treated for acute lymphoblastic leukemia.
“My initial reaction was, well if I did this before, I can do this again,” she said. “At least I know what to expect from chemo but I was very angry that at the ripe old age of 33, I was already diagnosed with cancer twice.”

# data[].attributes.metatag_normalized[].attributes.content
A New Normal. A Strident Supporter Of Research.

# data[].attributes.body.value
Rebecca Scheinkman was six days shy of her 33rd birthday when learned she had metastatic breast cancer. While the diagnosis came as a shock, she turned to her past for support. At 14 years old, she was diagnosed and successfully treated for acute lymphoblastic leukemia.

“My initial reaction was, well if I did this before, I can do this again,” she said. “At least I know what to expect from chemo but I was very angry that at the ripe old age of 33, I was already diagnosed with cancer twice.”

Today, two years after her breast cancer diagnosis, Scheinkman remains in treatment and a strident supporter of breast cancer research – raising $20,000 for BCRF.

“Breast cancer research is important to me for a very selfish reason,” she said. “I want to live as long a life as possible.”

Metastatic or stage IV breast cancer has a poor survival rate, with 22 percent living five years post-diagnosis.

“I need that statistic to change so I can live to at least see my 40th birthday!” she said. “Without continued research and the development of new treatment options that won’t happen.”

New Normal

As a young woman living with breast cancer, Scheinkman has learned to adjust to a new normal.

“Normal for me means frequent blood tests, seeing at least four different doctors on a regular basis, brain MRIs and PET-scans every few months and having to plan ahead for everything,” she said.

Unfortunately this reality harks back to her experience with childhood cancer where her afterschool activities consisted of chemotherapy treatments and doctor’s appointments.

“I went through my freshman and sophomore years completely bald, bloated from steroids, exhausted and constantly nauseous from the heavy duty chemotherapies – and pale as a ghost. It was a very isolating experience,” she said.

Tremendous Support

The 19-year gap between her two cancer diagnoses has given Scheinkman a new perspective on the disease.  Not only has she seen how research advancements have lead to better treatments, but she also draws her strength from her extensive support circle.

“Now living with breast cancer, I get above and beyond the support that I craved as a teenage cancer patient. My friends and family have also all amazed me and surpassed any expectations I had,” she said describing their ongoing support whether it’s accompanying her to a doctor’s appointments or simply being a good listener.

Their support also extends to Scheinkman’s dedication to advancing breast cancer research. She has chronicled her journey through her BCRF personal fundraising page and encouraged family and friends to donate in her honor.

“I was particularly drawn to BCRF due to their commitment specifically to research,” she said. “I like knowing that the money I raise is mostly going to research and to support grants, and not administrative fees.”

She hopes support like hers will allow researchers to make the next big breakthrough and change the way cancer is viewed altogether.

“Cancer is not a sorority or a sisterhood that is joined by choice. BCRF has a much more realistic approach to a very serious disease,” she said.

“I hope someday all cancers will become a disease of the past – like small pox and polio – and that future generations will not ever have to be diagnosed with it.”

To visit Rebecca's fundraising page, click here.

# data[].attributes.body.processed
Rebecca Scheinkman was six days shy of her 33rd birthday when learned she had metastatic breast cancer. While the diagnosis came as a shock, she turned to her past for support. At 14 years old, she was diagnosed and successfully treated for acute lymphoblastic leukemia.

“My initial reaction was, well if I did this before, I can do this again,” she said. “At least I know what to expect from chemo but I was very angry that at the ripe old age of 33, I was already diagnosed with cancer twice.”

Today, two years after her breast cancer diagnosis, Scheinkman remains in treatment and a strident supporter of breast cancer research – raising $20,000 for BCRF.

“Breast cancer research is important to me for a very selfish reason,” she said. “I want to live as long a life as possible.”

Metastatic or stage IV breast cancer has a poor survival rate, with 22 percent living five years post-diagnosis.

“I need that statistic to change so I can live to at least see my 40th birthday!” she said. “Without continued research and the development of new treatment options that won’t happen.”

New Normal

As a young woman living with breast cancer, Scheinkman has learned to adjust to a new normal.

“Normal for me means frequent blood tests, seeing at least four different doctors on a regular basis, brain MRIs and PET-scans every few months and having to plan ahead for everything,” she said.

Unfortunately this reality harks back to her experience with childhood cancer where her afterschool activities consisted of chemotherapy treatments and doctor’s appointments.

“I went through my freshman and sophomore years completely bald, bloated from steroids, exhausted and constantly nauseous from the heavy duty chemotherapies – and pale as a ghost. It was a very isolating experience,” she said.

Tremendous Support

The 19-year gap between her two cancer diagnoses has given Scheinkman a new perspective on the disease.  Not only has she seen how research advancements have lead to better treatments, but she also draws her strength from her extensive support circle.

“Now living with breast cancer, I get above and beyond the support that I craved as a teenage cancer patient. My friends and family have also all amazed me and surpassed any expectations I had,” she said describing their ongoing support whether it’s accompanying her to a doctor’s appointments or simply being a good listener.

Their support also extends to Scheinkman’s dedication to advancing breast cancer research. She has chronicled her journey through her BCRF personal fundraising page and encouraged family and friends to donate in her honor.

“I was particularly drawn to BCRF due to their commitment specifically to research,” she said. “I like knowing that the money I raise is mostly going to research and to support grants, and not administrative fees.”

She hopes support like hers will allow researchers to make the next big breakthrough and change the way cancer is viewed altogether.

“Cancer is not a sorority or a sisterhood that is joined by choice. BCRF has a much more realistic approach to a very serious disease,” she said.

“I hope someday all cancers will become a disease of the past – like small pox and polio – and that future generations will not ever have to be diagnosed with it.”

To visit Rebecca's fundraising page, click here.

# data[].attributes.field_subtitle
Diagnosed at 33 with metastatic breast cancer, Rebecca Scheinkman has inspired others to donate to BCRF, raising $20,000 in two years

# data[].attributes.title
Call for Artists: Breast Cancer Commemorative Coin

# data[].attributes.metatag_normalized[].attributes.content
Call for Artists: Breast Cancer Commemorative Coin | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Earlier this spring we gathered around Congresswoman Carolyn B. Maloney at BCRF’s headquarters as she announced the signing of the Breast Cancer Commemorative Coin Bill into law by President Obama. The Breast Cancer Commemorative Coin, to be sold by the U.S. Mint in 2018, is the first pink-gold coin ever produced by the Mint and will benefit BCRF, potentially raising well over $8 million to fund lifesaving research. 
Pictured above, Congresswoman Maloney was joined by BCRF Honorary Chairman Leonard Lauder, President Myra Biblowit, Scientific Director Larry Norton and breast cancer survivors Nicole Seagriff and Roz Goldstein.
Today, the U.S. Mint is launching a public competition to design the Breast Cancer Commemorative Coin. During Phase One of the competition, which will be open from August 1 – October 17, 2016, artists are encouraged to submit their contact information and three to five work samples using the online form.
Up to 20 applicants from Phase One will be selected to participate in Phase Two, where they will create and submit designs and/or plasters for the final coin.
Ultimately one design winner will be named by the Secretary of the Treasury in spring of 2017. The winner will receive $10,000 and their initials will appear on the coins.
It provides an incredibly unique opportunity for an artist to have his or her work memorialized by a limited edition, U.S. commemorative coin. Make a lasting imprint while funding lifesaving research. Enter the competition.

# data[].attributes.metatag_normalized[].attributes.content
Call for Artists: Breast Cancer Commemorative Coin

# data[].attributes.metatag_normalized[].attributes.content
Earlier this spring we gathered around Congresswoman Carolyn B. Maloney at BCRF’s headquarters as she announced the signing of the Breast Cancer Commemorative Coin Bill into law by President Obama. The Breast Cancer Commemorative Coin, to be sold by the U.S.

# data[].attributes.metatag_normalized[].attributes.content
https://manage.bcrf.organd President Myra Biblowit" title="BCRF Scientific Director Dr. Larry Norton

# data[].attributes.metatag_normalized[].attributes.content
Call for Artists: Breast Cancer Commemorative Coin

# data[].attributes.metatag_normalized[].attributes.content
U.S. Mint Launches Public Design Competition

# data[].attributes.metatag_normalized[].attributes.content.url[]
and President Myra Biblowit" title="BCRF Scientific Director Dr. Larry Norton

# data[].attributes.metatag_normalized[].attributes.content.url[]
and President Myra Biblowit" typeof="foaf:Image" />

# data[].attributes.metatag_normalized[].attributes.content
Earlier this spring we gathered around Congresswoman Carolyn B. Maloney at BCRF’s headquarters as she announced the signing of the Breast Cancer Commemorative Coin Bill into law by President Obama. The Breast Cancer Commemorative Coin, to be sold by the U.S.

# data[].attributes.metatag_normalized[].attributes.content
Call for Artists: Breast Cancer Commemorative Coin

# data[].attributes.body.value
Earlier this spring we gathered around Congresswoman Carolyn B. Maloney at BCRF’s headquarters as she announced the signing of the Breast Cancer Commemorative Coin Bill into law by President Obama. The Breast Cancer Commemorative Coin, to be sold by the U.S. Mint in 2018, is the first pink-gold coin ever produced by the Mint and will benefit BCRF, potentially raising well over $8 million to fund lifesaving research.

Pictured above, Congresswoman Maloney was joined by BCRF Honorary Chairman Leonard Lauder, President Myra Biblowit, Scientific Director Larry Norton and breast cancer survivors Nicole Seagriff and Roz Goldstein.

Today, the U.S. Mint is launching a public competition to design the Breast Cancer Commemorative Coin. During Phase One of the competition, which will be open from August 1 – October 17, 2016, artists are encouraged to submit their contact information and three to five work samples using the online form.

Up to 20 applicants from Phase One will be selected to participate in Phase Two, where they will create and submit designs and/or plasters for the final coin.

Ultimately one design winner will be named by the Secretary of the Treasury in spring of 2017. The winner will receive $10,000 and their initials will appear on the coins.

It provides an incredibly unique opportunity for an artist to have his or her work memorialized by a limited edition, U.S. commemorative coin. Make a lasting imprint while funding lifesaving research. Enter the competition.

# data[].attributes.body.processed
Earlier this spring we gathered around Congresswoman Carolyn B. Maloney at BCRF’s headquarters as she announced the signing of the Breast Cancer Commemorative Coin Bill into law by President Obama. The Breast Cancer Commemorative Coin, to be sold by the U.S. Mint in 2018, is the first pink-gold coin ever produced by the Mint and will benefit BCRF, potentially raising well over $8 million to fund lifesaving research.

Pictured above, Congresswoman Maloney was joined by BCRF Honorary Chairman Leonard Lauder, President Myra Biblowit, Scientific Director Larry Norton and breast cancer survivors Nicole Seagriff and Roz Goldstein.

Today, the U.S. Mint is launching a public competition to design the Breast Cancer Commemorative Coin. During Phase One of the competition, which will be open from August 1 – October 17, 2016, artists are encouraged to submit their contact information and three to five work samples using the online form.

Up to 20 applicants from Phase One will be selected to participate in Phase Two, where they will create and submit designs and/or plasters for the final coin.

Ultimately one design winner will be named by the Secretary of the Treasury in spring of 2017. The winner will receive $10,000 and their initials will appear on the coins.

It provides an incredibly unique opportunity for an artist to have his or her work memorialized by a limited edition, U.S. commemorative coin. Make a lasting imprint while funding lifesaving research. Enter the competition.

# data[].attributes.field_caption
BCRF Scientific Director Dr. Larry Norton, Advisory Board Member Roz Goldstein, The Pink Agenda President Nicole Seagriff, Congresswoman Maloney, BCRF Honorary Chairman Leonard Lauder, and President Myra Biblowit 

# data[].attributes.field_subtitle
U.S. Mint Launches Public Design Competition 

# data[].attributes.title
Paddling With a Purpose. Propelling Research Forward.

# data[].attributes.metatag_normalized[].attributes.content
Paddling With a Purpose. Propelling Research Forward. | BCRF

# data[].attributes.metatag_normalized[].attributes.content
With no family history of the disease, the news came as a complete shock when Maria Baum was diagnosed with breast cancer in 2011 at the age of 42. Shortly after her diagnosis, Maria was introduced to paddle boarding by her close friend, Richard Perry. The solace she found on the water prompted her to help others affected by the disease by inspiring her beloved Hamptons community to help raise funds for lifesaving research.
As a wife, mother of four and successful business woman, Maria started paddle boarding as a way to balance her body and mind as she underwent treatment.
“At the time I wanted to try to keep [the diagnosis] to myself, I didn’t want to burden family and friends. I wanted to be that strong person for everybody else, especially my children. It was my time to let it all go, and to feel strong.”
Maria immediately was inspired to use her experience as a means of inspiring her community to support critical research. She and her husband, Larry, combined Maria’s goal to give back with her love of paddle boarding by organizing a small race and party in the Hamptons with the help of friends Richard and Lisa Perry. They were blown away by the community’s support, and Maria recognized the event’s potential to make an even greater impact.
In 2012, the Baums and the Perrys came to BCRF with their idea and, together, the Hampton’s Paddle & Party for Pink was created. The two-part event has become an annual celebration of giving; it kicks off in the morning with a World Paddle Association (WPA) paddleboard race at Havens Beach in Sag Harbor, NY. At sunset, guests gather for an evening party to raise funds for breast cancer research.
“I am so proud of the actual advances and change that we are responsible for by supporting BCRF researchers,” stated Maria Baum, who now serves on BCRF’s Board of Directors.

What began as 85 paddlers on Haven’s Beach in 2012 has grown to over 200 paddlers, including pro-surfer Laird Hamilton and his wife, world- renowned athlete, author and model Gabby Reece, supporting BCRF and Maria’s vision.
“Some people may be nervous to start a fundraiser because they are worried that they won’t hit a goal they may initially set but It doesn’t matter how much you raise because you’ll see that it takes on a life of its own. There is no failure, people shouldn’t be afraid to start,” Maria said reflecting on taking the first steps of fundraising. “It started as something that was just in my head…then we made it actionable.”
Last year, the sunset party hosted over 600 guests including Tracy Anderson, Gwyneth Paltrow, Lena Dunham, among many others.
“My kids were little when it first started five years ago, and they know it’s part of me now. This year my 8-year-old asked me ‘Why do we do this for breast cancer?’ And I was so happy that he doesn’t think of me as a sick person, but he understands how vibrant the event is and wants to know why we do what we do,” stated Maria.
BCRF’s Hamptons Paddle and Party for Pink, which has raised over $5 million to date, returns this year on August 6.
“I look around and there is not a better feeling,” Maria said of the morning paddle race. “We see so many people want to give their own time and effort, it becomes exponential. It becomes personal to them…and that is what is really incredible.”
To learn more about Hamptons Paddle and Party for Pink or to purchase tickets, click here.
To bid on this year’s one-of-a-kind paddle boards in support of BCRF, click here.

# data[].attributes.metatag_normalized[].attributes.content
Paddling With a Purpose. Propelling Research Forward.

# data[].attributes.metatag_normalized[].attributes.content
With no family history of the disease, the news came as a complete shock when Maria Baum was diagnosed with breast cancer in 2011 at the age of 42. Shortly after her diagnosis, Maria was introduced to paddle boarding by her close friend, Richard Perry. The solace she found on the water prompted her to help others affected by the disease by inspiring her beloved Hamptons community to help raise funds for lifesaving research.
As a wife, mother of four and successful business woman, Maria started paddle boarding as a way to balance her body and mind as she underwent treatment.

# data[].attributes.metatag_normalized[].attributes.content
Paddling With a Purpose. Propelling Research Forward.

# data[].attributes.metatag_normalized[].attributes.content
After her breast cancer diagnosis, Maria Baum inspires Hampton’s community to paddle for a cause

# data[].attributes.metatag_normalized[].attributes.content
With no family history of the disease, the news came as a complete shock when Maria Baum was diagnosed with breast cancer in 2011 at the age of 42. Shortly after her diagnosis, Maria was introduced to paddle boarding by her close friend, Richard Perry. The solace she found on the water prompted her to help others affected by the disease by inspiring her beloved Hamptons community to help raise funds for lifesaving research.
As a wife, mother of four and successful business woman, Maria started paddle boarding as a way to balance her body and mind as she underwent treatment.

# data[].attributes.metatag_normalized[].attributes.content
Paddling With a Purpose. Propelling Research Forward.

# data[].attributes.body.value
With no family history of the disease, the news came as a complete shock when Maria Baum was diagnosed with breast cancer in 2011 at the age of 42. Shortly after her diagnosis, Maria was introduced to paddle boarding by her close friend, Richard Perry. The solace she found on the water prompted her to help others affected by the disease by inspiring her beloved Hamptons community to help raise funds for lifesaving research.

As a wife, mother of four and successful business woman, Maria started paddle boarding as a way to balance her body and mind as she underwent treatment.

“At the time I wanted to try to keep [the diagnosis] to myself, I didn’t want to burden family and friends. I wanted to be that strong person for everybody else, especially my children. It was my time to let it all go, and to feel strong.”

Maria immediately was inspired to use her experience as a means of inspiring her community to support critical research. She and her husband, Larry, combined Maria’s goal to give back with her love of paddle boarding by organizing a small race and party in the Hamptons with the help of friends Richard and Lisa Perry. They were blown away by the community’s support, and Maria recognized the event’s potential to make an even greater impact.

In 2012, the Baums and the Perrys came to BCRF with their idea and, together, the Hampton’s Paddle & Party for Pink was created. The two-part event has become an annual celebration of giving; it kicks off in the morning with a World Paddle Association (WPA) paddleboard race at Havens Beach in Sag Harbor, NY. At sunset, guests gather for an evening party to raise funds for breast cancer research.

“I am so proud of the actual advances and change that we are responsible for by supporting BCRF researchers,” stated Maria Baum, who now serves on BCRF’s Board of Directors.

What began as 85 paddlers on Haven’s Beach in 2012 has grown to over 200 paddlers, including pro-surfer Laird Hamilton and his wife, world- renowned athlete, author and model Gabby Reece, supporting BCRF and Maria’s vision.

“Some people may be nervous to start a fundraiser because they are worried that they won’t hit a goal they may initially set but It doesn’t matter how much you raise because you’ll see that it takes on a life of its own. There is no failure, people shouldn’t be afraid to start,” Maria said reflecting on taking the first steps of fundraising. “It started as something that was just in my head…then we made it actionable.”

Last year, the sunset party hosted over 600 guests including Tracy Anderson, Gwyneth Paltrow, Lena Dunham, among many others.

“My kids were little when it first started five years ago, and they know it’s part of me now. This year my 8-year-old asked me ‘Why do we do this for breast cancer?’ And I was so happy that he doesn’t think of me as a sick person, but he understands how vibrant the event is and wants to know why we do what we do,” stated Maria.

BCRF’s Hamptons Paddle and Party for Pink, which has raised over $5 million to date, returns this year on August 6.

“I look around and there is not a better feeling,” Maria said of the morning paddle race. “We see so many people want to give their own time and effort, it becomes exponential. It becomes personal to them…and that is what is really incredible.”

To learn more about Hamptons Paddle and Party for Pink or to purchase tickets, click here.

To bid on this year’s one-of-a-kind paddle boards in support of BCRF, click here.

# data[].attributes.body.processed
With no family history of the disease, the news came as a complete shock when Maria Baum was diagnosed with breast cancer in 2011 at the age of 42. Shortly after her diagnosis, Maria was introduced to paddle boarding by her close friend, Richard Perry. The solace she found on the water prompted her to help others affected by the disease by inspiring her beloved Hamptons community to help raise funds for lifesaving research.

As a wife, mother of four and successful business woman, Maria started paddle boarding as a way to balance her body and mind as she underwent treatment.

“At the time I wanted to try to keep [the diagnosis] to myself, I didn’t want to burden family and friends. I wanted to be that strong person for everybody else, especially my children. It was my time to let it all go, and to feel strong.”

Maria immediately was inspired to use her experience as a means of inspiring her community to support critical research. She and her husband, Larry, combined Maria’s goal to give back with her love of paddle boarding by organizing a small race and party in the Hamptons with the help of friends Richard and Lisa Perry. They were blown away by the community’s support, and Maria recognized the event’s potential to make an even greater impact.

In 2012, the Baums and the Perrys came to BCRF with their idea and, together, the Hampton’s Paddle & Party for Pink was created. The two-part event has become an annual celebration of giving; it kicks off in the morning with a World Paddle Association (WPA) paddleboard race at Havens Beach in Sag Harbor, NY. At sunset, guests gather for an evening party to raise funds for breast cancer research.

“I am so proud of the actual advances and change that we are responsible for by supporting BCRF researchers,” stated Maria Baum, who now serves on BCRF’s Board of Directors.

What began as 85 paddlers on Haven’s Beach in 2012 has grown to over 200 paddlers, including pro-surfer Laird Hamilton and his wife, world- renowned athlete, author and model Gabby Reece, supporting BCRF and Maria’s vision.

“Some people may be nervous to start a fundraiser because they are worried that they won’t hit a goal they may initially set but It doesn’t matter how much you raise because you’ll see that it takes on a life of its own. There is no failure, people shouldn’t be afraid to start,” Maria said reflecting on taking the first steps of fundraising. “It started as something that was just in my head…then we made it actionable.”

Last year, the sunset party hosted over 600 guests including Tracy Anderson, Gwyneth Paltrow, Lena Dunham, among many others.

“My kids were little when it first started five years ago, and they know it’s part of me now. This year my 8-year-old asked me ‘Why do we do this for breast cancer?’ And I was so happy that he doesn’t think of me as a sick person, but he understands how vibrant the event is and wants to know why we do what we do,” stated Maria.

BCRF’s Hamptons Paddle and Party for Pink, which has raised over $5 million to date, returns this year on August 6.

“I look around and there is not a better feeling,” Maria said of the morning paddle race. “We see so many people want to give their own time and effort, it becomes exponential. It becomes personal to them…and that is what is really incredible.”

To learn more about Hamptons Paddle and Party for Pink or to purchase tickets, click here.

To bid on this year’s one-of-a-kind paddle boards in support of BCRF, click here.

# data[].attributes.field_subtitle
After her breast cancer diagnosis, Maria Baum inspires Hampton’s community to paddle for a cause

# data[].attributes.metatag_normalized[].attributes.content
Spring/Summer 2016 Pink Press Is Here! | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Want to keep up with BCRF? Take a look at the Pink Press Spring/Summer 2016, available now.
Here's a sneak peak at BCRF President Myra Biblowit's letter, as published in the recent issue of the Pink Press.

Dear Friends,
With spring melding into summer, we are embracing the seasons that represent change, growth and rejuvenation. At BCRF, we welcomed new leadership: William Lauder as Co-Chairman of our Board alongside Kinga Lampert, Dr. Judy Garber as the Chairman of our Scientific Advisory Board and Dr. Marc Hurlbert as our Chief Mission Officer.
With Dr. Larry Norton at the helm, our scientific leadership has diligently charted a path forward by allocating our funding to the best minds in science. We are proud to support the work of internationally renowned investigators while simultaneously cultivating the next generation of researchers.
In this issue of the Pink Press, we will look back at all of the incredible achievements we made last fall. During Breast Cancer Awareness Month we created a time of learning and education at our symposia, while activating change through our collective strength alongside our corporate partners.
You will also get a sneak peek inside the events that brought our scientists together and in front of our supporters in New York, Boston, Long Island, Westchester and Palm Beach. You will see how our corporate partners are engaging their employees and rallying communities across the country; and how volunteers through organizations like Play for P.I.N.K. and The Pink Agenda are harnessing their power to spur research.
Riding the momentum from fall, we launched a new campaign earlier this year that speaks to the very heart of BCRF: “Cancer Divides. We Unite.” At BCRF, we unite around research — the only way to achieve a future beyond breast cancer.
We thank our donors, corporate partners, and volunteers who have united under this single purpose: to support the most promising breast cancer research. Through our shared determination and our undivided focus, we can be the end of cancer.
With my warmest regards and my deepest gratitude, 
Myra J. Biblowit, President and CEO
Breast Cancer Research Foundation

# data[].attributes.metatag_normalized[].attributes.content
Want to keep up with BCRF? Take a look at the Pink Press Spring/Summer 2016, available now.
Here's a sneak peak at BCRF President Myra Biblowit's letter, as published in the recent issue of the Pink Press.

Dear Friends,

# data[].attributes.metatag_normalized[].attributes.content
Read about recent BCRF events, independent fundraisers and grantee achievements in the new issue

# data[].attributes.metatag_normalized[].attributes.content
Want to keep up with BCRF? Take a look at the Pink Press Spring/Summer 2016, available now.
Here's a sneak peak at BCRF President Myra Biblowit's letter, as published in the recent issue of the Pink Press.

Dear Friends,

# data[].attributes.body.value
Want to keep up with BCRF? Take a look at the Pink Press Spring/Summer 2016, available now.

Here's a sneak peak at BCRF President Myra Biblowit's letter, as published in the recent issue of the Pink Press.

Dear Friends,

With spring melding into summer, we are embracing the seasons that represent change, growth and rejuvenation. At BCRF, we welcomed new leadership: William Lauder as Co-Chairman of our Board alongside Kinga Lampert, Dr. Judy Garber as the Chairman of our Scientific Advisory Board and Dr. Marc Hurlbert as our Chief Mission Officer.

With Dr. Larry Norton at the helm, our scientific leadership has diligently charted a path forward by allocating our funding to the best minds in science. We are proud to support the work of internationally renowned investigators while simultaneously cultivating the next generation of researchers.

In this issue of the Pink Press, we will look back at all of the incredible achievements we made last fall. During Breast Cancer Awareness Month we created a time of learning and education at our symposia, while activating change through our collective strength alongside our corporate partners.

You will also get a sneak peek inside the events that brought our scientists together and in front of our supporters in New York, Boston, Long Island, Westchester and Palm Beach. You will see how our corporate partners are engaging their employees and rallying communities across the country; and how volunteers through organizations like Play for P.I.N.K. and The Pink Agenda are harnessing their power to spur research.

Riding the momentum from fall, we launched a new campaign earlier this year that speaks to the very heart of BCRF: “Cancer Divides. We Unite.” At BCRF, we unite around research — the only way to achieve a future beyond breast cancer.

We thank our donors, corporate partners, and volunteers who have united under this single purpose: to support the most promising breast cancer research. Through our shared determination and our undivided focus, we can be the end of cancer.

With my warmest regards and my deepest gratitude,

Myra J. Biblowit, President and CEO

Breast Cancer Research Foundation

# data[].attributes.body.processed
Want to keep up with BCRF? Take a look at the Pink Press Spring/Summer 2016, available now.

Here's a sneak peak at BCRF President Myra Biblowit's letter, as published in the recent issue of the Pink Press.

Dear Friends,

With spring melding into summer, we are embracing the seasons that represent change, growth and rejuvenation. At BCRF, we welcomed new leadership: William Lauder as Co-Chairman of our Board alongside Kinga Lampert, Dr. Judy Garber as the Chairman of our Scientific Advisory Board and Dr. Marc Hurlbert as our Chief Mission Officer.

With Dr. Larry Norton at the helm, our scientific leadership has diligently charted a path forward by allocating our funding to the best minds in science. We are proud to support the work of internationally renowned investigators while simultaneously cultivating the next generation of researchers.

In this issue of the Pink Press, we will look back at all of the incredible achievements we made last fall. During Breast Cancer Awareness Month we created a time of learning and education at our symposia, while activating change through our collective strength alongside our corporate partners.

You will also get a sneak peek inside the events that brought our scientists together and in front of our supporters in New York, Boston, Long Island, Westchester and Palm Beach. You will see how our corporate partners are engaging their employees and rallying communities across the country; and how volunteers through organizations like Play for P.I.N.K. and The Pink Agenda are harnessing their power to spur research.

Riding the momentum from fall, we launched a new campaign earlier this year that speaks to the very heart of BCRF: “Cancer Divides. We Unite.” At BCRF, we unite around research — the only way to achieve a future beyond breast cancer.

We thank our donors, corporate partners, and volunteers who have united under this single purpose: to support the most promising breast cancer research. Through our shared determination and our undivided focus, we can be the end of cancer.

With my warmest regards and my deepest gratitude,

Myra J. Biblowit, President and CEO

Breast Cancer Research Foundation

# data[].attributes.field_subtitle
Read about recent BCRF events, independent fundraisers and grantee achievements in the new issue

# data[].attributes.metatag_normalized[].attributes.content
2016 Symposium: Meet the Panelists | BCRF

# data[].attributes.metatag_normalized[].attributes.content
This year, BCRF’s Annual Symposium and Awards Luncheon will be held at The Waldorf Astoria on Thursday, October 27. The topic for the symposium is “Breast Cancer: Where Are We Now? Where Are We Going?” The panel will discuss and field questions from guests on the progress we’ve made in research over the last twenty years and what’s on the horizon for breast cancer research, including interesting new areas of study and some of the latest options available to patients today. This year’s panelists include:
Larry Norton, MD. Dr. Norton is medical oncologist and the Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center, New York, NY. He is co-founder of the Breast Cancer Research Foundation and has served as its Scientific Director since the Foundation's inception in 1993. Dr. Norton has dedicated his life to the eradication of cancer by activities in medical care, laboratory and clinical research, advocacy, and government. His research has focused on improving the treatments of cancer, particularly the application of mathematical methods to optimizing dose and schedule.
Judy E. Garber, MD, MPH. Dr. Garber is a medical oncologist and Director of the Center for Cancer Genetics and Prevention at the Susan Smith Center for Women's Cancers at Dana-Farber Cancer Institute, Director of the Cancer Risk and Prevention Clinic at Brigham and Women’s Hospital, and Professor of Medicine at Harvard Medical School, Boston, MA. Dr. Garber is the Chair of BCRF’s Scientific Advisory Board. Her research focuses on breast cancer genetics, risk reduction and pharmacogenetics. Using epidemiology, biostatistics and molecular biology, she leads risk reduction studies that aid in the development of interventions for individuals identified with a hereditary predisposition to breast cancer.
Charles M. Perou, PhD. Dr. Perou will be honored at this year’s Luncheon with the 2016 Jill Rose Award. He is the May Goldman Shaw Distinguished Professor of Molecular Oncology Research Professor of Genetics & Pathology and Scientific Director of the UNC Bioinformatics Core at the Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill.  Dr. Perou's research laboratory is focused on using genomics, genetics, and laboratory models to decipher the underlying biology of the molecular subtypes of breast cancer. He then uses this biological information to develop novel therapeutic strategies that are specifically targeted against each of these distinct subtypes of breast cancer.
Silvia Formenti, MD. Dr. Formenti is a radiation oncologist, Professor and Chairman of the Department of Radiation Oncology at Weill Cornell Medical College, New York, NY. She pioneered the use of concurrent chemo-radiation in locally advanced breast cancer (LABC). Her current BCRF research is focused on combining immune-modulatory agents with radiotherapy to unleash powerful anti-tumor responses and improve the outcome of metastatic breast cancer. Her laboratory is testing different combination approached to optimize the ability of radiotherapy to immunize patients against their own breast cancer and overcome resistance.
Buy your tickets now.

# data[].attributes.metatag_normalized[].attributes.content
This year, BCRF’s Annual Symposium and Awards Luncheon will be held at The Waldorf Astoria on Thursday, October 27. The topic for the symposium is “Breast Cancer: Where Are We Now? Where Are We Going?” The panel will discuss and field questions from guests on the progress we’ve made in research over the last twenty years and what’s on the horizon for breast cancer research, including interesting new areas of study and some of the latest options available to patients today. This year’s panelists include:

# data[].attributes.metatag_normalized[].attributes.content
This year, BCRF’s Annual Symposium and Awards Luncheon will be held at The Waldorf Astoria on Thursday, October 27. The topic for the symposium is “Breast Cancer: Where Are We Now? Where Are We Going?” The panel will discuss and field questions from guests on the progress we’ve made in research over the last twenty years and what’s on the horizon for breast cancer research, including interesting new areas of study and some of the latest options available to patients today. This year’s panelists include:

# data[].attributes.body.value
This year, BCRF’s Annual Symposium and Awards Luncheon will be held at The Waldorf Astoria on Thursday, October 27. The topic for the symposium is “Breast Cancer: Where Are We Now? Where Are We Going?” The panel will discuss and field questions from guests on the progress we’ve made in research over the last twenty years and what’s on the horizon for breast cancer research, including interesting new areas of study and some of the latest options available to patients today. This year’s panelists include:

Larry Norton, MD. Dr. Norton is medical oncologist and the Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center, New York, NY. He is co-founder of the Breast Cancer Research Foundation and has served as its Scientific Director since the Foundation's inception in 1993. Dr. Norton has dedicated his life to the eradication of cancer by activities in medical care, laboratory and clinical research, advocacy, and government. His research has focused on improving the treatments of cancer, particularly the application of mathematical methods to optimizing dose and schedule.

Judy E. Garber, MD, MPH. Dr. Garber is a medical oncologist and Director of the Center for Cancer Genetics and Prevention at the Susan Smith Center for Women's Cancers at Dana-Farber Cancer Institute, Director of the Cancer Risk and Prevention Clinic at Brigham and Women’s Hospital, and Professor of Medicine at Harvard Medical School, Boston, MA. Dr. Garber is the Chair of BCRF’s Scientific Advisory Board. Her research focuses on breast cancer genetics, risk reduction and pharmacogenetics. Using epidemiology, biostatistics and molecular biology, she leads risk reduction studies that aid in the development of interventions for individuals identified with a hereditary predisposition to breast cancer.

Charles M. Perou, PhD. Dr. Perou will be honored at this year’s Luncheon with the 2016 Jill Rose Award. He is the May Goldman Shaw Distinguished Professor of Molecular Oncology Research Professor of Genetics & Pathology and Scientific Director of the UNC Bioinformatics Core at the Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill.  Dr. Perou's research laboratory is focused on using genomics, genetics, and laboratory models to decipher the underlying biology of the molecular subtypes of breast cancer. He then uses this biological information to develop novel therapeutic strategies that are specifically targeted against each of these distinct subtypes of breast cancer.

Silvia Formenti, MD. Dr. Formenti is a radiation oncologist, Professor and Chairman of the Department of Radiation Oncology at Weill Cornell Medical College, New York, NY. She pioneered the use of concurrent chemo-radiation in locally advanced breast cancer (LABC). Her current BCRF research is focused on combining immune-modulatory agents with radiotherapy to unleash powerful anti-tumor responses and improve the outcome of metastatic breast cancer. Her laboratory is testing different combination approached to optimize the ability of radiotherapy to immunize patients against their own breast cancer and overcome resistance.

Buy your tickets now.

# data[].attributes.body.processed
This year, BCRF’s Annual Symposium and Awards Luncheon will be held at The Waldorf Astoria on Thursday, October 27. The topic for the symposium is “Breast Cancer: Where Are We Now? Where Are We Going?” The panel will discuss and field questions from guests on the progress we’ve made in research over the last twenty years and what’s on the horizon for breast cancer research, including interesting new areas of study and some of the latest options available to patients today. This year’s panelists include:

Larry Norton, MD. Dr. Norton is medical oncologist and the Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center, New York, NY. He is co-founder of the Breast Cancer Research Foundation and has served as its Scientific Director since the Foundation's inception in 1993. Dr. Norton has dedicated his life to the eradication of cancer by activities in medical care, laboratory and clinical research, advocacy, and government. His research has focused on improving the treatments of cancer, particularly the application of mathematical methods to optimizing dose and schedule.

Judy E. Garber, MD, MPH. Dr. Garber is a medical oncologist and Director of the Center for Cancer Genetics and Prevention at the Susan Smith Center for Women's Cancers at Dana-Farber Cancer Institute, Director of the Cancer Risk and Prevention Clinic at Brigham and Women’s Hospital, and Professor of Medicine at Harvard Medical School, Boston, MA. Dr. Garber is the Chair of BCRF’s Scientific Advisory Board. Her research focuses on breast cancer genetics, risk reduction and pharmacogenetics. Using epidemiology, biostatistics and molecular biology, she leads risk reduction studies that aid in the development of interventions for individuals identified with a hereditary predisposition to breast cancer.

Charles M. Perou, PhD. Dr. Perou will be honored at this year’s Luncheon with the 2016 Jill Rose Award. He is the May Goldman Shaw Distinguished Professor of Molecular Oncology Research Professor of Genetics & Pathology and Scientific Director of the UNC Bioinformatics Core at the Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill.  Dr. Perou's research laboratory is focused on using genomics, genetics, and laboratory models to decipher the underlying biology of the molecular subtypes of breast cancer. He then uses this biological information to develop novel therapeutic strategies that are specifically targeted against each of these distinct subtypes of breast cancer.

Silvia Formenti, MD. Dr. Formenti is a radiation oncologist, Professor and Chairman of the Department of Radiation Oncology at Weill Cornell Medical College, New York, NY. She pioneered the use of concurrent chemo-radiation in locally advanced breast cancer (LABC). Her current BCRF research is focused on combining immune-modulatory agents with radiotherapy to unleash powerful anti-tumor responses and improve the outcome of metastatic breast cancer. Her laboratory is testing different combination approached to optimize the ability of radiotherapy to immunize patients against their own breast cancer and overcome resistance.

Buy your tickets now.

# data[].attributes.title
BCRF “Goes Wild” on April 12 Raising More Than $6.8 Million for Research

# data[].attributes.metatag_normalized[].attributes.content
BCRF “Goes Wild” on April 12 Raising More Than $6.8 Million for Research | BCRF

# data[].attributes.metatag_normalized[].attributes.content
BCRF held its annual Hot Pink Party on Tuesday, April 12 at New York City’s Waldorf Astoria Hotel. The event, hosted by Elizabeth Hurley, The Estée Lauder Companies Breast Cancer Awareness Campaign Global Ambassador, raised an incredible $6.8 million. This year’s vibrant occasion reflected the theme “BCRF Goes Wild.” The evening featured a show stopping concert performance by Rock and Roll Hall of Fame legend, Sir Elton John in honor of his dear friend and former BCRF Event Co-Chair, the late Ingrid Sischy.
Sir Elton John’s unforgettable performance capped off an evening that celebrated the gift of friendship. Just before his performance, Mr. Leonard A. Lauder recognized Sir Elton John’s commitment to BCRF for the past 15 years by endowing a BCRF research grant in his name. The Sir Elton John Award will be issued to a U.K. based researcher in perpetuity.
“I'm so honored to pay tribute to my dear friend Evelyn Lauder tonight,” said Sir Elton John. “Her memory along with everyone we've lost to this devastating disease is a constant reminder of how critically important research is. I'm deeply moved to be a part of BCRF's mission now and in the many years to come."

The Foundation’s dear friend Melinda Blinken received the 2016 Roslyn and Leslie Goldstein Unsung Hero Award from Gail Hilson for her unwavering support to many friends affected by breast cancer, including BCRF Founder, Evelyn H. Lauder.
The evening also featured a special announcement about a new formal collaboration between BCRF and the Women’s Cancer Research Fund (WCRF), founded by Kate Capshaw, Kelly Chapman Meyer, Anne Douglas, Quinn Ezralow, Marion Laurie, Jamie Tisch and Rita Wilson.
Noteworthy guests in attendance included: Tracy Anderson, LaLa Anthony, Nigel Barker, David Alan Basche, Ann Caruso, Olivia Culpo, Misty Copeland, Aviva Drescher, Bethenny Frankel, Jeff Gordon, Kinga Lampert, Leonard A. Lauder, Judith Glickman-Lauder, Jane Lauder, William P. Lauder, Katie Lee, Jill Martin, Patina Miller, Deborah Norville, Carole Radziwill, Alysia Reiner, Danielle Snyder, Beth Stern, Dominico Vacca, Vera Wang, Alison Wright and Lois Robbins Zaro.
Event co-chairs include Sandra Brant, Tory Burch, Cindy and Rob Citrone, Marjorie Reed Gordon, Mindy and Jon Gray, Donna Karan, Michael Kors, Kinga Lampert, Aerin Lauder, Jane Lauder, Jo Carole and Ronald S. Lauder, Judy and Leonard Lauder, Laura and Gary Lauder, William P. Lauder, Pat and John Rosenwald, Jeanne and Herbert Siegel, Jamie Tisch, Lizzie and Jonathan Tisch, Vera Wang, Lois Robbins and Andrew Zaro.
The elegant design and décor elements for the evening were generously provided by Bryan Rafanelli, longtime BCRF supporter.
The event’s underwriters included ANN Inc.; Kinga and Edward Lampert; von Mandl Family Foundation; Cindy and Rob Citrone; Condé Nast; Firmenich; Roslyn and Leslie Goldstein; Hearst Corporation; The Lauder Foundation—Leonard & Judy Lauder Fund; Rafanelli Events; Winston Flowers. 
To learn more about the Hot Pink Party or to donate, click here.

# data[].attributes.metatag_normalized[].attributes.content
BCRF “Goes Wild” on April 12 Raising More Than $6.8 Million for Research

# data[].attributes.metatag_normalized[].attributes.content
BCRF held its annual Hot Pink Party on Tuesday, April 12 at New York City’s Waldorf Astoria Hotel. The event, hosted by Elizabeth Hurley, The Estée Lauder Companies Breast Cancer Awareness Campaign Global Ambassador, raised an incredible $6.8 million. This year’s vibrant occasion reflected the theme “BCRF Goes Wild.” The evening featured a show stopping concert performance by Rock and Roll Hall of Fame legend, Sir Elton John in honor of his dear friend and former BCRF Event Co-Chair, the late Ingrid Sischy.

# data[].attributes.metatag_normalized[].attributes.content
BCRF “Goes Wild” on April 12 Raising More Than $6.8 Million for Research

# data[].attributes.metatag_normalized[].attributes.content
BCRF Honorary Chairman Leonard A. Lauder Endows New Grant in Honor of Sir Elton John’s Unwavering Support of BCRF

# data[].attributes.metatag_normalized[].attributes.content
BCRF held its annual Hot Pink Party on Tuesday, April 12 at New York City’s Waldorf Astoria Hotel. The event, hosted by Elizabeth Hurley, The Estée Lauder Companies Breast Cancer Awareness Campaign Global Ambassador, raised an incredible $6.8 million. This year’s vibrant occasion reflected the theme “BCRF Goes Wild.” The evening featured a show stopping concert performance by Rock and Roll Hall of Fame legend, Sir Elton John in honor of his dear friend and former BCRF Event Co-Chair, the late Ingrid Sischy.

# data[].attributes.metatag_normalized[].attributes.content
BCRF “Goes Wild” on April 12 Raising More Than $6.8 Million for Research

# data[].attributes.body.value
BCRF held its annual Hot Pink Party on Tuesday, April 12 at New York City’s Waldorf Astoria Hotel. The event, hosted by Elizabeth Hurley, The Estée Lauder Companies Breast Cancer Awareness Campaign Global Ambassador, raised an incredible $6.8 million. This year’s vibrant occasion reflected the theme “BCRF Goes Wild.” The evening featured a show stopping concert performance by Rock and Roll Hall of Fame legend, Sir Elton John in honor of his dear friend and former BCRF Event Co-Chair, the late Ingrid Sischy.

Sir Elton John’s unforgettable performance capped off an evening that celebrated the gift of friendship. Just before his performance, Mr. Leonard A. Lauder recognized Sir Elton John’s commitment to BCRF for the past 15 years by endowing a BCRF research grant in his name. The Sir Elton John Award will be issued to a U.K. based researcher in perpetuity.

“I'm so honored to pay tribute to my dear friend Evelyn Lauder tonight,” said Sir Elton John. “Her memory along with everyone we've lost to this devastating disease is a constant reminder of how critically important research is. I'm deeply moved to be a part of BCRF's mission now and in the many years to come."

The Foundation’s dear friend Melinda Blinken received the 2016 Roslyn and Leslie Goldstein Unsung Hero Award from Gail Hilson for her unwavering support to many friends affected by breast cancer, including BCRF Founder, Evelyn H. Lauder.

The evening also featured a special announcement about a new formal collaboration between BCRF and the Women’s Cancer Research Fund (WCRF), founded by Kate Capshaw, Kelly Chapman Meyer, Anne Douglas, Quinn Ezralow, Marion Laurie, Jamie Tisch and Rita Wilson.

Noteworthy guests in attendance included: Tracy Anderson, LaLa Anthony, Nigel Barker, David Alan Basche, Ann Caruso, Olivia Culpo, Misty Copeland, Aviva Drescher, Bethenny Frankel, Jeff Gordon, Kinga Lampert, Leonard A. Lauder, Judith Glickman-Lauder, Jane Lauder, William P. Lauder, Katie Lee, Jill Martin, Patina Miller, Deborah Norville, Carole Radziwill, Alysia Reiner, Danielle Snyder, Beth Stern, Dominico Vacca, Vera Wang, Alison Wright and Lois Robbins Zaro.

Event co-chairs include Sandra Brant, Tory Burch, Cindy and Rob Citrone, Marjorie Reed Gordon, Mindy and Jon Gray, Donna Karan, Michael Kors, Kinga Lampert, Aerin Lauder, Jane Lauder, Jo Carole and Ronald S. Lauder, Judy and Leonard Lauder, Laura and Gary Lauder, William P. Lauder, Pat and John Rosenwald, Jeanne and Herbert Siegel, Jamie Tisch, Lizzie and Jonathan Tisch, Vera Wang, Lois Robbins and Andrew Zaro.

The elegant design and décor elements for the evening were generously provided by Bryan Rafanelli, longtime BCRF supporter.

The event’s underwriters included ANN Inc.; Kinga and Edward Lampert; von Mandl Family Foundation; Cindy and Rob Citrone; Condé Nast; Firmenich; Roslyn and Leslie Goldstein; Hearst Corporation; The Lauder Foundation—Leonard & Judy Lauder Fund; Rafanelli Events; Winston Flowers.

To learn more about the Hot Pink Party or to donate, click here.

# data[].attributes.body.processed
BCRF held its annual Hot Pink Party on Tuesday, April 12 at New York City’s Waldorf Astoria Hotel. The event, hosted by Elizabeth Hurley, The Estée Lauder Companies Breast Cancer Awareness Campaign Global Ambassador, raised an incredible $6.8 million. This year’s vibrant occasion reflected the theme “BCRF Goes Wild.” The evening featured a show stopping concert performance by Rock and Roll Hall of Fame legend, Sir Elton John in honor of his dear friend and former BCRF Event Co-Chair, the late Ingrid Sischy.

Sir Elton John’s unforgettable performance capped off an evening that celebrated the gift of friendship. Just before his performance, Mr. Leonard A. Lauder recognized Sir Elton John’s commitment to BCRF for the past 15 years by endowing a BCRF research grant in his name. The Sir Elton John Award will be issued to a U.K. based researcher in perpetuity.

“I'm so honored to pay tribute to my dear friend Evelyn Lauder tonight,” said Sir Elton John. “Her memory along with everyone we've lost to this devastating disease is a constant reminder of how critically important research is. I'm deeply moved to be a part of BCRF's mission now and in the many years to come."

The Foundation’s dear friend Melinda Blinken received the 2016 Roslyn and Leslie Goldstein Unsung Hero Award from Gail Hilson for her unwavering support to many friends affected by breast cancer, including BCRF Founder, Evelyn H. Lauder.

The evening also featured a special announcement about a new formal collaboration between BCRF and the Women’s Cancer Research Fund (WCRF), founded by Kate Capshaw, Kelly Chapman Meyer, Anne Douglas, Quinn Ezralow, Marion Laurie, Jamie Tisch and Rita Wilson.

Noteworthy guests in attendance included: Tracy Anderson, LaLa Anthony, Nigel Barker, David Alan Basche, Ann Caruso, Olivia Culpo, Misty Copeland, Aviva Drescher, Bethenny Frankel, Jeff Gordon, Kinga Lampert, Leonard A. Lauder, Judith Glickman-Lauder, Jane Lauder, William P. Lauder, Katie Lee, Jill Martin, Patina Miller, Deborah Norville, Carole Radziwill, Alysia Reiner, Danielle Snyder, Beth Stern, Dominico Vacca, Vera Wang, Alison Wright and Lois Robbins Zaro.

Event co-chairs include Sandra Brant, Tory Burch, Cindy and Rob Citrone, Marjorie Reed Gordon, Mindy and Jon Gray, Donna Karan, Michael Kors, Kinga Lampert, Aerin Lauder, Jane Lauder, Jo Carole and Ronald S. Lauder, Judy and Leonard Lauder, Laura and Gary Lauder, William P. Lauder, Pat and John Rosenwald, Jeanne and Herbert Siegel, Jamie Tisch, Lizzie and Jonathan Tisch, Vera Wang, Lois Robbins and Andrew Zaro.

The elegant design and décor elements for the evening were generously provided by Bryan Rafanelli, longtime BCRF supporter.

The event’s underwriters included ANN Inc.; Kinga and Edward Lampert; von Mandl Family Foundation; Cindy and Rob Citrone; Condé Nast; Firmenich; Roslyn and Leslie Goldstein; Hearst Corporation; The Lauder Foundation—Leonard & Judy Lauder Fund; Rafanelli Events; Winston Flowers.

To learn more about the Hot Pink Party or to donate, click here.

# data[].attributes.field_caption
Sir Elton John performs at BCRF's Hot Pink Party

# data[].attributes.field_subtitle
 BCRF Honorary Chairman Leonard A. Lauder Endows New Grant in Honor of Sir Elton John’s Unwavering Support of BCRF

# data[].attributes.metatag_normalized[].attributes.content
Breaking Records While Funding Research | BCRF

# data[].attributes.metatag_normalized[].attributes.content
What do breaking a Guinness World Record and raising money for breast cancer research have in common? They both require tenacity, courage, and, as the folks behind One Square Mile of Hope know, the willingness to think outside the box.
One Square Mile of Hope is the brainchild of a small group of friends from Inlet, a tiny town of less than 400 people nestled in New York’s Adirondack Mountains. After Connie Perry, who owns a local kayak business, lost a friend to breast cancer in 2007, she and her neighbors wanted to come up with a creative way to rally behind research.
“Someone in town came up with the idea of a Guinness Record attempt for the largest raft of canoes, kayaks and guide boats,” said Carolyn Belknap, co-chair of the One Square Mile of Hope Committee.
The idea caught on quickly and, in 2008, the first One Square Mile of Hope took to the water. More than 1,100 boats converged on Fourth Lake and shattered the Guinness World Record set in 2001 by 776 boats on Cleveland’s Hinckley Lake. The Inlet team held the record until a Pennsylvania group topped it in 2010.
One Square Mile of Hope’s response? Take it back. And they did, setting a new record in 2011 with 1,902 boats. So in 2013, when a group on Lake Michigan broke One Square Mile’s second time as world champs, there was only one real option for the New York community.
“We geared up to take the record back,” Carolyn said. The One Square Mile of Hope 2014 committee, along with the Kiwanis Club of the Central Adirondacks, began planning in December 2013 to reclaim the Guinness title. The event, which has become a town favorite since its start six years ago, had people registering as soon as it was announced.
“It’s become much more than coming out to raise a little bit of money,” Carolyn said. “It’s the camaraderie and the support people feel for those who have lost someone and those who are survivors.”
So on Saturday, September 13, despite the rainy weather and cool winds, more than 2,700 boats gathered for the third time to reclaim their Guinness World Record and raise more than $100,000 for research. Though the official number will take some time for the Guinness group to confirm, Carolyn is confident that One Square Mile has pulled it off again.
“I’ve already had people asking me if we’ll do it again next year!” she laughed. “It’s quite something to see a small town like this galvanize for a cause. We all know people who have had breast cancer and it’s just caught on here for us.”
Watch a time-lapse video of the event here.

# data[].attributes.metatag_normalized[].attributes.content
What do breaking a Guinness World Record and raising money for breast cancer research have in common? They both require tenacity, courage, and, as the folks behind One Square Mile of Hope know, the willingness to think outside the box.

# data[].attributes.metatag_normalized[].attributes.content
How a group in tiny Inlet, NY, raised more than $100,000 for breast cancer research — and broke a Guinness World Record in the process.

# data[].attributes.metatag_normalized[].attributes.content
What do breaking a Guinness World Record and raising money for breast cancer research have in common? They both require tenacity, courage, and, as the folks behind One Square Mile of Hope know, the willingness to think outside the box.

# data[].attributes.body.value
What do breaking a Guinness World Record and raising money for breast cancer research have in common? They both require tenacity, courage, and, as the folks behind One Square Mile of Hope know, the willingness to think outside the box.

One Square Mile of Hope is the brainchild of a small group of friends from Inlet, a tiny town of less than 400 people nestled in New York’s Adirondack Mountains. After Connie Perry, who owns a local kayak business, lost a friend to breast cancer in 2007, she and her neighbors wanted to come up with a creative way to rally behind research.

“Someone in town came up with the idea of a Guinness Record attempt for the largest raft of canoes, kayaks and guide boats,” said Carolyn Belknap, co-chair of the One Square Mile of Hope Committee.

The idea caught on quickly and, in 2008, the first One Square Mile of Hope took to the water. More than 1,100 boats converged on Fourth Lake and shattered the Guinness World Record set in 2001 by 776 boats on Cleveland’s Hinckley Lake. The Inlet team held the record until a Pennsylvania group topped it in 2010.

One Square Mile of Hope’s response? Take it back. And they did, setting a new record in 2011 with 1,902 boats. So in 2013, when a group on Lake Michigan broke One Square Mile’s second time as world champs, there was only one real option for the New York community.

“We geared up to take the record back,” Carolyn said. The One Square Mile of Hope 2014 committee, along with the Kiwanis Club of the Central Adirondacks, began planning in December 2013 to reclaim the Guinness title. The event, which has become a town favorite since its start six years ago, had people registering as soon as it was announced.

“It’s become much more than coming out to raise a little bit of money,” Carolyn said. “It’s the camaraderie and the support people feel for those who have lost someone and those who are survivors.”

So on Saturday, September 13, despite the rainy weather and cool winds, more than 2,700 boats gathered for the third time to reclaim their Guinness World Record and raise more than $100,000 for research. Though the official number will take some time for the Guinness group to confirm, Carolyn is confident that One Square Mile has pulled it off again.

“I’ve already had people asking me if we’ll do it again next year!” she laughed. “It’s quite something to see a small town like this galvanize for a cause. We all know people who have had breast cancer and it’s just caught on here for us.”

Watch a time-lapse video of the event here.

# data[].attributes.body.processed
What do breaking a Guinness World Record and raising money for breast cancer research have in common? They both require tenacity, courage, and, as the folks behind One Square Mile of Hope know, the willingness to think outside the box.

One Square Mile of Hope is the brainchild of a small group of friends from Inlet, a tiny town of less than 400 people nestled in New York’s Adirondack Mountains. After Connie Perry, who owns a local kayak business, lost a friend to breast cancer in 2007, she and her neighbors wanted to come up with a creative way to rally behind research.

“Someone in town came up with the idea of a Guinness Record attempt for the largest raft of canoes, kayaks and guide boats,” said Carolyn Belknap, co-chair of the One Square Mile of Hope Committee.

The idea caught on quickly and, in 2008, the first One Square Mile of Hope took to the water. More than 1,100 boats converged on Fourth Lake and shattered the Guinness World Record set in 2001 by 776 boats on Cleveland’s Hinckley Lake. The Inlet team held the record until a Pennsylvania group topped it in 2010.

One Square Mile of Hope’s response? Take it back. And they did, setting a new record in 2011 with 1,902 boats. So in 2013, when a group on Lake Michigan broke One Square Mile’s second time as world champs, there was only one real option for the New York community.

“We geared up to take the record back,” Carolyn said. The One Square Mile of Hope 2014 committee, along with the Kiwanis Club of the Central Adirondacks, began planning in December 2013 to reclaim the Guinness title. The event, which has become a town favorite since its start six years ago, had people registering as soon as it was announced.

“It’s become much more than coming out to raise a little bit of money,” Carolyn said. “It’s the camaraderie and the support people feel for those who have lost someone and those who are survivors.”

So on Saturday, September 13, despite the rainy weather and cool winds, more than 2,700 boats gathered for the third time to reclaim their Guinness World Record and raise more than $100,000 for research. Though the official number will take some time for the Guinness group to confirm, Carolyn is confident that One Square Mile has pulled it off again.

“I’ve already had people asking me if we’ll do it again next year!” she laughed. “It’s quite something to see a small town like this galvanize for a cause. We all know people who have had breast cancer and it’s just caught on here for us.”

Watch a time-lapse video of the event here.

# data[].attributes.field_subtitle
How a group in tiny Inlet, NY, raised more than $100,000 for breast cancer research — and broke a Guinness World Record in the process. 

# data[].attributes.title
What You Need to Know About Consuming Soy

# data[].attributes.metatag_normalized[].attributes.content
What You Need to Know About Consuming Soy | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Earlier this month, a new study about soy made waves in the breast cancer community. With support from BCRF, grantee Dr. Moshe Shike and his coauthors, including Scientific Director Dr. Larry Norton, published a study in the Journal of the National Cancer Institute. The randomized trial discovered that, for some women with breast cancer, taking soy protein supplements promoted the expression of tumor genes associated with an increase in tumor cells.
We chatted with Dr. Shike to learn more about what this study means for women.
The study focused on women with estrogen-receptor positive breast cancer. Should women with all types of breast cancers be cautious about their soy consumption or only those with that particular type?
All women with any type of breast cancer should exercise caution. We did not have enough patients in the study to discriminate or to come up with specifics based on estrogen receptor breast cancer — or, for that matter, any other specific kind. Women should be moderate in their intake of soy. We’re not saying don’t take soy at all; we’re just saying the results of this study may indicate some increased risk, so it’s prudent to be cautious.
The amounts of soy supplements provided to each woman in the study were two doses of 25.8 grams each. What does this translate to in terms of a normal diet? Is there a “safe” amount?
The amount of soy each woman had in the study was a relatively high dose, equal to about 3.5 cups of soymilk or about 16 oz. of tofu, which is a lot for the average woman. In this particular study, it showed that large amounts might drive proliferation of breast cancer in some women. Most women are not getting that much soy in a day.Although soy has anti-estrogenic effects, we are not sure how these effects might impact breast cancer risk. Women should avoid extremes — there’s no need to cut out soy completely, but they also shouldn’t consume large quantities.
This study included only women who currently had breast cancer. Most were post-menopausal. Should younger women or those who don’t have the disease be concerned about their soy intake?
We haven’t examined this yet. But I would advocate that this principle of moderation be applied to all women across the board, even those without breast cancer or who are younger in age. Also, we only know about breast cancer in women who have already been diagnosed. There are women walking around with very early stages of breast cancer that haven’t been detected yet. Because we don’t know the effect of soy on normal breast tissue yet, both types of women should exercise caution in the amounts of soy they consume daily.

# data[].attributes.metatag_normalized[].attributes.content
What You Need to Know About Consuming Soy

# data[].attributes.metatag_normalized[].attributes.content
Earlier this month, a new study about soy made waves in the breast cancer community. With support from BCRF, grantee Dr. Moshe Shike and his coauthors, including Scientific Director Dr. Larry Norton, published a study in the Journal of the National Cancer Institute.

# data[].attributes.metatag_normalized[].attributes.content
What You Need to Know About Consuming Soy

# data[].attributes.metatag_normalized[].attributes.content
Earlier this month, a new study about soy made waves in the breast cancer community. With support from BCRF, grantee Dr. Moshe Shike and his coauthors, including Scientific Director Dr. Larry Norton, published a study in the Journal of the National Cancer Institute.

# data[].attributes.metatag_normalized[].attributes.content
What You Need to Know About Consuming Soy

# data[].attributes.body.value
Earlier this month, a new study about soy made waves in the breast cancer community. With support from BCRF, grantee Dr. Moshe Shike and his coauthors, including Scientific Director Dr. Larry Norton, published a study in the Journal of the National Cancer Institute. The randomized trial discovered that, for some women with breast cancer, taking soy protein supplements promoted the expression of tumor genes associated with an increase in tumor cells.

We chatted with Dr. Shike to learn more about what this study means for women.

The study focused on women with estrogen-receptor positive breast cancer. Should women with all types of breast cancers be cautious about their soy consumption or only those with that particular type?

All women with any type of breast cancer should exercise caution. We did not have enough patients in the study to discriminate or to come up with specifics based on estrogen receptor breast cancer — or, for that matter, any other specific kind. Women should be moderate in their intake of soy. We’re not saying don’t take soy at all; we’re just saying the results of this study may indicate some increased risk, so it’s prudent to be cautious.

The amounts of soy supplements provided to each woman in the study were two doses of 25.8 grams each. What does this translate to in terms of a normal diet? Is there a “safe” amount?

The amount of soy each woman had in the study was a relatively high dose, equal to about 3.5 cups of soymilk or about 16 oz. of tofu, which is a lot for the average woman. In this particular study, it showed that large amounts might drive proliferation of breast cancer in some women. Most women are not getting that much soy in a day.Although soy has anti-estrogenic effects, we are not sure how these effects might impact breast cancer risk. Women should avoid extremes — there’s no need to cut out soy completely, but they also shouldn’t consume large quantities.

This study included only women who currently had breast cancer. Most were post-menopausal. Should younger women or those who don’t have the disease be concerned about their soy intake?

We haven’t examined this yet. But I would advocate that this principle of moderation be applied to all women across the board, even those without breast cancer or who are younger in age. Also, we only know about breast cancer in women who have already been diagnosed. There are women walking around with very early stages of breast cancer that haven’t been detected yet. Because we don’t know the effect of soy on normal breast tissue yet, both types of women should exercise caution in the amounts of soy they consume daily.

# data[].attributes.body.processed
Earlier this month, a new study about soy made waves in the breast cancer community. With support from BCRF, grantee Dr. Moshe Shike and his coauthors, including Scientific Director Dr. Larry Norton, published a study in the Journal of the National Cancer Institute. The randomized trial discovered that, for some women with breast cancer, taking soy protein supplements promoted the expression of tumor genes associated with an increase in tumor cells.

We chatted with Dr. Shike to learn more about what this study means for women.

The study focused on women with estrogen-receptor positive breast cancer. Should women with all types of breast cancers be cautious about their soy consumption or only those with that particular type?

All women with any type of breast cancer should exercise caution. We did not have enough patients in the study to discriminate or to come up with specifics based on estrogen receptor breast cancer — or, for that matter, any other specific kind. Women should be moderate in their intake of soy. We’re not saying don’t take soy at all; we’re just saying the results of this study may indicate some increased risk, so it’s prudent to be cautious.

The amounts of soy supplements provided to each woman in the study were two doses of 25.8 grams each. What does this translate to in terms of a normal diet? Is there a “safe” amount?

The amount of soy each woman had in the study was a relatively high dose, equal to about 3.5 cups of soymilk or about 16 oz. of tofu, which is a lot for the average woman. In this particular study, it showed that large amounts might drive proliferation of breast cancer in some women. Most women are not getting that much soy in a day.Although soy has anti-estrogenic effects, we are not sure how these effects might impact breast cancer risk. Women should avoid extremes — there’s no need to cut out soy completely, but they also shouldn’t consume large quantities.

This study included only women who currently had breast cancer. Most were post-menopausal. Should younger women or those who don’t have the disease be concerned about their soy intake?

We haven’t examined this yet. But I would advocate that this principle of moderation be applied to all women across the board, even those without breast cancer or who are younger in age. Also, we only know about breast cancer in women who have already been diagnosed. There are women walking around with very early stages of breast cancer that haven’t been detected yet. Because we don’t know the effect of soy on normal breast tissue yet, both types of women should exercise caution in the amounts of soy they consume daily.

# data[].attributes.title
BCRF Welcomes You to Shop Pink this October!

# data[].attributes.metatag_normalized[].attributes.content
BCRF Welcomes You to Shop Pink this October! | BCRF

# data[].attributes.metatag_normalized[].attributes.content
BCRF’s 2014 annual Shop Pink catalog has arrived just in time for Breast Cancer Awareness Month! We are excited to feature an array of new products from our more than 130 valued partners.  
Our corporate partners share our passion to find a cure, and their donations fuel our ability to grant millions of dollars directly to breast cancer research. This year, BCRF will fund over 220 researchers who work towards bringing an end to this devastating disease. 
Since 1993, we have made a point to join forces with a diverse range of brands to offer everyone the opportunity to support our cause. Whether cooking dinner with a Cuisinart blender or sporting the latest Tory Burch tote, you can make a difference in the fight against breast cancer—all because of a simple Shop Pink purchase.
Every time you buy a Shop Pink item, you help to drive donations to BCRF which directly support our mission of advancing the world's most promising research.
Some of our favorites this year include Clinique’s Dramatically Different Moisturizing+ Lotion, a perfect staple to add to your beauty regime, and the beautiful statement jewelry created by HOLST+LEE for LOFT.  Charles and Colvard’s The Survivor Collection moves us all; each three stone Moissanite piece is inspired by the journey of diagnosis, treatment, and a cancer-free future. If you are looking for a way to incorporate BCRF in your home, check out the classic NEST Fragrances Passion Candle, the Fragrance Foundations’ 2014 Interior Scent Collection of the Year!
BCRF’s Shop Pink program turns awareness into action year-round with your support. Research is key and any donation, no matter how small, contributes to the critical research that will end breast cancer as we know it. Shop Pink and make a difference today!

# data[].attributes.metatag_normalized[].attributes.content
BCRF Welcomes You to Shop Pink this October!

# data[].attributes.metatag_normalized[].attributes.content
BCRF’s 2014 annual Shop Pink catalog has arrived just in time for Breast Cancer Awareness Month! We are excited to feature an array of new products from our more than 130 valued partners.  
Our corporate partners share our passion to find a cure, and their donations fuel our ability to grant millions of dollars directly to breast cancer research. This year, BCRF will fund over 220 researchers who work towards bringing an end to this devastating disease. 

# data[].attributes.metatag_normalized[].attributes.content
BCRF Welcomes You to Shop Pink this October!

# data[].attributes.metatag_normalized[].attributes.content
The 2014 Shop Pink catalog launches with a new season of partner products

# data[].attributes.metatag_normalized[].attributes.content
BCRF’s 2014 annual Shop Pink catalog has arrived just in time for Breast Cancer Awareness Month! We are excited to feature an array of new products from our more than 130 valued partners.  
Our corporate partners share our passion to find a cure, and their donations fuel our ability to grant millions of dollars directly to breast cancer research. This year, BCRF will fund over 220 researchers who work towards bringing an end to this devastating disease. 

# data[].attributes.metatag_normalized[].attributes.content
BCRF Welcomes You to Shop Pink this October!

# data[].attributes.body.value
BCRF’s 2014 annual Shop Pink catalog has arrived just in time for Breast Cancer Awareness Month! We are excited to feature an array of new products from our more than 130 valued partners.

Our corporate partners share our passion to find a cure, and their donations fuel our ability to grant millions of dollars directly to breast cancer research. This year, BCRF will fund over 220 researchers who work towards bringing an end to this devastating disease.

Since 1993, we have made a point to join forces with a diverse range of brands to offer everyone the opportunity to support our cause. Whether cooking dinner with a Cuisinart blender or sporting the latest Tory Burch tote, you can make a difference in the fight against breast cancer—all because of a simple Shop Pink purchase.

Every time you buy a Shop Pink item, you help to drive donations to BCRF which directly support our mission of advancing the world's most promising research.

Some of our favorites this year include Clinique’s Dramatically Different Moisturizing+ Lotion, a perfect staple to add to your beauty regime, and the beautiful statement jewelry created by HOLST+LEE for LOFT.  Charles and Colvard’s The Survivor Collection moves us all; each three stone Moissanite piece is inspired by the journey of diagnosis, treatment, and a cancer-free future. If you are looking for a way to incorporate BCRF in your home, check out the classic NEST Fragrances Passion Candle, the Fragrance Foundations’ 2014 Interior Scent Collection of the Year!

BCRF’s Shop Pink program turns awareness into action year-round with your support. Research is key and any donation, no matter how small, contributes to the critical research that will end breast cancer as we know it. Shop Pink and make a difference today!

# data[].attributes.body.processed
BCRF’s 2014 annual Shop Pink catalog has arrived just in time for Breast Cancer Awareness Month! We are excited to feature an array of new products from our more than 130 valued partners.

Our corporate partners share our passion to find a cure, and their donations fuel our ability to grant millions of dollars directly to breast cancer research. This year, BCRF will fund over 220 researchers who work towards bringing an end to this devastating disease.

Since 1993, we have made a point to join forces with a diverse range of brands to offer everyone the opportunity to support our cause. Whether cooking dinner with a Cuisinart blender or sporting the latest Tory Burch tote, you can make a difference in the fight against breast cancer—all because of a simple Shop Pink purchase.

Every time you buy a Shop Pink item, you help to drive donations to BCRF which directly support our mission of advancing the world's most promising research.

Some of our favorites this year include Clinique’s Dramatically Different Moisturizing+ Lotion, a perfect staple to add to your beauty regime, and the beautiful statement jewelry created by HOLST+LEE for LOFT.  Charles and Colvard’s The Survivor Collection moves us all; each three stone Moissanite piece is inspired by the journey of diagnosis, treatment, and a cancer-free future. If you are looking for a way to incorporate BCRF in your home, check out the classic NEST Fragrances Passion Candle, the Fragrance Foundations’ 2014 Interior Scent Collection of the Year!

BCRF’s Shop Pink program turns awareness into action year-round with your support. Research is key and any donation, no matter how small, contributes to the critical research that will end breast cancer as we know it. Shop Pink and make a difference today!

# data[].attributes.field_subtitle
The 2014 Shop Pink catalog launches with a new season of partner products

# data[].attributes.title
The Breast Cancer Research Foundation and Good Morning America’s Amy Robach Kick off October With #BeTheEnd Campaign

# data[].attributes.metatag_normalized[].attributes.content
BCRF and GMA’s Amy Robach start October With #BeTheEnd Campaign | BCRF

# data[].attributes.metatag_normalized[].attributes.content
New York, NY, September 30, 2014 – The Breast Cancer Research Foundation (BCRF) is proud to announce its #BeTheEnd campaign for Breast Cancer Awareness Month and throughout the year. The call to action was built from the belief that research will bring an end to cancer and everyone has the power to play a role in eradicating the disease.
“We are all part of the solution,” said Myra Biblowit, President of BCRF. “We want to empower the public to be the end of cancer by joining us to help fuel the research today needed to save lives tomorrow. We believe that research has the power to bring an end to cancer. When you donate to BCRF, every dollar has an impact because research produces results and will lead us to prevention and a cure.”
Joining BCRF in its pursuit to turn awareness into action is Good Morning America anchor and breast cancer survivor Amy Robach. Last October, Robach received her first mammogram on air only to discover she had breast cancer. She has partnered with BCRF as an ambassador promoting breast health and the importance of research to help inform and activate the public. On October 9, Robach will also host the foundation’s annual Symposium & Awards Luncheon, which will honor ABC veteran and broadcast legend Barbara Walters for her humanitarian efforts.
“We couldn’t be more thrilled to welcome Amy to the BCRF family,” said Leonard Lauder, BCRF Co-Chairman. “Not only did she demonstrate incredible poise and strength during her journey with breast cancer, but she also is using her experience to advocate for the cause and galvanize women and men across the nation.”
BCRF Scientific Director Dr. Larry Norton and grantee Dr. Edith Perez have also joined ABC’s October initiative, Pink Pledge, as leading breast cancer experts.
Lifetime also signed on to support #BeTheEnd through a number of platforms including a public service announcement featuring Heidi Klum, the Emmy-winning host and executive producer of Project Runway. The PSA will run across Lifetime’s broadcast and digital channels. Lifetime further solidified its partnership with BCRF by sponsoring in part the foundation’s fundraiser at the Waldorf Astoria. This year marks Lifetime’s 20th anniversary advocating for the end of breast cancer.
Beginning October 1, BCRF will launch a number of engagements as part of #BeTheEnd:

Breast Cancer Research Symposium & Awards Luncheon – Each October, BCRF hosts two signature events in New York and Boston establishing its position as a leading global resource on breast cancer research and innovation. In New York, BCRF will award $47 million in annual grants as more than 220 researchers from around the world come together to shed light on the critical advances made possible by the foundation’s support. In addition, BCRF is committing $11.6 million this year through the Evelyn H. Lauder Founder’s Fund to support an international research initiative focused on breast cancer metastasis. In Boston, BCRF grantees from New England’s top medical institutions will offer scientific insight on the ever-changing breast cancer landscape in an open forum with the public. Learn more at www.bcrfcure.org/events. 
Shop Pink – BCRF’s corporate partnerships program harnesses the power of many of the world’s most iconic and beloved brands to fund lifesaving research. Shop Pink features products, retail activations, employee fundraising, and social engagement programs from BCRF’s more than 130 corporate partners. Each program triggers donations to support BCRF research.  
#BeTheEnd Fundraising Platform – BCRF’s newly designed website features an interactive fundraising platform that helps to make raising money for research fun and easy in October and all year long. 
#BeTheEnd Social Media Campaign - BCRF wants to empower its supporters to share their stories on Facebook, Twitter and Instagram and to encourage them to #BeTheEnd of breast cancer and all that comes with it—fear, hospital visits, needless suffering and losing loved ones.

Join BCRF and #BeTheEnd of breast cancer. 

# data[].attributes.metatag_normalized[].attributes.content
The Breast Cancer Research Foundation and Good Morning America’s Amy Robach Kick off October With #BeTheEnd Campaign

# data[].attributes.metatag_normalized[].attributes.content
New York, NY, September 30, 2014 – The Breast Cancer Research Foundation (BCRF) is proud to announce its #BeTheEnd campaign for Breast Cancer Awareness Month and throughout the year. The call to action was built from the belief that research will bring an end to cancer and everyone has the power to play a role in eradicating the disease.

# data[].attributes.metatag_normalized[].attributes.content
The Breast Cancer Research Foundation and Good Morning America’s Amy Robach Kick off October With #BeTheEnd Campaign

# data[].attributes.metatag_normalized[].attributes.content
Lifetime rallies around #BeTheEnd with PSA featuring Project Runway’s Heidi Klum

# data[].attributes.metatag_normalized[].attributes.content
New York, NY, September 30, 2014 – The Breast Cancer Research Foundation (BCRF) is proud to announce its #BeTheEnd campaign for Breast Cancer Awareness Month and throughout the year. The call to action was built from the belief that research will bring an end to cancer and everyone has the power to play a role in eradicating the disease.

# data[].attributes.metatag_normalized[].attributes.content
The Breast Cancer Research Foundation and Good Morning America’s Amy Robach Kick off October With #BeTheEnd Campaign

# data[].attributes.body.value
New York, NY, September 30, 2014 – The Breast Cancer Research Foundation (BCRF) is proud to announce its #BeTheEnd campaign for Breast Cancer Awareness Month and throughout the year. The call to action was built from the belief that research will bring an end to cancer and everyone has the power to play a role in eradicating the disease.

“We are all part of the solution,” said Myra Biblowit, President of BCRF. “We want to empower the public to be the end of cancer by joining us to help fuel the research today needed to save lives tomorrow. We believe that research has the power to bring an end to cancer. When you donate to BCRF, every dollar has an impact because research produces results and will lead us to prevention and a cure.”

Joining BCRF in its pursuit to turn awareness into action is Good Morning America anchor and breast cancer survivor Amy Robach. Last October, Robach received her first mammogram on air only to discover she had breast cancer. She has partnered with BCRF as an ambassador promoting breast health and the importance of research to help inform and activate the public. On October 9, Robach will also host the foundation’s annual Symposium & Awards Luncheon, which will honor ABC veteran and broadcast legend Barbara Walters for her humanitarian efforts.

“We couldn’t be more thrilled to welcome Amy to the BCRF family,” said Leonard Lauder, BCRF Co-Chairman. “Not only did she demonstrate incredible poise and strength during her journey with breast cancer, but she also is using her experience to advocate for the cause and galvanize women and men across the nation.”

BCRF Scientific Director Dr. Larry Norton and grantee Dr. Edith Perez have also joined ABC’s October initiative, Pink Pledge, as leading breast cancer experts.

Lifetime also signed on to support #BeTheEnd through a number of platforms including a public service announcement featuring Heidi Klum, the Emmy-winning host and executive producer of Project Runway. The PSA will run across Lifetime’s broadcast and digital channels. Lifetime further solidified its partnership with BCRF by sponsoring in part the foundation’s fundraiser at the Waldorf Astoria. This year marks Lifetime’s 20th anniversary advocating for the end of breast cancer.

Beginning October 1, BCRF will launch a number of engagements as part of #BeTheEnd:

Breast Cancer Research Symposium & Awards Luncheon – Each October, BCRF hosts two signature events in New York and Boston establishing its position as a leading global resource on breast cancer research and innovation. In New York, BCRF will award $47 million in annual grants as more than 220 researchers from around the world come together to shed light on the critical advances made possible by the foundation’s support. In addition, BCRF is committing $11.6 million this year through the Evelyn H. Lauder Founder’s Fund to support an international research initiative focused on breast cancer metastasis. In Boston, BCRF grantees from New England’s top medical institutions will offer scientific insight on the ever-changing breast cancer landscape in an open forum with the public. Learn more at www.bcrfcure.org/events.

Shop Pink – BCRF’s corporate partnerships program harnesses the power of many of the world’s most iconic and beloved brands to fund lifesaving research. Shop Pink features products, retail activations, employee fundraising, and social engagement programs from BCRF’s more than 130 corporate partners. Each program triggers donations to support BCRF research.

#BeTheEnd Fundraising Platform – BCRF’s newly designed website features an interactive fundraising platform that helps to make raising money for research fun and easy in October and all year long.

#BeTheEnd Social Media Campaign - BCRF wants to empower its supporters to share their stories on Facebook, Twitter and Instagram and to encourage them to #BeTheEnd of breast cancer and all that comes with it—fear, hospital visits, needless suffering and losing loved ones.

Join BCRF and #BeTheEnd of breast cancer.

# data[].attributes.body.processed
New York, NY, September 30, 2014 – The Breast Cancer Research Foundation (BCRF) is proud to announce its #BeTheEnd campaign for Breast Cancer Awareness Month and throughout the year. The call to action was built from the belief that research will bring an end to cancer and everyone has the power to play a role in eradicating the disease.

“We are all part of the solution,” said Myra Biblowit, President of BCRF. “We want to empower the public to be the end of cancer by joining us to help fuel the research today needed to save lives tomorrow. We believe that research has the power to bring an end to cancer. When you donate to BCRF, every dollar has an impact because research produces results and will lead us to prevention and a cure.”

Joining BCRF in its pursuit to turn awareness into action is Good Morning America anchor and breast cancer survivor Amy Robach. Last October, Robach received her first mammogram on air only to discover she had breast cancer. She has partnered with BCRF as an ambassador promoting breast health and the importance of research to help inform and activate the public. On October 9, Robach will also host the foundation’s annual Symposium & Awards Luncheon, which will honor ABC veteran and broadcast legend Barbara Walters for her humanitarian efforts.

“We couldn’t be more thrilled to welcome Amy to the BCRF family,” said Leonard Lauder, BCRF Co-Chairman. “Not only did she demonstrate incredible poise and strength during her journey with breast cancer, but she also is using her experience to advocate for the cause and galvanize women and men across the nation.”

BCRF Scientific Director Dr. Larry Norton and grantee Dr. Edith Perez have also joined ABC’s October initiative, Pink Pledge, as leading breast cancer experts.

Lifetime also signed on to support #BeTheEnd through a number of platforms including a public service announcement featuring Heidi Klum, the Emmy-winning host and executive producer of Project Runway. The PSA will run across Lifetime’s broadcast and digital channels. Lifetime further solidified its partnership with BCRF by sponsoring in part the foundation’s fundraiser at the Waldorf Astoria. This year marks Lifetime’s 20th anniversary advocating for the end of breast cancer.

Beginning October 1, BCRF will launch a number of engagements as part of #BeTheEnd:

Breast Cancer Research Symposium & Awards Luncheon – Each October, BCRF hosts two signature events in New York and Boston establishing its position as a leading global resource on breast cancer research and innovation. In New York, BCRF will award $47 million in annual grants as more than 220 researchers from around the world come together to shed light on the critical advances made possible by the foundation’s support. In addition, BCRF is committing $11.6 million this year through the Evelyn H. Lauder Founder’s Fund to support an international research initiative focused on breast cancer metastasis. In Boston, BCRF grantees from New England’s top medical institutions will offer scientific insight on the ever-changing breast cancer landscape in an open forum with the public. Learn more at www.bcrfcure.org/events.

Shop Pink – BCRF’s corporate partnerships program harnesses the power of many of the world’s most iconic and beloved brands to fund lifesaving research. Shop Pink features products, retail activations, employee fundraising, and social engagement programs from BCRF’s more than 130 corporate partners. Each program triggers donations to support BCRF research.

#BeTheEnd Fundraising Platform – BCRF’s newly designed website features an interactive fundraising platform that helps to make raising money for research fun and easy in October and all year long.

#BeTheEnd Social Media Campaign - BCRF wants to empower its supporters to share their stories on Facebook, Twitter and Instagram and to encourage them to #BeTheEnd of breast cancer and all that comes with it—fear, hospital visits, needless suffering and losing loved ones.

Join BCRF and #BeTheEnd of breast cancer.

# data[].attributes.field_meta_tags.title
BCRF and GMA’s Amy Robach start October With #BeTheEnd Campaign | BCRF

# data[].attributes.field_subtitle
Lifetime rallies around #BeTheEnd with PSA featuring Project Runway’s Heidi Klum

# data[].attributes.metatag_normalized[].attributes.content
This October, join us and turn awareness into action!
It all started in 1993 in Evelyn Lauder’s kitchen. Over a cup of coffee, Mrs. Lauder and her dear friend Dr. Larry Norton began a conversation that, over time, would change the history of breast cancer. Recognizing the power of research and its potential to change the lives of millions of women and men, they realized that to tackle this disease a new approach was critical. 
They believed research was the way forward and founded BCRF on the belief that funding research was the only obstacle between breast cancer and a cure. Today, we remain committed as ever to advancing the world’s most promising research because we see its ability to transform lives each and every day. Evelyn’s mission has become ours, and we want to make it yours. 
Everyone has the power to play a role in eradicating this disease. This October, we invite you to #BeTheEnd. Be the end of fear. Be the end of hospital visits. Be the end of side effects and needless suffering. Be the end of loss. The end of breast cancer begins with each and every one of us. 
Start a fundraiser. Share your story. Make a donation. Spread the word by sharing your commitment to BCRF with friends and family on your social networks. Honor someone you love who has been affected by breast cancer. Inspire your friends and family to #BeTheEnd.
No matter what you do, when you support BCRF, you support research. And when you support research, you are making a lasting impact in the fight against breast cancer.
Until the number of deaths from breast cancer is zero, we will not stop. Join us, and help fuel the research needed today to save lives tomorrow. Everyone can be part of the solution. We are all part of the cure.
How will you #BeTheEnd of breast cancer?

# data[].attributes.metatag_normalized[].attributes.content
This October, join us and turn awareness into action!
It all started in 1993 in Evelyn Lauder’s kitchen. Over a cup of coffee, Mrs. Lauder and her dear friend Dr. Larry Norton began a conversation that, over time, would change the history of breast cancer. Recognizing the power of research and its potential to change the lives of millions of women and men, they realized that to tackle this disease a new approach was critical. 

# data[].attributes.metatag_normalized[].attributes.content
This October, join us and turn awareness into action!
It all started in 1993 in Evelyn Lauder’s kitchen. Over a cup of coffee, Mrs. Lauder and her dear friend Dr. Larry Norton began a conversation that, over time, would change the history of breast cancer. Recognizing the power of research and its potential to change the lives of millions of women and men, they realized that to tackle this disease a new approach was critical. 

# data[].attributes.body.value
This October, join us and turn awareness into action!

It all started in 1993 in Evelyn Lauder’s kitchen. Over a cup of coffee, Mrs. Lauder and her dear friend Dr. Larry Norton began a conversation that, over time, would change the history of breast cancer. Recognizing the power of research and its potential to change the lives of millions of women and men, they realized that to tackle this disease a new approach was critical.

They believed research was the way forward and founded BCRF on the belief that funding research was the only obstacle between breast cancer and a cure. Today, we remain committed as ever to advancing the world’s most promising research because we see its ability to transform lives each and every day. Evelyn’s mission has become ours, and we want to make it yours.

Everyone has the power to play a role in eradicating this disease. This October, we invite you to #BeTheEnd. Be the end of fear. Be the end of hospital visits. Be the end of side effects and needless suffering. Be the end of loss. The end of breast cancer begins with each and every one of us.

Start a fundraiser. Share your story. Make a donation. Spread the word by sharing your commitment to BCRF with friends and family on your social networks. Honor someone you love who has been affected by breast cancer. Inspire your friends and family to #BeTheEnd.

No matter what you do, when you support BCRF, you support research. And when you support research, you are making a lasting impact in the fight against breast cancer.

Until the number of deaths from breast cancer is zero, we will not stop. Join us, and help fuel the research needed today to save lives tomorrow. Everyone can be part of the solution. We are all part of the cure.

How will you #BeTheEnd of breast cancer?

# data[].attributes.body.processed
This October, join us and turn awareness into action!

It all started in 1993 in Evelyn Lauder’s kitchen. Over a cup of coffee, Mrs. Lauder and her dear friend Dr. Larry Norton began a conversation that, over time, would change the history of breast cancer. Recognizing the power of research and its potential to change the lives of millions of women and men, they realized that to tackle this disease a new approach was critical.

They believed research was the way forward and founded BCRF on the belief that funding research was the only obstacle between breast cancer and a cure. Today, we remain committed as ever to advancing the world’s most promising research because we see its ability to transform lives each and every day. Evelyn’s mission has become ours, and we want to make it yours.

Everyone has the power to play a role in eradicating this disease. This October, we invite you to #BeTheEnd. Be the end of fear. Be the end of hospital visits. Be the end of side effects and needless suffering. Be the end of loss. The end of breast cancer begins with each and every one of us.

Start a fundraiser. Share your story. Make a donation. Spread the word by sharing your commitment to BCRF with friends and family on your social networks. Honor someone you love who has been affected by breast cancer. Inspire your friends and family to #BeTheEnd.

No matter what you do, when you support BCRF, you support research. And when you support research, you are making a lasting impact in the fight against breast cancer.

Until the number of deaths from breast cancer is zero, we will not stop. Join us, and help fuel the research needed today to save lives tomorrow. Everyone can be part of the solution. We are all part of the cure.

How will you #BeTheEnd of breast cancer?

# data[].attributes.metatag_normalized[].attributes.content
Breast Cancer One, Ready For Takeoff! | BCRF

# data[].attributes.metatag_normalized[].attributes.content
One by one, they boarded the plane. Many were cancer free, some were still in treatment and others, like pilot Deborah Johnson, were newly diagnosed.
But for the 145 women aboard  Delta’s signature pink plane, this would be no ordinary flight. The women, all Delta employees, were taking flight for the fight against breast cancer on the airline’s annual survivor flight. This tradition, which Delta launched as part of its partnership with BCRF, honors employees affected by breast cancer and kicks off the airline’s efforts for Breast Cancer Awareness Month.
This year, Delta celebrated the 10th anniversary of its survivor flight with a very special guest: Good Morning America anchor, BCRF ambassador and breast cancer survivor Amy Robach.
Emotions were running high as the Delta employees boarded “Breast Cancer One”—a Delta Boeing 767 with BCRF founder Evelyn Lauder’s signature emblazoned on its side—at Atlanta’s Hartsfield-Jackson International Airport. Decked out in head-to-toe pink, the women, including flight attendants, corporate employees and senior management, were all smiles as they buckled up and prepared to head to New York.

  
      
              



      
  

The women, who had flown in from across the country for the company-wide event, were enjoying their first-class treatment when a flight attendant came on the intercom with a special announcement: “I just realized that I think we’re short a flight attendant on today’s flight. What’s this? Good Morning America anchor and breast cancer survivor Amy Robach!”
As soon as Robach stepped on to the plane, the women jumped to their feet and the plane resounded with screams of laughter and excitement. Robach, who was dressed in Delta’s iconic pink flight attendant uniform which is reserved for the month of October, was greeted with hugs and high fives as she made her way down the aisles to talk to each and every one of the women.
As Breast Cancer One prepared for takeoff, Robach enthusiastically stepped into her role as an honorary flight attendant,  assisting with the safety demonstration before joining in on the festivities. For the duration of the flight, Robach, BCRF President Myra Biblowit and the Delta employees shared their personal stories of the disease that affects 1 in 8 American women. Survivors doled out advice to women undergoing treatment while others praised Delta and BCRF for championing the research that brought forth the treatments that helped them endure.

  
      
              



      
  

“My mother had breast cancer so I have always supported this cause, but I didn’t know the extent of Delta’s commitment or how far BCRF research has come in making this disease close to curable,” said Deborah Johnson. A Delta pilot for 17 years, Johnson was diagnosed with breast cancer just four weeks ago. “Being new to breast cancer, I look at it as an uphill battle. But knowing that Delta and BCRF have supported the research that has minimized the harshness of my treatment is amazing. Of all the things in this world, I’ll take this and smile my way through it.”
Since partnering with BCRF in 2005, Delta has raised more than $7.9 million to fund 31 research projects and support five researchers who hail from Michigan to the United Kingdom. All 80,000 of the airline’s employees, starting with President Richard Anderson, who lost his mother to breast cancer at a young age, are united in their passion for finding a cure through research.
As the flight prepared for landing, Sara Bareilles’ “Brave” played over the speakers and the Delta employees began to dance and sing along. The song has become an anthem for many of the women, including Robach. There were tears quelled by group hugs, but mostly there were smiles as Breast Cancer One arrived at New York’s John F. Kennedy International Airport.
Walking off the plane, the women were welcomed to New York by their fellow employees and a youth choir singing “Ain’t No Mountain High Enough”—a perfect close to a day that celebrated life, gratitude and the value of community. 

# data[].attributes.metatag_normalized[].attributes.content
One by one, they boarded the plane. Many were cancer free, some were still in treatment and others, like pilot Deborah Johnson, were newly diagnosed.

# data[].attributes.metatag_normalized[].attributes.content
BCRF and longtime partner Delta celebrate 10 years of Taking Flight for the Fight with special guest Amy Robach

# data[].attributes.metatag_normalized[].attributes.content
One by one, they boarded the plane. Many were cancer free, some were still in treatment and others, like pilot Deborah Johnson, were newly diagnosed.

# data[].attributes.body.value
One by one, they boarded the plane. Many were cancer free, some were still in treatment and others, like pilot Deborah Johnson, were newly diagnosed.

But for the 145 women aboard  Delta’s signature pink plane, this would be no ordinary flight. The women, all Delta employees, were taking flight for the fight against breast cancer on the airline’s annual survivor flight. This tradition, which Delta launched as part of its partnership with BCRF, honors employees affected by breast cancer and kicks off the airline’s efforts for Breast Cancer Awareness Month.

This year, Delta celebrated the 10th anniversary of its survivor flight with a very special guest: Good Morning America anchor, BCRF ambassador and breast cancer survivor Amy Robach.

Emotions were running high as the Delta employees boarded “Breast Cancer One”—a Delta Boeing 767 with BCRF founder Evelyn Lauder’s signature emblazoned on its side—at Atlanta’s Hartsfield-Jackson International Airport. Decked out in head-to-toe pink, the women, including flight attendants, corporate employees and senior management, were all smiles as they buckled up and prepared to head to New York.

The women, who had flown in from across the country for the company-wide event, were enjoying their first-class treatment when a flight attendant came on the intercom with a special announcement: “I just realized that I think we’re short a flight attendant on today’s flight. What’s this? Good Morning America anchor and breast cancer survivor Amy Robach!”

As soon as Robach stepped on to the plane, the women jumped to their feet and the plane resounded with screams of laughter and excitement. Robach, who was dressed in Delta’s iconic pink flight attendant uniform which is reserved for the month of October, was greeted with hugs and high fives as she made her way down the aisles to talk to each and every one of the women.

As Breast Cancer One prepared for takeoff, Robach enthusiastically stepped into her role as an honorary flight attendant,  assisting with the safety demonstration before joining in on the festivities. For the duration of the flight, Robach, BCRF President Myra Biblowit and the Delta employees shared their personal stories of the disease that affects 1 in 8 American women. Survivors doled out advice to women undergoing treatment while others praised Delta and BCRF for championing the research that brought forth the treatments that helped them endure.

“My mother had breast cancer so I have always supported this cause, but I didn’t know the extent of Delta’s commitment or how far BCRF research has come in making this disease close to curable,” said Deborah Johnson. A Delta pilot for 17 years, Johnson was diagnosed with breast cancer just four weeks ago. “Being new to breast cancer, I look at it as an uphill battle. But knowing that Delta and BCRF have supported the research that has minimized the harshness of my treatment is amazing. Of all the things in this world, I’ll take this and smile my way through it.”

Since partnering with BCRF in 2005, Delta has raised more than $7.9 million to fund 31 research projects and support five researchers who hail from Michigan to the United Kingdom. All 80,000 of the airline’s employees, starting with President Richard Anderson, who lost his mother to breast cancer at a young age, are united in their passion for finding a cure through research.

As the flight prepared for landing, Sara Bareilles’ “Brave” played over the speakers and the Delta employees began to dance and sing along. The song has become an anthem for many of the women, including Robach. There were tears quelled by group hugs, but mostly there were smiles as Breast Cancer One arrived at New York’s John F. Kennedy International Airport.

Walking off the plane, the women were welcomed to New York by their fellow employees and a youth choir singing “Ain’t No Mountain High Enough”—a perfect close to a day that celebrated life, gratitude and the value of community.

# data[].attributes.body.processed
One by one, they boarded the plane. Many were cancer free, some were still in treatment and others, like pilot Deborah Johnson, were newly diagnosed.

But for the 145 women aboard  Delta’s signature pink plane, this would be no ordinary flight. The women, all Delta employees, were taking flight for the fight against breast cancer on the airline’s annual survivor flight. This tradition, which Delta launched as part of its partnership with BCRF, honors employees affected by breast cancer and kicks off the airline’s efforts for Breast Cancer Awareness Month.

This year, Delta celebrated the 10th anniversary of its survivor flight with a very special guest: Good Morning America anchor, BCRF ambassador and breast cancer survivor Amy Robach.

Emotions were running high as the Delta employees boarded “Breast Cancer One”—a Delta Boeing 767 with BCRF founder Evelyn Lauder’s signature emblazoned on its side—at Atlanta’s Hartsfield-Jackson International Airport. Decked out in head-to-toe pink, the women, including flight attendants, corporate employees and senior management, were all smiles as they buckled up and prepared to head to New York.

The women, who had flown in from across the country for the company-wide event, were enjoying their first-class treatment when a flight attendant came on the intercom with a special announcement: “I just realized that I think we’re short a flight attendant on today’s flight. What’s this? Good Morning America anchor and breast cancer survivor Amy Robach!”

As soon as Robach stepped on to the plane, the women jumped to their feet and the plane resounded with screams of laughter and excitement. Robach, who was dressed in Delta’s iconic pink flight attendant uniform which is reserved for the month of October, was greeted with hugs and high fives as she made her way down the aisles to talk to each and every one of the women.

As Breast Cancer One prepared for takeoff, Robach enthusiastically stepped into her role as an honorary flight attendant,  assisting with the safety demonstration before joining in on the festivities. For the duration of the flight, Robach, BCRF President Myra Biblowit and the Delta employees shared their personal stories of the disease that affects 1 in 8 American women. Survivors doled out advice to women undergoing treatment while others praised Delta and BCRF for championing the research that brought forth the treatments that helped them endure.

“My mother had breast cancer so I have always supported this cause, but I didn’t know the extent of Delta’s commitment or how far BCRF research has come in making this disease close to curable,” said Deborah Johnson. A Delta pilot for 17 years, Johnson was diagnosed with breast cancer just four weeks ago. “Being new to breast cancer, I look at it as an uphill battle. But knowing that Delta and BCRF have supported the research that has minimized the harshness of my treatment is amazing. Of all the things in this world, I’ll take this and smile my way through it.”

Since partnering with BCRF in 2005, Delta has raised more than $7.9 million to fund 31 research projects and support five researchers who hail from Michigan to the United Kingdom. All 80,000 of the airline’s employees, starting with President Richard Anderson, who lost his mother to breast cancer at a young age, are united in their passion for finding a cure through research.

As the flight prepared for landing, Sara Bareilles’ “Brave” played over the speakers and the Delta employees began to dance and sing along. The song has become an anthem for many of the women, including Robach. There were tears quelled by group hugs, but mostly there were smiles as Breast Cancer One arrived at New York’s John F. Kennedy International Airport.

Walking off the plane, the women were welcomed to New York by their fellow employees and a youth choir singing “Ain’t No Mountain High Enough”—a perfect close to a day that celebrated life, gratitude and the value of community.

# data[].attributes.field_subtitle
BCRF and longtime partner Delta celebrate 10 years of Taking Flight for the Fight with special guest Amy Robach

# data[].attributes.title
Lifetime and BCRF Launch #BeTheEnd PSA for October

# data[].attributes.metatag_normalized[].attributes.content
Lifetime and BCRF Launch #BeTheEnd PSA for October | BCRF

# data[].attributes.metatag_normalized[].attributes.content
BCRF and Lifetime have partnered to kick off Breast Cancer Awareness month to call attention to the importance of research. Together, we have launched a new PSA, starring Heidi Klum, Emmy-winning host and executive producer of Project Runway. She takes the audience through a visual journey of the alarming statistic: 1 in 8 women will be diagnosed with breast cancer in their lifetime. The cable channel has actively supported breast cancer research for 20 years and its partnership with BCRF will bring its contribution to unprecedented heights. The PSA will air on Lifetime and all of A&E Network’s channels throughout the month of October as well as on Taxi TV in select cities nationwide.
Read more about our #BeTheEnd campaign or help us spread the word on social media.

# data[].attributes.metatag_normalized[].attributes.content
Lifetime and BCRF Launch #BeTheEnd PSA for October

# data[].attributes.metatag_normalized[].attributes.content
BCRF and Lifetime have partnered to kick off Breast Cancer Awareness month to call attention to the importance of research. Together, we have launched a new PSA, starring Heidi Klum, Emmy-winning host and executive producer of Project Runway. She takes the audience through a visual journey of the alarming statistic: 1 in 8 women will be diagnosed with breast cancer in their lifetime.

# data[].attributes.metatag_normalized[].attributes.content
Lifetime and BCRF Launch #BeTheEnd PSA for October

# data[].attributes.metatag_normalized[].attributes.content
Heidi Klum, Top Model and Host of Project Runway, Stars to Raise Awareness

# data[].attributes.metatag_normalized[].attributes.content
BCRF and Lifetime have partnered to kick off Breast Cancer Awareness month to call attention to the importance of research. Together, we have launched a new PSA, starring Heidi Klum, Emmy-winning host and executive producer of Project Runway. She takes the audience through a visual journey of the alarming statistic: 1 in 8 women will be diagnosed with breast cancer in their lifetime.

# data[].attributes.metatag_normalized[].attributes.content
Lifetime and BCRF Launch #BeTheEnd PSA for October

# data[].attributes.body.value
BCRF and Lifetime have partnered to kick off Breast Cancer Awareness month to call attention to the importance of research. Together, we have launched a new PSA, starring Heidi Klum, Emmy-winning host and executive producer of Project Runway. She takes the audience through a visual journey of the alarming statistic: 1 in 8 women will be diagnosed with breast cancer in their lifetime. The cable channel has actively supported breast cancer research for 20 years and its partnership with BCRF will bring its contribution to unprecedented heights. The PSA will air on Lifetime and all of A&E Network’s channels throughout the month of October as well as on Taxi TV in select cities nationwide.

Read more about our #BeTheEnd campaign or help us spread the word on social media.

# data[].attributes.body.processed
BCRF and Lifetime have partnered to kick off Breast Cancer Awareness month to call attention to the importance of research. Together, we have launched a new PSA, starring Heidi Klum, Emmy-winning host and executive producer of Project Runway. She takes the audience through a visual journey of the alarming statistic: 1 in 8 women will be diagnosed with breast cancer in their lifetime. The cable channel has actively supported breast cancer research for 20 years and its partnership with BCRF will bring its contribution to unprecedented heights. The PSA will air on Lifetime and all of A&E Network’s channels throughout the month of October as well as on Taxi TV in select cities nationwide.

Read more about our #BeTheEnd campaign or help us spread the word on social media.

# data[].attributes.field_caption
Heidi Klum stars in Lifetime's PSA for Breast Cancer Awareness

# data[].attributes.field_subtitle
Heidi Klum, Top Model and Host of Project Runway, Stars to Raise Awareness

# data[].attributes.metatag_normalized[].attributes.content
The Pink Agenda Makes Philanthropy Fun | BCRF

# data[].attributes.metatag_normalized[].attributes.content
In 2012, BCRF officially partnered with The Pink Agenda (TPA), a nonprofit that engages today’s generation to find a cure for tomorrow. Marisa Renee Lee and Jaquelyn Scharnick founded the organization with friend Liana Douillet Guzman to honor their loved one's battles with breast cancer and mobilize their friends and family to contribute to a cure. With BCRF as its sole beneficiary, TPA is growing rapidly and touching more lives every year with their enthusiasm and generosity. To date, TPA has raised nearly $1 million dollars for breast cancer research.
On Thursday, October 2, The Pink Agenda welcomed more than 700 guests to its annual gala at the Frank Gehry-designed IAC building in New York. The gala, which began as a small house party, raised nearly $250,000 for breast cancer research.
On the eve of the 7th annual gala, we had a chance to sit down with Jaquelyn Scharnick to get the scoop on all things TPA.
By working mainly with young professionals, TPA is unique among other breast cancer charities. Why do you think it's important to work with young men and women?
From the very beginning, we’ve believed that fun and philanthropy are not mutually exclusive, and, at The Pink Agenda, we prove that every day in every way.  While we’re serious about our mission, we’re also serious about having a good time and believe that together we can make breast cancer history.
How has partnering with BCRF in 2012 affected TPA?
We entered into a strategic partnership with BCRF because we believed that the skills and scale of the organization would help ensure that The Pink Agenda flourishes in the future so that breast cancer can become a thing of the past. 
As a result of our partnership, TPA has grown and become more sustainable and we’ve been able to even more effectively deliver on our mission and our commitment to making breast cancer history.
Tell us more about your relationship with Dana-Farber Cancer Institute in Boston. Can you expand on the direct care grants TPA provides and the Program for Young Women with Breast Cancer?
The Pink Agenda finds, funds and partners with people and programs that are improving the lives of those suffering from breast cancer and conducting the groundbreaking research necessary to improve their odds. To accomplish the former, we work with the Dana-Farber Cancer Institute’s Program for Young Women with Breast Cancer to identify a project that will have a direct and positive impact on women’s cancer care. 
Dana-Farber’s Program for Young Women with Breast Cancer was the first program of its kind in New England and remains one of the only such programs in the United States. For me, supporting Dana-Farber has particular meaning, as it’s where I was treated for leukemia in 1997 and 1999. I know firsthand that its work saves lives, and it’s a real privilege to be able to support it.
What are some TPA’s biggest accomplishments?
We have had so many milestones along the way. I can remember securing our first corporate sponsorship in 2007, and now we’ve partnered companies around the country. Ultimately, I think our biggest accomplishment has been engaging individuals and organizations in our cause and continuing to find new and exciting ways for them to get and stay involved, so that we can continue to move toward a future without breast cancer. 
You recently partnered with Giuliana Rancic's FAB-U-WISH. What do you think working together will bring to TPA?
Giuliana is an inspiration to so many, and partnering with her and her fantastic initiative FAB-U-WISH allows us to deliver on our commitment to improve the lives of those suffering from breast cancer. At the same time, working together will enable us to expand our reach and generate additional awareness about who we are, what we do and how people can join us.
After seven years of leading TPA, what is one of your favorite memories?
There really are so many terrific ones. One of my favorite ones, though, was speaking at our gala in May 2009. My mother was in the audience and, much to her surprise, my remarks focused on her. She had been first diagnosed with breast cancer 20 years ago that month, and honoring her and the strength she showed through her diagnoses and my leukemia diagnosis was really special.  
My commitment to The Pink Agenda is due, in part, to the fact that, yes, we throw fantastic parties and have a terrific time. But it is even more directly connected to the important work we’re doing and the very real strides we’re making toward eradicating the disease that has been a part of my life for even further back than I can remember. And while my story—and my inspiration—may be unique, everyone has one. Over the years, it has been wonderful to see so many people adopt The Pink Agenda as their charity of choice because of its ability to allow them to tell those stories and honor them in a way that makes a real difference.
Lastly, what are your long-term goals for TPA?
I want The Pink Agenda to continue to grow while staying true to its original mission and maintaining the level of creativity and organizational efficiency that has always set it apart. I hope that, in time, The Pink Agenda will become the charity of choice for young professionals within the breast cancer space and beyond it, but ultimately, I hope that the work we do and the money we raise helps makes breast cancer a thing of the past. 

# data[].attributes.metatag_normalized[].attributes.content
In 2012, BCRF officially partnered with The Pink Agenda (TPA), a nonprofit that engages today’s generation to find a cure for tomorrow. Marisa Renee Lee and Jaquelyn Scharnick founded the organization with friend Liana Douillet Guzman to honor their loved one's battles with breast cancer and mobilize their friends and family to contribute to a cure. With BCRF as its sole beneficiary, TPA is growing rapidly and touching more lives every year with their enthusiasm and generosity. To date, TPA has raised nearly $1 million dollars for breast cancer research.

# data[].attributes.metatag_normalized[].attributes.content
BCRF sits down with TPA to talk how it all started, the mission and its future

# data[].attributes.metatag_normalized[].attributes.content
In 2012, BCRF officially partnered with The Pink Agenda (TPA), a nonprofit that engages today’s generation to find a cure for tomorrow. Marisa Renee Lee and Jaquelyn Scharnick founded the organization with friend Liana Douillet Guzman to honor their loved one's battles with breast cancer and mobilize their friends and family to contribute to a cure. With BCRF as its sole beneficiary, TPA is growing rapidly and touching more lives every year with their enthusiasm and generosity. To date, TPA has raised nearly $1 million dollars for breast cancer research.

# data[].attributes.body.value
In 2012, BCRF officially partnered with The Pink Agenda (TPA), a nonprofit that engages today’s generation to find a cure for tomorrow. Marisa Renee Lee and Jaquelyn Scharnick founded the organization with friend Liana Douillet Guzman to honor their loved one's battles with breast cancer and mobilize their friends and family to contribute to a cure. With BCRF as its sole beneficiary, TPA is growing rapidly and touching more lives every year with their enthusiasm and generosity. To date, TPA has raised nearly $1 million dollars for breast cancer research.

On Thursday, October 2, The Pink Agenda welcomed more than 700 guests to its annual gala at the Frank Gehry-designed IAC building in New York. The gala, which began as a small house party, raised nearly $250,000 for breast cancer research.

On the eve of the 7th annual gala, we had a chance to sit down with Jaquelyn Scharnick to get the scoop on all things TPA.

By working mainly with young professionals, TPA is unique among other breast cancer charities. Why do you think it's important to work with young men and women?

From the very beginning, we’ve believed that fun and philanthropy are not mutually exclusive, and, at The Pink Agenda, we prove that every day in every way.  While we’re serious about our mission, we’re also serious about having a good time and believe that together we can make breast cancer history.

How has partnering with BCRF in 2012 affected TPA?

We entered into a strategic partnership with BCRF because we believed that the skills and scale of the organization would help ensure that The Pink Agenda flourishes in the future so that breast cancer can become a thing of the past.

As a result of our partnership, TPA has grown and become more sustainable and we’ve been able to even more effectively deliver on our mission and our commitment to making breast cancer history.

Tell us more about your relationship with Dana-Farber Cancer Institute in Boston. Can you expand on the direct care grants TPA provides and the Program for Young Women with Breast Cancer?

The Pink Agenda finds, funds and partners with people and programs that are improving the lives of those suffering from breast cancer and conducting the groundbreaking research necessary to improve their odds. To accomplish the former, we work with the Dana-Farber Cancer Institute’s Program for Young Women with Breast Cancer to identify a project that will have a direct and positive impact on women’s cancer care.

Dana-Farber’s Program for Young Women with Breast Cancer was the first program of its kind in New England and remains one of the only such programs in the United States. For me, supporting Dana-Farber has particular meaning, as it’s where I was treated for leukemia in 1997 and 1999. I know firsthand that its work saves lives, and it’s a real privilege to be able to support it.

What are some TPA’s biggest accomplishments?

We have had so many milestones along the way. I can remember securing our first corporate sponsorship in 2007, and now we’ve partnered companies around the country. Ultimately, I think our biggest accomplishment has been engaging individuals and organizations in our cause and continuing to find new and exciting ways for them to get and stay involved, so that we can continue to move toward a future without breast cancer.

You recently partnered with Giuliana Rancic's FAB-U-WISH. What do you think working together will bring to TPA?

Giuliana is an inspiration to so many, and partnering with her and her fantastic initiative FAB-U-WISH allows us to deliver on our commitment to improve the lives of those suffering from breast cancer. At the same time, working together will enable us to expand our reach and generate additional awareness about who we are, what we do and how people can join us.

After seven years of leading TPA, what is one of your favorite memories?

There really are so many terrific ones. One of my favorite ones, though, was speaking at our gala in May 2009. My mother was in the audience and, much to her surprise, my remarks focused on her. She had been first diagnosed with breast cancer 20 years ago that month, and honoring her and the strength she showed through her diagnoses and my leukemia diagnosis was really special.

My commitment to The Pink Agenda is due, in part, to the fact that, yes, we throw fantastic parties and have a terrific time. But it is even more directly connected to the important work we’re doing and the very real strides we’re making toward eradicating the disease that has been a part of my life for even further back than I can remember. And while my story—and my inspiration—may be unique, everyone has one. Over the years, it has been wonderful to see so many people adopt The Pink Agenda as their charity of choice because of its ability to allow them to tell those stories and honor them in a way that makes a real difference.

Lastly, what are your long-term goals for TPA?

I want The Pink Agenda to continue to grow while staying true to its original mission and maintaining the level of creativity and organizational efficiency that has always set it apart. I hope that, in time, The Pink Agenda will become the charity of choice for young professionals within the breast cancer space and beyond it, but ultimately, I hope that the work we do and the money we raise helps makes breast cancer a thing of the past.

# data[].attributes.body.processed
In 2012, BCRF officially partnered with The Pink Agenda (TPA), a nonprofit that engages today’s generation to find a cure for tomorrow. Marisa Renee Lee and Jaquelyn Scharnick founded the organization with friend Liana Douillet Guzman to honor their loved one's battles with breast cancer and mobilize their friends and family to contribute to a cure. With BCRF as its sole beneficiary, TPA is growing rapidly and touching more lives every year with their enthusiasm and generosity. To date, TPA has raised nearly $1 million dollars for breast cancer research.

On Thursday, October 2, The Pink Agenda welcomed more than 700 guests to its annual gala at the Frank Gehry-designed IAC building in New York. The gala, which began as a small house party, raised nearly $250,000 for breast cancer research.

On the eve of the 7th annual gala, we had a chance to sit down with Jaquelyn Scharnick to get the scoop on all things TPA.

By working mainly with young professionals, TPA is unique among other breast cancer charities. Why do you think it's important to work with young men and women?

From the very beginning, we’ve believed that fun and philanthropy are not mutually exclusive, and, at The Pink Agenda, we prove that every day in every way.  While we’re serious about our mission, we’re also serious about having a good time and believe that together we can make breast cancer history.

How has partnering with BCRF in 2012 affected TPA?

We entered into a strategic partnership with BCRF because we believed that the skills and scale of the organization would help ensure that The Pink Agenda flourishes in the future so that breast cancer can become a thing of the past.

As a result of our partnership, TPA has grown and become more sustainable and we’ve been able to even more effectively deliver on our mission and our commitment to making breast cancer history.

Tell us more about your relationship with Dana-Farber Cancer Institute in Boston. Can you expand on the direct care grants TPA provides and the Program for Young Women with Breast Cancer?

The Pink Agenda finds, funds and partners with people and programs that are improving the lives of those suffering from breast cancer and conducting the groundbreaking research necessary to improve their odds. To accomplish the former, we work with the Dana-Farber Cancer Institute’s Program for Young Women with Breast Cancer to identify a project that will have a direct and positive impact on women’s cancer care.

Dana-Farber’s Program for Young Women with Breast Cancer was the first program of its kind in New England and remains one of the only such programs in the United States. For me, supporting Dana-Farber has particular meaning, as it’s where I was treated for leukemia in 1997 and 1999. I know firsthand that its work saves lives, and it’s a real privilege to be able to support it.

What are some TPA’s biggest accomplishments?

We have had so many milestones along the way. I can remember securing our first corporate sponsorship in 2007, and now we’ve partnered companies around the country. Ultimately, I think our biggest accomplishment has been engaging individuals and organizations in our cause and continuing to find new and exciting ways for them to get and stay involved, so that we can continue to move toward a future without breast cancer.

You recently partnered with Giuliana Rancic's FAB-U-WISH. What do you think working together will bring to TPA?

Giuliana is an inspiration to so many, and partnering with her and her fantastic initiative FAB-U-WISH allows us to deliver on our commitment to improve the lives of those suffering from breast cancer. At the same time, working together will enable us to expand our reach and generate additional awareness about who we are, what we do and how people can join us.

After seven years of leading TPA, what is one of your favorite memories?

There really are so many terrific ones. One of my favorite ones, though, was speaking at our gala in May 2009. My mother was in the audience and, much to her surprise, my remarks focused on her. She had been first diagnosed with breast cancer 20 years ago that month, and honoring her and the strength she showed through her diagnoses and my leukemia diagnosis was really special.

My commitment to The Pink Agenda is due, in part, to the fact that, yes, we throw fantastic parties and have a terrific time. But it is even more directly connected to the important work we’re doing and the very real strides we’re making toward eradicating the disease that has been a part of my life for even further back than I can remember. And while my story—and my inspiration—may be unique, everyone has one. Over the years, it has been wonderful to see so many people adopt The Pink Agenda as their charity of choice because of its ability to allow them to tell those stories and honor them in a way that makes a real difference.

Lastly, what are your long-term goals for TPA?

I want The Pink Agenda to continue to grow while staying true to its original mission and maintaining the level of creativity and organizational efficiency that has always set it apart. I hope that, in time, The Pink Agenda will become the charity of choice for young professionals within the breast cancer space and beyond it, but ultimately, I hope that the work we do and the money we raise helps makes breast cancer a thing of the past.

# data[].attributes.field_caption
(From Left) Liana Douillet Guzman, Jaquelyn Scharnick, Marisa Renee Lee

# data[].attributes.field_subtitle
BCRF sits down with TPA to talk how it all started, the mission and its future

# data[].attributes.metatag_normalized[].attributes.content
This year, we are investing $47 million in annual grants to 222 researchers at leading medical institutions across six continents, making the foundation one of the largest nonprofit funders of breast cancer research in the world. Hailing from Princeton University to the University of California-San Francisco, the five investigators we will begin supporting this year will add to our portfolio of leaders in tumor biology, genetics, prevention, treatment, survivorship and metastasis. 


Dr. Suzanne Fuqua’s laboratory at Baylor College of Medicine was the first to discover a mutation in the estrogen receptor gene, ESR1. Mutations in ESR1 are associated with resistance to aromatase inhibitors, commonly used anti-hormone drugs that block the production of estrogen, a major driver of most breast cancers. The goal of Dr. Fuqua’s BCRF project is to identify ways to target these alterations and restore sensitivity to aromatase inhibitor therapies and to find other mechanisms of resistance to improve outcomes in drug-resistant breast cancers. 


Approximately one third of breast cancers will spread, or metastasize. Metastasis is the leading cause of death in breast cancer, making it a significant clinical challenge and one of BCRF’s top priorities. Dr. Yibin Kang will combine genetic and pharmacological approaches to develop new strategies to target a protein called MTDH, which promotes cancer progression and resistance to chemotherapy. Our hope is that his studies may accelerate the development of better treatments for metastatic breast cancer. 


Triple negative breast cancers are typically aggressive cancers that frequently occur in young women and women of African descent, and for which we have no targeted treatments. To develop personalized medicines for this type of cancer, scientists need experimental model systems that accurately reflect human disease to test new therapies. Drs. Elisa Port and Hanna Irie are working with a new model system derived from patient tumors that reflects the genetic and biological uniqueness of the patient’s cancer. With BCRF support, they will explore whether this model will work for testing chemotherapeutic agents against triple negative breast cancer.


Women who respond well to therapy before surgery, known as neoadjuvant chemotherapy, have a much better prognosis than those who fail to respond. The challenge for clinicians is determining what to do when a woman does not respond. Dr. Laura van't Veer will assess early changes in gene and protein expression caused by neoadjuvant chemotherapy to identify markers that can predict who will or will not respond. Early predictors of non-response can help clinicians better determine the best treatment for a patient’s cancer and spare women from ineffective treatment.


Our mission to eradicate breast cancer depends on maintaining an intellectual pool of highly trained clinical and research scientists. To support the continuing education and career development of postdoctoral and early career scientists, BCRF has partnered with the Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF/ASCO) since 2001 and the American Association for Cancer Research (AACR) since 2006. To date, we have contributed more than $10.5 million to insure that research will advance as promising young scientists gain career independence. This year we welcome seven scientists selected by CCF/ASCO and AACR as new grantees.
Our Conquer Cancer Foundation Grantees


Treating triple negative breast cancer is a challenge because it is a very heterogeneous disease, made up of different subtypes that respond differently to therapies. Dr. Vanada Abramson is testing new combination therapies based on the genetic and biological underpinnings of specific triple negative subtypes. The ultimate objective of her research is to improve the survival of these patients by uncovering subtype-specific combination therapies.


To achieve local control of early-stage breast cancer, removing the complete tumor is essential. But microscopic disease, which cannot be seen or felt, is often left behind, increasing the risk of local recurrence. Dr. Mekhail Anwar is working with a multi-disciplinary team to test new methods of fluorescent imaging that will enable live visualization of microscopic cancer while surgery is performed. This innovative technique will improve detection of microscopic disease and guide real‐time surgical resection that could decrease the risk of the cancer returning.


Metastatic triple negative breast cancer is incurable using standard therapies. Dr. Erin Macrae is studying genes and proteins that may be important to the growth and spread of this type of breast cancer. She will determine how often these pathways are active in metastatic tumor tissue and assess if new drugs that inhibit key proteins will reduce tumor growth and improve the lives of patients.  


Roughly one third of all breast cancers occur in women 70 years or older. Studies have shown that radiation therapy does not significantly improve outcomes for these women, yet many continue to receive radiation regardless of their tumor grade and risk of recurrence. Dr. Dean Shumway is conducting studies to identify barriers that limit the adoption of evidence-based clinical practice. His goal is to improve how doctors communicate the risks and benefits of available therapies with their patients and reduce unnecessary treatments in older cancer patients. 


Research has shown that cancer stem cells, which are common in estrogen receptor negative and triple negative breast cancers, are relatively resistant to radiation, a key component of treatment of this disease. Dr. Corey Speers is investigating ways to improve response to radiation in triple negative breast cancers by targeting stem cells with the hopes of providing a viable therapeutic option for these aggressive tumors.


Our American Association for Cancer Research Grantees


Ductal carcinoma in situ (DCIS) is considered a non-invasive precursor to breast cancer. While many DCIS will never progress to invasive breast cancer, they are treated the in the same way, exposing some women to unnecessary drugs and their side effects. Dr. Fariba Behbod is studying a protein that may help predict whether DCIS will progress. Her studies could improve risk prediction and identify women who should be treated aggressively to prevent future breast cancer and reduce overtreatment of benign breast lesions.


DCIS occurs in the cells lining the breast ducts and is by definition confined to the duct tissue. As we learn more about the unique gene signature of DCIS, It may be possible to target specific genes to prevent it from becoming an invasive cancer. Dr. Amy Brock’s lab pioneered an innovative targeted approach to “silence” cancer-specific genes by injecting a gene silencing therapy directly into the mammary ducts. This method of localized treatment could reduce adverse side effects while maximizing the therapy’s efficiency. 


As our family of grantees grows, we continue to foster a collaborative environment linking scientific research with clinical medicine. Staying true to the vision of our founder Evelyn Lauder, BCRF remains committed to providing scientists with the security and flexibility to pioneer the research that will address the most urgent issues in breast cancer and to build relationships that will facilitate those goals. 

# data[].attributes.metatag_normalized[].attributes.content
This year, we are investing $47 million in annual grants to 222 researchers at leading medical institutions across six continents, making the foundation one of the largest nonprofit funders of breast cancer research in the world. Hailing from Princeton University to the University of California-San Francisco, the five investigators we will begin supporting this year will add to our portfolio of leaders in tumor biology, genetics, prevention, treatment, survivorship and metastasis. 

# data[].attributes.metatag_normalized[].attributes.content
BCRF’s longstanding commitment to the most promising research continues with its 2014-2015 grantees

# data[].attributes.metatag_normalized[].attributes.content
This year, we are investing $47 million in annual grants to 222 researchers at leading medical institutions across six continents, making the foundation one of the largest nonprofit funders of breast cancer research in the world. Hailing from Princeton University to the University of California-San Francisco, the five investigators we will begin supporting this year will add to our portfolio of leaders in tumor biology, genetics, prevention, treatment, survivorship and metastasis. 

# data[].attributes.body.value
This year, we are investing $47 million in annual grants to 222 researchers at leading medical institutions across six continents, making the foundation one of the largest nonprofit funders of breast cancer research in the world. Hailing from Princeton University to the University of California-San Francisco, the five investigators we will begin supporting this year will add to our portfolio of leaders in tumor biology, genetics, prevention, treatment, survivorship and metastasis.

Dr. Suzanne Fuqua’s laboratory at Baylor College of Medicine was the first to discover a mutation in the estrogen receptor gene, ESR1. Mutations in ESR1 are associated with resistance to aromatase inhibitors, commonly used anti-hormone drugs that block the production of estrogen, a major driver of most breast cancers. The goal of Dr. Fuqua’s BCRF project is to identify ways to target these alterations and restore sensitivity to aromatase inhibitor therapies and to find other mechanisms of resistance to improve outcomes in drug-resistant breast cancers.

Approximately one third of breast cancers will spread, or metastasize. Metastasis is the leading cause of death in breast cancer, making it a significant clinical challenge and one of BCRF’s top priorities. Dr. Yibin Kang will combine genetic and pharmacological approaches to develop new strategies to target a protein called MTDH, which promotes cancer progression and resistance to chemotherapy. Our hope is that his studies may accelerate the development of better treatments for metastatic breast cancer.

Triple negative breast cancers are typically aggressive cancers that frequently occur in young women and women of African descent, and for which we have no targeted treatments. To develop personalized medicines for this type of cancer, scientists need experimental model systems that accurately reflect human disease to test new therapies. Drs. Elisa Port and Hanna Irie are working with a new model system derived from patient tumors that reflects the genetic and biological uniqueness of the patient’s cancer. With BCRF support, they will explore whether this model will work for testing chemotherapeutic agents against triple negative breast cancer.

Women who respond well to therapy before surgery, known as neoadjuvant chemotherapy, have a much better prognosis than those who fail to respond. The challenge for clinicians is determining what to do when a woman does not respond. Dr. Laura van't Veer will assess early changes in gene and protein expression caused by neoadjuvant chemotherapy to identify markers that can predict who will or will not respond. Early predictors of non-response can help clinicians better determine the best treatment for a patient’s cancer and spare women from ineffective treatment.

Our mission to eradicate breast cancer depends on maintaining an intellectual pool of highly trained clinical and research scientists. To support the continuing education and career development of postdoctoral and early career scientists, BCRF has partnered with the Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF/ASCO) since 2001 and the American Association for Cancer Research (AACR) since 2006. To date, we have contributed more than $10.5 million to insure that research will advance as promising young scientists gain career independence. This year we welcome seven scientists selected by CCF/ASCO and AACR as new grantees.

Our Conquer Cancer Foundation Grantees

Treating triple negative breast cancer is a challenge because it is a very heterogeneous disease, made up of different subtypes that respond differently to therapies. Dr. Vanada Abramson is testing new combination therapies based on the genetic and biological underpinnings of specific triple negative subtypes. The ultimate objective of her research is to improve the survival of these patients by uncovering subtype-specific combination therapies.

To achieve local control of early-stage breast cancer, removing the complete tumor is essential. But microscopic disease, which cannot be seen or felt, is often left behind, increasing the risk of local recurrence. Dr. Mekhail Anwar is working with a multi-disciplinary team to test new methods of fluorescent imaging that will enable live visualization of microscopic cancer while surgery is performed. This innovative technique will improve detection of microscopic disease and guide real‐time surgical resection that could decrease the risk of the cancer returning.

Metastatic triple negative breast cancer is incurable using standard therapies. Dr. Erin Macrae is studying genes and proteins that may be important to the growth and spread of this type of breast cancer. She will determine how often these pathways are active in metastatic tumor tissue and assess if new drugs that inhibit key proteins will reduce tumor growth and improve the lives of patients.

Roughly one third of all breast cancers occur in women 70 years or older. Studies have shown that radiation therapy does not significantly improve outcomes for these women, yet many continue to receive radiation regardless of their tumor grade and risk of recurrence. Dr. Dean Shumway is conducting studies to identify barriers that limit the adoption of evidence-based clinical practice. His goal is to improve how doctors communicate the risks and benefits of available therapies with their patients and reduce unnecessary treatments in older cancer patients.

Research has shown that cancer stem cells, which are common in estrogen receptor negative and triple negative breast cancers, are relatively resistant to radiation, a key component of treatment of this disease. Dr. Corey Speers is investigating ways to improve response to radiation in triple negative breast cancers by targeting stem cells with the hopes of providing a viable therapeutic option for these aggressive tumors.

Our American Association for Cancer Research Grantees

Ductal carcinoma in situ (DCIS) is considered a non-invasive precursor to breast cancer. While many DCIS will never progress to invasive breast cancer, they are treated the in the same way, exposing some women to unnecessary drugs and their side effects. Dr. Fariba Behbod is studying a protein that may help predict whether DCIS will progress. Her studies could improve risk prediction and identify women who should be treated aggressively to prevent future breast cancer and reduce overtreatment of benign breast lesions.

DCIS occurs in the cells lining the breast ducts and is by definition confined to the duct tissue. As we learn more about the unique gene signature of DCIS, It may be possible to target specific genes to prevent it from becoming an invasive cancer. Dr. Amy Brock’s lab pioneered an innovative targeted approach to “silence” cancer-specific genes by injecting a gene silencing therapy directly into the mammary ducts. This method of localized treatment could reduce adverse side effects while maximizing the therapy’s efficiency.

As our family of grantees grows, we continue to foster a collaborative environment linking scientific research with clinical medicine. Staying true to the vision of our founder Evelyn Lauder, BCRF remains committed to providing scientists with the security and flexibility to pioneer the research that will address the most urgent issues in breast cancer and to build relationships that will facilitate those goals.

# data[].attributes.body.processed
This year, we are investing $47 million in annual grants to 222 researchers at leading medical institutions across six continents, making the foundation one of the largest nonprofit funders of breast cancer research in the world. Hailing from Princeton University to the University of California-San Francisco, the five investigators we will begin supporting this year will add to our portfolio of leaders in tumor biology, genetics, prevention, treatment, survivorship and metastasis.

Dr. Suzanne Fuqua’s laboratory at Baylor College of Medicine was the first to discover a mutation in the estrogen receptor gene, ESR1. Mutations in ESR1 are associated with resistance to aromatase inhibitors, commonly used anti-hormone drugs that block the production of estrogen, a major driver of most breast cancers. The goal of Dr. Fuqua’s BCRF project is to identify ways to target these alterations and restore sensitivity to aromatase inhibitor therapies and to find other mechanisms of resistance to improve outcomes in drug-resistant breast cancers.

Approximately one third of breast cancers will spread, or metastasize. Metastasis is the leading cause of death in breast cancer, making it a significant clinical challenge and one of BCRF’s top priorities. Dr. Yibin Kang will combine genetic and pharmacological approaches to develop new strategies to target a protein called MTDH, which promotes cancer progression and resistance to chemotherapy. Our hope is that his studies may accelerate the development of better treatments for metastatic breast cancer.

Triple negative breast cancers are typically aggressive cancers that frequently occur in young women and women of African descent, and for which we have no targeted treatments. To develop personalized medicines for this type of cancer, scientists need experimental model systems that accurately reflect human disease to test new therapies. Drs. Elisa Port and Hanna Irie are working with a new model system derived from patient tumors that reflects the genetic and biological uniqueness of the patient’s cancer. With BCRF support, they will explore whether this model will work for testing chemotherapeutic agents against triple negative breast cancer.

Women who respond well to therapy before surgery, known as neoadjuvant chemotherapy, have a much better prognosis than those who fail to respond. The challenge for clinicians is determining what to do when a woman does not respond. Dr. Laura van't Veer will assess early changes in gene and protein expression caused by neoadjuvant chemotherapy to identify markers that can predict who will or will not respond. Early predictors of non-response can help clinicians better determine the best treatment for a patient’s cancer and spare women from ineffective treatment.

Our mission to eradicate breast cancer depends on maintaining an intellectual pool of highly trained clinical and research scientists. To support the continuing education and career development of postdoctoral and early career scientists, BCRF has partnered with the Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF/ASCO) since 2001 and the American Association for Cancer Research (AACR) since 2006. To date, we have contributed more than $10.5 million to insure that research will advance as promising young scientists gain career independence. This year we welcome seven scientists selected by CCF/ASCO and AACR as new grantees.

Our Conquer Cancer Foundation Grantees

Treating triple negative breast cancer is a challenge because it is a very heterogeneous disease, made up of different subtypes that respond differently to therapies. Dr. Vanada Abramson is testing new combination therapies based on the genetic and biological underpinnings of specific triple negative subtypes. The ultimate objective of her research is to improve the survival of these patients by uncovering subtype-specific combination therapies.

To achieve local control of early-stage breast cancer, removing the complete tumor is essential. But microscopic disease, which cannot be seen or felt, is often left behind, increasing the risk of local recurrence. Dr. Mekhail Anwar is working with a multi-disciplinary team to test new methods of fluorescent imaging that will enable live visualization of microscopic cancer while surgery is performed. This innovative technique will improve detection of microscopic disease and guide real‐time surgical resection that could decrease the risk of the cancer returning.

Metastatic triple negative breast cancer is incurable using standard therapies. Dr. Erin Macrae is studying genes and proteins that may be important to the growth and spread of this type of breast cancer. She will determine how often these pathways are active in metastatic tumor tissue and assess if new drugs that inhibit key proteins will reduce tumor growth and improve the lives of patients.

Roughly one third of all breast cancers occur in women 70 years or older. Studies have shown that radiation therapy does not significantly improve outcomes for these women, yet many continue to receive radiation regardless of their tumor grade and risk of recurrence. Dr. Dean Shumway is conducting studies to identify barriers that limit the adoption of evidence-based clinical practice. His goal is to improve how doctors communicate the risks and benefits of available therapies with their patients and reduce unnecessary treatments in older cancer patients.

Research has shown that cancer stem cells, which are common in estrogen receptor negative and triple negative breast cancers, are relatively resistant to radiation, a key component of treatment of this disease. Dr. Corey Speers is investigating ways to improve response to radiation in triple negative breast cancers by targeting stem cells with the hopes of providing a viable therapeutic option for these aggressive tumors.

Our American Association for Cancer Research Grantees

Ductal carcinoma in situ (DCIS) is considered a non-invasive precursor to breast cancer. While many DCIS will never progress to invasive breast cancer, they are treated the in the same way, exposing some women to unnecessary drugs and their side effects. Dr. Fariba Behbod is studying a protein that may help predict whether DCIS will progress. Her studies could improve risk prediction and identify women who should be treated aggressively to prevent future breast cancer and reduce overtreatment of benign breast lesions.

DCIS occurs in the cells lining the breast ducts and is by definition confined to the duct tissue. As we learn more about the unique gene signature of DCIS, It may be possible to target specific genes to prevent it from becoming an invasive cancer. Dr. Amy Brock’s lab pioneered an innovative targeted approach to “silence” cancer-specific genes by injecting a gene silencing therapy directly into the mammary ducts. This method of localized treatment could reduce adverse side effects while maximizing the therapy’s efficiency.

As our family of grantees grows, we continue to foster a collaborative environment linking scientific research with clinical medicine. Staying true to the vision of our founder Evelyn Lauder, BCRF remains committed to providing scientists with the security and flexibility to pioneer the research that will address the most urgent issues in breast cancer and to build relationships that will facilitate those goals.

# data[].attributes.field_subtitle
BCRF’s longstanding commitment to the most promising research continues with its 2014-2015 grantees 

# data[].attributes.title
The Breast Cancer Research Foundation Commits Record $58.6 Million  in Research Grants

# data[].attributes.metatag_normalized[].attributes.content
The BCRF Commits Record $58.6 Million in Grants | BCRF

# data[].attributes.metatag_normalized[].attributes.content
NEW YORK, NY – October 9, 2014 – The Breast Cancer Research Foundation (BCRF), announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF’s mission of advancing the world’s most innovative research. In addition, $11.6 million has been committed to the international Founder’s Fund project focused on metastasis.
“At BCRF, we fund the game changers,” President of BCRF Myra Biblowit said. “Thanks to the generosity of our donors and corporate communities, we are able to support over 220 women and men through our grants that will make a real difference and accelerate advances in the battle against breast cancer.”
Every year, BCRF brings together its international roster of grantees at its Symposium & Awards Luncheon in an effort to encourage collaboration and move the field forward with more speed and excitement. BCRF’s unique approach established by Scientific Director Dr. Larry Norton and Chairman of the foundation’s Scientific Advisory Board Dr. Clifford Hudis, fosters creativity and freedom to quickly move ideas from the lab to the bedside.
This year’s symposium, titled “Breast Cancer: Prevention is the Best Cure,” included a panel featuring renowned BCRF researchers Graham A. Colditz, MD, Dr.PH (Washington University School of Medicine); Andrew J. Dannenberg, MD (Weill Cornell Medical College), Susan M. Domchek, MD (University of Pennsylvania) and Peter Greenwald, MD, Dr.PH (National Cancer Institute).
The luncheon, which raised $2.2 million, was hosted by Good Morning America anchor, breast cancer survivor and BCRF ambassador, Amy Robach. ABC News broadcast legend Barbara Walters received the Sandra Taub Humanitarian Award for her contributions to women’s health. The Jill Rose Award for outstanding research excellence was presented to Dr. Greenwald in recognition of his lifelong contributions to research on cancer prevention.
“As someone who believes in the power of investigation, in the power of discovery and uncovering the truth, I am an advocate for research and education,” Walters said. “I believe that we all have an obligation and a responsibility, to support and fund medical research. Some years back, I discovered a small lump in my breast. Under the expert care of Dr. Larry Norton, I had a lumpectomy. There were other choices possible. This was mine. I told few people and I am fine...no recurrence. Nor was I worried. I knew the advances that had been made in treating breast cancer, including lumpectomies when possible. I can remember when such treatments were not available. Research made my treatment possible.”

Closing her remarks thanking everyone again for the incredible honor, Walters left the stage as the crowd of over 1000 rose to their feet for a standing ovation.
Over the last 20 years, research funded by BCRF has played a significant part in some of the biggest breakthroughs in breast cancer, including:

the finding that breast cancer is not one but many diseases
the role of genetics in breast cancer
the use of immunotherapy as a means to attack breast cancer
understanding the biology underlying the spread of cancer, known as metastasis
the links between obesity, inflammation and breast cancer

Follow @BCRFcure and join the conversation at #BCRF and #BeTheEnd.

# data[].attributes.metatag_normalized[].attributes.content
The Breast Cancer Research Foundation Commits Record $58.6 Million  in Research Grants

# data[].attributes.metatag_normalized[].attributes.content
NEW YORK, NY – October 9, 2014 – The Breast Cancer Research Foundation (BCRF), announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF’s mission of advancing the world’s most innovative research.

# data[].attributes.metatag_normalized[].attributes.content
The Breast Cancer Research Foundation Commits Record $58.6 Million  in Research Grants

# data[].attributes.metatag_normalized[].attributes.content
Barbara Walters Reveals Her Personal Story with Breast Cancer at BCRF Symposium & Luncheon

# data[].attributes.metatag_normalized[].attributes.content
NEW YORK, NY – October 9, 2014 – The Breast Cancer Research Foundation (BCRF), announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF’s mission of advancing the world’s most innovative research.

# data[].attributes.metatag_normalized[].attributes.content
The Breast Cancer Research Foundation Commits Record $58.6 Million  in Research Grants

# data[].attributes.body.value
NEW YORK, NY – October 9, 2014 – The Breast Cancer Research Foundation (BCRF), announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF’s mission of advancing the world’s most innovative research. In addition, $11.6 million has been committed to the international Founder’s Fund project focused on metastasis.

“At BCRF, we fund the game changers,” President of BCRF Myra Biblowit said. “Thanks to the generosity of our donors and corporate communities, we are able to support over 220 women and men through our grants that will make a real difference and accelerate advances in the battle against breast cancer.”

Every year, BCRF brings together its international roster of grantees at its Symposium & Awards Luncheon in an effort to encourage collaboration and move the field forward with more speed and excitement. BCRF’s unique approach established by Scientific Director Dr. Larry Norton and Chairman of the foundation’s Scientific Advisory Board Dr. Clifford Hudis, fosters creativity and freedom to quickly move ideas from the lab to the bedside.

This year’s symposium, titled “Breast Cancer: Prevention is the Best Cure,” included a panel featuring renowned BCRF researchers Graham A. Colditz, MD, Dr.PH (Washington University School of Medicine); Andrew J. Dannenberg, MD (Weill Cornell Medical College), Susan M. Domchek, MD (University of Pennsylvania) and Peter Greenwald, MD, Dr.PH (National Cancer Institute).

The luncheon, which raised $2.2 million, was hosted by Good Morning America anchor, breast cancer survivor and BCRF ambassador, Amy Robach. ABC News broadcast legend Barbara Walters received the Sandra Taub Humanitarian Award for her contributions to women’s health. The Jill Rose Award for outstanding research excellence was presented to Dr. Greenwald in recognition of his lifelong contributions to research on cancer prevention.

“As someone who believes in the power of investigation, in the power of discovery and uncovering the truth, I am an advocate for research and education,” Walters said. “I believe that we all have an obligation and a responsibility, to support and fund medical research. Some years back, I discovered a small lump in my breast. Under the expert care of Dr. Larry Norton, I had a lumpectomy. There were other choices possible. This was mine. I told few people and I am fine...no recurrence. Nor was I worried. I knew the advances that had been made in treating breast cancer, including lumpectomies when possible. I can remember when such treatments were not available. Research made my treatment possible.”

Closing her remarks thanking everyone again for the incredible honor, Walters left the stage as the crowd of over 1000 rose to their feet for a standing ovation.

Over the last 20 years, research funded by BCRF has played a significant part in some of the biggest breakthroughs in breast cancer, including:

the finding that breast cancer is not one but many diseases

the role of genetics in breast cancer

the use of immunotherapy as a means to attack breast cancer

understanding the biology underlying the spread of cancer, known as metastasis

the links between obesity, inflammation and breast cancer

Follow @BCRFcure and join the conversation at #BCRF and #BeTheEnd.

# data[].attributes.body.processed
NEW YORK, NY – October 9, 2014 – The Breast Cancer Research Foundation (BCRF), announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF’s mission of advancing the world’s most innovative research. In addition, $11.6 million has been committed to the international Founder’s Fund project focused on metastasis.

“At BCRF, we fund the game changers,” President of BCRF Myra Biblowit said. “Thanks to the generosity of our donors and corporate communities, we are able to support over 220 women and men through our grants that will make a real difference and accelerate advances in the battle against breast cancer.”

Every year, BCRF brings together its international roster of grantees at its Symposium & Awards Luncheon in an effort to encourage collaboration and move the field forward with more speed and excitement. BCRF’s unique approach established by Scientific Director Dr. Larry Norton and Chairman of the foundation’s Scientific Advisory Board Dr. Clifford Hudis, fosters creativity and freedom to quickly move ideas from the lab to the bedside.

This year’s symposium, titled “Breast Cancer: Prevention is the Best Cure,” included a panel featuring renowned BCRF researchers Graham A. Colditz, MD, Dr.PH (Washington University School of Medicine); Andrew J. Dannenberg, MD (Weill Cornell Medical College), Susan M. Domchek, MD (University of Pennsylvania) and Peter Greenwald, MD, Dr.PH (National Cancer Institute).

The luncheon, which raised $2.2 million, was hosted by Good Morning America anchor, breast cancer survivor and BCRF ambassador, Amy Robach. ABC News broadcast legend Barbara Walters received the Sandra Taub Humanitarian Award for her contributions to women’s health. The Jill Rose Award for outstanding research excellence was presented to Dr. Greenwald in recognition of his lifelong contributions to research on cancer prevention.

“As someone who believes in the power of investigation, in the power of discovery and uncovering the truth, I am an advocate for research and education,” Walters said. “I believe that we all have an obligation and a responsibility, to support and fund medical research. Some years back, I discovered a small lump in my breast. Under the expert care of Dr. Larry Norton, I had a lumpectomy. There were other choices possible. This was mine. I told few people and I am fine...no recurrence. Nor was I worried. I knew the advances that had been made in treating breast cancer, including lumpectomies when possible. I can remember when such treatments were not available. Research made my treatment possible.”

Closing her remarks thanking everyone again for the incredible honor, Walters left the stage as the crowd of over 1000 rose to their feet for a standing ovation.

Over the last 20 years, research funded by BCRF has played a significant part in some of the biggest breakthroughs in breast cancer, including:

the finding that breast cancer is not one but many diseases

the role of genetics in breast cancer

the use of immunotherapy as a means to attack breast cancer

understanding the biology underlying the spread of cancer, known as metastasis

the links between obesity, inflammation and breast cancer

Follow @BCRFcure and join the conversation at #BCRF and #BeTheEnd.

# data[].attributes.field_meta_tags.title
The BCRF Commits Record $58.6 Million in Grants | BCRF

# data[].attributes.field_subtitle
Barbara Walters Reveals Her Personal Story with Breast Cancer at BCRF Symposium & Luncheon

# data[].attributes.title
No Time For Complacency: Advanced Breast Cancer Calls For Advanced Research

# data[].attributes.metatag_normalized[].attributes.content
No Time For Complacency: Advanced Breast Cancer Calls For Advanced Research | BCRF

# data[].attributes.metatag_normalized[].attributes.content
There’s nothing more important than stopping breast cancer in its tracks. But what people don’t always understand is that, if detected early, breast cancer can often be controlled. It’s when the disease spreads, or metastasizes, that it turns lethal. One in eight women in the United States will develop breast cancer in her lifetime but, for nearly 30 percent of them, the cancer will metastasize.
Today, an estimated 150,000 to 250,000 women and men are living with metastatic breast cancer in the U.S. alone. Many people believe that advanced breast cancer is curable if diagnosed early, but the sad truth is that the median survival after a metastatic diagnosis is only three years.
While there has been significant progress in early detection and treatment for primary breast cancer, advances in treatment and prevention of metastasis are lagging behind. It’s a wily disease that works in mysterious ways. Metastatic cancer cells can lie dormant for years, even decades, only to “wake up” and find their way into different parts of the body, such as the lungs, liver, brain or bones.
How to circumvent and stop metastasis is the most pressing question in cancer medicine today. And it’s one the Breast Cancer Research Foundation is trying to answer.
In 2012, BCRF dedicated $27 million to launch the Evelyn H. Lauder Founder’s Fund, a multi-year, multi-institutional international collaboration focused exclusively on unraveling the mysteries of metastasis. The Founder’s Fund seeks to understand what makes the disease tick, why some breast cancers spread while others do not, and how to use this knowledge to predict, treat and even prevent metastasis. Our aim is to get to the heart of this under-researched matter to improve outcomes of real people in real time.
Under the direction of our Scientific Director Dr. Larry Norton and Chairman of our Scientific Advisory Board Dr. Clifford Hudis, the Founder’s Fund brings together BCRF’s world-class investigators in an unprecedented effort to dissect the molecular basis of metastasis. To accelerate advances in understanding the disease, the project will:

Identify changes in molecular and genetic markers that occur when breast cancers metastasize;
Follow individual patients to see how the molecular markers in their metastases change over time;
Perform comprehensive analyses of metastases being treated with medicines that target specific molecular changes.

The Founder’s Fund will tackle these objectives through a two-pronged research enterprise, known as AURORA, in Europe and North America: AURORA EU is based in Belgium and led by Dr. Martine Piccart-Gebhart of the Institut Jules Bordet through the Breast International Group, and AURORA US is spearheaded by Dr. Nancy Davidson of the University of Pittsburgh Cancer Institute through the North American Breast Cancer Group and the Translational Breast Cancer Research Consortium (TBCRC).
Through AURORA EU, BCRF investigators are conducting precise molecular analyses of primary and metastatic breast cancer samples to better understand the evolution of metastasis and the mechanisms of drug resistance that allow tumors to grow and spread. Our grantees are working to identify tumor markers in cancer patients’ blood that could be used as a non-invasive test to determine tumor progression and response to treatment.
In AURORA US, BCRF researchers are utilizing the TBCRC’s extensive clinical trial infrastructure for clinical trial development and molecular and pathological evaluation of metastatic breast cancer samples. Efforts will include the development of an experimental model system that precisely mimics human breast metastases in a laboratory setting. The system will use patient tumor cells to evaluate the effect of specific gene mutations on drug response and tumor development.
Through the Founder’s Fund, we expect to collect and analyze thousands of cases of metastatic breast cancer and to make that data available for future research by investigators around the globe. Collaboration has long been a tenet of BCRF, allowing us to make critical headway in cancer research. Last year, we became a founding member of the Metastatic Breast Cancer Alliance, joining forces with a number of other organizations dedicated to addressing the challenges of advanced disease. Following an initial investment of $5 million to launch the Founder’s Fund last year, BCRF committed another $11.6 million in 2014 to continue to support the under-funded area of metastasis.
We are 100-percent committed to tackling advanced breast cancer and hope that this research will open doors and provide insight to other kinds of metastatic disease. At BCRF, research has always been our mission and saving lives our ultimate goal.
 
 
This article was originally published on Huffington Post. 

# data[].attributes.metatag_normalized[].attributes.content
No Time For Complacency: Advanced Breast Cancer Calls For Advanced Research

# data[].attributes.metatag_normalized[].attributes.content
There’s nothing more important than stopping breast cancer in its tracks. But what people don’t always understand is that, if detected early, breast cancer can often be controlled. It’s when the disease spreads, or metastasizes, that it turns lethal. One in eight women in the United States will develop breast cancer in her lifetime but, for nearly 30 percent of them, the cancer will metastasize.

# data[].attributes.metatag_normalized[].attributes.content
No Time For Complacency: Advanced Breast Cancer Calls For Advanced Research

# data[].attributes.metatag_normalized[].attributes.content
Myra Biblowit, President of the Breast Cancer Research Foundation

# data[].attributes.metatag_normalized[].attributes.content
There’s nothing more important than stopping breast cancer in its tracks. But what people don’t always understand is that, if detected early, breast cancer can often be controlled. It’s when the disease spreads, or metastasizes, that it turns lethal. One in eight women in the United States will develop breast cancer in her lifetime but, for nearly 30 percent of them, the cancer will metastasize.

# data[].attributes.metatag_normalized[].attributes.content
No Time For Complacency: Advanced Breast Cancer Calls For Advanced Research

# data[].attributes.body.value
There’s nothing more important than stopping breast cancer in its tracks. But what people don’t always understand is that, if detected early, breast cancer can often be controlled. It’s when the disease spreads, or metastasizes, that it turns lethal. One in eight women in the United States will develop breast cancer in her lifetime but, for nearly 30 percent of them, the cancer will metastasize.

Today, an estimated 150,000 to 250,000 women and men are living with metastatic breast cancer in the U.S. alone. Many people believe that advanced breast cancer is curable if diagnosed early, but the sad truth is that the median survival after a metastatic diagnosis is only three years.

While there has been significant progress in early detection and treatment for primary breast cancer, advances in treatment and prevention of metastasis are lagging behind. It’s a wily disease that works in mysterious ways. Metastatic cancer cells can lie dormant for years, even decades, only to “wake up” and find their way into different parts of the body, such as the lungs, liver, brain or bones.

How to circumvent and stop metastasis is the most pressing question in cancer medicine today. And it’s one the Breast Cancer Research Foundation is trying to answer.

In 2012, BCRF dedicated $27 million to launch the Evelyn H. Lauder Founder’s Fund, a multi-year, multi-institutional international collaboration focused exclusively on unraveling the mysteries of metastasis. The Founder’s Fund seeks to understand what makes the disease tick, why some breast cancers spread while others do not, and how to use this knowledge to predict, treat and even prevent metastasis. Our aim is to get to the heart of this under-researched matter to improve outcomes of real people in real time.

Under the direction of our Scientific Director Dr. Larry Norton and Chairman of our Scientific Advisory Board Dr. Clifford Hudis, the Founder’s Fund brings together BCRF’s world-class investigators in an unprecedented effort to dissect the molecular basis of metastasis. To accelerate advances in understanding the disease, the project will:

Identify changes in molecular and genetic markers that occur when breast cancers metastasize;

Follow individual patients to see how the molecular markers in their metastases change over time;

Perform comprehensive analyses of metastases being treated with medicines that target specific molecular changes.

The Founder’s Fund will tackle these objectives through a two-pronged research enterprise, known as AURORA, in Europe and North America: AURORA EU is based in Belgium and led by Dr. Martine Piccart-Gebhart of the Institut Jules Bordet through the Breast International Group, and AURORA US is spearheaded by Dr. Nancy Davidson of the University of Pittsburgh Cancer Institute through the North American Breast Cancer Group and the Translational Breast Cancer Research Consortium (TBCRC).

Through AURORA EU, BCRF investigators are conducting precise molecular analyses of primary and metastatic breast cancer samples to better understand the evolution of metastasis and the mechanisms of drug resistance that allow tumors to grow and spread. Our grantees are working to identify tumor markers in cancer patients’ blood that could be used as a non-invasive test to determine tumor progression and response to treatment.

In AURORA US, BCRF researchers are utilizing the TBCRC’s extensive clinical trial infrastructure for clinical trial development and molecular and pathological evaluation of metastatic breast cancer samples. Efforts will include the development of an experimental model system that precisely mimics human breast metastases in a laboratory setting. The system will use patient tumor cells to evaluate the effect of specific gene mutations on drug response and tumor development.

Through the Founder’s Fund, we expect to collect and analyze thousands of cases of metastatic breast cancer and to make that data available for future research by investigators around the globe. Collaboration has long been a tenet of BCRF, allowing us to make critical headway in cancer research. Last year, we became a founding member of the Metastatic Breast Cancer Alliance, joining forces with a number of other organizations dedicated to addressing the challenges of advanced disease. Following an initial investment of $5 million to launch the Founder’s Fund last year, BCRF committed another $11.6 million in 2014 to continue to support the under-funded area of metastasis.

We are 100-percent committed to tackling advanced breast cancer and hope that this research will open doors and provide insight to other kinds of metastatic disease. At BCRF, research has always been our mission and saving lives our ultimate goal.

This article was originally published on Huffington Post.

# data[].attributes.body.processed
There’s nothing more important than stopping breast cancer in its tracks. But what people don’t always understand is that, if detected early, breast cancer can often be controlled. It’s when the disease spreads, or metastasizes, that it turns lethal. One in eight women in the United States will develop breast cancer in her lifetime but, for nearly 30 percent of them, the cancer will metastasize.

Today, an estimated 150,000 to 250,000 women and men are living with metastatic breast cancer in the U.S. alone. Many people believe that advanced breast cancer is curable if diagnosed early, but the sad truth is that the median survival after a metastatic diagnosis is only three years.

While there has been significant progress in early detection and treatment for primary breast cancer, advances in treatment and prevention of metastasis are lagging behind. It’s a wily disease that works in mysterious ways. Metastatic cancer cells can lie dormant for years, even decades, only to “wake up” and find their way into different parts of the body, such as the lungs, liver, brain or bones.

How to circumvent and stop metastasis is the most pressing question in cancer medicine today. And it’s one the Breast Cancer Research Foundation is trying to answer.

In 2012, BCRF dedicated $27 million to launch the Evelyn H. Lauder Founder’s Fund, a multi-year, multi-institutional international collaboration focused exclusively on unraveling the mysteries of metastasis. The Founder’s Fund seeks to understand what makes the disease tick, why some breast cancers spread while others do not, and how to use this knowledge to predict, treat and even prevent metastasis. Our aim is to get to the heart of this under-researched matter to improve outcomes of real people in real time.

Under the direction of our Scientific Director Dr. Larry Norton and Chairman of our Scientific Advisory Board Dr. Clifford Hudis, the Founder’s Fund brings together BCRF’s world-class investigators in an unprecedented effort to dissect the molecular basis of metastasis. To accelerate advances in understanding the disease, the project will:

Identify changes in molecular and genetic markers that occur when breast cancers metastasize;

Follow individual patients to see how the molecular markers in their metastases change over time;

Perform comprehensive analyses of metastases being treated with medicines that target specific molecular changes.

The Founder’s Fund will tackle these objectives through a two-pronged research enterprise, known as AURORA, in Europe and North America: AURORA EU is based in Belgium and led by Dr. Martine Piccart-Gebhart of the Institut Jules Bordet through the Breast International Group, and AURORA US is spearheaded by Dr. Nancy Davidson of the University of Pittsburgh Cancer Institute through the North American Breast Cancer Group and the Translational Breast Cancer Research Consortium (TBCRC).

Through AURORA EU, BCRF investigators are conducting precise molecular analyses of primary and metastatic breast cancer samples to better understand the evolution of metastasis and the mechanisms of drug resistance that allow tumors to grow and spread. Our grantees are working to identify tumor markers in cancer patients’ blood that could be used as a non-invasive test to determine tumor progression and response to treatment.

In AURORA US, BCRF researchers are utilizing the TBCRC’s extensive clinical trial infrastructure for clinical trial development and molecular and pathological evaluation of metastatic breast cancer samples. Efforts will include the development of an experimental model system that precisely mimics human breast metastases in a laboratory setting. The system will use patient tumor cells to evaluate the effect of specific gene mutations on drug response and tumor development.

Through the Founder’s Fund, we expect to collect and analyze thousands of cases of metastatic breast cancer and to make that data available for future research by investigators around the globe. Collaboration has long been a tenet of BCRF, allowing us to make critical headway in cancer research. Last year, we became a founding member of the Metastatic Breast Cancer Alliance, joining forces with a number of other organizations dedicated to addressing the challenges of advanced disease. Following an initial investment of $5 million to launch the Founder’s Fund last year, BCRF committed another $11.6 million in 2014 to continue to support the under-funded area of metastasis.

We are 100-percent committed to tackling advanced breast cancer and hope that this research will open doors and provide insight to other kinds of metastatic disease. At BCRF, research has always been our mission and saving lives our ultimate goal.

This article was originally published on Huffington Post.

# data[].attributes.field_subtitle
Myra Biblowit, President of the Breast Cancer Research Foundation

# data[].attributes.title
Ann Taylor and Glamour Present a “Conversation for a Cure”

# data[].attributes.metatag_normalized[].attributes.content
Ann Taylor and Glamour Present a “Conversation for a Cure” | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Last week, BCRF partner Ann Taylor and Glamour celebrated Breast Cancer Awareness Month with a "Conversation for a Cure." Taking place at Ann Taylor’s Rockefeller Center boutique and hosted by Glamour’s Genevieve Roth, the discussion on breast health featured a panel including BCRF President Myra Biblowit, BCRF grantee Dr. Nancy Lin and Emmy-nominated TV host Samantha Harris.
Harris, who was diagnosed earlier this year at age 40, kicked off the session sharing her turbulent journey from treatment to survivorship. After a clear mammogram, she found a lump in the shower during a self-exam just weeks later. Harris became vehement about sourcing a proper diagnosis. After seeking guidance from multiple specialists, her biggest fear was eventually confirmed by a needle biopsy: she had breast cancer. Samantha underwent a double mastectomy and stands today cancer-free, thanks to her diligence.
“You have to trust your gut, and be aware of your body,” Harris said. “You know your body better than any doctor.” She credits her unwavering quest for answers and modern medicine to her survival.
The modern miracles Samantha described are direct results of critical research and proper funding. As BCRF president, Myra Biblowit spoke about the importance of funding research to continue making the advances needed to help women today as well as tomorrow. While announcing that BCRF will award $47 million this year to support 225 researchers, she also stressed for more companies to follow ANN INC.’s example.  
“When I talk to companies that want to give more and they ask for examples, I say ‘Ann Taylor,’” Biblowit said. She praised ANN INC., one of BCRF’s largest and longstanding corporate partners, and their contribution of more than $18 million to date. 
Dr. Nancy Lin, a BCRF grantee fully funded by ANN INC.’s generous donations, addressed the crowd to touch upon her research. Currently a medical oncologist at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, Lin is mainly focused on targeted therapies. Her research looks at how the personalization of treatment will affect advanced breast cancer, warranting less unwanted side effects and increased treatment efficiency overall.  With the continuation of this research, and that of her fellow BCRF grantees, her outlook was promising for those affected by the disease.
“When you think about breast cancer, the good news is that, in the U.S. nowadays, most women diagnosed with breast cancer will be cured of the disease,” Dr. Lin said. “That’s not something we could say before.”
As the panel wrapped up, the support for Breast Cancer Awareness Month continued as guests hit the racks to shop. Ten percent of the night’s sales went directly to BCRF, and Glamour fashion experts were on hand to help style the latest Ann Taylor looks.
To get an inside look at the “Conversation for a Cure” or learn more about ANN INC.’s ongoing efforts to support BCRF, check out #AnnCares on Twitter and Instagram or go to www.anncares.com.

# data[].attributes.metatag_normalized[].attributes.content
Ann Taylor and Glamour Present a “Conversation for a Cure”

# data[].attributes.metatag_normalized[].attributes.content
Last week, BCRF partner Ann Taylor and Glamour celebrated Breast Cancer Awareness Month with a "Conversation for a Cure." Taking place at Ann Taylor’s Rockefeller Center boutique and hosted by Glamour’s Genevieve Roth, the discussion on breast health featured a panel including BCRF President Myra Biblowit, BCRF grantee Dr. Nancy Lin and Emmy-nominated TV host Samantha Harris.

# data[].attributes.metatag_normalized[].attributes.content
Ann Taylor and Glamour Present a “Conversation for a Cure”

# data[].attributes.metatag_normalized[].attributes.content
A panel discussion in honor of Breast Cancer Awareness Month

# data[].attributes.metatag_normalized[].attributes.content
Last week, BCRF partner Ann Taylor and Glamour celebrated Breast Cancer Awareness Month with a "Conversation for a Cure." Taking place at Ann Taylor’s Rockefeller Center boutique and hosted by Glamour’s Genevieve Roth, the discussion on breast health featured a panel including BCRF President Myra Biblowit, BCRF grantee Dr. Nancy Lin and Emmy-nominated TV host Samantha Harris.

# data[].attributes.metatag_normalized[].attributes.content
Ann Taylor and Glamour Present a “Conversation for a Cure”

# data[].attributes.body.value
Last week, BCRF partner Ann Taylor and Glamour celebrated Breast Cancer Awareness Month with a "Conversation for a Cure." Taking place at Ann Taylor’s Rockefeller Center boutique and hosted by Glamour’s Genevieve Roth, the discussion on breast health featured a panel including BCRF President Myra Biblowit, BCRF grantee Dr. Nancy Lin and Emmy-nominated TV host Samantha Harris.

Harris, who was diagnosed earlier this year at age 40, kicked off the session sharing her turbulent journey from treatment to survivorship. After a clear mammogram, she found a lump in the shower during a self-exam just weeks later. Harris became vehement about sourcing a proper diagnosis. After seeking guidance from multiple specialists, her biggest fear was eventually confirmed by a needle biopsy: she had breast cancer. Samantha underwent a double mastectomy and stands today cancer-free, thanks to her diligence.

“You have to trust your gut, and be aware of your body,” Harris said. “You know your body better than any doctor.” She credits her unwavering quest for answers and modern medicine to her survival.

The modern miracles Samantha described are direct results of critical research and proper funding. As BCRF president, Myra Biblowit spoke about the importance of funding research to continue making the advances needed to help women today as well as tomorrow. While announcing that BCRF will award $47 million this year to support 225 researchers, she also stressed for more companies to follow ANN INC.’s example.

“When I talk to companies that want to give more and they ask for examples, I say ‘Ann Taylor,’” Biblowit said. She praised ANN INC., one of BCRF’s largest and longstanding corporate partners, and their contribution of more than $18 million to date.

Dr. Nancy Lin, a BCRF grantee fully funded by ANN INC.’s generous donations, addressed the crowd to touch upon her research. Currently a medical oncologist at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, Lin is mainly focused on targeted therapies. Her research looks at how the personalization of treatment will affect advanced breast cancer, warranting less unwanted side effects and increased treatment efficiency overall.  With the continuation of this research, and that of her fellow BCRF grantees, her outlook was promising for those affected by the disease.

“When you think about breast cancer, the good news is that, in the U.S. nowadays, most women diagnosed with breast cancer will be cured of the disease,” Dr. Lin said. “That’s not something we could say before.”

As the panel wrapped up, the support for Breast Cancer Awareness Month continued as guests hit the racks to shop. Ten percent of the night’s sales went directly to BCRF, and Glamour fashion experts were on hand to help style the latest Ann Taylor looks.

To get an inside look at the “Conversation for a Cure” or learn more about ANN INC.’s ongoing efforts to support BCRF, check out #AnnCares on Twitter and Instagram or go to www.anncares.com.

# data[].attributes.body.processed
Last week, BCRF partner Ann Taylor and Glamour celebrated Breast Cancer Awareness Month with a "Conversation for a Cure." Taking place at Ann Taylor’s Rockefeller Center boutique and hosted by Glamour’s Genevieve Roth, the discussion on breast health featured a panel including BCRF President Myra Biblowit, BCRF grantee Dr. Nancy Lin and Emmy-nominated TV host Samantha Harris.

Harris, who was diagnosed earlier this year at age 40, kicked off the session sharing her turbulent journey from treatment to survivorship. After a clear mammogram, she found a lump in the shower during a self-exam just weeks later. Harris became vehement about sourcing a proper diagnosis. After seeking guidance from multiple specialists, her biggest fear was eventually confirmed by a needle biopsy: she had breast cancer. Samantha underwent a double mastectomy and stands today cancer-free, thanks to her diligence.

“You have to trust your gut, and be aware of your body,” Harris said. “You know your body better than any doctor.” She credits her unwavering quest for answers and modern medicine to her survival.

The modern miracles Samantha described are direct results of critical research and proper funding. As BCRF president, Myra Biblowit spoke about the importance of funding research to continue making the advances needed to help women today as well as tomorrow. While announcing that BCRF will award $47 million this year to support 225 researchers, she also stressed for more companies to follow ANN INC.’s example.

“When I talk to companies that want to give more and they ask for examples, I say ‘Ann Taylor,’” Biblowit said. She praised ANN INC., one of BCRF’s largest and longstanding corporate partners, and their contribution of more than $18 million to date.

Dr. Nancy Lin, a BCRF grantee fully funded by ANN INC.’s generous donations, addressed the crowd to touch upon her research. Currently a medical oncologist at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, Lin is mainly focused on targeted therapies. Her research looks at how the personalization of treatment will affect advanced breast cancer, warranting less unwanted side effects and increased treatment efficiency overall.  With the continuation of this research, and that of her fellow BCRF grantees, her outlook was promising for those affected by the disease.

“When you think about breast cancer, the good news is that, in the U.S. nowadays, most women diagnosed with breast cancer will be cured of the disease,” Dr. Lin said. “That’s not something we could say before.”

As the panel wrapped up, the support for Breast Cancer Awareness Month continued as guests hit the racks to shop. Ten percent of the night’s sales went directly to BCRF, and Glamour fashion experts were on hand to help style the latest Ann Taylor looks.

To get an inside look at the “Conversation for a Cure” or learn more about ANN INC.’s ongoing efforts to support BCRF, check out #AnnCares on Twitter and Instagram or go to www.anncares.com.

# data[].attributes.field_subtitle
A panel discussion in honor of Breast Cancer Awareness Month

# data[].attributes.title
Meet BCRF's Largest Independent Fundraiser 

# data[].attributes.metatag_normalized[].attributes.content
Meet BCRF's Largest Independent Fundraiser  | BCRF

# data[].attributes.metatag_normalized[].attributes.content
When Cathy Jolly was only 35 years old, a breast cancer diagnosis threatened to turn her life upside down. After surviving her battle and empathizing with other women with stories just like hers, she set out to raise as much money as possible for research toward better treatments and cures for other patients.
Over the past seven years, Jolly, a native of Kansas City, Missouri, has successfully raised more than $335,000 for the Breast Cancer Research Foundation -- more money than any other individual has ever raised for the group. She was able to set this record thanks to the overwhelming support of her community. Utilizing her previous position as a city councilwoman in Kansas City, and her current role as a senior adviser for Jackson County Executive Mike Sanders, Jolly was able not only to harness the power of her connections, but to give the people of Kansas City a philanthropic cause to which they could personally relate.
Many of the people who support Jolly's fundraising efforts have been by her side since she was 27, when she successfully ran for Missouri state representative. She served for six years, married her husband, Scott Taylor, and gave birth to their son, Drake. When a seat on the Kansas City Council opened up in 2007, Jolly ran for it and won, excited to be working closer to home and for a community she loves. But her triumph in being elected councilwoman was thwarted by her breast cancer diagnosis, which occurred immediately after she took her seat.
"It was completely devastating and shocking because I was so young," Jolly told The Huffington Post. "And it was interesting being an elected person during that time. I led our local nightly news with 'Councilwoman Cathy Jolly Has Breast Cancer.' I took a leave of absence for a few months, and just really focused on treatment and getting better."
As she underwent chemotherapy, her parents and mother-in-law helped her and her husband care for Drake, who was 3 years old at the time.
"There were weak times where I thought, 'I can't do this,' and my husband would say, 'You don't have a choice. This is the treatment that they have, and it's not going to be fun,'" said Jolly. "You don't know how tough you are and what you're made of, really, until you have to go through something like that. I always say women who get through breast cancer are warriors, because that's really how I felt, and that was the mindset I was in."
During her battle with breast cancer, Jolly's love for helping others as a public servant transformed into a need specifically to help women coping with a similar struggle. She made it her new mission to fundraise as much as possible for the science that could lend itself to new treatments and cures.
"I really, really strongly committed myself to raising money for research," she said. "I know other women, young moms going through it, and I just got to the point where I thought: 'It's 2014. We've landed a man on the moon -- everybody was committed to that in 1968 and 1969. Today you can talk to people all around the world about advances in technology with the Internet. We've got cars that you can plug into your garage at night and hop in them the next morning and go to work because they've been charged electrically. So why can't we have that kind of thrust to have funding and better research for treatment and cures?' I was fed up."
After some online research, Jolly decided to channel her efforts into fundraising for the Breast Cancer Research Foundation, a nonprofit based in New York City. She admired the group's support for a variety of doctors and promising research projects, and the way it responded with enthusiasm to her desire to help.
Jolly returned to the Kansas City Council after a leave of absence that lasted several months. Her treatment worked, placing her in remission and giving her an incredible sense of gratitude for the people who supported her along the way. When her fellow council members mentioned celebrating her return with a party, Jolly suggested an alternative.
In October 2007, together with then-Mayor Mark Funkhouser and the rest of the Kansas City Council, Jolly hosted her first gala to raise money for the Breast Cancer Research Foundation. More than 200 people attended the event, which included dinner, drinks and remarks from Funkhouser, the city council and Jolly herself. The ball was such a success that Jolly has gone on to host one every October, reflecting on her journey and offering support to anyone who has or who will experience a similar struggle.
"You know, it was difficult that my cancer was so public, but at the same time, we have a great community here and the support I received then and for these events is tremendous," she said. "It really is touching what a close community we are. Kansas City has about half a million people, so it was overwhelming."
The annual gala has approximately 36 sponsors, including but not limited to law firms, civic leaders, local businesses, labor unions and the Kansas City fire department. Each year, the gala raises $30,000 from these sponsorships alone, and takes in about another $18,000 from the $100 event ticket and various fundraising projects.
Gala organizers invite 300 guests every year, using beautiful five-piece invitations donated by the local printers who once helped Jolly with her political campaign materials. The fire department custom-designs a new T-shirt each year, while local taxi mogul Bill George paints several of his cabs pink with the BCRF logo for the month of October. Others throughout the community lend Jolly a hand in her overall fundraising mission.
"These are people who were with me when I was 27 years old running for state representative, and have just stayed with me through every endeavor," said Jolly. "I'm humbled and fortunate that I have great friends."
She's looking forward to hosting the eighth annual gala on Oct. 28, and seeing all the people who have made a contribution thus far.
"My favorite part is when I get to thank everyone at the event," she said. "I know it sounds silly, but when I'm standing in the front and I've got a microphone in my hand and I'm looking out, I get emotional about it. There are so many people there, and breast cancer touches everyone. You can't find anyone who isn't affected by it."
 
* This article was originally published on Huffington Post, October 21, 2014.

# data[].attributes.metatag_normalized[].attributes.content
Meet BCRF's Largest Independent Fundraiser

# data[].attributes.metatag_normalized[].attributes.content
When Cathy Jolly was only 35 years old, a breast cancer diagnosis threatened to turn her life upside down. After surviving her battle and empathizing with other women with stories just like hers, she set out to raise as much money as possible for research toward better treatments and cures for other patients.

# data[].attributes.metatag_normalized[].attributes.content
Meet BCRF's Largest Independent Fundraiser

# data[].attributes.metatag_normalized[].attributes.content
Missouri native and breast cancer survivor, Cathy Jolly turns awareness into action and sets fundraising record

# data[].attributes.metatag_normalized[].attributes.content
When Cathy Jolly was only 35 years old, a breast cancer diagnosis threatened to turn her life upside down. After surviving her battle and empathizing with other women with stories just like hers, she set out to raise as much money as possible for research toward better treatments and cures for other patients.

# data[].attributes.metatag_normalized[].attributes.content
Meet BCRF's Largest Independent Fundraiser

# data[].attributes.body.value
When Cathy Jolly was only 35 years old, a breast cancer diagnosis threatened to turn her life upside down. After surviving her battle and empathizing with other women with stories just like hers, she set out to raise as much money as possible for research toward better treatments and cures for other patients.

Over the past seven years, Jolly, a native of Kansas City, Missouri, has successfully raised more than $335,000 for the Breast Cancer Research Foundation -- more money than any other individual has ever raised for the group. She was able to set this record thanks to the overwhelming support of her community. Utilizing her previous position as a city councilwoman in Kansas City, and her current role as a senior adviser for Jackson County Executive Mike Sanders, Jolly was able not only to harness the power of her connections, but to give the people of Kansas City a philanthropic cause to which they could personally relate.

Many of the people who support Jolly's fundraising efforts have been by her side since she was 27, when she successfully ran for Missouri state representative. She served for six years, married her husband, Scott Taylor, and gave birth to their son, Drake. When a seat on the Kansas City Council opened up in 2007, Jolly ran for it and won, excited to be working closer to home and for a community she loves. But her triumph in being elected councilwoman was thwarted by her breast cancer diagnosis, which occurred immediately after she took her seat.

"It was completely devastating and shocking because I was so young," Jolly told The Huffington Post. "And it was interesting being an elected person during that time. I led our local nightly news with 'Councilwoman Cathy Jolly Has Breast Cancer.' I took a leave of absence for a few months, and just really focused on treatment and getting better."

As she underwent chemotherapy, her parents and mother-in-law helped her and her husband care for Drake, who was 3 years old at the time.

"There were weak times where I thought, 'I can't do this,' and my husband would say, 'You don't have a choice. This is the treatment that they have, and it's not going to be fun,'" said Jolly. "You don't know how tough you are and what you're made of, really, until you have to go through something like that. I always say women who get through breast cancer are warriors, because that's really how I felt, and that was the mindset I was in."

During her battle with breast cancer, Jolly's love for helping others as a public servant transformed into a need specifically to help women coping with a similar struggle. She made it her new mission to fundraise as much as possible for the science that could lend itself to new treatments and cures.

"I really, really strongly committed myself to raising money for research," she said. "I know other women, young moms going through it, and I just got to the point where I thought: 'It's 2014. We've landed a man on the moon -- everybody was committed to that in 1968 and 1969. Today you can talk to people all around the world about advances in technology with the Internet. We've got cars that you can plug into your garage at night and hop in them the next morning and go to work because they've been charged electrically. So why can't we have that kind of thrust to have funding and better research for treatment and cures?' I was fed up."

After some online research, Jolly decided to channel her efforts into fundraising for the Breast Cancer Research Foundation, a nonprofit based in New York City. She admired the group's support for a variety of doctors and promising research projects, and the way it responded with enthusiasm to her desire to help.

Jolly returned to the Kansas City Council after a leave of absence that lasted several months. Her treatment worked, placing her in remission and giving her an incredible sense of gratitude for the people who supported her along the way. When her fellow council members mentioned celebrating her return with a party, Jolly suggested an alternative.

In October 2007, together with then-Mayor Mark Funkhouser and the rest of the Kansas City Council, Jolly hosted her first gala to raise money for the Breast Cancer Research Foundation. More than 200 people attended the event, which included dinner, drinks and remarks from Funkhouser, the city council and Jolly herself. The ball was such a success that Jolly has gone on to host one every October, reflecting on her journey and offering support to anyone who has or who will experience a similar struggle.

"You know, it was difficult that my cancer was so public, but at the same time, we have a great community here and the support I received then and for these events is tremendous," she said. "It really is touching what a close community we are. Kansas City has about half a million people, so it was overwhelming."

The annual gala has approximately 36 sponsors, including but not limited to law firms, civic leaders, local businesses, labor unions and the Kansas City fire department. Each year, the gala raises $30,000 from these sponsorships alone, and takes in about another $18,000 from the $100 event ticket and various fundraising projects.

Gala organizers invite 300 guests every year, using beautiful five-piece invitations donated by the local printers who once helped Jolly with her political campaign materials. The fire department custom-designs a new T-shirt each year, while local taxi mogul Bill George paints several of his cabs pink with the BCRF logo for the month of October. Others throughout the community lend Jolly a hand in her overall fundraising mission.

"These are people who were with me when I was 27 years old running for state representative, and have just stayed with me through every endeavor," said Jolly. "I'm humbled and fortunate that I have great friends."

She's looking forward to hosting the eighth annual gala on Oct. 28, and seeing all the people who have made a contribution thus far.

"My favorite part is when I get to thank everyone at the event," she said. "I know it sounds silly, but when I'm standing in the front and I've got a microphone in my hand and I'm looking out, I get emotional about it. There are so many people there, and breast cancer touches everyone. You can't find anyone who isn't affected by it."

* This article was originally published on Huffington Post, October 21, 2014.

# data[].attributes.body.processed
When Cathy Jolly was only 35 years old, a breast cancer diagnosis threatened to turn her life upside down. After surviving her battle and empathizing with other women with stories just like hers, she set out to raise as much money as possible for research toward better treatments and cures for other patients.

Over the past seven years, Jolly, a native of Kansas City, Missouri, has successfully raised more than $335,000 for the Breast Cancer Research Foundation -- more money than any other individual has ever raised for the group. She was able to set this record thanks to the overwhelming support of her community. Utilizing her previous position as a city councilwoman in Kansas City, and her current role as a senior adviser for Jackson County Executive Mike Sanders, Jolly was able not only to harness the power of her connections, but to give the people of Kansas City a philanthropic cause to which they could personally relate.

Many of the people who support Jolly's fundraising efforts have been by her side since she was 27, when she successfully ran for Missouri state representative. She served for six years, married her husband, Scott Taylor, and gave birth to their son, Drake. When a seat on the Kansas City Council opened up in 2007, Jolly ran for it and won, excited to be working closer to home and for a community she loves. But her triumph in being elected councilwoman was thwarted by her breast cancer diagnosis, which occurred immediately after she took her seat.

"It was completely devastating and shocking because I was so young," Jolly told The Huffington Post. "And it was interesting being an elected person during that time. I led our local nightly news with 'Councilwoman Cathy Jolly Has Breast Cancer.' I took a leave of absence for a few months, and just really focused on treatment and getting better."

As she underwent chemotherapy, her parents and mother-in-law helped her and her husband care for Drake, who was 3 years old at the time.

"There were weak times where I thought, 'I can't do this,' and my husband would say, 'You don't have a choice. This is the treatment that they have, and it's not going to be fun,'" said Jolly. "You don't know how tough you are and what you're made of, really, until you have to go through something like that. I always say women who get through breast cancer are warriors, because that's really how I felt, and that was the mindset I was in."

During her battle with breast cancer, Jolly's love for helping others as a public servant transformed into a need specifically to help women coping with a similar struggle. She made it her new mission to fundraise as much as possible for the science that could lend itself to new treatments and cures.

"I really, really strongly committed myself to raising money for research," she said. "I know other women, young moms going through it, and I just got to the point where I thought: 'It's 2014. We've landed a man on the moon -- everybody was committed to that in 1968 and 1969. Today you can talk to people all around the world about advances in technology with the Internet. We've got cars that you can plug into your garage at night and hop in them the next morning and go to work because they've been charged electrically. So why can't we have that kind of thrust to have funding and better research for treatment and cures?' I was fed up."

After some online research, Jolly decided to channel her efforts into fundraising for the Breast Cancer Research Foundation, a nonprofit based in New York City. She admired the group's support for a variety of doctors and promising research projects, and the way it responded with enthusiasm to her desire to help.

Jolly returned to the Kansas City Council after a leave of absence that lasted several months. Her treatment worked, placing her in remission and giving her an incredible sense of gratitude for the people who supported her along the way. When her fellow council members mentioned celebrating her return with a party, Jolly suggested an alternative.

In October 2007, together with then-Mayor Mark Funkhouser and the rest of the Kansas City Council, Jolly hosted her first gala to raise money for the Breast Cancer Research Foundation. More than 200 people attended the event, which included dinner, drinks and remarks from Funkhouser, the city council and Jolly herself. The ball was such a success that Jolly has gone on to host one every October, reflecting on her journey and offering support to anyone who has or who will experience a similar struggle.

"You know, it was difficult that my cancer was so public, but at the same time, we have a great community here and the support I received then and for these events is tremendous," she said. "It really is touching what a close community we are. Kansas City has about half a million people, so it was overwhelming."

The annual gala has approximately 36 sponsors, including but not limited to law firms, civic leaders, local businesses, labor unions and the Kansas City fire department. Each year, the gala raises $30,000 from these sponsorships alone, and takes in about another $18,000 from the $100 event ticket and various fundraising projects.

Gala organizers invite 300 guests every year, using beautiful five-piece invitations donated by the local printers who once helped Jolly with her political campaign materials. The fire department custom-designs a new T-shirt each year, while local taxi mogul Bill George paints several of his cabs pink with the BCRF logo for the month of October. Others throughout the community lend Jolly a hand in her overall fundraising mission.

"These are people who were with me when I was 27 years old running for state representative, and have just stayed with me through every endeavor," said Jolly. "I'm humbled and fortunate that I have great friends."

She's looking forward to hosting the eighth annual gala on Oct. 28, and seeing all the people who have made a contribution thus far.

"My favorite part is when I get to thank everyone at the event," she said. "I know it sounds silly, but when I'm standing in the front and I've got a microphone in my hand and I'm looking out, I get emotional about it. There are so many people there, and breast cancer touches everyone. You can't find anyone who isn't affected by it."

* This article was originally published on Huffington Post, October 21, 2014.

# data[].attributes.field_caption
Cathy Jolly, BCRF's largest independent fundraiser

# data[].attributes.field_subtitle
Missouri native and breast cancer survivor, Cathy Jolly turns awareness into action and sets fundraising record

# data[].attributes.title
Tijuana Flats Adds Fire to the Breast Cancer Fight

# data[].attributes.metatag_normalized[].attributes.content
Tijuana Flats Adds Fire to the Breast Cancer Fight | BCRF

# data[].attributes.metatag_normalized[].attributes.content
How does a small Tex-Mex restaurant end up with 100 locations in 6 states—and a philanthropic organization that’s donated more than $3 million to charity? For BCRF partner Tijuana Flats, it all dates back to the restaurant’s first year in 1995, when that first location threw a Christmas party for 25 local Head Start students.
“We made it a priority to be involved in the community since day one,” said Ben Kuykendall, Senior Philanthropy Manager of the Just In Queso Foundation, Tijuana Flats’ charitable organization. “It wasn’t for any reason other than employees and managers wanting to make a difference.”
And what a difference they are making. Tijuana Flats, through Just In Queso, has donated more than $479,000 toward breast cancer research since teaming up with BCRF in 2007.
“We never say, ‘Now it’s October, we’re going to give back and help out," Kuykendall said. “We constantly give our employees opportunities to give back, and now they expect it. It’s become part of our culture.”
The opportunities that benefit BCRF come in two forms: in-store and online sales of “The Sauce That Saves BCRF Edition” and substituting pink tortillas for an extra $1 during October. Aside from the gratification employees feel from contributing to a cure, there’s an extra incentive for them to rally behind research, too.

  
      
              



      
  

The company’s CEO announced that employees of the restaurant location that raised the most money for research during October would get the day off—and management would wait their tables instead.
“It was very motivating to our restaurant employees. When they realized the corporate team would take a whole day off, it emphasized how important this was,” Kuykendall said. They felt more connected to the cause.”
“It Became Our Mission to Sell for Cathy”
Throughout the month, restaurant managers, like Diane “Dee” Bell, encourage each location’s staff to sell the hot sauce and tortillas to patrons. When Bell heard about the competition, she relished the opportunity to rally her staff, even though she had no direct connection to the disease. It wasn’t until she shared the news about the competition with her family that her mother-in-law filled her in on a secret: she was a breast cancer survivor.
“You don’t realize how many lives you touch doing this,” Bell said. “They don’t necessarily share their stories because they think no one wants to hear it, but they’re there.”
Many of her mostly teenage staff also had personal experiences with the disease, whether it was a mother, aunt or grandmother who had battled breast cancer. Then one day, the disease hit even closer to home for Bell and her employees. A frequent customer, an older woman named Cathy, came in with her husband before undergoing a double mastectomy the next day. Unfortunately, she didn’t make it.

  
      
              



      
  

“All the kids had interacted with her and heard her story—I’ll never forget that,” Bell said. “After that, they all put in 110 percent. It became a mission for these kids to sell as many hot sauce bottles and tortillas they could for Cathy.”
Bell and her employees gave it their all during October. Her staff camped outside grocery stores on their days off to sell more bottles of hot sauce. They egged customers on to buy more. And the friendly competition between restaurant locations just pushed her employees to work harder. It paid off. Bell’s restaurant in Stuart, Fla., sold more than 1,100 bottles of hot sauce in October 2013.
“I cried when we won, “ Bell said, “I was so ecstatic for these kids. They got recognition for being so passionate.”
As the location manager, Bell was invited to join Tijuana Flats executives at BCRF’s annual Hot Pink Party in New York and present Tijuana Flats’ check to the foundation. “It’s a sense of pride to be able to present a check from such a small company,” she said.
This year, Bell is managing a restaurant in a different location, but she has no doubt her team will win again.

  
      
              



      
  
“I’m fueling the fire here!” she laughed. “I’m using my personal funds to buy little things for the girls, like headbands, ribbons and tutus, to make it a fun atmosphere.”
Already, her employees have organized a pancake breakfast at a local church and, on Oct. 21, they donated all their tips to BCRF.
“I’ve told them whatever you donate, I’ll match myself,” Bell said. “I don’t want my staff to give 100 percent if I’m not giving it too. This is a cause we don’t want thanks for—we just want to know we’re closer to a cure. Today, I’m 100 percent healthy but, tomorrow, I could be suffering from breast cancer, too. I hope people would fight that much harder for me.”

# data[].attributes.metatag_normalized[].attributes.content
Tijuana Flats Adds Fire to the Breast Cancer Fight

# data[].attributes.metatag_normalized[].attributes.content
How does a small Tex-Mex restaurant end up with 100 locations in 6 states—and a philanthropic organization that’s donated more than $3 million to charity? For BCRF partner Tijuana Flats, it all dates back to the restaurant’s first year in 1995, when that first location threw a Christmas party for 25 local Head Start students.

# data[].attributes.metatag_normalized[].attributes.content
Tijuana Flats Adds Fire to the Breast Cancer Fight

# data[].attributes.metatag_normalized[].attributes.content
By using hot sauce and a whole lot of teamwork, Tijuana Flats is supporting research in a big way.

# data[].attributes.metatag_normalized[].attributes.content
How does a small Tex-Mex restaurant end up with 100 locations in 6 states—and a philanthropic organization that’s donated more than $3 million to charity? For BCRF partner Tijuana Flats, it all dates back to the restaurant’s first year in 1995, when that first location threw a Christmas party for 25 local Head Start students.

# data[].attributes.metatag_normalized[].attributes.content
Tijuana Flats Adds Fire to the Breast Cancer Fight

# data[].attributes.body.value
How does a small Tex-Mex restaurant end up with 100 locations in 6 states—and a philanthropic organization that’s donated more than $3 million to charity? For BCRF partner Tijuana Flats, it all dates back to the restaurant’s first year in 1995, when that first location threw a Christmas party for 25 local Head Start students.

“We made it a priority to be involved in the community since day one,” said Ben Kuykendall, Senior Philanthropy Manager of the Just In Queso Foundation, Tijuana Flats’ charitable organization. “It wasn’t for any reason other than employees and managers wanting to make a difference.”

And what a difference they are making. Tijuana Flats, through Just In Queso, has donated more than $479,000 toward breast cancer research since teaming up with BCRF in 2007.

“We never say, ‘Now it’s October, we’re going to give back and help out," Kuykendall said. “We constantly give our employees opportunities to give back, and now they expect it. It’s become part of our culture.”

The opportunities that benefit BCRF come in two forms: in-store and online sales of “The Sauce That Saves BCRF Edition” and substituting pink tortillas for an extra $1 during October. Aside from the gratification employees feel from contributing to a cure, there’s an extra incentive for them to rally behind research, too.

The company’s CEO announced that employees of the restaurant location that raised the most money for research during October would get the day off—and management would wait their tables instead.

“It was very motivating to our restaurant employees. When they realized the corporate team would take a whole day off, it emphasized how important this was,” Kuykendall said. They felt more connected to the cause.”

“It Became Our Mission to Sell for Cathy”

Throughout the month, restaurant managers, like Diane “Dee” Bell, encourage each location’s staff to sell the hot sauce and tortillas to patrons. When Bell heard about the competition, she relished the opportunity to rally her staff, even though she had no direct connection to the disease. It wasn’t until she shared the news about the competition with her family that her mother-in-law filled her in on a secret: she was a breast cancer survivor.

“You don’t realize how many lives you touch doing this,” Bell said. “They don’t necessarily share their stories because they think no one wants to hear it, but they’re there.”

Many of her mostly teenage staff also had personal experiences with the disease, whether it was a mother, aunt or grandmother who had battled breast cancer. Then one day, the disease hit even closer to home for Bell and her employees. A frequent customer, an older woman named Cathy, came in with her husband before undergoing a double mastectomy the next day. Unfortunately, she didn’t make it.

“All the kids had interacted with her and heard her story—I’ll never forget that,” Bell said. “After that, they all put in 110 percent. It became a mission for these kids to sell as many hot sauce bottles and tortillas they could for Cathy.”

Bell and her employees gave it their all during October. Her staff camped outside grocery stores on their days off to sell more bottles of hot sauce. They egged customers on to buy more. And the friendly competition between restaurant locations just pushed her employees to work harder. It paid off. Bell’s restaurant in Stuart, Fla., sold more than 1,100 bottles of hot sauce in October 2013.

“I cried when we won, “ Bell said, “I was so ecstatic for these kids. They got recognition for being so passionate.”

As the location manager, Bell was invited to join Tijuana Flats executives at BCRF’s annual Hot Pink Party in New York and present Tijuana Flats’ check to the foundation. “It’s a sense of pride to be able to present a check from such a small company,” she said.

This year, Bell is managing a restaurant in a different location, but she has no doubt her team will win again.

“I’m fueling the fire here!” she laughed. “I’m using my personal funds to buy little things for the girls, like headbands, ribbons and tutus, to make it a fun atmosphere.”

Already, her employees have organized a pancake breakfast at a local church and, on Oct. 21, they donated all their tips to BCRF.

“I’ve told them whatever you donate, I’ll match myself,” Bell said. “I don’t want my staff to give 100 percent if I’m not giving it too. This is a cause we don’t want thanks for—we just want to know we’re closer to a cure. Today, I’m 100 percent healthy but, tomorrow, I could be suffering from breast cancer, too. I hope people would fight that much harder for me.”

# data[].attributes.body.processed
How does a small Tex-Mex restaurant end up with 100 locations in 6 states—and a philanthropic organization that’s donated more than $3 million to charity? For BCRF partner Tijuana Flats, it all dates back to the restaurant’s first year in 1995, when that first location threw a Christmas party for 25 local Head Start students.

“We made it a priority to be involved in the community since day one,” said Ben Kuykendall, Senior Philanthropy Manager of the Just In Queso Foundation, Tijuana Flats’ charitable organization. “It wasn’t for any reason other than employees and managers wanting to make a difference.”

And what a difference they are making. Tijuana Flats, through Just In Queso, has donated more than $479,000 toward breast cancer research since teaming up with BCRF in 2007.

“We never say, ‘Now it’s October, we’re going to give back and help out," Kuykendall said. “We constantly give our employees opportunities to give back, and now they expect it. It’s become part of our culture.”

The opportunities that benefit BCRF come in two forms: in-store and online sales of “The Sauce That Saves BCRF Edition” and substituting pink tortillas for an extra $1 during October. Aside from the gratification employees feel from contributing to a cure, there’s an extra incentive for them to rally behind research, too.

The company’s CEO announced that employees of the restaurant location that raised the most money for research during October would get the day off—and management would wait their tables instead.

“It was very motivating to our restaurant employees. When they realized the corporate team would take a whole day off, it emphasized how important this was,” Kuykendall said. They felt more connected to the cause.”

“It Became Our Mission to Sell for Cathy”

Throughout the month, restaurant managers, like Diane “Dee” Bell, encourage each location’s staff to sell the hot sauce and tortillas to patrons. When Bell heard about the competition, she relished the opportunity to rally her staff, even though she had no direct connection to the disease. It wasn’t until she shared the news about the competition with her family that her mother-in-law filled her in on a secret: she was a breast cancer survivor.

“You don’t realize how many lives you touch doing this,” Bell said. “They don’t necessarily share their stories because they think no one wants to hear it, but they’re there.”

Many of her mostly teenage staff also had personal experiences with the disease, whether it was a mother, aunt or grandmother who had battled breast cancer. Then one day, the disease hit even closer to home for Bell and her employees. A frequent customer, an older woman named Cathy, came in with her husband before undergoing a double mastectomy the next day. Unfortunately, she didn’t make it.

“All the kids had interacted with her and heard her story—I’ll never forget that,” Bell said. “After that, they all put in 110 percent. It became a mission for these kids to sell as many hot sauce bottles and tortillas they could for Cathy.”

Bell and her employees gave it their all during October. Her staff camped outside grocery stores on their days off to sell more bottles of hot sauce. They egged customers on to buy more. And the friendly competition between restaurant locations just pushed her employees to work harder. It paid off. Bell’s restaurant in Stuart, Fla., sold more than 1,100 bottles of hot sauce in October 2013.

“I cried when we won, “ Bell said, “I was so ecstatic for these kids. They got recognition for being so passionate.”

As the location manager, Bell was invited to join Tijuana Flats executives at BCRF’s annual Hot Pink Party in New York and present Tijuana Flats’ check to the foundation. “It’s a sense of pride to be able to present a check from such a small company,” she said.

This year, Bell is managing a restaurant in a different location, but she has no doubt her team will win again.

“I’m fueling the fire here!” she laughed. “I’m using my personal funds to buy little things for the girls, like headbands, ribbons and tutus, to make it a fun atmosphere.”

Already, her employees have organized a pancake breakfast at a local church and, on Oct. 21, they donated all their tips to BCRF.

“I’ve told them whatever you donate, I’ll match myself,” Bell said. “I don’t want my staff to give 100 percent if I’m not giving it too. This is a cause we don’t want thanks for—we just want to know we’re closer to a cure. Today, I’m 100 percent healthy but, tomorrow, I could be suffering from breast cancer, too. I hope people would fight that much harder for me.”

# data[].attributes.field_subtitle
By using hot sauce and a whole lot of teamwork, Tijuana Flats is supporting research in a big way.

# data[].attributes.metatag_normalized[].attributes.content
A Survivor Turned Champion of Research | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Today, we’re hosting our Hot Pink Luncheon & Symposium at the Boston Harbor Hotel. Next to our home base of New York, New England houses the largest number of our grantees at their state-of-the-art institutions. One of the key members of BCRF’s Boston family is Kelley Tuthill of ABC affiliate WCVB NewsCenter 5. A breast cancer survivor, Tuthill has used her prominence as a TV reporter to help promote the importance of cancer research and her broadcast skills to become our “Boston spokesperson,” emceeing our many events throughout the year.
Diagnosed eight years ago, she looks back at her experience with breast cancer and makes her case for supporting research and wearing pink this October.
Originally posted on WCVB Boston Channel 5
 
I didn't need to look at a calendar to know that October had arrived.
As I grabbed an egg to make breakfast I saw my first pink ribbon of the month imprinted on the shell. Before cracking it open, I went on the Internet to check out whether this ribbon actually meant anything. I was relieved to see indeed this company gives $50,000 a year to the Susan G. Komen Foundation.
I hear a lot of grousing from my fellow survivors about "pink washing" or pink overload during National Breast Cancer Awareness Month. I actually love pink. It's pretty, feminine and perky. Pink makes me think of spring, hope and new life. So bring on the ribbons as long as it honestly represents a commitment to saving lives.
I know that's what my friend the late, great Evelyn Lauder had in mind when she started her Breast Cancer Research Foundation in 1993. She established the pink ribbon to raise awareness of this horrible disease. But she knew awareness alone was not going to cure cancer.
That's why her foundation will award more than $47 million this year to hundreds of scientists worldwide, including dozens in New England. In my reporting on their cutting edge work, I'm more convinced than ever they will find a cure.
According to cancer.gov, federal funding of breast cancer research is declining each year. In 2012 the government spent $602.7 million down from $631.2 million in 2010. So, private funding is more important than ever.
I am alive today because brilliant scientists discovered Herceptin, a targeted treatment for my type of breast cancer. My daughters were just 2 and a half years and 6 months old when I was diagnosed with no family history. Now, they are 10 and 8 and their mom is cancer free.
I am a grateful survivor who continuously tries to bring women information through news stories on WCVB, public talks and my book "You Can Do This: Surviving Breast Cancer Without Losing Your Sanity or Your Style." My October calendar is filled with events supporting BCRF, Dana-Farber, the Ellie Fund, Komen and Silent Spring.
Everywhere I go I meet survivors and hear their stories. Rather than feeling overloaded by pink, I feel enveloped and comforted by it. According to the American Cancer Society, 240,000 women will be diagnosed with invasive breast cancer this year; 5,600 in Massachusetts.
Although those numbers are overwhelming, it means we have resources and support. I can tell you my friends with rarer types of cancer wish they had even a fraction of the attention breast cancer gets.
This disease affects so many of us; let's use our power to force companies to think before they pink.  That's a point made by Breast Cancer Action and its Think Before You Pink® campaign.
Ask why they are displaying a pink ribbon? How much do they donate? And to which charity? Ask how that charity spends the money. Demand more than just awareness. We are all very aware of this disease. What we want is a cure. And a cure takes funding.
Forty-thousand women will die of breast cancer this year, 800 of them from Massachusetts. Since I was diagnosed in 2006, I have painfully watched many friends die including Ingrid, Erin, Bridget, Tina, Colleen, Elizabeth, Kristin and Peter. With each death, my resolve strengthens to do whatever I can to help find a cure and save lives.
Someone recently asked me why I list breast cancer survivor/advocate on my Twitter profile. He thought it was strange for a journalist to describe herself as an "advocate." He makes a good point, but I simply cannot sit on the sidelines and watch any more patients die. I owe my advocacy in any appropriate form to their families.
This month, you won't catch me wearing a "Save the Ta-Tas" shirt or fighting to save "second base." I’ve already given up one breast and would gladly sacrifice another to save my life.
When you see me wearing pink, know it's an acknowledgment of a difficult fight and a celebration of survival.
This October, let the message be clear: We need to fund research and cure this insidious disease. 

# data[].attributes.metatag_normalized[].attributes.content
Today, we’re hosting our Hot Pink Luncheon & Symposium at the Boston Harbor Hotel. Next to our home base of New York, New England houses the largest number of our grantees at their state-of-the-art institutions. One of the key members of BCRF’s Boston family is Kelley Tuthill of ABC affiliate WCVB NewsCenter 5.

# data[].attributes.metatag_normalized[].attributes.content
BCRF supporter shares her thoughts on breast cancer eight years after her diagnosis.

# data[].attributes.metatag_normalized[].attributes.content
Today, we’re hosting our Hot Pink Luncheon & Symposium at the Boston Harbor Hotel. Next to our home base of New York, New England houses the largest number of our grantees at their state-of-the-art institutions. One of the key members of BCRF’s Boston family is Kelley Tuthill of ABC affiliate WCVB NewsCenter 5.

# data[].attributes.body.value
Today, we’re hosting our Hot Pink Luncheon & Symposium at the Boston Harbor Hotel. Next to our home base of New York, New England houses the largest number of our grantees at their state-of-the-art institutions. One of the key members of BCRF’s Boston family is Kelley Tuthill of ABC affiliate WCVB NewsCenter 5. A breast cancer survivor, Tuthill has used her prominence as a TV reporter to help promote the importance of cancer research and her broadcast skills to become our “Boston spokesperson,” emceeing our many events throughout the year.

Diagnosed eight years ago, she looks back at her experience with breast cancer and makes her case for supporting research and wearing pink this October.

O riginally posted on WCVB Boston Channel 5

I didn't need to look at a calendar to know that October had arrived.

As I grabbed an egg to make breakfast I saw my first pink ribbon of the month imprinted on the shell. Before cracking it open, I went on the Internet to check out whether this ribbon actually meant anything. I was relieved to see indeed this company gives $50,000 a year to the Susan G. Komen Foundation.

I hear a lot of grousing from my fellow survivors about "pink washing" or pink overload during National Breast Cancer Awareness Month. I actually love pink. It's pretty, feminine and perky. Pink makes me think of spring, hope and new life. So bring on the ribbons as long as it honestly represents a commitment to saving lives.

I know that's what my friend the late, great Evelyn Lauder had in mind when she started her Breast Cancer Research Foundation in 1993. She established the pink ribbon to raise awareness of this horrible disease. But she knew awareness alone was not going to cure cancer.

That's why her foundation will award more than $47 million this year to hundreds of scientists worldwide, including dozens in New England. In my reporting on their cutting edge work, I'm more convinced than ever they will find a cure.

According to cancer.gov, federal funding of breast cancer research is declining each year. In 2012 the government spent $602.7 million down from $631.2 million in 2010. So, private funding is more important than ever.

I am alive today because brilliant scientists discovered Herceptin, a targeted treatment for my type of breast cancer. My daughters were just 2 and a half years and 6 months old when I was diagnosed with no family history. Now, they are 10 and 8 and their mom is cancer free.

I am a grateful survivor who continuously tries to bring women information through news stories on WCVB, public talks and my book "You Can Do This: Surviving Breast Cancer Without Losing Your Sanity or Your Style." My October calendar is filled with events supporting BCRF, Dana-Farber, the Ellie Fund, Komen and Silent Spring.

Everywhere I go I meet survivors and hear their stories. Rather than feeling overloaded by pink, I feel enveloped and comforted by it. According to the American Cancer Society, 240,000 women will be diagnosed with invasive breast cancer this year; 5,600 in Massachusetts.

Although those numbers are overwhelming, it means we have resources and support. I can tell you my friends with rarer types of cancer wish they had even a fraction of the attention breast cancer gets.

This disease affects so many of us; let's use our power to force companies to think before they pink.  That's a point made by Breast Cancer Action and its Think Before You Pink® campaign.

Ask why they are displaying a pink ribbon? How much do they donate? And to which charity? Ask how that charity spends the money. Demand more than just awareness. We are all very aware of this disease. What we want is a cure. And a cure takes funding.

Forty-thousand women will die of breast cancer this year, 800 of them from Massachusetts. Since I was diagnosed in 2006, I have painfully watched many friends die including Ingrid, Erin, Bridget, Tina, Colleen, Elizabeth, Kristin and Peter. With each death, my resolve strengthens to do whatever I can to help find a cure and save lives.

Someone recently asked me why I list breast cancer survivor/advocate on my Twitter profile. He thought it was strange for a journalist to describe herself as an "advocate." He makes a good point, but I simply cannot sit on the sidelines and watch any more patients die. I owe my advocacy in any appropriate form to their families.

This month, you won't catch me wearing a "Save the Ta-Tas" shirt or fighting to save "second base." I’ve already given up one breast and would gladly sacrifice another to save my life.

When you see me wearing pink, know it's an acknowledgment of a difficult fight and a celebration of survival.

This October, let the message be clear: We need to fund research and cure this insidious disease.

# data[].attributes.body.processed
Today, we’re hosting our Hot Pink Luncheon & Symposium at the Boston Harbor Hotel. Next to our home base of New York, New England houses the largest number of our grantees at their state-of-the-art institutions. One of the key members of BCRF’s Boston family is Kelley Tuthill of ABC affiliate WCVB NewsCenter 5. A breast cancer survivor, Tuthill has used her prominence as a TV reporter to help promote the importance of cancer research and her broadcast skills to become our “Boston spokesperson,” emceeing our many events throughout the year.

Diagnosed eight years ago, she looks back at her experience with breast cancer and makes her case for supporting research and wearing pink this October.

O riginally posted on WCVB Boston Channel 5

I didn't need to look at a calendar to know that October had arrived.

As I grabbed an egg to make breakfast I saw my first pink ribbon of the month imprinted on the shell. Before cracking it open, I went on the Internet to check out whether this ribbon actually meant anything. I was relieved to see indeed this company gives $50,000 a year to the Susan G. Komen Foundation.

I hear a lot of grousing from my fellow survivors about "pink washing" or pink overload during National Breast Cancer Awareness Month. I actually love pink. It's pretty, feminine and perky. Pink makes me think of spring, hope and new life. So bring on the ribbons as long as it honestly represents a commitment to saving lives.

I know that's what my friend the late, great Evelyn Lauder had in mind when she started her Breast Cancer Research Foundation in 1993. She established the pink ribbon to raise awareness of this horrible disease. But she knew awareness alone was not going to cure cancer.

That's why her foundation will award more than $47 million this year to hundreds of scientists worldwide, including dozens in New England. In my reporting on their cutting edge work, I'm more convinced than ever they will find a cure.

According to cancer.gov, federal funding of breast cancer research is declining each year. In 2012 the government spent $602.7 million down from $631.2 million in 2010. So, private funding is more important than ever.

I am alive today because brilliant scientists discovered Herceptin, a targeted treatment for my type of breast cancer. My daughters were just 2 and a half years and 6 months old when I was diagnosed with no family history. Now, they are 10 and 8 and their mom is cancer free.

I am a grateful survivor who continuously tries to bring women information through news stories on WCVB, public talks and my book "You Can Do This: Surviving Breast Cancer Without Losing Your Sanity or Your Style." My October calendar is filled with events supporting BCRF, Dana-Farber, the Ellie Fund, Komen and Silent Spring.

Everywhere I go I meet survivors and hear their stories. Rather than feeling overloaded by pink, I feel enveloped and comforted by it. According to the American Cancer Society, 240,000 women will be diagnosed with invasive breast cancer this year; 5,600 in Massachusetts.

Although those numbers are overwhelming, it means we have resources and support. I can tell you my friends with rarer types of cancer wish they had even a fraction of the attention breast cancer gets.

This disease affects so many of us; let's use our power to force companies to think before they pink.  That's a point made by Breast Cancer Action and its Think Before You Pink® campaign.

Ask why they are displaying a pink ribbon? How much do they donate? And to which charity? Ask how that charity spends the money. Demand more than just awareness. We are all very aware of this disease. What we want is a cure. And a cure takes funding.

Forty-thousand women will die of breast cancer this year, 800 of them from Massachusetts. Since I was diagnosed in 2006, I have painfully watched many friends die including Ingrid, Erin, Bridget, Tina, Colleen, Elizabeth, Kristin and Peter. With each death, my resolve strengthens to do whatever I can to help find a cure and save lives.

Someone recently asked me why I list breast cancer survivor/advocate on my Twitter profile. He thought it was strange for a journalist to describe herself as an "advocate." He makes a good point, but I simply cannot sit on the sidelines and watch any more patients die. I owe my advocacy in any appropriate form to their families.

This month, you won't catch me wearing a "Save the Ta-Tas" shirt or fighting to save "second base." I’ve already given up one breast and would gladly sacrifice another to save my life.

When you see me wearing pink, know it's an acknowledgment of a difficult fight and a celebration of survival.

This October, let the message be clear: We need to fund research and cure this insidious disease.

# data[].attributes.field_subtitle
BCRF supporter shares her thoughts on breast cancer eight years after her diagnosis.

# data[].attributes.title
From Patient to Researcher: A 360-Experience With Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
From Patient to Researcher: A 360-Experience With Breast Cancer | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Though my mother and grandmother both had breast cancer, I never intended to focus on cancer research when I chose a career in public health. I had always been interested in women's health and began focusing on breast cancer, screening and diet during my studies. But as luck would have it, my science background would prepare me when I was diagnosed with the disease at 40 -- and continues to shape my career.
Deemed high-risk because of my family history, I had a baseline mammogram at an early age, but it was during a routine mammogram at 40 that my breast cancer was discovered. I originally had a lumpectomy and radiation therapy, but had a reoccurrence just four years later. After further treatment, I was prescribed five years of an aromatase inhibitor. Then, nine years later, I had some other abnormalities in the same breast. This time, I had a prophylactic double mastectomy.
As a scientist and former breast cancer patient, I am fortunate that my personal experience with the disease has been able to shape the direction of my research. For example, after my first cancer in 1997, I was diagnosed with lymphedema, a swelling in the arms or legs that results from removing the lymph nodes as part of the cancer treatment. As the time, there was no patient education or awareness about the issue and treatments were pretty archaic, so I began studying it.
In the 17 years since I was first diagnosed, I have watched treatments improve and change the way women and their doctors approach breast cancer. Back then, sentinel lymph node biopsies were not often practiced. A procedure that helps determine the extent of cancer in the body, it is less invasive than standard lymph node surgery. Today, it's just one more option readily available to women. During my bouts with cancer, my only choice for adjuvant hormonal therapy was tamoxifen, which I unfortunately could not take, but today we have a host of other choices in aromatase inhibitors. There are even changes in how often women have to have radiation therapy. This progress is all a result of research.
While discovering new ways of treating breast cancer is vital, my recent research focuses on preventing the disease from ever manifesting in a woman or man. One area I am studying is the role of diet and nutrition in breast cancer. Because obesity is a leading yet preventable cause of breast cancer, losing weight can reduce a person's risk of breast cancer. We have learned that it is easier for women to introduce exercise into their lives than to change their diet. Going forward, I am interested in looking at ways to get women to start -- and stick with -- an exercise routine and get regularly screened for breast cancer.
And while we are always learning more about the disease, there are certain recommendations I can make today:
1. Exercise is essential in reducing obesity. In my studies with women, we set a goal of at least 10,000 steps a day. Use a pedometer, Fitbit or even a cell phone app to keep count of your steps every day.
2. Diets low in fat and carbs can both result in weight loss. What is most important is to eat all foods in moderation -- that includes alcohol consumption.
3. Know your family history and learn your personal risk. If appropriate, seek genetic counseling.
4. If you notice a change in your body, follow up. Prompt and proper follow-up care and adherence to treatment can provide the best chances of successfully fighting breast cancer.
As a researcher who has both studied and personally grappled with breast cancer, I know firsthand that the only way to continue making progress is by funding more research. I have seen the results of our research go from the lab to the bedside to the community, and I am confident that the answers are within our reach.
This article was orginally published on Huffington Post where Dr. Electra Paskett who blogged on behalf of the Breast Cancer Research Foundation. A grantee since 2001, Dr. Paskett is a Professor at the Ohio State University College of Medicine.
 

# data[].attributes.metatag_normalized[].attributes.content
From Patient to Researcher: A 360-Experience With Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
Though my mother and grandmother both had breast cancer, I never intended to focus on cancer research when I chose a career in public health. I had always been interested in women's health and began focusing on breast cancer, screening and diet during my studies. But as luck would have it, my science background would prepare me when I was diagnosed with the disease at 40 -- and continues to shape my career.

# data[].attributes.metatag_normalized[].attributes.content
From Patient to Researcher: A 360-Experience With Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
BCRF grantee Dr. Electra Paskett talks about her personal and professional connection with breast cancer.

# data[].attributes.metatag_normalized[].attributes.content
Though my mother and grandmother both had breast cancer, I never intended to focus on cancer research when I chose a career in public health. I had always been interested in women's health and began focusing on breast cancer, screening and diet during my studies. But as luck would have it, my science background would prepare me when I was diagnosed with the disease at 40 -- and continues to shape my career.

# data[].attributes.metatag_normalized[].attributes.content
From Patient to Researcher: A 360-Experience With Breast Cancer

# data[].attributes.body.value
Though my mother and grandmother both had breast cancer, I never intended to focus on cancer research when I chose a career in public health. I had always been interested in women's health and began focusing on breast cancer, screening and diet during my studies. But as luck would have it, my science background would prepare me when I was diagnosed with the disease at 40 -- and continues to shape my career.

Deemed high-risk because of my family history, I had a baseline mammogram at an early age, but it was during a routine mammogram at 40 that my breast cancer was discovered. I originally had a lumpectomy and radiation therapy, but had a reoccurrence just four years later. After further treatment, I was prescribed five years of an aromatase inhibitor. Then, nine years later, I had some other abnormalities in the same breast. This time, I had a prophylactic double mastectomy.

As a scientist and former breast cancer patient, I am fortunate that my personal experience with the disease has been able to shape the direction of my research. For example, after my first cancer in 1997, I was diagnosed with lymphedema, a swelling in the arms or legs that results from removing the lymph nodes as part of the cancer treatment. As the time, there was no patient education or awareness about the issue and treatments were pretty archaic, so I began studying it.

In the 17 years since I was first diagnosed, I have watched treatments improve and change the way women and their doctors approach breast cancer. Back then, sentinel lymph node biopsies were not often practiced. A procedure that helps determine the extent of cancer in the body, it is less invasive than standard lymph node surgery. Today, it's just one more option readily available to women. During my bouts with cancer, my only choice for adjuvant hormonal therapy was tamoxifen, which I unfortunately could not take, but today we have a host of other choices in aromatase inhibitors. There are even changes in how often women have to have radiation therapy. This progress is all a result of research.

While discovering new ways of treating breast cancer is vital, my recent research focuses on preventing the disease from ever manifesting in a woman or man. One area I am studying is the role of diet and nutrition in breast cancer. Because obesity is a leading yet preventable cause of breast cancer, losing weight can reduce a person's risk of breast cancer. We have learned that it is easier for women to introduce exercise into their lives than to change their diet. Going forward, I am interested in looking at ways to get women to start -- and stick with -- an exercise routine and get regularly screened for breast cancer.

And while we are always learning more about the disease, there are certain recommendations I can make today:

1. Exercise is essential in reducing obesity. In my studies with women, we set a goal of at least 10,000 steps a day. Use a pedometer, Fitbit or even a cell phone app to keep count of your steps every day.

2. Diets low in fat and carbs can both result in weight loss. What is most important is to eat all foods in moderation -- that includes alcohol consumption.

3. Know your family history and learn your personal risk. If appropriate, seek genetic counseling.

4. If you notice a change in your body, follow up. Prompt and proper follow-up care and adherence to treatment can provide the best chances of successfully fighting breast cancer.

As a researcher who has both studied and personally grappled with breast cancer, I know firsthand that the only way to continue making progress is by funding more research. I have seen the results of our research go from the lab to the bedside to the community, and I am confident that the answers are within our reach.

This article was orginally published on Huffington Post where Dr. Electra Paskett who blogged on behalf of the Breast Cancer Research Foundation. A grantee since 2001, Dr. Paskett is a Professor at the Ohio State University College of Medicine.

# data[].attributes.body.processed
Though my mother and grandmother both had breast cancer, I never intended to focus on cancer research when I chose a career in public health. I had always been interested in women's health and began focusing on breast cancer, screening and diet during my studies. But as luck would have it, my science background would prepare me when I was diagnosed with the disease at 40 -- and continues to shape my career.

Deemed high-risk because of my family history, I had a baseline mammogram at an early age, but it was during a routine mammogram at 40 that my breast cancer was discovered. I originally had a lumpectomy and radiation therapy, but had a reoccurrence just four years later. After further treatment, I was prescribed five years of an aromatase inhibitor. Then, nine years later, I had some other abnormalities in the same breast. This time, I had a prophylactic double mastectomy.

As a scientist and former breast cancer patient, I am fortunate that my personal experience with the disease has been able to shape the direction of my research. For example, after my first cancer in 1997, I was diagnosed with lymphedema, a swelling in the arms or legs that results from removing the lymph nodes as part of the cancer treatment. As the time, there was no patient education or awareness about the issue and treatments were pretty archaic, so I began studying it.

In the 17 years since I was first diagnosed, I have watched treatments improve and change the way women and their doctors approach breast cancer. Back then, sentinel lymph node biopsies were not often practiced. A procedure that helps determine the extent of cancer in the body, it is less invasive than standard lymph node surgery. Today, it's just one more option readily available to women. During my bouts with cancer, my only choice for adjuvant hormonal therapy was tamoxifen, which I unfortunately could not take, but today we have a host of other choices in aromatase inhibitors. There are even changes in how often women have to have radiation therapy. This progress is all a result of research.

While discovering new ways of treating breast cancer is vital, my recent research focuses on preventing the disease from ever manifesting in a woman or man. One area I am studying is the role of diet and nutrition in breast cancer. Because obesity is a leading yet preventable cause of breast cancer, losing weight can reduce a person's risk of breast cancer. We have learned that it is easier for women to introduce exercise into their lives than to change their diet. Going forward, I am interested in looking at ways to get women to start -- and stick with -- an exercise routine and get regularly screened for breast cancer.

And while we are always learning more about the disease, there are certain recommendations I can make today:

1. Exercise is essential in reducing obesity. In my studies with women, we set a goal of at least 10,000 steps a day. Use a pedometer, Fitbit or even a cell phone app to keep count of your steps every day.

2. Diets low in fat and carbs can both result in weight loss. What is most important is to eat all foods in moderation -- that includes alcohol consumption.

3. Know your family history and learn your personal risk. If appropriate, seek genetic counseling.

4. If you notice a change in your body, follow up. Prompt and proper follow-up care and adherence to treatment can provide the best chances of successfully fighting breast cancer.

As a researcher who has both studied and personally grappled with breast cancer, I know firsthand that the only way to continue making progress is by funding more research. I have seen the results of our research go from the lab to the bedside to the community, and I am confident that the answers are within our reach.

This article was orginally published on Huffington Post where Dr. Electra Paskett who blogged on behalf of the Breast Cancer Research Foundation. A grantee since 2001, Dr. Paskett is a Professor at the Ohio State University College of Medicine.

# data[].attributes.field_subtitle
BCRF grantee Dr. Electra Paskett talks about her personal and professional connection with breast cancer. 

# data[].attributes.title
Obesity & Breast Cancer: Making the Connection

# data[].attributes.metatag_normalized[].attributes.content
Obesity & Breast Cancer: Making the Connection | BCRF

# data[].attributes.metatag_normalized[].attributes.content
In honor of National Healthy Eating Day, Dr. Clifford Hudis clarifies the link between obesity and breast cancer while sharing BCRF research focused on addressing this public health concern.
One of the key questions asked by most patients diagnosed with cancer is “Why did this happen to me?” In an increasing number of cases, scientists can provide answers, such as the inheritance of a cancer-causing gene or exposure to a specific toxin. Just in the last year, researchers uncovered new information about the risks associated with another specific inherited abnormality—Partner and Localizer of BRCA2 (PALB2). Yet these kinds of specific causes are rare overall, and most cases of cancer appear to be spontaneous or random.
At the same time, from studies of large populations of patients, associations can be seen between some risk factors and malignancy. One early example of this was the recognition more than a half century ago that cigarette smokers had increased risks of lung and then other cancers. Without knowing the “molecular why,” we were able to identify the what and take action to reduce the harm. Now, as tobacco control has improved in some parts of the world, obesity is emerging as a newly recognized and growing risk factor associated with several of the most common cancers, including breast. There are two key points in this regard. First, rates of overweight and obesity have been increasing dramatically—perhaps reflecting societal successes from agriculture to childhood immunization to blood pressure control. Second, obesity is associated not merely with changes in body size and shape, but with reproducible pathologic and physiological alterations relevant to the biology of cancer. 
We have learned that most overweight or obese patients have dead or dying fat cells that attract scavengers (macrophages) that, in turn, produce inflammatory molecules. This inflammatory process is normally needed to “clean up” the dead cells but, when over-revved, it leads to additional consequences. For example, these inflammatory molecules are known to turn on the aromatase gene. More aromatase means more estrogen production. This is one possible explanation for the increased risk of estrogen-driven cancers (such as many breast and uterine cancers) associated with obesity. Increased presence of these inflammatory molecules is also associated with worsened outcomes after diagnosis.
To address this emerging problem, we need to both understand it better and develop useful interventions. On the one hand, it seems obvious and even easy to suggest exercise and avoidance of excess body fat but, despite such advice for decades, the problem clearly continues to worsen and we are not sure why. Hence, an alternative strategy is needed. BCRF investigators are studying many aspects of this problem, seeking both that fundamental understanding of why obesity is a risk factor and also clinically relevant strategies to address it or reverse its biological consequences in a productive fashion. In the past decade, we have uncovered the role of insulin resistance and inflammation as promoters of cancer-cell growth and learned the benefits of targeted counseling and support for weight control. We are now poised to study the role of specific drugs—such as those that inhibit specific components of the inflammatory pathways—to decrease the risks of cancers associated with obesity.
This story was originally featured on the Robb Report as part of a monthly series from BCRF. 

# data[].attributes.metatag_normalized[].attributes.content
Obesity & Breast Cancer: Making the Connection

# data[].attributes.metatag_normalized[].attributes.content
In honor of National Healthy Eating Day, Dr. Clifford Hudis clarifies the link between obesity and breast cancer while sharing BCRF research focused on addressing this public health concern.

# data[].attributes.metatag_normalized[].attributes.content
Obesity & Breast Cancer: Making the Connection

# data[].attributes.metatag_normalized[].attributes.content
The Chair of BCRF’s Scientific Advisory Board talks about obesity as an emerging risk factor.

# data[].attributes.metatag_normalized[].attributes.content
In honor of National Healthy Eating Day, Dr. Clifford Hudis clarifies the link between obesity and breast cancer while sharing BCRF research focused on addressing this public health concern.

# data[].attributes.metatag_normalized[].attributes.content
Obesity & Breast Cancer: Making the Connection

# data[].attributes.body.value
In honor of National Healthy Eating Day, Dr. Clifford Hudis clarifies the link between obesity and breast cancer while sharing BCRF research focused on addressing this public health concern.

One of the key questions asked by most patients diagnosed with cancer is “Why did this happen to me?” In an increasing number of cases, scientists can provide answers, such as the inheritance of a cancer-causing gene or exposure to a specific toxin. Just in the last year, researchers uncovered new information about the risks associated with another specific inherited abnormality—Partner and Localizer of BRCA2 (PALB2). Yet these kinds of specific causes are rare overall, and most cases of cancer appear to be spontaneous or random.

At the same time, from studies of large populations of patients, associations can be seen between some risk factors and malignancy. One early example of this was the recognition more than a half century ago that cigarette smokers had increased risks of lung and then other cancers. Without knowing the “molecular why,” we were able to identify the what and take action to reduce the harm. Now, as tobacco control has improved in some parts of the world, obesity is emerging as a newly recognized and growing risk factor associated with several of the most common cancers, including breast. There are two key points in this regard. First, rates of overweight and obesity have been increasing dramatically—perhaps reflecting societal successes from agriculture to childhood immunization to blood pressure control. Second, obesity is associated not merely with changes in body size and shape, but with reproducible pathologic and physiological alterations relevant to the biology of cancer.

We have learned that most overweight or obese patients have dead or dying fat cells that attract scavengers (macrophages) that, in turn, produce inflammatory molecules. This inflammatory process is normally needed to “clean up” the dead cells but, when over-revved, it leads to additional consequences. For example, these inflammatory molecules are known to turn on the aromatase gene. More aromatase means more estrogen production. This is one possible explanation for the increased risk of estrogen-driven cancers (such as many breast and uterine cancers) associated with obesity. Increased presence of these inflammatory molecules is also associated with worsened outcomes after diagnosis.

To address this emerging problem, we need to both understand it better and develop useful interventions. On the one hand, it seems obvious and even easy to suggest exercise and avoidance of excess body fat but, despite such advice for decades, the problem clearly continues to worsen and we are not sure why. Hence, an alternative strategy is needed. BCRF investigators are studying many aspects of this problem, seeking both that fundamental understanding of why obesity is a risk factor and also clinically relevant strategies to address it or reverse its biological consequences in a productive fashion. In the past decade, we have uncovered the role of insulin resistance and inflammation as promoters of cancer-cell growth and learned the benefits of targeted counseling and support for weight control. We are now poised to study the role of specific drugs—such as those that inhibit specific components of the inflammatory pathways—to decrease the risks of cancers associated with obesity.

This story was originally featured on the Robb Report as part of a monthly series from BCRF.

# data[].attributes.body.processed
In honor of National Healthy Eating Day, Dr. Clifford Hudis clarifies the link between obesity and breast cancer while sharing BCRF research focused on addressing this public health concern.

One of the key questions asked by most patients diagnosed with cancer is “Why did this happen to me?” In an increasing number of cases, scientists can provide answers, such as the inheritance of a cancer-causing gene or exposure to a specific toxin. Just in the last year, researchers uncovered new information about the risks associated with another specific inherited abnormality—Partner and Localizer of BRCA2 (PALB2). Yet these kinds of specific causes are rare overall, and most cases of cancer appear to be spontaneous or random.

At the same time, from studies of large populations of patients, associations can be seen between some risk factors and malignancy. One early example of this was the recognition more than a half century ago that cigarette smokers had increased risks of lung and then other cancers. Without knowing the “molecular why,” we were able to identify the what and take action to reduce the harm. Now, as tobacco control has improved in some parts of the world, obesity is emerging as a newly recognized and growing risk factor associated with several of the most common cancers, including breast. There are two key points in this regard. First, rates of overweight and obesity have been increasing dramatically—perhaps reflecting societal successes from agriculture to childhood immunization to blood pressure control. Second, obesity is associated not merely with changes in body size and shape, but with reproducible pathologic and physiological alterations relevant to the biology of cancer.

We have learned that most overweight or obese patients have dead or dying fat cells that attract scavengers (macrophages) that, in turn, produce inflammatory molecules. This inflammatory process is normally needed to “clean up” the dead cells but, when over-revved, it leads to additional consequences. For example, these inflammatory molecules are known to turn on the aromatase gene. More aromatase means more estrogen production. This is one possible explanation for the increased risk of estrogen-driven cancers (such as many breast and uterine cancers) associated with obesity. Increased presence of these inflammatory molecules is also associated with worsened outcomes after diagnosis.

To address this emerging problem, we need to both understand it better and develop useful interventions. On the one hand, it seems obvious and even easy to suggest exercise and avoidance of excess body fat but, despite such advice for decades, the problem clearly continues to worsen and we are not sure why. Hence, an alternative strategy is needed. BCRF investigators are studying many aspects of this problem, seeking both that fundamental understanding of why obesity is a risk factor and also clinically relevant strategies to address it or reverse its biological consequences in a productive fashion. In the past decade, we have uncovered the role of insulin resistance and inflammation as promoters of cancer-cell growth and learned the benefits of targeted counseling and support for weight control. We are now poised to study the role of specific drugs—such as those that inhibit specific components of the inflammatory pathways—to decrease the risks of cancers associated with obesity.

This story was originally featured on the Robb Report as part of a monthly series from BCRF.

# data[].attributes.field_subtitle
The Chair of BCRF’s Scientific Advisory Board talks about obesity as an emerging risk factor.

# data[].attributes.title
How to Shop Responsibly When Buying Pink 

# data[].attributes.metatag_normalized[].attributes.content
How to Shop Responsibly When Buying Pink  | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Here at BCRF we love to hear from our longstanding partners and learn more about their personal connection to our cause. We invited Tanger Outlets’ President and CEO Steve Tanger to share his thoughts on corporate responsibility and provide insight on shopping pink this holiday season. A BCRF partner since 2011, Tanger raised more than $1.3 million to support our world-class scientists dedicated to finding a cure.
The giving season generates much discourse about the over-usage of “pink” as a profit-motivated marketing tactic. Without a doubt, there are some companies that have less than charitable motives and for whom corporate citizenship is not a part of their DNA. But rather than paint all companies with the same “pink-washing” brush, it may serve the cause by investigating and understanding the underlying motivation of corporations seeking to support breast cancer awareness. 
For Tanger Outlets, supporting BCRF is more than just business—it’s personal. My mother is a breast cancer survivor of over 45 years, so this cause is deeply personal for me. The disease has also impacted a number of our customers, employees and tenants, directly and indirectly. This is Tanger Outlets’ motivation to support breast cancer awareness and research.  
Every year breast cancer affects millions of women across the world including our sisters, mothers, daughters and dear friends. It is important to recognize that all pink is not created equal.  Here are some tips to keep in mind when buying pink:
1)   Transparency is key. Know where your money goes and how much of your purchase supports breast cancer research. Products that do not directly state where the money goes should have you seeing red instead of pink.   Websites such as Charity Navigator and CharityWatch are great tools for assessing the efficiency and effectiveness of an organization. 
2)   Identify companies that have an active track record of corporate philanthropy and social responsibility. Look for businesses that have a legacy of supporting breast cancer research. Do not support companies that have little to no philanthropic presence. A company with a legacy of supporting breast cancer research also indicates authenticity and credibility behind their support.
3)   If you are not in the market for something pink right now, there are countless ways to get involved and support breast cancer research including donating directly or starting your own fundraiser. For more ideas, visit www.bcrfcure.org. 
 

# data[].attributes.metatag_normalized[].attributes.content
How to Shop Responsibly When Buying Pink

# data[].attributes.metatag_normalized[].attributes.content
Here at BCRF we love to hear from our longstanding partners and learn more about their personal connection to our cause. We invited Tanger Outlets’ President and CEO Steve Tanger to share his thoughts on corporate responsibility and provide insight on shopping pink this holiday season. A BCRF partner since 2011, Tanger raised more than $1.3 million to support our world-class scientists dedicated to finding a cure.

# data[].attributes.metatag_normalized[].attributes.content
How to Shop Responsibly When Buying Pink

# data[].attributes.metatag_normalized[].attributes.content
BCRF partner Tanger Outlets offers tips for giving this holiday season

# data[].attributes.metatag_normalized[].attributes.content
Here at BCRF we love to hear from our longstanding partners and learn more about their personal connection to our cause. We invited Tanger Outlets’ President and CEO Steve Tanger to share his thoughts on corporate responsibility and provide insight on shopping pink this holiday season. A BCRF partner since 2011, Tanger raised more than $1.3 million to support our world-class scientists dedicated to finding a cure.

# data[].attributes.metatag_normalized[].attributes.content
How to Shop Responsibly When Buying Pink

# data[].attributes.body.value
Here at BCRF we love to hear from our longstanding partners and learn more about their personal connection to our cause. We invited Tanger Outlets’ President and CEO Steve Tanger to share his thoughts on corporate responsibility and provide insight on shopping pink this holiday season. A BCRF partner since 2011, Tanger raised more than $1.3 million to support our world-class scientists dedicated to finding a cure.

The giving season generates much discourse about the over-usage of “pink” as a profit-motivated marketing tactic. Without a doubt, there are some companies that have less than charitable motives and for whom corporate citizenship is not a part of their DNA. But rather than paint all companies with the same “pink-washing” brush, it may serve the cause by investigating and understanding the underlying motivation of corporations seeking to support breast cancer awareness.

For Tanger Outlets, supporting BCRF is more than just business—it’s personal. My mother is a breast cancer survivor of over 45 years, so this cause is deeply personal for me. The disease has also impacted a number of our customers, employees and tenants, directly and indirectly. This is Tanger Outlets’ motivation to support breast cancer awareness and research.

Every year breast cancer affects millions of women across the world including our sisters, mothers, daughters and dear friends. It is important to recognize that all pink is not created equal.  Here are some tips to keep in mind when buying pink:

1)   Transparency is key. Know where your money goes and how much of your purchase supports breast cancer research. Products that do not directly state where the money goes should have you seeing red instead of pink.   Websites such as Charity Navigator and CharityWatch are great tools for assessing the efficiency and effectiveness of an organization.

2)   Identify companies that have an active track record of corporate philanthropy and social responsibility. Look for businesses that have a legacy of supporting breast cancer research. Do not support companies that have little to no philanthropic presence. A company with a legacy of supporting breast cancer research also indicates authenticity and credibility behind their support.

3)   If you are not in the market for something pink right now, there are countless ways to get involved and support breast cancer research including donating directly or starting your own fundraiser. For more ideas, visit www.bcrfcure.org.

# data[].attributes.body.processed
Here at BCRF we love to hear from our longstanding partners and learn more about their personal connection to our cause. We invited Tanger Outlets’ President and CEO Steve Tanger to share his thoughts on corporate responsibility and provide insight on shopping pink this holiday season. A BCRF partner since 2011, Tanger raised more than $1.3 million to support our world-class scientists dedicated to finding a cure.

The giving season generates much discourse about the over-usage of “pink” as a profit-motivated marketing tactic. Without a doubt, there are some companies that have less than charitable motives and for whom corporate citizenship is not a part of their DNA. But rather than paint all companies with the same “pink-washing” brush, it may serve the cause by investigating and understanding the underlying motivation of corporations seeking to support breast cancer awareness.

For Tanger Outlets, supporting BCRF is more than just business—it’s personal. My mother is a breast cancer survivor of over 45 years, so this cause is deeply personal for me. The disease has also impacted a number of our customers, employees and tenants, directly and indirectly. This is Tanger Outlets’ motivation to support breast cancer awareness and research.

Every year breast cancer affects millions of women across the world including our sisters, mothers, daughters and dear friends. It is important to recognize that all pink is not created equal.  Here are some tips to keep in mind when buying pink:

1)   Transparency is key. Know where your money goes and how much of your purchase supports breast cancer research. Products that do not directly state where the money goes should have you seeing red instead of pink.   Websites such as Charity Navigator and CharityWatch are great tools for assessing the efficiency and effectiveness of an organization.

2)   Identify companies that have an active track record of corporate philanthropy and social responsibility. Look for businesses that have a legacy of supporting breast cancer research. Do not support companies that have little to no philanthropic presence. A company with a legacy of supporting breast cancer research also indicates authenticity and credibility behind their support.

3)   If you are not in the market for something pink right now, there are countless ways to get involved and support breast cancer research including donating directly or starting your own fundraiser. For more ideas, visit www.bcrfcure.org.

# data[].attributes.field_subtitle
BCRF partner Tanger Outlets offers tips for giving this holiday season

# data[].attributes.metatag_normalized[].attributes.content
We had a busy October and we have you, our online community, to thank for it! Because of your commitment to research during Breast Cancer Awareness Month and your generous donations via our site and your personal fundraisers, we are able to fund the equivalent of two new research grants.
We’re so impressed by the passion so many of you have shown. Here, we share a few of your stories in the hopes of inspiring future fundraisers just like you!
Cindy Camacho, A Mother’s Legacy: The Camacho siblings are raising money in honor of their mother, Gloria, who passed away from breast cancer in 2011. We’re touched that, by supporting BCRF, they’re keeping their mom’s generous spirit alive.
Beth House and the Dopey at Disney Challenge: Running 48 miles isn’t easy but, then again, neither is battling breast cancer. In January 2015, Beth House and her husband will tackle the Dopey Challenge at Walt Disney World. Over the course of four days, the couple will run a 5k, 10k, half marathon and, finally, a full marathon in honor of Beth’s mom, who is fighting breast cancer for the second time.
UNH Maiden Harmony: Fight Like: Maiden Harmony, an all-female a capella group at the University of New Hampshire, is organizing a benefit show to engage the college community to support research. They’re so close to reaching their goal—give them the final boost!
October might be over, but our researchers are working year-round to prevent and put an end to this disease. Help us #BeTheEnd of breast cancer by starting your fundraiser today. 
 

# data[].attributes.metatag_normalized[].attributes.content
We had a busy October and we have you, our online community, to thank for it! Because of your commitment to research during Breast Cancer Awareness Month and your generous donations via our site and your personal fundraisers, we are able to fund the equivalent of two new research grants.
We’re so impressed by the passion so many of you have shown. Here, we share a few of your stories in the hopes of inspiring future fundraisers just like you!

# data[].attributes.metatag_normalized[].attributes.content
October fundraising gives life to two new research grants

# data[].attributes.metatag_normalized[].attributes.content
We had a busy October and we have you, our online community, to thank for it! Because of your commitment to research during Breast Cancer Awareness Month and your generous donations via our site and your personal fundraisers, we are able to fund the equivalent of two new research grants.
We’re so impressed by the passion so many of you have shown. Here, we share a few of your stories in the hopes of inspiring future fundraisers just like you!

# data[].attributes.body.value
We had a busy October and we have you, our online community, to thank for it! Because of your commitment to research during Breast Cancer Awareness Month and your generous donations via our site and your personal fundraisers, we are able to fund the equivalent of two new research grants.

We’re so impressed by the passion so many of you have shown. Here, we share a few of your stories in the hopes of inspiring future fundraisers just like you!

Cindy Camacho, A Mother’s Legacy: The Camacho siblings are raising money in honor of their mother, Gloria, who passed away from breast cancer in 2011. We’re touched that, by supporting BCRF, they’re keeping their mom’s generous spirit alive.

Beth House and the Dopey at Disney Challenge: Running 48 miles isn’t easy but, then again, neither is battling breast cancer. In January 2015, Beth House and her husband will tackle the Dopey Challenge at Walt Disney World. Over the course of four days, the couple will run a 5k, 10k, half marathon and, finally, a full marathon in honor of Beth’s mom, who is fighting breast cancer for the second time.

UNH Maiden Harmony: Fight Like: Maiden Harmony, an all-female a capella group at the University of New Hampshire, is organizing a benefit show to engage the college community to support research. They’re so close to reaching their goal—give them the final boost!

October might be over, but our researchers are working year-round to prevent and put an end to this disease. Help us #BeTheEnd of breast cancer by starting your fundraiser today.

# data[].attributes.body.processed
We had a busy October and we have you, our online community, to thank for it! Because of your commitment to research during Breast Cancer Awareness Month and your generous donations via our site and your personal fundraisers, we are able to fund the equivalent of two new research grants.

We’re so impressed by the passion so many of you have shown. Here, we share a few of your stories in the hopes of inspiring future fundraisers just like you!

Cindy Camacho, A Mother’s Legacy: The Camacho siblings are raising money in honor of their mother, Gloria, who passed away from breast cancer in 2011. We’re touched that, by supporting BCRF, they’re keeping their mom’s generous spirit alive.

Beth House and the Dopey at Disney Challenge: Running 48 miles isn’t easy but, then again, neither is battling breast cancer. In January 2015, Beth House and her husband will tackle the Dopey Challenge at Walt Disney World. Over the course of four days, the couple will run a 5k, 10k, half marathon and, finally, a full marathon in honor of Beth’s mom, who is fighting breast cancer for the second time.

UNH Maiden Harmony: Fight Like: Maiden Harmony, an all-female a capella group at the University of New Hampshire, is organizing a benefit show to engage the college community to support research. They’re so close to reaching their goal—give them the final boost!

October might be over, but our researchers are working year-round to prevent and put an end to this disease. Help us #BeTheEnd of breast cancer by starting your fundraiser today.

# data[].attributes.field_subtitle
October fundraising gives life to two new research grants

# data[].attributes.title
Pink Promises Shines Bright on Long Island 

# data[].attributes.metatag_normalized[].attributes.content
Pink Promises Shines Bright on Long Island  | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Tomorrow, we'll be heading to Long Island for one of our signature events, Pink Promises. Here, we share the story behind the fundraiser and its founder, who has been a longtime supporter of BCRF.
In 2009, Stephanie Ginsberg and her sister, Betsy, attended BCRF’s October Symposium & Awards Luncheon at the Waldorf Astoria for the first time. Betsy had triple negative breast cancer, and the sisters wanted to educate themselves on the disease. They left not just informed but inspired by BCRF founder Evelyn Lauder and the foundation’s researchers—and wanting to do more.
Over the next year, Ginsberg and her family collaborated with BCRF to create a fundraiser in her community of Long Island to unite her friends and neighbors in the crusade against breast cancer.
“With the prevalence of breast cancer so strong on Long Island, it was critical we take an active role,” she said.
And so Pink Promises was born. What was originally intended as a one-time event is now in its fifth year, providing substantial support to BCRF and the breast cancer community. With Ginsberg at the helm, Pink Promises has cumulatively raised more than $3 million to fund 10 research projects to date. 
“Pink Promises has become a way to educate Long Islanders on BCRF’s mission and the importance of supporting research,” Ginsberg said. “Without research, there is no cure.”

Every year, Ginsberg returns to BCRF’s October Symposium & Awards Luncheon and leaves with an even greater desire to support BCRF. “It’s extremely rewarding to hear directly from the researchers or sit and talk to the grantees, like Dr. Lisa Carey who is funded by Pink Promises, and know that the work we’re supporting is bringing about real results and impacting the lives of many people. It’s impossible to witness 200+ of the world’s best and brightest researchers stand on the stage together and not leave more inspired to help.”

# data[].attributes.metatag_normalized[].attributes.content
Pink Promises Shines Bright on Long Island

# data[].attributes.metatag_normalized[].attributes.content
Tomorrow, we'll be heading to Long Island for one of our signature events, Pink Promises. Here, we share the story behind the fundraiser and its founder, who has been a longtime supporter of BCRF.

# data[].attributes.metatag_normalized[].attributes.content
Pink Promises Shines Bright on Long Island

# data[].attributes.metatag_normalized[].attributes.content
A sit-down with Founder Stephanie Ginsberg

# data[].attributes.metatag_normalized[].attributes.content
Tomorrow, we'll be heading to Long Island for one of our signature events, Pink Promises. Here, we share the story behind the fundraiser and its founder, who has been a longtime supporter of BCRF.

# data[].attributes.metatag_normalized[].attributes.content
Pink Promises Shines Bright on Long Island

# data[].attributes.body.value
Tomorrow, we'll be heading to Long Island for one of our signature events, Pink Promises. Here, we share the story behind the fundraiser and its founder, who has been a longtime supporter of BCRF.

In 2009, Stephanie Ginsberg and her sister, Betsy, attended BCRF’s October Symposium & Awards Luncheon at the Waldorf Astoria for the first time. Betsy had triple negative breast cancer, and the sisters wanted to educate themselves on the disease. They left not just informed but inspired by BCRF founder Evelyn Lauder and the foundation’s researchers—and wanting to do more.

Over the next year, Ginsberg and her family collaborated with BCRF to create a fundraiser in her community of Long Island to unite her friends and neighbors in the crusade against breast cancer.

“With the prevalence of breast cancer so strong on Long Island, it was critical we take an active role,” she said.

And so Pink Promises was born. What was originally intended as a one-time event is now in its fifth year, providing substantial support to BCRF and the breast cancer community. With Ginsberg at the helm, Pink Promises has cumulatively raised more than $3 million to fund 10 research projects to date.

“Pink Promises has become a way to educate Long Islanders on BCRF’s mission and the importance of supporting research,” Ginsberg said. “Without research, there is no cure.”

Every year, Ginsberg returns to BCRF’s October Symposium & Awards Luncheon and leaves with an even greater desire to support BCRF. “It’s extremely rewarding to hear directly from the researchers or sit and talk to the grantees, like Dr. Lisa Carey who is funded by Pink Promises, and know that the work we’re supporting is bringing about real results and impacting the lives of many people. It’s impossible to witness 200+ of the world’s best and brightest researchers stand on the stage together and not leave more inspired to help.”

# data[].attributes.body.processed
Tomorrow, we'll be heading to Long Island for one of our signature events, Pink Promises. Here, we share the story behind the fundraiser and its founder, who has been a longtime supporter of BCRF.

In 2009, Stephanie Ginsberg and her sister, Betsy, attended BCRF’s October Symposium & Awards Luncheon at the Waldorf Astoria for the first time. Betsy had triple negative breast cancer, and the sisters wanted to educate themselves on the disease. They left not just informed but inspired by BCRF founder Evelyn Lauder and the foundation’s researchers—and wanting to do more.

Over the next year, Ginsberg and her family collaborated with BCRF to create a fundraiser in her community of Long Island to unite her friends and neighbors in the crusade against breast cancer.

“With the prevalence of breast cancer so strong on Long Island, it was critical we take an active role,” she said.

And so Pink Promises was born. What was originally intended as a one-time event is now in its fifth year, providing substantial support to BCRF and the breast cancer community. With Ginsberg at the helm, Pink Promises has cumulatively raised more than $3 million to fund 10 research projects to date.

“Pink Promises has become a way to educate Long Islanders on BCRF’s mission and the importance of supporting research,” Ginsberg said. “Without research, there is no cure.”

Every year, Ginsberg returns to BCRF’s October Symposium & Awards Luncheon and leaves with an even greater desire to support BCRF. “It’s extremely rewarding to hear directly from the researchers or sit and talk to the grantees, like Dr. Lisa Carey who is funded by Pink Promises, and know that the work we’re supporting is bringing about real results and impacting the lives of many people. It’s impossible to witness 200+ of the world’s best and brightest researchers stand on the stage together and not leave more inspired to help.”

# data[].attributes.field_subtitle
A sit-down with Founder Stephanie Ginsberg

# data[].attributes.title
12 Facts About Our Founder, Evelyn H. Lauder

# data[].attributes.metatag_normalized[].attributes.content
12 Facts About Our Founder, Evelyn H. Lauder | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Mrs. Evelyn Lauder was the Chairman of the Breast Cancer Research Foundation, which she founded in 1993. She was passionately committed to preventing breast cancer and finding a cure by funding the most innovative clinical and translational research in the world.
In honor of Mrs. Lauder’s passing on Nov. 12, 2011, we’ve collected some of our favorite facts about our formidable founder. 
1. Mrs. Evelyn H. Lauder was born Evelyn Hausner on Aug. 12, 1936 in Vienna, Austria. As a refugee of Nazi-occupied Europe, she came to New York with her family in 1940. When the ship bringing them to the United States arrived in New York, Mrs. Lauder’s mother woke Evelyn to see the Statue of Liberty, and it served as a source of inspiration for the rest of her life. Her remarkable life is truly the story of the American dream.
2. She met Leonard A. Lauder, her husband of 52 years, on a blind date at the age of 18. They married at New York’s famous Plaza Hotel.
3. Mrs. Lauder attended New York City public schools and was a public school teacher in Harlem before joining the Lauder family business.
4. She held many positions at The Estée Lauder Companies Inc., including serving as Senior Corporate Vice President and Head of Fragrance Development Worldwide until her passing in 2011.
5. In 1989, Mrs. Lauder initiated the fundraising drive that established a state-of the-art breast and diagnostic center at New York’s Memorial Sloan Kettering Cancer Center. Today the facility, known as the Evelyn H. Lauder Breast Center, sets a global standard for cancer care offering prevention, diagnosis and treatment services under one roof. 
6. In 1992, Mrs. Lauder and Alexandra Penney, then editor of SELF, created the signature pink ribbon, which has become the international symbol of breast cancer awareness. In that same year, she launched The Estée Lauder Companies Breast Cancer Awareness (BCA) Campaign.
7. Mrs. Lauder, along with The BCA Campaign, achieved a first-ever Guinness World Record by illuminating 38 historic and iconic landmarks, ranging from New York’s Rockefeller Center to Australia’s Parliament House, in 24 hours all in honor of breast cancer awareness and research.
8. Mrs. Lauder was an avid and very talented photographer. Her work has been featured at The Whitney Museum of American Art in New York, Gagosian Gallery in Los Angeles, Galeries Lafayette in Paris and numerous other galleries around the world.  She had two photography books published of her own work: The Seasons Observed and An Eye for Beauty.
9. Mrs. Lauder loved to cook. In 2006, she published a cookbook, In Great Taste: Fresh, Simple Recipes for Eating and Living Well. The book featured more than 125 deliciously healthy recipes inspired by her own diet and years of working with doctors and nutritionists at renowned hospitals around the country.
10. A vision of grace and beauty, Mrs. Lauder was featured on Vanity Fair’s International Best Dressed List. She was also named one of New York’s 100 Most Influential Women in Business by Crain’s New York Business.
11. In 2011, Mrs. Lauder and the entire Lauder family received the Carnegie Medal of Philanthropy. The award is given to individuals who have dedicated their private wealth to the public good. 
12. Mrs. Lauder’s warmth, sense of humor, charm, extraordinary compassion and endless generosity made her beloved by anyone fortunate to cross her path. Nearly 1,500 people, from all walks of life, attended her funeral. The Empire State Building was lit pink the day of her funeral in her memory.
 

# data[].attributes.metatag_normalized[].attributes.content
12 Facts About Our Founder, Evelyn H. Lauder

# data[].attributes.metatag_normalized[].attributes.content
Mrs. Evelyn Lauder was the Chairman of the Breast Cancer Research Foundation, which she founded in 1993. She was passionately committed to preventing breast cancer and finding a cure by funding the most innovative clinical and translational research in the world.
In honor of Mrs. Lauder’s passing on Nov. 12, 2011, we’ve collected some of our favorite facts about our formidable founder. 

# data[].attributes.metatag_normalized[].attributes.content
12 Facts About Our Founder, Evelyn H. Lauder

# data[].attributes.metatag_normalized[].attributes.content
Mrs. Evelyn Lauder was the Chairman of the Breast Cancer Research Foundation, which she founded in 1993. She was passionately committed to preventing breast cancer and finding a cure by funding the most innovative clinical and translational research in the world.
In honor of Mrs. Lauder’s passing on Nov. 12, 2011, we’ve collected some of our favorite facts about our formidable founder. 

# data[].attributes.metatag_normalized[].attributes.content
12 Facts About Our Founder, Evelyn H. Lauder

# data[].attributes.body.value
Mrs. Evelyn Lauder was the Chairman of the Breast Cancer Research Foundation, which she founded in 1993. She was passionately committed to preventing breast cancer and finding a cure by funding the most innovative clinical and translational research in the world.

In honor of Mrs. Lauder’s passing on Nov. 12, 2011, we’ve collected some of our favorite facts about our formidable founder.

1. Mrs. Evelyn H. Lauder was born Evelyn Hausner on Aug. 12, 1936 in Vienna, Austria. As a refugee of Nazi-occupied Europe, she came to New York with her family in 1940. When the ship bringing them to the United States arrived in New York, Mrs. Lauder’s mother woke Evelyn to see the Statue of Liberty, and it served as a source of inspiration for the rest of her life. Her remarkable life is truly the story of the American dream.

2. She met Leonard A. Lauder, her husband of 52 years, on a blind date at the age of 18. They married at New York’s famous Plaza Hotel.

3. Mrs. Lauder attended New York City public schools and was a public school teacher in Harlem before joining the Lauder family business.

4. She held many positions at The Estée Lauder Companies Inc., including serving as Senior Corporate Vice President and Head of Fragrance Development Worldwide until her passing in 2011.

5. In 1989, Mrs. Lauder initiated the fundraising drive that established a state-of the-art breast and diagnostic center at New York’s Memorial Sloan Kettering Cancer Center. Today the facility, known as the Evelyn H. Lauder Breast Center, sets a global standard for cancer care offering prevention, diagnosis and treatment services under one roof.

6. In 1992, Mrs. Lauder and Alexandra Penney, then editor of SELF, created the signature pink ribbon, which has become the international symbol of breast cancer awareness. In that same year, she launched The Estée Lauder Companies Breast Cancer Awareness (BCA) Campaign.

7. Mrs. Lauder, along with The BCA Campaign, achieved a first-ever Guinness World Record by illuminating 38 historic and iconic landmarks, ranging from New York’s Rockefeller Center to Australia’s Parliament House, in 24 hours all in honor of breast cancer awareness and research.

8. Mrs. Lauder was an avid and very talented photographer. Her work has been featured at The Whitney Museum of American Art in New York, Gagosian Gallery in Los Angeles, Galeries Lafayette in Paris and numerous other galleries around the world.  She had two photography books published of her own work: The Seasons Observed and An Eye for Beauty.

9. Mrs. Lauder loved to cook. In 2006, she published a cookbook, In Great Taste: Fresh, Simple Recipes for Eating and Living Well. The book featured more than 125 deliciously healthy recipes inspired by her own diet and years of working with doctors and nutritionists at renowned hospitals around the country.

10. A vision of grace and beauty, Mrs. Lauder was featured on Vanity Fair’s International Best Dressed List. She was also named one of New York’s 100 Most Influential Women in Business by Crain’s New York Business.

11. In 2011, Mrs. Lauder and the entire Lauder family received the Carnegie Medal of Philanthropy. The award is given to individuals who have dedicated their private wealth to the public good.

12. Mrs. Lauder’s warmth, sense of humor, charm, extraordinary compassion and endless generosity made her beloved by anyone fortunate to cross her path. Nearly 1,500 people, from all walks of life, attended her funeral. The Empire State Building was lit pink the day of her funeral in her memory.

# data[].attributes.body.processed
Mrs. Evelyn Lauder was the Chairman of the Breast Cancer Research Foundation, which she founded in 1993. She was passionately committed to preventing breast cancer and finding a cure by funding the most innovative clinical and translational research in the world.

In honor of Mrs. Lauder’s passing on Nov. 12, 2011, we’ve collected some of our favorite facts about our formidable founder.

1. Mrs. Evelyn H. Lauder was born Evelyn Hausner on Aug. 12, 1936 in Vienna, Austria. As a refugee of Nazi-occupied Europe, she came to New York with her family in 1940. When the ship bringing them to the United States arrived in New York, Mrs. Lauder’s mother woke Evelyn to see the Statue of Liberty, and it served as a source of inspiration for the rest of her life. Her remarkable life is truly the story of the American dream.

2. She met Leonard A. Lauder, her husband of 52 years, on a blind date at the age of 18. They married at New York’s famous Plaza Hotel.

3. Mrs. Lauder attended New York City public schools and was a public school teacher in Harlem before joining the Lauder family business.

4. She held many positions at The Estée Lauder Companies Inc., including serving as Senior Corporate Vice President and Head of Fragrance Development Worldwide until her passing in 2011.

5. In 1989, Mrs. Lauder initiated the fundraising drive that established a state-of the-art breast and diagnostic center at New York’s Memorial Sloan Kettering Cancer Center. Today the facility, known as the Evelyn H. Lauder Breast Center, sets a global standard for cancer care offering prevention, diagnosis and treatment services under one roof.

6. In 1992, Mrs. Lauder and Alexandra Penney, then editor of SELF, created the signature pink ribbon, which has become the international symbol of breast cancer awareness. In that same year, she launched The Estée Lauder Companies Breast Cancer Awareness (BCA) Campaign.

7. Mrs. Lauder, along with The BCA Campaign, achieved a first-ever Guinness World Record by illuminating 38 historic and iconic landmarks, ranging from New York’s Rockefeller Center to Australia’s Parliament House, in 24 hours all in honor of breast cancer awareness and research.

8. Mrs. Lauder was an avid and very talented photographer. Her work has been featured at The Whitney Museum of American Art in New York, Gagosian Gallery in Los Angeles, Galeries Lafayette in Paris and numerous other galleries around the world.  She had two photography books published of her own work: The Seasons Observed and An Eye for Beauty.

9. Mrs. Lauder loved to cook. In 2006, she published a cookbook, In Great Taste: Fresh, Simple Recipes for Eating and Living Well. The book featured more than 125 deliciously healthy recipes inspired by her own diet and years of working with doctors and nutritionists at renowned hospitals around the country.

10. A vision of grace and beauty, Mrs. Lauder was featured on Vanity Fair’s International Best Dressed List. She was also named one of New York’s 100 Most Influential Women in Business by Crain’s New York Business.

11. In 2011, Mrs. Lauder and the entire Lauder family received the Carnegie Medal of Philanthropy. The award is given to individuals who have dedicated their private wealth to the public good.

12. Mrs. Lauder’s warmth, sense of humor, charm, extraordinary compassion and endless generosity made her beloved by anyone fortunate to cross her path. Nearly 1,500 people, from all walks of life, attended her funeral. The Empire State Building was lit pink the day of her funeral in her memory.

# data[].attributes.title
Fostering Collaborations for Future Discovery

# data[].attributes.metatag_normalized[].attributes.content
Fostering Collaborations for Future Discovery | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Each year, we invite our grantees to New York for our October Symposium and Awards Luncheon. Before taking the stage, our researchers take part in a scientific meeting, a tradition that’s been in place since 2003. Conceived by Scientific Director Dr. Larry Norton, the conference presents the opportunity to explore important topics in breast cancer research, with a program carefully chosen by BCRF’s Scientific Advisory Board. This year’s meeting, held at Memorial Sloan Kettering Cancer Center, featured a series of presentations and lively discussion from BCRF-supported experts on the genetic and environmental risks of breast cancer and strategies to improve outcomes through prevention and better screening.
Defining Genetic Risk Across Populations: BRCA and Beyond
Advances in DNA sequencing now allow scientists to examine the minute details of DNA and identify changes that occur in tumors as cancer begins and progresses. This information is changing how we think about cancer, how it occurs, and how to prevent and treat it. 
Work by Dr. Funmi Olopade has revealed differences in genetic risk across populations of African descent. Part of this diversity can be explained by widespread migration from Africa and subsequent marriages across racial and ethnic lines. The blended ethnicities add to the complexity of a population-wide risk prediction. At the meeting, Dr. Olopade emphasized the need to study how genetic risks may differ across African populations around the world. 
The BRCA genes are the most commonly mutated genes in hereditary breast cancer, but the types of mutations and their impact on risk vary widely. In recent years, scientists have uncovered many less common gene mutations associated with breast cancer, and work by Dr. Kenneth Offit and others suggests that many of these act to modify risk (either increasing or decreasing it) when combined with BRCA or other mutations. Dr. Offit discussed international efforts to study these risk modifiers and plans for a clinical trial in BRCA2 mutation carriers to test how knowledge of modifying mutations will impact patient treatment decisions and outcomes.
Mutations in the BRCA1 and BRCA2 genes are highly prevalent in Ashkenazi Jews, but genetic screening is typically only recommended for those with a family history of cancer. Drs. Mary-Claire King, Ephrat Levy-Lahad and Moein Kanaan, who collaborate on international studies in Israel, the United States and the Palestine Authority, presented findings that suggest that population-wide screening for BRCA mutations in Ashkenazi Jews—including the novel method of screening men in families without a known history of cancer—will identify high-risk women who wouldn’t otherwise be screened. Dr. King proposed that early genetic screening in the general population could ultimately identify other high-risk women with no family history and provide opportunities for early preventive measures.
Prevention: What We’ve Learned & Where We Need To Go
Research suggests that at least 30 percent of breast cancers could be prevented by lifestyle changes such as weight loss and exercise. Dr. Melinda Irwin has shown that these factors can also improve outcomes after diagnosis. At the meeting, she discussed how weight loss affects the way tumors utilize energy and reduces levels of inflammatory molecules that promote tumor growth and spread. Weight loss and exercise can also work together to improve quality of life during and after cancer treatment and reduce chemotherapy-related side effects. Dr. Irwin’s work underscores the need to include weight management and counseling as part of cancer care. 
Obesity increases the risk for many cancers, including breast cancer, particularly after menopause. While scientists have known about this relationship for many years, there has not been a clear cause-and-effect explanation.
Drs. Andrew Dannenberg and Clifford Hudis have uncovered a very important link between obesity, inflammation and breast cancer that helps to explain why obesity increases risk after menopause. During his presentation, Dr. Dannenberg showed that crown-like structures (CLS) in fat tissue release inflammatory molecules that promote the production of estrogen, a driver of most post-menopausal breast cancers. A striking discovery from their research revealed that about 30 percent of women at a healthy weight had CLS in their fat tissue. Their next step is to develop a blood test that can identify otherwise healthy women who may be at risk of breast cancer. 
Because risk factors, both modifiable (weight and other lifestyle choices) and non-modifiable (age, family history or inherited genes) vary widely, prevention needs to be individualized. Dr. Powel Brown presented some of the challenges and opportunities in improving risk assessment and prevention. He emphasized the need to identify biomarkers that can better predict risk and inform the best preventive strategy, the importance of public perception of risk, and clinical trials to test chemopreventive drugs that can reduce the risk of triple negative breast cancer. Opportunities on the horizon include the potential development of preventive vaccines and the re-purposing of existing drugs for chemoprevention. 
The Sum Is Greater Than Its Parts
At BCRF, we have always recognized the power of collaboration and know the complexities of cancer will only be resolved when our researchers come together to catalyze each other’s thinking and provide new perspectives. These meetings have historically inspired new collaborations and scientific discourse that accelerate discovery, and we are confident that the outcomes of this year’s meeting will be no different in taking us to our ultimate goal of better prevention and treatment of breast cancer.

# data[].attributes.metatag_normalized[].attributes.content
Fostering Collaborations for Future Discovery

# data[].attributes.metatag_normalized[].attributes.content
Each year, we invite our grantees to New York for our October Symposium and Awards Luncheon. Before taking the stage, our researchers take part in a scientific meeting, a tradition that’s been in place since 2003. Conceived by Scientific Director Dr. Larry Norton, the conference presents the opportunity to explore important topics in breast cancer research, with a program carefully chosen by BCRF’s Scientific Advisory Board.

# data[].attributes.metatag_normalized[].attributes.content
Fostering Collaborations for Future Discovery

# data[].attributes.metatag_normalized[].attributes.content
BCRF Grantees Gather to Discuss Genetic and Environmental Risks of Breast Cancer

# data[].attributes.metatag_normalized[].attributes.content
Each year, we invite our grantees to New York for our October Symposium and Awards Luncheon. Before taking the stage, our researchers take part in a scientific meeting, a tradition that’s been in place since 2003. Conceived by Scientific Director Dr. Larry Norton, the conference presents the opportunity to explore important topics in breast cancer research, with a program carefully chosen by BCRF’s Scientific Advisory Board.

# data[].attributes.metatag_normalized[].attributes.content
Fostering Collaborations for Future Discovery

# data[].attributes.body.value
Each year, we invite our grantees to New York for our October Symposium and Awards Luncheon. Before taking the stage, our researchers take part in a scientific meeting, a tradition that’s been in place since 2003. Conceived by Scientific Director Dr. Larry Norton, the conference presents the opportunity to explore important topics in breast cancer research, with a program carefully chosen by BCRF’s Scientific Advisory Board. This year’s meeting, held at Memorial Sloan Kettering Cancer Center, featured a series of presentations and lively discussion from BCRF-supported experts on the genetic and environmental risks of breast cancer and strategies to improve outcomes through prevention and better screening.

Defining Genetic Risk Across Populations: BRCA and Beyond

Advances in DNA sequencing now allow scientists to examine the minute details of DNA and identify changes that occur in tumors as cancer begins and progresses. This information is changing how we think about cancer, how it occurs, and how to prevent and treat it.

Work by Dr. Funmi Olopade has revealed differences in genetic risk across populations of African descent. Part of this diversity can be explained by widespread migration from Africa and subsequent marriages across racial and ethnic lines. The blended ethnicities add to the complexity of a population-wide risk prediction. At the meeting, Dr. Olopade emphasized the need to study how genetic risks may differ across African populations around the world.

The BRCA genes are the most commonly mutated genes in hereditary breast cancer, but the types of mutations and their impact on risk vary widely. In recent years, scientists have uncovered many less common gene mutations associated with breast cancer, and work by Dr. Kenneth Offit and others suggests that many of these act to modify risk (either increasing or decreasing it) when combined with BRCA or other mutations. Dr. Offit discussed international efforts to study these risk modifiers and plans for a clinical trial in BRCA2 mutation carriers to test how knowledge of modifying mutations will impact patient treatment decisions and outcomes.

Mutations in the BRCA1 and BRCA2 genes are highly prevalent in Ashkenazi Jews, but genetic screening is typically only recommended for those with a family history of cancer. Drs. Mary-Claire King, Ephrat Levy-Lahad and Moein Kanaan, who collaborate on international studies in Israel, the United States and the Palestine Authority, presented findings that suggest that population-wide screening for BRCA mutations in Ashkenazi Jews—including the novel method of screening men in families without a known history of cancer—will identify high-risk women who wouldn’t otherwise be screened. Dr. King proposed that early genetic screening in the general population could ultimately identify other high-risk women with no family history and provide opportunities for early preventive measures.

Prevention: What We’ve Learned & Where We Need To Go

Research suggests that at least 30 percent of breast cancers could be prevented by lifestyle changes such as weight loss and exercise. Dr. Melinda Irwin has shown that these factors can also improve outcomes after diagnosis. At the meeting, she discussed how weight loss affects the way tumors utilize energy and reduces levels of inflammatory molecules that promote tumor growth and spread. Weight loss and exercise can also work together to improve quality of life during and after cancer treatment and reduce chemotherapy-related side effects. Dr. Irwin’s work underscores the need to include weight management and counseling as part of cancer care.

Obesity increases the risk for many cancers, including breast cancer, particularly after menopause. While scientists have known about this relationship for many years, there has not been a clear cause-and-effect explanation.

Drs. Andrew Dannenberg and Clifford Hudis have uncovered a very important link between obesity, inflammation and breast cancer that helps to explain why obesity increases risk after menopause. During his presentation, Dr. Dannenberg showed that crown-like structures (CLS) in fat tissue release inflammatory molecules that promote the production of estrogen, a driver of most post-menopausal breast cancers. A striking discovery from their research revealed that about 30 percent of women at a healthy weight had CLS in their fat tissue. Their next step is to develop a blood test that can identify otherwise healthy women who may be at risk of breast cancer.

Because risk factors, both modifiable (weight and other lifestyle choices) and non-modifiable (age, family history or inherited genes) vary widely, prevention needs to be individualized. Dr. Powel Brown presented some of the challenges and opportunities in improving risk assessment and prevention. He emphasized the need to identify biomarkers that can better predict risk and inform the best preventive strategy, the importance of public perception of risk, and clinical trials to test chemopreventive drugs that can reduce the risk of triple negative breast cancer. Opportunities on the horizon include the potential development of preventive vaccines and the re-purposing of existing drugs for chemoprevention.

The Sum Is Greater Than Its Parts

At BCRF, we have always recognized the power of collaboration and know the complexities of cancer will only be resolved when our researchers come together to catalyze each other’s thinking and provide new perspectives. These meetings have historically inspired new collaborations and scientific discourse that accelerate discovery, and we are confident that the outcomes of this year’s meeting will be no different in taking us to our ultimate goal of better prevention and treatment of breast cancer.

# data[].attributes.body.processed
Each year, we invite our grantees to New York for our October Symposium and Awards Luncheon. Before taking the stage, our researchers take part in a scientific meeting, a tradition that’s been in place since 2003. Conceived by Scientific Director Dr. Larry Norton, the conference presents the opportunity to explore important topics in breast cancer research, with a program carefully chosen by BCRF’s Scientific Advisory Board. This year’s meeting, held at Memorial Sloan Kettering Cancer Center, featured a series of presentations and lively discussion from BCRF-supported experts on the genetic and environmental risks of breast cancer and strategies to improve outcomes through prevention and better screening.

Defining Genetic Risk Across Populations: BRCA and Beyond

Advances in DNA sequencing now allow scientists to examine the minute details of DNA and identify changes that occur in tumors as cancer begins and progresses. This information is changing how we think about cancer, how it occurs, and how to prevent and treat it.

Work by Dr. Funmi Olopade has revealed differences in genetic risk across populations of African descent. Part of this diversity can be explained by widespread migration from Africa and subsequent marriages across racial and ethnic lines. The blended ethnicities add to the complexity of a population-wide risk prediction. At the meeting, Dr. Olopade emphasized the need to study how genetic risks may differ across African populations around the world.

The BRCA genes are the most commonly mutated genes in hereditary breast cancer, but the types of mutations and their impact on risk vary widely. In recent years, scientists have uncovered many less common gene mutations associated with breast cancer, and work by Dr. Kenneth Offit and others suggests that many of these act to modify risk (either increasing or decreasing it) when combined with BRCA or other mutations. Dr. Offit discussed international efforts to study these risk modifiers and plans for a clinical trial in BRCA2 mutation carriers to test how knowledge of modifying mutations will impact patient treatment decisions and outcomes.

Mutations in the BRCA1 and BRCA2 genes are highly prevalent in Ashkenazi Jews, but genetic screening is typically only recommended for those with a family history of cancer. Drs. Mary-Claire King, Ephrat Levy-Lahad and Moein Kanaan, who collaborate on international studies in Israel, the United States and the Palestine Authority, presented findings that suggest that population-wide screening for BRCA mutations in Ashkenazi Jews—including the novel method of screening men in families without a known history of cancer—will identify high-risk women who wouldn’t otherwise be screened. Dr. King proposed that early genetic screening in the general population could ultimately identify other high-risk women with no family history and provide opportunities for early preventive measures.

Prevention: What We’ve Learned & Where We Need To Go

Research suggests that at least 30 percent of breast cancers could be prevented by lifestyle changes such as weight loss and exercise. Dr. Melinda Irwin has shown that these factors can also improve outcomes after diagnosis. At the meeting, she discussed how weight loss affects the way tumors utilize energy and reduces levels of inflammatory molecules that promote tumor growth and spread. Weight loss and exercise can also work together to improve quality of life during and after cancer treatment and reduce chemotherapy-related side effects. Dr. Irwin’s work underscores the need to include weight management and counseling as part of cancer care.

Obesity increases the risk for many cancers, including breast cancer, particularly after menopause. While scientists have known about this relationship for many years, there has not been a clear cause-and-effect explanation.

Drs. Andrew Dannenberg and Clifford Hudis have uncovered a very important link between obesity, inflammation and breast cancer that helps to explain why obesity increases risk after menopause. During his presentation, Dr. Dannenberg showed that crown-like structures (CLS) in fat tissue release inflammatory molecules that promote the production of estrogen, a driver of most post-menopausal breast cancers. A striking discovery from their research revealed that about 30 percent of women at a healthy weight had CLS in their fat tissue. Their next step is to develop a blood test that can identify otherwise healthy women who may be at risk of breast cancer.

Because risk factors, both modifiable (weight and other lifestyle choices) and non-modifiable (age, family history or inherited genes) vary widely, prevention needs to be individualized. Dr. Powel Brown presented some of the challenges and opportunities in improving risk assessment and prevention. He emphasized the need to identify biomarkers that can better predict risk and inform the best preventive strategy, the importance of public perception of risk, and clinical trials to test chemopreventive drugs that can reduce the risk of triple negative breast cancer. Opportunities on the horizon include the potential development of preventive vaccines and the re-purposing of existing drugs for chemoprevention.

The Sum Is Greater Than Its Parts

At BCRF, we have always recognized the power of collaboration and know the complexities of cancer will only be resolved when our researchers come together to catalyze each other’s thinking and provide new perspectives. These meetings have historically inspired new collaborations and scientific discourse that accelerate discovery, and we are confident that the outcomes of this year’s meeting will be no different in taking us to our ultimate goal of better prevention and treatment of breast cancer.

# data[].attributes.field_subtitle
BCRF Grantees Gather to Discuss Genetic and Environmental Risks of Breast Cancer 

# data[].attributes.metatag_normalized[].attributes.content
In January 2013, Smart Circle International and RGS Labs began working together to create the FW1 Pink Promotion to raise money for BCRF. Smart Circle is the exclusive distributor of FW1 automobile waterless car wash and wax products through face-to-face marketing events at gas stations, car washes and other local businesses throughout the country. For every can sold, fifty cents is dedicated to BCRF. Since its culmination, the FW1 Pink Promotion has donated a cumulative $4 million to BCRF.
What inspired Smart Circle International and RGS Labs to choose breast cancer research as its cause of choice?
We chose breast cancer research as the cause for the FW1 Pink Promotion in an effort to give back to our consumers. So many men and women are affected by breast cancer; we felt it was a cause that would affect a high volume of our customers, employees and retail partners.
What drew you to partner with BCRF versus other breast cancer organizations?
BCRF’s financial efficiency and goal of a cure is what drew us to BCRF.
Do you meet many people affected by breast cancer during your promotions?
Over just the last year, we have met thousands of men and women who openly share their experiences with cancer. It is amazing to see both men and women share their personal stories of survival and how happy they are to see FW1 supporting this cause close to their hearts all year long.
Do you have any inspiring stories you can share of meeting those closely affected by breast cancer?
During a pilot program in California last June, we had a female customer approach our promotion in tears overwhelmed with enthusiasm regarding the FW1 Pink Promotion. She was impressed we had taken a product used by what many people assume to be men and partnered with an organization so dear to her heart. Her story really helped put the program into perspective!
What encourages Smart Circle and RGS year after year to continue its partnership with BCRF?
First and foremost, in partnering with BCRF, Smart Circle and RGS wanted to be socially responsible and good corporate citizens. Both Smart Circle and RGS believe that giving back and making our world stronger is not an option but a responsibility. 
Additionally, by partnering with BCRF, we hope to continue to attract and retain passionate, motivated sales team members. Most applicants and sales representatives are genuinely excited and motivated to be part of such a wonderful campaign. Similarly, so are retailers and convenience stores. 
As such, it is our hope that our continued partnership with BCRF allows us to continue to engage and secure high traffic, volume retailers and convenience stores to host our events.
Do you think the FW1 Pink Promotion is affected in any way by the predominately male culture of the auto industry? 
The FW1 Pink Promotion continues to push the envelope of social responsibility by bringing awareness of breast cancer to both men and women. While fuel stations and the automotive industries are predominately male, their consumers are a good mix. Our retail partners continue to be impressed with what the FW1 Pink Promotion has donated since the launch of the campaign on March 1, 2013.
Do you have any plans to expand your partnership offerings in the future?
Our program’s success is predicated on the real estate of our retail partners. The FW1 Pink Promotion will grow as we grow partnerships with various retail and convenient store companies.

# data[].attributes.metatag_normalized[].attributes.content
In January 2013, Smart Circle International and RGS Labs began working together to create the FW1 Pink Promotion to raise money for BCRF. Smart Circle is the exclusive distributor of FW1 automobile waterless car wash and wax products through face-to-face marketing events at gas stations, car washes and other local businesses throughout the country. For every can sold, fifty cents is dedicated to BCRF. Since its culmination, the FW1 Pink Promotion has donated a cumulative $4 million to BCRF.

# data[].attributes.metatag_normalized[].attributes.content
Smart Circle International/RGS Labs drives home the importance of supporting research

# data[].attributes.metatag_normalized[].attributes.content
In January 2013, Smart Circle International and RGS Labs began working together to create the FW1 Pink Promotion to raise money for BCRF. Smart Circle is the exclusive distributor of FW1 automobile waterless car wash and wax products through face-to-face marketing events at gas stations, car washes and other local businesses throughout the country. For every can sold, fifty cents is dedicated to BCRF. Since its culmination, the FW1 Pink Promotion has donated a cumulative $4 million to BCRF.

# data[].attributes.body.value
In January 2013, Smart Circle International and RGS Labs began working together to create the FW1 Pink Promotion to raise money for BCRF. Smart Circle is the exclusive distributor of FW1 automobile waterless car wash and wax products through face-to-face marketing events at gas stations, car washes and other local businesses throughout the country. For every can sold, fifty cents is dedicated to BCRF. Since its culmination, the FW1 Pink Promotion has donated a cumulative $4 million to BCRF.

What inspired Smart Circle International and RGS Labs to choose breast cancer research as its cause of choice?

We chose breast cancer research as the cause for the FW1 Pink Promotion in an effort to give back to our consumers. So many men and women are affected by breast cancer; we felt it was a cause that would affect a high volume of our customers, employees and retail partners.

What drew you to partner with BCRF versus other breast cancer organizations?

BCRF’s financial efficiency and goal of a cure is what drew us to BCRF.

Do you meet many people affected by breast cancer during your promotions?

Over just the last year, we have met thousands of men and women who openly share their experiences with cancer. It is amazing to see both men and women share their personal stories of survival and how happy they are to see FW1 supporting this cause close to their hearts all year long.

Do you have any inspiring stories you can share of meeting those closely affected by breast cancer?

During a pilot program in California last June, we had a female customer approach our promotion in tears overwhelmed with enthusiasm regarding the FW1 Pink Promotion. She was impressed we had taken a product used by what many people assume to be men and partnered with an organization so dear to her heart. Her story really helped put the program into perspective!

What encourages Smart Circle and RGS year after year to continue its partnership with BCRF?

First and foremost, in partnering with BCRF, Smart Circle and RGS wanted to be socially responsible and good corporate citizens. Both Smart Circle and RGS believe that giving back and making our world stronger is not an option but a responsibility.

Additionally, by partnering with BCRF, we hope to continue to attract and retain passionate, motivated sales team members. Most applicants and sales representatives are genuinely excited and motivated to be part of such a wonderful campaign. Similarly, so are retailers and convenience stores.

As such, it is our hope that our continued partnership with BCRF allows us to continue to engage and secure high traffic, volume retailers and convenience stores to host our events.

Do you think the FW1 Pink Promotion is affected in any way by the predominately male culture of the auto industry?

The FW1 Pink Promotion continues to push the envelope of social responsibility by bringing awareness of breast cancer to both men and women. While fuel stations and the automotive industries are predominately male, their consumers are a good mix. Our retail partners continue to be impressed with what the FW1 Pink Promotion has donated since the launch of the campaign on March 1, 2013.

Do you have any plans to expand your partnership offerings in the future?

Our program’s success is predicated on the real estate of our retail partners. The FW1 Pink Promotion will grow as we grow partnerships with various retail and convenient store companies.

# data[].attributes.body.processed
In January 2013, Smart Circle International and RGS Labs began working together to create the FW1 Pink Promotion to raise money for BCRF. Smart Circle is the exclusive distributor of FW1 automobile waterless car wash and wax products through face-to-face marketing events at gas stations, car washes and other local businesses throughout the country. For every can sold, fifty cents is dedicated to BCRF. Since its culmination, the FW1 Pink Promotion has donated a cumulative $4 million to BCRF.

What inspired Smart Circle International and RGS Labs to choose breast cancer research as its cause of choice?

We chose breast cancer research as the cause for the FW1 Pink Promotion in an effort to give back to our consumers. So many men and women are affected by breast cancer; we felt it was a cause that would affect a high volume of our customers, employees and retail partners.

What drew you to partner with BCRF versus other breast cancer organizations?

BCRF’s financial efficiency and goal of a cure is what drew us to BCRF.

Do you meet many people affected by breast cancer during your promotions?

Over just the last year, we have met thousands of men and women who openly share their experiences with cancer. It is amazing to see both men and women share their personal stories of survival and how happy they are to see FW1 supporting this cause close to their hearts all year long.

Do you have any inspiring stories you can share of meeting those closely affected by breast cancer?

During a pilot program in California last June, we had a female customer approach our promotion in tears overwhelmed with enthusiasm regarding the FW1 Pink Promotion. She was impressed we had taken a product used by what many people assume to be men and partnered with an organization so dear to her heart. Her story really helped put the program into perspective!

What encourages Smart Circle and RGS year after year to continue its partnership with BCRF?

First and foremost, in partnering with BCRF, Smart Circle and RGS wanted to be socially responsible and good corporate citizens. Both Smart Circle and RGS believe that giving back and making our world stronger is not an option but a responsibility.

Additionally, by partnering with BCRF, we hope to continue to attract and retain passionate, motivated sales team members. Most applicants and sales representatives are genuinely excited and motivated to be part of such a wonderful campaign. Similarly, so are retailers and convenience stores.

As such, it is our hope that our continued partnership with BCRF allows us to continue to engage and secure high traffic, volume retailers and convenience stores to host our events.

Do you think the FW1 Pink Promotion is affected in any way by the predominately male culture of the auto industry?

The FW1 Pink Promotion continues to push the envelope of social responsibility by bringing awareness of breast cancer to both men and women. While fuel stations and the automotive industries are predominately male, their consumers are a good mix. Our retail partners continue to be impressed with what the FW1 Pink Promotion has donated since the launch of the campaign on March 1, 2013.

Do you have any plans to expand your partnership offerings in the future?

Our program’s success is predicated on the real estate of our retail partners. The FW1 Pink Promotion will grow as we grow partnerships with various retail and convenient store companies.

# data[].attributes.field_subtitle
Smart Circle International/RGS Labs drives home the importance of supporting research

# data[].attributes.title
Immunotherapy as a Breast Cancer Vaccine

# data[].attributes.metatag_normalized[].attributes.content
Immunotherapy as a Breast Cancer Vaccine | BCRF

# data[].attributes.metatag_normalized[].attributes.content
Here at BCRF, we work hard to find and fund the most innovative minds in breast cancer research. Longstanding grantees Drs. Robert Vonderheide and Susan Domchek are no exception. Most recently, the duo was interviewed for Robb Report’s Health and Wellness column to discuss their cutting-edge research projects.
Together, Vonderheide and Domchek aim to improve immunotherapies that will increase the body’s ability to fight off existing cancers and also develop vaccines that will prevent the development and recurrence of breast cancer. The team is currently managing clinical trials and working in real-time to make cancer prevention a reality. 
This story was originally published in Robb Report’s Health and Wellness column on October 22, 2014.
How is immunotherapy being studied and applied as a treatment for breast cancer?
VONDERHEIDE: We believe the immune system is constantly trying to fight the development of cancer. But cancer has a way of derailing the immune system, so we need to boost the immune system with vaccines and other therapies. This approach has begun to work for patients with melanoma, lung cancer, and other cancers. We are now on the verge of making this happen for patients with breast cancer, too.
 What led you to this specialty?
VONDERHEIDE: I studied immunology as a graduate student in Oxford and then decided to go to medical school so I could bring these ideas to patients. As an oncology fellow, I was fascinated by this emerging field of cancer immunotherapy, and it was during my time as a postdoc that I began to work on a preventive cancer vaccine.
DOMCHEK: My biggest goal is to prevent cancer, especially in people with BRCA1 or 2 mutations. To me, the immune system holds the power to make this a reality. We want to develop a “polio vaccine” for cancer.
Tells us about the two clinical trials you have already begun and the third that is scheduled to start.
DOMCHEK: Two of these approaches are vaccines, each designed to start an immune response against the protein telomerase, which nearly every breast cancer expresses. We think telomerase is a good bull’s-eye for the immune system, and one that might work well to prevent cancer. One of these vaccines is based on a novel gene-therapy approach and in the laboratory is extremely potent.
VONDERHEIDE: The third clinical trial is another type of gene therapy in which we reengineer a patient’s own white blood cells so that they specifically target breast cancer once reinfused into the patients. At Penn, we have had success with this type of therapy in leukemia. This is the first test in patients with breast cancer.
What kinds of patients are selected to participate in your trials?
VONDERHEIDE: It varies. Two of our trials are designed for patients with metastatic disease. The other is for patients who have had their tumors surgically excised and have also completed adjuvant therapy. The vaccine is designed to prevent tumor recurrence.
What role will immunotherapy play in customizing treatment for breast-cancer patients?
DOMCHEK: There is no more personal a therapy than boosting one’s own immune system to attack cancer. One of the therapies we are testing is built by reengineering a patient’s own immune cells, so it is a separate therapy for every patient.
VONDERHEIDE: Personalized immune therapy will be different than the kind of personalized medicine in which mutations in tumors are identified and drugs are found to block those mutations. Immune therapy so far has not been restricted to a particular type of tumor mutation.
Someday in the future, can immunotherapy be utilized as a preventive tool?
DOMCHEK: A prevention vaccine is the ultimate goal of our BCRF-funded study. We hope we are just three years away from testing our new gene-therapy vaccine in healthy individuals with BRCA1 or 2 germ-line mutations who are at high risk of developing cancer. This is what I meant by a “polio vaccine for cancer.” Can you imagine the impact?
Where do you believe this path of discovery will take us as part of finding a cure for breast cancer?
VONDERHEIDE: As a colleague of mine once said, if we are going to talk about curing cancer, we will need to involve the immune system. Cancer vaccines have been difficult to use as therapy, just as a flu vaccine or pneumonia vaccine cannot treat patients who have already developed those infections. Prevention is what vaccines do best.
Are your trials open to new participants? If so, how can readers learn more about enrolling?
VONDERHEIDE: Two of the three trials are open, and the other (for patients in remission after initial surgery) will open soon. Patients or their doctors can call us for more information (800.789.7322).

# data[].attributes.metatag_normalized[].attributes.content
Immunotherapy as a Breast Cancer Vaccine

# data[].attributes.metatag_normalized[].attributes.content
Here at BCRF, we work hard to find and fund the most innovative minds in breast cancer research. Longstanding grantees Drs. Robert Vonderheide and Susan Domchek are no exception. Most recently, the duo was interviewed for Robb Report’s Health and Wellness column to discuss their cutting-edge research projects.

# data[].attributes.metatag_normalized[].attributes.content
Immunotherapy as a Breast Cancer Vaccine

# data[].attributes.metatag_normalized[].attributes.content
Drs. Robert Vonderheide and Susan Domchek discuss their cutting-edge research.

# data[].attributes.metatag_normalized[].attributes.content
Here at BCRF, we work hard to find and fund the most innovative minds in breast cancer research. Longstanding grantees Drs. Robert Vonderheide and Susan Domchek are no exception. Most recently, the duo was interviewed for Robb Report’s Health and Wellness column to discuss their cutting-edge research projects.

# data[].attributes.metatag_normalized[].attributes.content
Immunotherapy as a Breast Cancer Vaccine

# data[].attributes.body.value
Here at BCRF, we work hard to find and fund the most innovative minds in breast cancer research. Longstanding grantees Drs. Robert Vonderheide and Susan Domchek are no exception. Most recently, the duo was interviewed for Robb Report’s Health and Wellness column to discuss their cutting-edge research projects.

Together, Vonderheide and Domchek aim to improve immunotherapies that will increase the body’s ability to fight off existing cancers and also develop vaccines that will prevent the development and recurrence of breast cancer. The team is currently managing clinical trials and working in real-time to make cancer prevention a reality.

This story was originally published in Robb Report’s Health and Wellness column on October 22, 2014.

How is immunotherapy being studied and applied as a treatment for breast cancer?

VONDERHEIDE: We believe the immune system is constantly trying to fight the development of cancer. But cancer has a way of derailing the immune system, so we need to boost the immune system with vaccines and other therapies. This approach has begun to work for patients with melanoma, lung cancer, and other cancers. We are now on the verge of making this happen for patients with breast cancer, too.

What led you to this specialty?

VONDERHEIDE: I studied immunology as a graduate student in Oxford and then decided to go to medical school so I could bring these ideas to patients. As an oncology fellow, I was fascinated by this emerging field of cancer immunotherapy, and it was during my time as a postdoc that I began to work on a preventive cancer vaccine.

DOMCHEK: My biggest goal is to prevent cancer, especially in people with BRCA1 or 2 mutations. To me, the immune system holds the power to make this a reality. We want to develop a “polio vaccine” for cancer.

Tells us about the two clinical trials you have already begun and the third that is scheduled to start.

DOMCHEK: Two of these approaches are vaccines, each designed to start an immune response against the protein telomerase, which nearly every breast cancer expresses. We think telomerase is a good bull’s-eye for the immune system, and one that might work well to prevent cancer. One of these vaccines is based on a novel gene-therapy approach and in the laboratory is extremely potent.

VONDERHEIDE: The third clinical trial is another type of gene therapy in which we reengineer a patient’s own white blood cells so that they specifically target breast cancer once reinfused into the patients. At Penn, we have had success with this type of therapy in leukemia. This is the first test in patients with breast cancer.

What kinds of patients are selected to participate in your trials?

VONDERHEIDE: It varies. Two of our trials are designed for patients with metastatic disease. The other is for patients who have had their tumors surgically excised and have also completed adjuvant therapy. The vaccine is designed to prevent tumor recurrence.

What role will immunotherapy play in customizing treatment for breast-cancer patients?

DOMCHEK: There is no more personal a therapy than boosting one’s own immune system to attack cancer. One of the therapies we are testing is built by reengineering a patient’s own immune cells, so it is a separate therapy for every patient.

VONDERHEIDE: Personalized immune therapy will be different than the kind of personalized medicine in which mutations in tumors are identified and drugs are found to block those mutations. Immune therapy so far has not been restricted to a particular type of tumor mutation.

Someday in the future, can immunotherapy be utilized as a preventive tool?

DOMCHEK: A prevention vaccine is the ultimate goal of our BCRF-funded study. We hope we are just three years away from testing our new gene-therapy vaccine in healthy individuals with BRCA1 or 2 germ-line mutations who are at high risk of developing cancer. This is what I meant by a “polio vaccine for cancer.” Can you imagine the impact?

Where do you believe this path of discovery will take us as part of finding a cure for breast cancer?

VONDERHEIDE: As a colleague of mine once said, if we are going to talk about curing cancer, we will need to involve the immune system. Cancer vaccines have been difficult to use as therapy, just as a flu vaccine or pneumonia vaccine cannot treat patients who have already developed those infections. Prevention is what vaccines do best.

Are your trials open to new participants? If so, how can readers learn more about enrolling?

VONDERHEIDE: Two of the three trials are open, and the other (for patients in remission after initial surgery) will open soon. Patients or their doctors can call us for more information (800.789.7322).

# data[].attributes.body.processed
Here at BCRF, we work hard to find and fund the most innovative minds in breast cancer research. Longstanding grantees Drs. Robert Vonderheide and Susan Domchek are no exception. Most recently, the duo was interviewed for Robb Report’s Health and Wellness column to discuss their cutting-edge research projects.

Together, Vonderheide and Domchek aim to improve immunotherapies that will increase the body’s ability to fight off existing cancers and also develop vaccines that will prevent the development and recurrence of breast cancer. The team is currently managing clinical trials and working in real-time to make cancer prevention a reality.

This story was originally published in Robb Report’s Health and Wellness column on October 22, 2014.

How is immunotherapy being studied and applied as a treatment for breast cancer?

VONDERHEIDE: We believe the immune system is constantly trying to fight the development of cancer. But cancer has a way of derailing the immune system, so we need to boost the immune system with vaccines and other therapies. This approach has begun to work for patients with melanoma, lung cancer, and other cancers. We are now on the verge of making this happen for patients with breast cancer, too.

What led you to this specialty?

VONDERHEIDE: I studied immunology as a graduate student in Oxford and then decided to go to medical school so I could bring these ideas to patients. As an oncology fellow, I was fascinated by this emerging field of cancer immunotherapy, and it was during my time as a postdoc that I began to work on a preventive cancer vaccine.

DOMCHEK: My biggest goal is to prevent cancer, especially in people with BRCA1 or 2 mutations. To me, the immune system holds the power to make this a reality. We want to develop a “polio vaccine” for cancer.

Tells us about the two clinical trials you have already begun and the third that is scheduled to start.

DOMCHEK: Two of these approaches are vaccines, each designed to start an immune response against the protein telomerase, which nearly every breast cancer expresses. We think telomerase is a good bull’s-eye for the immune system, and one that might work well to prevent cancer. One of these vaccines is based on a novel gene-therapy approach and in the laboratory is extremely potent.

VONDERHEIDE: The third clinical trial is another type of gene therapy in which we reengineer a patient’s own white blood cells so that they specifically target breast cancer once reinfused into the patients. At Penn, we have had success with this type of therapy in leukemia. This is the first test in patients with breast cancer.

What kinds of patients are selected to participate in your trials?

VONDERHEIDE: It varies. Two of our trials are designed for patients with metastatic disease. The other is for patients who have had their tumors surgically excised and have also completed adjuvant therapy. The vaccine is designed to prevent tumor recurrence.

What role will immunotherapy play in customizing treatment for breast-cancer patients?

DOMCHEK: There is no more personal a therapy than boosting one’s own immune system to attack cancer. One of the therapies we are testing is built by reengineering a patient’s own immune cells, so it is a separate therapy for every patient.

VONDERHEIDE: Personalized immune therapy will be different than the kind of personalized medicine in which mutations in tumors are identified and drugs are found to block those mutations. Immune therapy so far has not been restricted to a particular type of tumor mutation.

Someday in the future, can immunotherapy be utilized as a preventive tool?

DOMCHEK: A prevention vaccine is the ultimate goal of our BCRF-funded study. We hope we are just three years away from testing our new gene-therapy vaccine in healthy individuals with BRCA1 or 2 germ-line mutations who are at high risk of developing cancer. This is what I meant by a “polio vaccine for cancer.” Can you imagine the impact?

Where do you believe this path of discovery will take us as part of finding a cure for breast cancer?

VONDERHEIDE: As a colleague of mine once said, if we are going to talk about curing cancer, we will need to involve the immune system. Cancer vaccines have been difficult to use as therapy, just as a flu vaccine or pneumonia vaccine cannot treat patients who have already developed those infections. Prevention is what vaccines do best.

Are your trials open to new participants? If so, how can readers learn more about enrolling?

VONDERHEIDE: Two of the three trials are open, and the other (for patients in remission after initial surgery) will open soon. Patients or their doctors can call us for more information (800.789.7322).

# data[].attributes.field_caption
Drs. Robert Vonderheide and Susan Domchek

# data[].attributes.field_subtitle
Drs. Robert Vonderheide and Susan Domchek discuss their cutting-edge research.

# data[].attributes.metatag_normalized[].attributes.content
Holiday House Opens for 2014 Season | BCRF

# data[].attributes.metatag_normalized[].attributes.content
The much-anticipated Holiday House is officially open for the 2014 season as a showhouse for the very best in interior design. Founder Iris Dankner, a breast cancer survivor and interior designer, combines the very best in entertainment and design each year to support the Breast Cancer Research Foundation.
Holiday House was created to seamlessly celebrate Dankner’s love of interiors and philanthropy. Guests of Holiday House are welcome to explore the curated Upper East Side home designed room-by-room by today’s most talented decorators.
"The most rewarding part of Holiday House is the people I meet and the lives I touch each and every day," says Dankner. "I am so thrilled that last year's Holiday House was able to fund an entire research project. My goal is to be able to do that again this year!"

The home is open to the public from November 20-December 21. For each ticket purchased, 100 percent of the proceeds will go directly to serve BCRF’s mission. Holiday House has raised over $650,000 for BCRF since 2012 and has expanded to include a summer showhouse in the Hamptons every season.
For tickets and schedule information, please visit Holiday House NYC.

# data[].attributes.metatag_normalized[].attributes.content
The much-anticipated Holiday House is officially open for the 2014 season as a showhouse for the very best in interior design. Founder Iris Dankner, a breast cancer survivor and interior designer, combines the very best in entertainment and design each year to support the Breast Cancer Research Foundation.

# data[].attributes.metatag_normalized[].attributes.content
The New York City designer showhouse raises money and awareness for BCRF.

# data[].attributes.metatag_normalized[].attributes.content
The much-anticipated Holiday House is officially open for the 2014 season as a showhouse for the very best in interior design. Founder Iris Dankner, a breast cancer survivor and interior designer, combines the very best in entertainment and design each year to support the Breast Cancer Research Foundation.

# data[].attributes.body.value
The much-anticipated Holiday House is officially open for the 2014 season as a showhouse for the very best in interior design. Founder Iris Dankner, a breast cancer survivor and interior designer, combines the very best in entertainment and design each year to support the Breast Cancer Research Foundation.

Holiday House was created to seamlessly celebrate Dankner’s love of interiors and philanthropy. Guests of Holiday House are welcome to explore the curated Upper East Side home designed room-by-room by today’s most talented decorators.

"The most rewarding part of Holiday House is the people I meet and the lives I touch each and every day," says Dankner. "I am so thrilled that last year's Holiday House was able to fund an entire research project. My goal is to be able to do that again this year!"

The home is open to the public from November 20-December 21. For each ticket purchased, 100 percent of the proceeds will go directly to serve BCRF’s mission. Holiday House has raised over $650,000 for BCRF since 2012 and has expanded to include a summer showhouse in the Hamptons every season.

For tickets and schedule information, please visit Holiday House NYC.

# data[].attributes.body.processed
The much-anticipated Holiday House is officially open for the 2014 season as a showhouse for the very best in interior design. Founder Iris Dankner, a breast cancer survivor and interior designer, combines the very best in entertainment and design each year to support the Breast Cancer Research Foundation.

Holiday House was created to seamlessly celebrate Dankner’s love of interiors and philanthropy. Guests of Holiday House are welcome to explore the curated Upper East Side home designed room-by-room by today’s most talented decorators.

"The most rewarding part of Holiday House is the people I meet and the lives I touch each and every day," says Dankner. "I am so thrilled that last year's Holiday House was able to fund an entire research project. My goal is to be able to do that again this year!"

The home is open to the public from November 20-December 21. For each ticket purchased, 100 percent of the proceeds will go directly to serve BCRF’s mission. Holiday House has raised over $650,000 for BCRF since 2012 and has expanded to include a summer showhouse in the Hamptons every season.

For tickets and schedule information, please visit Holiday House NYC.

# data[].attributes.field_subtitle
The New York City designer showhouse raises money and awareness for BCRF.

# data[].attributes.metatag_normalized[].attributes.content
How much of a difference in the fight against breast cancer can one #GivingTuesday make? A huge difference! Every dollar you give matters and will get us to the finish line—prevention and a cure—faster.
On this day dedicated to giving back, BCRF has teamed up with CrowdRise and some other amazing nonprofit organizations to help build a Giving Tower that’s taller than any building in the world. Every donation—no matter the dollar amount—adds a brick to the tower, showing the world our supporters’ impact and spreading the word about the importance of breast cancer research.  
And every donation on behalf of BCRF helps us create treatment options that have fewer side effects and improve the outcomes for the women and men battling the disease today. It also allows our researchers to uncover the relationship between genetics and breast cancer so we they can better predict who is at risk. And, most importantly, it helps save lives every day.
We’re thrilled to be part of this global movement. Join us in building the tower and helping to #BeTheEnd of breast cancer. 

  
      
            

      
  

 

# data[].attributes.metatag_normalized[].attributes.content
How much of a difference in the fight against breast cancer can one #GivingTuesday make? A huge difference! Every dollar you give matters and will get us to the finish line—prevention and a cure—faster.

# data[].attributes.metatag_normalized[].attributes.content
BCRF has teamed up with CrowdRise to show much we care about giving—and supporting breast cancer research

# data[].attributes.metatag_normalized[].attributes.content
How much of a difference in the fight against breast cancer can one #GivingTuesday make? A huge difference! Every dollar you give matters and will get us to the finish line—prevention and a cure—faster.

# data[].attributes.body.value
How much of a difference in the fight against breast cancer can one #GivingTuesday make? A huge difference! Every dollar you give matters and will get us to the finish line—prevention and a cure—faster.

On this day dedicated to giving back, BCRF has teamed up with CrowdRise and some other amazing nonprofit organizations to help build a Giving Tower that’s taller than any building in the world. Every donation—no matter the dollar amount—adds a brick to the tower, showing the world our supporters’ impact and spreading the word about the importance of breast cancer research.

And every donation on behalf of BCRF helps us create treatment options that have fewer side effects and improve the outcomes for the women and men battling the disease today. It also allows our researchers to uncover the relationship between genetics and breast cancer so we they can better predict who is at risk. And, most importantly, it helps save lives every day.

We’re thrilled to be part of this global movement. Join us in building the tower and helping to #BeTheEnd of breast cancer.

# data[].attributes.body.processed
How much of a difference in the fight against breast cancer can one #GivingTuesday make? A huge difference! Every dollar you give matters and will get us to the finish line—prevention and a cure—faster.

On this day dedicated to giving back, BCRF has teamed up with CrowdRise and some other amazing nonprofit organizations to help build a Giving Tower that’s taller than any building in the world. Every donation—no matter the dollar amount—adds a brick to the tower, showing the world our supporters’ impact and spreading the word about the importance of breast cancer research.

And every donation on behalf of BCRF helps us create treatment options that have fewer side effects and improve the outcomes for the women and men battling the disease today. It also allows our researchers to uncover the relationship between genetics and breast cancer so we they can better predict who is at risk. And, most importantly, it helps save lives every day.

We’re thrilled to be part of this global movement. Join us in building the tower and helping to #BeTheEnd of breast cancer.

# data[].attributes.field_subtitle
BCRF has teamed up with CrowdRise to show much we care about giving—and supporting breast cancer research